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ext supporting unchanged recommendations has not
een updated.
It is important that the medical profession play a significant
le in critically evaluating the use of diagnostic procedures
d therapies in the detection, management, or prevention of
sease states. Rigorous and expert analysis of the available
ta documenting absolute and relative benefits and risks of
ose procedures and therapies can produce helpful guide-
nes that improve the effectiveness of care, optimize patient
tcomes, and favorably affect the overall cost of care by
cusing resources on the most effective strategies.
The American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) have jointly
gaged in the production of such guidelines in the area of
rdiovascular disease since 1980. The American College of
ardiology (ACC)/AHA Task Force on Practice Guidelines,
hose charge is to develop, update, or revise practice
idelines for important cardiovascular diseases and proce-
res, directs this effort. Writing committees are charged with
e task of performing an assessment of the evidence and
ting as an independent group of authors to develop, update,
revise written recommendations for clinical practice.
Experts in the subject under consideration have been
lected from both organizations to examine subject-specific
ta and write guidelines. The process includes additional
presentatives from other medical practitioner and specialty
oups when appropriate. Writing committees are specifically
arged to perform a formal literature review, weigh the
rength of evidence for or against a particular treatment or
ocedure, and include estimates of expected health outcomes
here data exist. Patient-specific modifiers, comorbidities,
d issues of patient preference that might influence the
oice of particular tests or therapies are considered, as well
frequency of follow-up and cost effectiveness. When
ailable, information from studies on cost will be consid-
ed; however, review of data on efficacy and clinical
tcomes will constitute the primary basis for preparing
commendations in these guidelines. reThe ACC/AHA Task Force on Practice Guidelines makes
ery effort to avoid any actual, potential, or perceived
nflict of interest that may arise as a result of an industry
lationship or personal interest of a member of the Writing
ommittee. Specifically, all members of the Writing Com-
ittee, as well as peer reviewers of the document, were asked
provide disclosure statements of all such relationships that
ay be perceived as real or potential conflicts of interest.
riting Committee members are also strongly encouraged to
clare a previous relationship with industry that may be
rceived as relevant to guideline development. If a Writing
ommittee member develops a new relationship with indus-
y during their tenure, they are required to notify guideline
aff in writing. The continued participation of the Writing
ommittee member will be reviewed. These statements are
viewed by the parent task force, reported orally to all
embers of the Writing Committee at each meeting, and
dated and reviewed by the Writing Committee as changes
cur. Please refer to the methodology manual for ACC/AHA
uideline Writing Committees further description of relation-
ips with industry policy, available on the ACC and AHA
orld Wide Web sites (http://www.acc.org/qualityandscience/
inical/manual/manual%/5Fi.htm and http://www.circ.ahajournals.
g/manual). See Appendix 1 for a list of Writing Committee
ember relationships with industry and Appendix 2 for a listing
peer reviewer relationships with industry that are pertinent to
is guideline.
These practice guidelines are intended to assist health care
oviders in clinical decision making by describing a range of
nerally acceptable approaches for the diagnosis, manage-
ent, and prevention of specific diseases or conditions.
linical decision making should consider the quality and
ailability of expertise in the area where care is provided.
hese guidelines attempt to define practices that meet the
eds of most patients in most circumstances. These guide-
ne recommendations reflect a consensus of expert opinion
ter a thorough review of the available, current scientific
idence and are intended to improve patient care.
Patient adherence to prescribed and agreed upon medical
gimens and lifestyles is an important aspect of treatment.
rescribed courses of treatment in accordance with these
commendations will only be effective if they are followed.
ince lack of patient understanding and adherence may
versely affect treatment outcomes, physicians and other
alth care providers should make every effort to engage the
tient in active participation with prescribed medical regi-
ens and lifestyles.
If these guidelines are used as the basis for regulatory/
yer decisions, the ultimate goal is quality of care and
rving the patient’s best interests. The ultimate judgment
garding care of a particular patient must be made by the
alth care provider and patient in light of all the circum-
ances presented by that patient. There are circumstances in
hich derivations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/
HA Task Force on Practice Guidelines and will be consid-
ed current unless they are updated, revised, or sunsetted and
ithdrawn from distribution. The executive summary and
commendations are published in the August 7, 2007, issue
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ugust 7, 2007, issue of Circulation. The full-text guidelines
e e-published in the same issue of the journals noted above,
well as posted on the ACC (www.acc.org) and AHA
ww.americanheart.org) World Wide Web sites. Copies of
e full text and the executive summary are available from
th organizations.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
. Introduction
.1. Organization of Committee and
vidence Review (UPDATED)
or new or updated text, view the 2011 Focused Update.
ext supporting unchanged recommendations has not
een updated.
The ACC/AHA Task Force on Practice Guidelines was
rmed to make recommendations regarding the diagnosis
d treatment of patients with known or suspected cardiovas-
lar disease (CVD). Coronary artery disease (CAD) is the
ading cause of death in the United States. Unstable angina
A) and the closely related condition of non–ST-segment
evation myocardial infarction (NSTEMI) are very common
anifestations of this disease.
The committee members reviewed and compiled published
ports through a series of computerized literature searches of
e English-language literature since 2002 and a final manual
arch of selected articles. Details of the specific searches
nducted for particular sections are provided when appro-
iate. Detailed evidence tables were developed whenever
cessary with the specific criteria outlined in the individual
ctions. The recommendations made were based primarily
these published data. The weight of the evidence was
nked highest (A) to lowest (C). The final recommendations
r indications for a diagnostic procedure, a particular ther-
y, or an intervention in patients with UA/NSTEMI sum-
arize both clinical evidence and expert opinion.
lassification of Recommendations
he schema for classification of recommendations and level
evidence is summarized in Table 1, which also illustrates
w the grading system provides an estimate of the size of the
eatment effect and an estimate of the certainty of the
eatment effect.
A complete list of the thousands of publications on various
pects of this subject is beyond the scope of these guidelines;
ly selected references are included. The Committee con-
sted of acknowledged experts in general internal medicine
presenting the American College of Physicians (ACP),
mily medicine from the American Academy of Family
hysicians (AAFP), emergency medicine from the American
ollege of Emergency Physicians (ACEP), thoracic surgery
om the Society of Thoracic Surgeons (STS), interventional
rdiology from the Society for Cardiovascular Angiography
d Interventions (SCAI), and general and critical care
rdiology, as well as individuals with recognized expertise
more specialized areas, including noninvasive testing, Ueventive cardiology, coronary intervention, and cardiovas-
lar surgery. Both the academic and private practice sectors
ere represented. This document was reviewed by 2 outside
viewers nominated by each of the ACC and AHA and by 49
er reviewers. These guidelines will be considered current
less the Task Force revises them or withdraws them from
stribution.
These guidelines overlap several previously published
CC/AHA practice guidelines, including the ACC/AHA
uidelines for the Management of Patients With ST-
levation Myocardial Infarction (1), the ACC/AHA/SCAI
05 Guideline Update for Percutaneous Coronary Interven-
on (2), the AHA/ACC Guidelines for Secondary Prevention
r Patients With Coronary and Other Atherosclerotic Vas-
lar Disease: 2006 Update (3), and the ACC/AHA 2002
uideline Update for the Management of Patients With
hronic Stable Angina (4).
.2. Purpose of These Guidelines
hese guidelines address the diagnosis and management of
tients with UA and the closely related condition of
STEMI. These life-threatening disorders are a major cause
emergency medical care and hospitalization in the United
tates. In 2004, the National Center for Health Statistics
ported 1,565,000 hospitalizations for primary or secondary
agnosis of an acute coronary syndrome (ACS), 669,000 for
A and 896,000 for myocardial infarction (MI) (5). The
erage age of a person having a first heart attack is 65.8
ars for men and 70.4 years for women, and 43% of ACS
tients of all ages are women. In 2003, there were 4,497,000
sits to US emergency departments (EDs) for primary
agnosis of CVD (5). The prevalence of this presentation of
VD ensures that many health care providers who are not
rdiovascular specialists will encounter patients with UA/
STEMI in the course of the treatment of other diseases,
pecially in outpatient and ED settings. These guidelines are
tended to assist both cardiovascular specialists and nonspe-
alists in the proper evaluation and management of patients
ith an acute onset of symptoms suggestive of these condi-
ons. These clinical practice guidelines also provide recom-
endations and supporting evidence for the continued man-
ement of patients with these conditions in both inpatient
d outpatient settings. The diagnostic and therapeutic strat-
ies that are recommended are supported by the best
ailable evidence and expert opinion. The application of
ese principles with carefully reasoned clinical judgment
duces but does not eliminate the risk of cardiac damage and
ath in patients who present with symptoms suggestive of
A/NSTEMI.
.3. Overview of the
cute Coronary Syndromes
.3.1. Definition of Terms
nstable angina/NSTEMI constitutes a clinical syndrome
bset of the ACS that is usually, but not always, caused by
herosclerotic CAD and is associated with an increased risk
cardiac death and subsequent MI. In the spectrum of ACS,A/NSTEMI is defined by electrocardiographic (ECG) ST-
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sitive biomarkers of necrosis (e.g., troponin) in the absence
ST-segment elevation and in an appropriate clinical setting
hest discomfort or anginal equivalent) (Table 2, Fig. 1). The
sults of angiographic and angioscopic studies suggest that
A/NSTEMI often results from the disruption or erosion of
atherosclerotic plaque and a subsequent cascade of path-
ogical processes that decrease coronary blood flow. Most
tients who die during UA/NSTEMI do so because of
dden death or the development (or recurrence) of acute MI.
he efficient diagnosis and optimal management of these
tients must derive from information readily available at the
me of the initial clinical presentation. The clinical presen-
tion of patients with a life-threatening ACS often overlaps
at of patients subsequently found not to have CAD. More-
er, some forms of MI cannot always be differentiated from
ble 1. Applying Classification of Recommendations and Level
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use. A recommend
any important clinical questions addressed in the guidelines do not lend them
a very clear clinical consensus that a particular test or therapy is useful or
†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a
commendations have been written in full sentences that express a complete
e rest of the document (including headings above sets of recommendations),
crease readers’ comprehension of the guidelines and will allow queries at theA at the time of initial presentation. ca“Acute coronary syndrome” has evolved as a useful
erational term to refer to any constellation of clinical
mptoms that are compatible with acute myocardial isch-
ia (Fig. 1). It encompasses MI (ST-segment elevation and
pression, Q wave and non-Q wave) and UA. These guide-
nes focus on 2 components of this syndrome: UA and
STEMI. In practice, the term “possible ACS” is often
signed first by ancillary personnel, such as emergency
edical technicians and triage nurses, early in the evaluation
ocess. A guideline of the National Heart Attack Alert
rogram (6) summarizes the clinical information needed to
ake the diagnosis of possible ACS at the earliest phase of
inical evaluation (Table 2). The implication of this early
agnosis for clinical management is that a patient who is
nsidered to have an ACS should be placed in an environ-
ent with continuous ECG monitoring and defibrillation
ence† (UPDATED) (see the 2011 Focused Update)
nt subpopulations, such as gender, age, history of diabetes, history of prior
th Level of Evidence B or C does not imply that the recommendation is weak.
o clinical trials. Even though randomized trials are not available, there may
.
suggested phrases to use when writing recommendations. All guideline
, such that a recommendation, even if separated and presented apart from
still convey the full intent of the recommendation. It is hoped that this will
ual recommendation level.of Evid
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wouldpability, where a 12-lead ECG can be obtained expedi-
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionously and definitively interpreted, ideally within 10 min of
rival in the ED. The most urgent priority of early evaluation
to identify patients with ST-elevation MI (STEMI) who
ould be considered for immediate reperfusion therapy and
recognize other potentially catastrophic causes of patient
mptoms, such as aortic dissection.
Patients diagnosed as having STEMI are excluded from
anagement according to these guidelines and should be
anaged as indicated according to the ACC/AHA Guidelines
r the Management of Patients With ST-Elevation Myocar-
alInfarction (1,10). Similarly, management of electrocar-
ographic true posterior MI, which can masquerade as
STEMI, is covered in the STEMI guidelines (1). The
anagement of patients who experience periprocedural myo-
rdial damage, as reflected in the release of biomarkers of
crosis, such as the MB isoenzyme of creatine kinase
K-MB) or troponin, also is not considered here.
Patients with MI and with definite ischemic ECG changes
r whom acute reperfusion therapy is not suitable should be
agnosed and managed as patients with UA. The residual
oup of patients with an initial diagnosis of ACS will include
any patients who will ultimately be proven to have a
ncardiac cause for the initial clinical presentation that was
ggestive of ACS. Therefore, at the conclusion of the initial
aluation, which is frequently performed in the ED but
ble 2. Guidelines for the Identification of ACS Patients by ED
egistration/clerical staff
Patients with the following chief complaints require immediate assessment
● Chest pain, pressure, tightness, or heaviness; pain that radiates to neck,
● Indigestion or “heartburn” nausea and/or vomiting associated with chest d
● Persistent shortness of breath
● Weakness, dizziness, lightheadedness, loss of consciousness
iage nurse
Patients with the following symptoms and signs require immediate assessm
● Chest pain or severe epigastric pain, nontraumatic in origin, with compon
X Central/substernal compression or crushing chest pain
X Pressure, tightness, heaviness, cramping, burning, aching sensation
X Unexplained indigestion, belching, epigastric pain
X Radiating pain in neck, jaw, shoulders, back, or 1 or both arms
● Associated dyspnea
● Associated nausea and/or vomiting
● Associated diaphoresis
If these symptoms are present, obtain stat ECG.
edical history
The triage nurse should take a brief, targeted, initial history with an assessm
● CABG, PCI, CAD, angina on effort, or MI
● NTG use to relieve chest discomfort
● Risk factors, including smoking, hyperlipidemia, hypertension, diabetes m
● Regular and recent medication use
The brief history must not delay entry into the ACS protocol.
pecial considerations
Women may present more frequently than men with atypical chest pain and
Diabetic patients may have atypical presentations due to autonomic dysfunc
Elderly patients may have atypical symptoms such as generalized weakness
Adapted from National Heart Attack Alert Program. Emergency Department: rap
D: US Department of Health and Human Services. US Public Health Service. Na
H Publication No. 93-3278 (6).
ACS  acute coronary syndrome; CABG  coronary artery bypass graft sur
partment; MI  myocardial infarction; NTG  nitroglycerin; PCI  percutanemetimes occurs during the initial hours of inpatient hospi- stlization, each patient should have a provisional diagnosis of
ACS (Fig. 1), which in turn is classified as a) STEMI, a
ndition for which immediate reperfusion therapy (fibrino-
sis or percutaneous coronary intervention [PCI]) should be
nsidered, b) NSTEMI, or c) UA (definite, probable, or
ssible); 2) a non-ACS cardiovascular condition (e.g., acute
ricarditis); 3) a noncardiac condition with another specific
sease (e.g., chest pain secondary to esophageal spasm); or
a noncardiac condition that is undefined. In addition, the
itial evaluation should be used to determine risk and to treat
fe-threatening events.
In these guidelines, UA and NSTEMI are considered to be
osely related conditions whose pathogenesis and clinical
esentations are similar but of differing severity; that is, they
ffer primarily in whether the ischemia is severe enough to
use sufficient myocardial damage to release detectable
antities of a marker of myocardial injury, most commonly
oponin I (TnI), troponin T (TnT), or CK-MB. Once it has
en established that no biomarker of myocardial necrosis
s been released (based on 2 or more samples collected at
ast 6 h apart, with a reference limit of the 99th percentile of
e normal population) (11), the patient with ACS may be
nsidered to have experienced UA, whereas the diagnosis of
STEMI is established if a biomarker has been released.
arkers of myocardial injury can be detected in the blood-
ation Clerks or Triage Nurses
iage nurse and should be referred for further evaluation:
ulders, back, or 1 or both arms
rt
he triage nurse for the initiation of the ACS protocol:
ical of myocardial ischemia or MI:
current or past history of:
amily history, and cocaine or methamphetamine use
ms.
, syncope, or a change in mental status.
ification and treatment of patients with acute myocardial infarction. Bethesda,
stitutes of Health. National Heart, Lung and Blood Institute, September 1993.
D  coronary artery disease; ECG  electrocardiogram; ED  emergency
onary intervention.Registr
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367gure 1. Acute Coronary Syndromes. The top half of the figure illustrates the chronology of the interface between the patient and the clini-
an through the progression of plaque formation, onset, and complications of UA/NSTEMI, along with relevant management considerations
each stage. The longitudinal section of an artery depicts the “timeline” of atherogenesis from 1) a normal artery to 2) lesion initiation and
cumulation of extracellular lipid in the intima, to 3) the evolution to the fibrofatty stage, to 4) lesion progression with procoagulant expres-
on and weakening of the fibrous cap. An acute coronary syndrome (ACS) develops when the vulnerable or high-risk plaque undergoes dis-
ption of the fibrous cap 5); disruption of the plaque is the stimulus for thrombogenesis. Thrombus resorption may be followed by collagen
cumulation and smooth muscle cell growth 6). After disruption of a vulnerable or high-risk plaque, patients experience ischemic discomfort
at results from a reduction of flow through the affected epicardial coronary artery. The flow reduction may be caused by a completely oc-
usive thrombus (bottom half, right side) or subtotally occlusive thrombus (bottom half, left side). Patients with ischemic discomfort may
esent with or without ST-segment elevation on the ECG. Among patients with ST-segment elevation, most (thick white arrow in bottom
nel) ultimately develop a Q-wave MI (QwMI), although a few (thin white arrow) develop a non–Q-wave MI (NQMI). Patients who present
ithout ST-segment elevation are suffering from either unstable angina (UA) or a non–ST-segment elevation MI (NSTEMI) (thick red arrows), a
stinction that is ultimately made on the basis of the presence or absence of a serum cardiac marker such as CK-MB or a cardiac troponin
tected in the blood. Most patients presenting with NSTEMI ultimately develop a NQMI on the ECG; a few may develop a QwMI. The spec-
m of clinical presentations ranging from UA through NSTEMI and STEMI is referred to as the acute coronary syndromes. This UA/NSTEMI
ideline, as diagrammed in the upper panel, includes sections on initial management before UA/NSTEMI, at the onset of UA/NSTEMI, and
ring the hospital phase. Secondary prevention and plans for long-term management begin early during the hospital phase of treatment.
ositive serum cardiac marker. Modified with permission from Libby P. Current concepts of the pathogenesis of the acute coronary syn-
omes. Circulation 2001;104:365;(7) © 2001 Lippincott, Williams & Wilkins; The Lancet, 358, Hamm CW, Bertrand M, Braunwald E. Acute
ronary syndrome without ST elevation: implementation of new guidelines, 1533–8. Copyright 2001, with permission from Elsevier (8); and
avies MJ. The pathophysiology of acute coronary syndromes. Heart 2000;83:361–6 (9). © 2000 Lippincott, Williams & Wilkins. CK-MB 
B fraction of creatine kinase; Dx  diagnosis; ECG  electrocardiogram.
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tween UA (i.e., no biomarkers in circulation; usually
ansient, if any, ECG changes of ischemia) and NSTEMI
.e., elevated biomarkers). Thus, at the time of presentation,
tients with UA and NSTEMI can be indistinguishable and
erefore are considered together in these guidelines.
.3.2. Pathogenesis of UA/NSTEMI
hese conditions are characterized by an imbalance between
yocardial oxygen supply and demand. They are not a
ecific disease, such as pneumococcal pneumonia, but rather
syndrome, analogous to hypertension. A relatively few
nexclusive causes are recognized (12) (Table 3).
The most common mechanisms involve an imbalance that
caused primarily by a reduction in oxygen supply to the
yocardium, whereas with the fifth mechanism noted below,
e imbalance is principally due to increased myocardial
ygen requirements, usually in the presence of a fixed,
stricted oxygen supply:
The most common cause of UA/NSTEMI is reduced
myocardial perfusion that results from coronary artery
narrowing caused by a thrombus that developed on a
disrupted atherosclerotic plaque and is usually nonocclu-
sive. Microembolization of platelet aggregates and com-
ponents of the disrupted plaque are believed to be respon-
sible for the release of myocardial markers in many of
these patients. An occlusive thrombus/plaque also can
cause this syndrome in the presence of an extensive
collateral blood supply.
The most common underlying molecular and cellular
pathophysiology of disrupted atherosclerotic plaque is
arterial inflammation, caused by noninfectious (e.g., oxi-
dized lipids) and, possibly, infectious stimuli, which can
ble 3. Causes of UA/NSTEMI*
rombus or thromboembolism, usually arising on disrupted or eroded
plaque
Occlusive thrombus, usually with collateral vessels†
Subtotally occlusive thrombus on pre-existing plaque
Distal microvascular thromboembolism from plaque-associated thrombus
romboembolism from plaque erosion
Non-plaque-associated coronary thromboembolism
namic obstruction (coronary spasm‡ or vasoconstriction) of epicardial
and/or microvascular vessels
ogressive mechanical obstruction to coronary flow
ronary arterial inflammation
condary UA
ronary artery dissection§
*These causes are not mutually exclusive; some patients have 2 or more
uses.
†DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic
dings soon after non-Q-wave myocardial infarction. N Engl J Med 1986;315:
7–23 (13).
‡May occur on top of an atherosclerotic plaque, producing missed-etiology
gina or UA/NSTEMI.
§Rare. Modified with permission from Braunwald E. Unstable angina: an
iologic approach to management. Circulation 1998;98:2219–22 (12).
UA  unstable angina; UA/NSTEMI  unstable angina/non-ST-elevation
yocardial infarction.lead to plaque expansion and destabilization, rupture or Cerosion, and thrombogenesis. Activated macrophages and
T lymphocytes located at the shoulder of a plaque increase
the expression of enzymes such as metalloproteinases that
cause thinning and disruption of the plaque, which in turn
can lead to UA/NSTEMI.
A less common cause is dynamic obstruction, which may
be triggered by intense focal spasm of a segment of an
epicardial coronary artery (Prinzmetal’s angina) (see Sec-
tion 6.7). This local spasm is caused by hypercontractility
of vascular smooth muscle and/or by endothelial dysfunc-
tion. Large-vessel spasm can occur on top of obstructive or
destabilized plaque, resulting in angina of “mixed” origin
or UA/NSTEMI. Dynamic coronary obstruction can also
be caused by diffuse microvascular dysfunction; for exam-
ple, due to endothelial dysfunction or the abnormal con-
striction of small intramural resistance vessels. Coronary
spasm also is the presumed mechanism underlying
cocaine-induced UA/NSTEMI.
A third cause of UA/NSTEMI is severe narrowing without
spasm or thrombus. This occurs in some patients with
progressive atherosclerosis or with restenosis after a PCI.
A fourth cause of UA/NSTEMI is coronary artery dissec-
tion (e.g., as a cause of ACS in peripartal women).
The fifth mechanism is secondary UA, in which the
precipitating condition is extrinsic to the coronary arterial
bed. Patients with secondary UA usually, but not always,
have underlying coronary atherosclerotic narrowing that
limits myocardial perfusion, and they often have chronic
stable angina. Secondary UA is precipitated by conditions
that 1) increase myocardial oxygen requirements, such as
fever, tachycardia, or thyrotoxicosis; 2) reduce coronary
blood flow, such as hypotension; or 3) reduce myocardial
oxygen delivery, such as anemia or hypoxemia.
These causes of UA/NSTEMI are not mutually exclusive.
.3.3. Presentations of UA and NSTEMI
here are 3 principal presentations of UA: 1) rest angina
ngina commencing when the patient is at rest), 2) new-onset
ess than 2 months) severe angina, and 3) increasing angina
ncreasing in intensity, duration, and/or frequency) (Table 4)
4). Criteria for the diagnosis of UA are based on the
ration and intensity of angina as graded according to the
ble 4. Three Principal Presentations of UA
Class Presentation
st angina* Angina occurring at rest and prolonged, usually greater
than 20 min
w-onset angina New-onset angina of at least CCS class III severity
creasing angina Previously diagnosed angina that has becomedistinctly
more frequent, longer in duration, or lowerin
threshold (i.e., increased by 1 or more CCS classto
at least CCS class III severity)
*Patients with non-ST-elevated myocardial infarction usually present with
gina at rest. Adapted with permission from Braunwald E. Unstable angina: a
assification. Circulation 1989;80:410–4 (14).
CCS  Canadian Cardiovascular Society classification; UA  unstable
gina.anadian Cardiovascular Society classification (Table 5)
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.4. Management Before UA/NSTEMI and
nset of UA/NSTEMI
he ACS spectrum (UA/MI) has a variable but potentially
rious prognosis. The major risk factors for development of
ronary heart disease (CHD) and UA/NSTEMI are well
tablished. Clinical trials have demonstrated that modifica-
on of those risk factors can prevent the development of
HD (primary prevention) or reduce the risk of experiencing
A/NSTEMI in patients who have CHD (secondary preven-
on). All practitioners should emphasize prevention and refer
tients to primary care providers for appropriate long-term
eventive care. In addition to internists and family physi-
ans, cardiologists have an important leadership role in
imary (and secondary) prevention efforts.
.4.1. Identification of Patients at Risk
f UA/NSTEMI
ASS I
Primary care providers should evaluate the presence and
status of control of major risk factors for CHD for all patients at
regular intervals (approximately every 3 to 5 years). (Level of
Evidence: C)
Ten-year risk (National Cholesterol Education Program [NCEP]
global risk) of developing symptomatic CHD should be calcu-
lated for all patients who have 2 or more major risk factors to
assess the need for primary prevention strategies (16,17).
(Level of Evidence: B)
Patients with established CHD should be identified for second-
ary prevention efforts, and patients with a CHD risk equivalent
(e.g., atherosclerosis in other vascular beds, diabetes melli-
tus, chronic kidney disease, or 10-year risk greater than 20%
ble 5. Grading of Angina Pectoris According to CCS
assification
lass Description of Stage
“Ordinary physical activity does not cause . . . angina,” such
as walking or climbing stairs. Angina occurs with
strenuous, rapid, or prolonged exertion at work or
recreation.
“Slight limitation of ordinary activity.” Angina occurs on
walking or climbing stairs rapidly; walking uphill; walking
or stair climbing after meals; in cold, in wind, or under
emotional stress; or only during the few hours after
awakening. Angina occurs on walking more than 2 blocks
on the level and climbing more than 1 flight of ordinary
stairs at a normal pace and under normal conditions.
“Marked limitations of ordinary physical activity.” Angina
occurs on walking
1 to 2 blocks on the level and climbing 1 flight of stairs
under normal conditions and at a normal pace.
“Inability to carry on any physical activity without
discomfort—anginal symptoms may be present at rest.”
Adapted with permission from Campeau L. Grading of angina pectoris
tter). Circulation 1976;54:522-3 (15).
CCS  Canadian Cardiovascular Society.as calculated by Framingham equations) should receive tiequally intensive risk factor intervention as those with clini-
cally apparent CHD. (Level of Evidence: A)
Major risk factors for developing CHD (i.e., smoking,
mily history, adverse lipid profiles, diabetes mellitus, and
evated blood pressure) have been established from large,
ng-term epidemiological studies (18,19). These risk factors
e predictive for most populations in the United States.
rimary and secondary prevention interventions aimed at
ese risk factors are effective when used properly. They can
so be costly in terms of primary care provider time,
version of attention from other competing and important
alth care needs, and expense, and they may not be effective
less targeted at higher-risk patients (20). It is therefore
portant for primary care providers to make the identifica-
on of patients at risk, who are most likely to benefit from
imary prevention, a routine part of everyone’s health care.
he Third Report of the NCEP provides guidance on identi-
ing such patients (18). Furthermore, the Writing Committee
pports public health efforts to reach all adults at risk, not
st those under the care of a primary care physician.
Patients with 2 or more risk factors who are at increased
-year and lifetime risk will have the greatest benefit from
imary prevention, but any individual with a single elevated
sk factor is a candidate for primary prevention (19). Waiting
til the patient develops multiple risk factors and increased
-year risk contributes to the high prevalence of CHD in the
nited States (18,21). Such patients should have their risk
ecifically calculated by any of the several valid prognostic
ols available in print (18,22), on the Internet (23), or for use
a personal computer or personal digital assistant (PDA)
8). Patients’ specific risk levels determine the absolute risk
ductions they can obtain from preventive interventions and
ide selection and prioritization of those interventions. For
ample, target levels for lipid lowering and for antihyper-
nsive therapy vary by patients’ baseline risk. A specific risk
mber can also serve as a powerful educational intervention
motivate lifestyle changes (24).
The detection of subclinical atherosclerosis by noninvasive
aging represents a new, evolving approach for refining
dividual risk in asymptomatic individuals beyond tradi-
onal risk factor assessment alone. A recent AHA scientific
atement indicates that it may be reasonable to measure
herosclerosis burden using electron-beam or multidetector
mputed tomography (CT) in clinically selected
termediate-CAD-risk individuals (e.g., those with a 10% to
% Framingham 10-year risk estimate) to refine clinical risk
ediction and to select patients for aggressive target values for
id-lowering therapies (Class IIb, Level of Evidence: B) (25).
.4.2. Interventions to Reduce Risk of UA/NSTEMI
he benefits of prevention of UA/NSTEMI in patients with
HD are well documented and of large magnitude (3,21,
–28). Patients with established CHD should be identified
r secondary prevention efforts, and patients with a CHD risk
uivalent should receive equally intensive risk factor inter-
ntion for high-risk primary prevention regardless of sex
9). Patients with diabetes mellitus and peripheral vascular
sease have baseline risks of UA/NSTEMI similar to pa-
ents with known CHD, as do patients with multiple risk
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionctors that predict a calculated risk of greater than 20% over
years as estimated by the Framingham equations (18).
uch patients should be considered to have the risk equiva-
nts of CHD, and they can be expected to have an absolute
nefit similar to those with established CHD.
All patients who use tobacco should be encouraged to quit
d should be provided with help in quitting at every
portunity (30). Recommendations by a clinician to avoid
bacco can have a meaningful impact on the rate of cessation
tobacco use. The most effective strategies for encouraging
itting are those that identify the patient’s level or stage of
adiness and provide information, support, and, if necessary,
armacotherapy targeted at the individual’s readiness and
ecific needs (26,31). Pharmacotherapy may include nico-
ne replacement or withdrawal-relieving medication such as
propion. Varenicline, a nicotine acetylcholine receptor
rtial antagonist, is a newly approved nonnicotine replace-
ent therapy for tobacco avoidance (32–35). Many patients
quire several attempts before they succeed in quitting
rmanently (36,37). Additional discussion in this area can be
und in other contemporary documents (e.g., the ACC/AHA
02 Guideline Update for the Management of Patients With
hronic Stable Angina [4]).
All patients should be instructed in and encouraged to
aintain appropriate low-saturated-fat, low-trans-fat, and
w-cholesterol diets high in soluble (viscous) fiber and rich
vegetables, fruits, and whole grains. All patients also
ould be encouraged to be involved with a regular aerobic
ercise program, including 30 to 60 min of moderate-
tensity physical activity (such as brisk walking) on most
d preferably all days of the week (3,38). For those who
ed to weigh less, an appropriate balance of increased
ysical activity (i.e., 60 to 90 min daily), caloric restriction,
d formal behavioral programs is encouraged to achieve and
aintain a body mass index between 18.5 and 24.9 kg/m2 and
waist circumference of less than or equal to 35 inches in
omen and less than or equal to 40 inches in men. For those
ho need lipid lowering beyond lifestyle measures, the statin
ugs have the best outcome evidence supporting their use
d should be the mainstay of pharmacological intervention
1). The appropriate levels for lipid management are depen-
nt on baseline risk; the reader is referred to the NCEP report
ttp://www.nhlbi.nih.gov/guidelines/cholesterol/index.
m) for details (17,18,39–41).
Primary prevention patients with high blood pressure
ould be treated according to the recommendations of the
eventh Joint National Committee on High Blood Pressure
NC 7) (42,43). Specific treatment recommendations are
sed on the level of hypertension and the patient’s other risk
ctors. A diet low in salt and rich in vegetables, fruits, and
w-fat dairy products should be encouraged for all hyper-
nsive patients, as should a regular aerobic exercise program
4–47). Most patients will require more than 1 medication
achieve blood pressure control, and pharmacotherapy
ould begin with known outcome-improving medications
rimarily thiazide diuretics as first choice, with the addition
beta blockers, angiotensin-converting enzyme [ACE] in-
bitors, angiotensin receptor blockers, and/or long-acting
lcium channel blockers) (42,48). Systolic hypertension is a nowerful predictor of adverse outcome, particularly among
e elderly, and it should be treated even if diastolic pressures
e normal (49).
Detection of hyperglycemic risk (e.g., metabolic syn-
ome) and diabetes mellitus should be pursued as part of risk
sessment. Lifestyle changes and pharmacotherapy are indi-
ted in individuals with diabetes mellitus to achieve a
ycosylated hemoglobin [HbA1c] level less than 7% but to
oid hypoglycemia (3,50,51).
Aspirin prophylaxis can uncommonly result in hemor-
agic complications and should only be used in primary
evention when the level of risk justifies it. Patients whose
-year risk of CHD is 10% or more are most likely to
nefit, and 75 to 162 mg of aspirin (ASA) per day as primary
rophylaxis should be discussed with such patients
9,38,52–55).
.5. Onset of UA/NSTEMI
.5.1. Recognition of Symptoms by Patient
arly recognition of symptoms of UA/NSTEMI by the
tient or someone with the patient is the first step that must
cur before evaluation and life-saving treatment can be
tained. Although many laypersons are generally aware that
est pain is a presenting symptom of UA/NSTEMI, they are
aware of the other common symptoms, such as arm pain,
wer jaw pain, shortness of breath (56), and diaphoresis (57)
anginal equivalents, such as dyspnea or extreme fatigue
6,58). The average patient with NSTEMI or prolonged rest
A (e.g., longer than 20 min) does not seek medical care for
proximately 2 h after symptom onset, and this pattern
pears unchanged over the last decade (58–60). A baseline
alysis from the Rapid Early Action for Coronary Treatment
EACT) research program demonstrated longer delay times
ong non-Hispanic blacks, older patients, and Medicaid-
ly recipients and shorter delay times among Medicare
cipients (compared with privately insured patients) and
tients who came to the hospital by ambulance (58). In the
ajority of studies examined to date, women in both
ivariate- and multivariate-adjusted analyses (in which age
d other potentially confounding variables have been con-
olled) exhibit more prolonged delay patterns than men (61).
A number of studies have provided insight into why
tients delay in seeking early care for heart symptoms (62).
ocus groups conducted for the REACT research program
3,64) revealed that patients commonly hold a preexisting
pectation that a heart attack would present dramatically
ith severe, crushing chest pain, such that there would be no
ubt that one was occurring. This was in contrast to their
tual reported symptom experience of a gradual onset of
scomfort involving midsternal chest pressure or tightness,
ith other associated symptoms often increasing in intensity.
he ambiguity of these symptoms, due to this disconnect
tween prior expectations and actual experience, resulted in
certainty about the origin of symptoms and thus a “wait-
d-see” posture by patients and those around them (62).
ther reported reasons for delay were that patients thought
e symptoms were self-limited and would go away or were
t serious (65–67); that they attributed symptoms to other
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367eexisting chronic conditions, especially among older adults
ith multiple chronic conditions (e.g., arthritis), or some-
mes to a common illness such as influenza; that they were
raid of being embarrassed if symptoms turned out to be a
alse alarm”; that they were reluctant to trouble others (e.g.,
alth care providers, Emergency Medical Services [EMS])
less they were “really sick” (65–67); that they held
ereotypes of who is at risk for a heart attack; and that they
cked awareness of the importance of rapid action, knowl-
ge of reperfusion treatment, or knowledge of the benefits of
lling EMS/9-1-1 to ensure earlier treatment (62). Notably,
omen did not perceive themselves to be at risk (69).
.5.2. Silent and Unrecognized Events
atients experiencing UA/NSTEMI do not always present
ith chest discomfort (70). The Framingham Study was the
rst to show that as many as half of all MIs may be clinically
lent and unrecognized by the patient (71). Canto et al. (72)
und that one third of the 434,877 patients with confirmed
I in the National Registry of Myocardial Infarction pre-
nted to the hospital with symptoms other than chest
scomfort. Compared with MI patients with chest discom-
rt, MI patients without chest discomfort were more likely to
older, to be women, to have diabetes, and/or to have prior
art failure [HF]. Myocardial infarction patients without
est discomfort delayed longer before they went to the
spital (mean 7.9 vs. 5.3 h) and were less likely to be
agnosed as having an MI when admitted (22.2% vs.
.3%). They also were less likely to receive fibrinolysis or
imary PCI, ASA, beta blockers, or heparin. Silent MI
tients were 2.2 times more likely to die during the hospi-
lization (in-hospital mortality rate 23.3% vs. 9.3%). Unex-
ained dyspnea, even without angina, is a particularly
orrisome symptom, with more than twice the risk of death
an for typical angina in patients undergoing cardiovascular
aluation (56). Recently, the prognostic significance of
spnea has been emphasized in patients undergoing cardiac
aluation. Self-reported dyspnea alone among 17,991 pa-
ents undergoing stress perfusion testing was an independent
edictor of cardiac and total mortality and increased the risk
sudden cardiac death 4-fold even in those with no prior
story of CAD (56).
Health care providers should maintain a high index of
spicion for UA/NSTEMI when evaluating women, patients
ith diabetes mellitus, older patients, those with unexplained
spnea (56), and those with a history of HF or stroke, as well
those patients who complain of chest discomfort but who
ve a permanent pacemaker that may confound recognition
UA/NSTEMI on their 12-lead ECG (73).
. Initial Evaluation and Management
.1. Clinical Assessment
ecause symptoms are similar and the differentiation of
A/NSTEMI and STEMI requires medical evaluation, we
ill refer to prediagnostic clinical presentation as ACS,
fined as UA or MI (NSTEMI or STEMI) (Fig. 2).ecommendations
ASS I
Patients with symptoms that may represent ACS (Table 2)
should not be evaluated solely over the telephone but should
be referred to a facility that allows evaluation by a physician
and the recording of a 12-lead ECG and biomarker determina-
tion (e.g., an ED or other acute care facility). (Level of
Evidence: C)
Patients with symptoms of ACS (chest discomfort with or
without radiation to the arm[s], back, neck, jaw or epigas-
trium; shortness of breath; weakness; diaphoresis; nausea;
lightheadedness) should be instructed to call 9-1-1 and should
be transported to the hospital by ambulance rather than by
friends or relatives. (Level of Evidence: B)
Health care providers should actively address the following
issues regarding ACS with patients with or at risk for CHD and
their families or other responsible caregivers:
a. The patient’s heart attack risk; (Level of Evidence: C)
b. How to recognize symptoms of ACS; (Level of Evidence: C)
c. The advisability of calling 9-1-1 if symptoms are unim-
proved or worsening after 5 min, despite feelings of uncer-
tainty about the symptoms and fear of potential embarrass-
ment; (Level of Evidence: C)
d. A plan for appropriate recognition and response to a
potential acute cardiac event, including the phone number
to access EMS, generally 9-1-1 (74). (Level of Evidence: C)
Prehospital EMS providers should administer 162 to 325 mg of
ASA (chewed) to chest pain patients suspected of having ACS
unless contraindicated or already taken by the patient. Al-
though some trials have used enteric-coated ASA for initial
dosing, more rapid buccal absorption occurs with non–enteric-
coated formulations. (Level of Evidence: C)
Health care providers should instruct patients with suspected
ACS for whom nitroglycerin [NTG] has been prescribed previ-
ously to take not more than 1 dose of NTG sublingually in
response to chest discomfort/pain. If chest discomfort/pain is
unimproved or is worsening 5 min after 1 NTG dose has been
taken, it is recommended that the patient or family member/
friend/caregiver call 9-1-1 immediately to access EMS before
taking additional NTG. In patients with chronic stable angina, if
symptoms are significantly improved by 1 dose of NTG, it is
appropriate to instruct the patient or family member/friend/
caregiver to repeat NTG every 5 min for a maximum of 3 doses
and call 9-1-1 if symptoms have not resolved completely. (Level
of Evidence: C)
Patients with a suspected ACS with chest discomfort or other
ischemic symptoms at rest for greater than 20 min, hemody-
namic instability, or recent syncope or presyncope should be
referred immediately to an ED. Other patients with suspected
ACS who are experiencing less severe symptoms and who have
none of the above high-risk features, including those who
respond to an NTG dose, may be seen initially in an ED or an
outpatient facility able to provide an acute evaluation. (Level of
Evidence: C)
ASS IIa
It is reasonable for health care providers and 9-1-1 dispatchers
to advise patients without a history of ASA allergy who have
symptoms of ACS to chew ASA (162 to 325 mg) while awaiting
arrival of prehospital EMS providers. Although some trials have
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absorption occurs with non–enteric-coated formulations.
(Level of Evidence: B)
It is reasonable for health care providers and 9-1-1 dispatchers
to advise patients who tolerate NTG to repeat NTG every 5 min
for a maximum of 3 doses while awaiting ambulance arrival.
(Level of Evidence: C)
It is reasonable that all prehospital EMS providers perform and
evaluate 12-lead ECGs in the field (if available) on chest pain
patients suspected of ACS to assist in triage decisions. Elec-
trocardiographs with validated computer-generated interpreta-
tion algorithms are recommended for this purpose. (Level of
Evidence: B)
If the 12-lead ECG shows evidence of acute injury or ischemia,
it is reasonable that prehospital ACLS providers relay the ECG
to a predetermined medical control facility and/or receiving
hospital. (Level of Evidence: B)
Patients with suspected ACS must be evaluated rapidly.
ecisions made on the basis of the initial evaluation have
bstantial clinical and economic consequences (75). The first
iage decision is made by the patient, who must decide
hether to access the health care system. Media campaigns
ch as “Act in Time,” sponsored by the National Heart,
ung, and Blood Institute (NHLBI), provide patient education
garding this triage decision (www.nhlbi.nih.gov/actintime).
he campaign urges both men and women who feel heart
tack symptoms or observe the signs in others to wait no
gure 2. Algorithm for Evaluation and Management of Patients Su
d a more detailed discussion in the text, each box is assigned a
allocated from left to right across the diagram on a given level. A
ion; ACS  acute coronary syndrome; ECG  electrocardiogramore than a few minutes, 5 min at most, before calling 9-1-1 an6,77). Campaign materials point out that patients can
crease their chance of surviving a heart attack by learning
e symptoms and filling out a survival plan. They also are
vised to talk with their doctor about heart attacks and how
reduce their risk of having one. The patient materials
clude a free brochure about symptoms and recommended
tions for survival, in English (78) and Spanish (79), as well
a free wallet card that can be filled in with emergency
edical information (80). Materials geared directly to pro-
ders include a Patient Action Plan Tablet (81), which
ntains the heart attack warning symptoms and steps for
veloping a survival plan, individualized with the patient’s
me; a quick reference card for addressing common patient
estions about seeking early treatment to survive a heart
tack (82), including a PDA version (83); and a warning
gns wall chart (84). These materials and others are available
the “Act in Time” Web page (www.nhlbi.nih.gov/health/
blic/heart/mi/core_bk.pdf) (77).
When the patient first makes contact with the medical care
stem, a critical decision must be made about where the
aluation will take place. The health care provider then must
ace the evaluation in the context of 2 critical questions: Are
e symptoms a manifestation of an ACS? If so, what is the
ognosis? The answers to these 2 questions lead logically to
series of decisions about where the patient will be best
anaged, what medications will be prescribed, and whether
ed of Having ACS. To facilitate interpretation of this algorithm
code that reflects its level in the algorithm and a number that
HA  American College of Cardiology/American Heart Associ-
left ventricular.spect
letter
CC/Aangiographic evaluation will be required.
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tible with ACS, the heterogeneity of the population, and a
ustering of events shortly after the onset of symptoms, a
rategy for the initial evaluation and management is essen-
al. Health care providers may be informed about signs and
mptoms of ACS over the telephone or in person by the
tient or family members. The objectives of the initial
aluation are first to identify signs of immediate life-
reatening instability and then to ensure that the patient is
oved rapidly to the most appropriate environment for the
vel of care needed based on diagnostic criteria and an
timation of the underlying risk of specific negative outcomes.
Health practitioners frequently receive telephone calls
om patients or family members/friends/caregivers who are
ncerned that their symptoms could reflect heart disease.
ost such calls regarding chest discomfort of possible
rdiac origin in patients without known CAD do not repre-
nt an emergency; rather, these patients usually seek reas-
rance that they do not have heart disease or that there is
ttle risk due to their symptoms. Despite the frequent incli-
tion to dismiss such symptoms over the telephone, health
re providers, EMS dispatchers, and staff positioned to
ceive these calls should advise patients with possible
celerating angina or angina at rest that an evaluation cannot
performed solely via the telephone. This advice is essential
cause of the need for timely evaluation, including a
ysical examination, ECG, and appropriate blood tests to
easure cardiac biomarkers.
Patients with known CAD—including those with chronic
able angina, recent MI, or prior intervention (i.e., coronary
tery bypass graft surgery [CABG] or PCI)—who contact a
ysician or other appropriate member of the health care
am because of worsening or recurrent symptoms should be
structed to proceed rapidly to an ED, preferably one
uipped to perform prompt reperfusion therapy. When the
scomfort is moderate to severe or sustained, they should be
structed to access the EMS system directly by calling 9-1-1.
atients who have been evaluated recently and who are
lling for advice regarding modification of medications as
rt of an ongoing treatment plan represent exceptions.
Even in the most urgent subgroup of patients who present
ith acute-onset chest pain, there usually is adequate time for
ansport to an environment in which they can be evaluated
d treated (85). In a large study of consecutive patients with
est pain suspected to be of cardiac origin who were
ansported to the ED via ambulance, one third had a final
agnosis of MI, one third had a final diagnosis of UA, and
e third had a final diagnosis of a noncardiac cause; 1.5% of
ese patients developed cardiopulmonary arrest before ar-
val at the hospital or in the ED (86).
Every community should have a written protocol that
ides EMS system personnel in determining where to take
tients with suspected or confirmed ACS. Active involve-
ent of local health care providers, particularly cardiologists
d emergency physicians, is needed to formulate local EMS
stination protocols for these patients. In general, patients
ith suspected ACS should be taken to the nearest appropri-
e hospital; however, patients with known STEMI and/or cardiogenic shock should be sent as directly as possible to
spitals with interventional and surgical capability (1).
The advent of highly effective, time-dependent treatment
r ACS, coupled with the need to reduce health care costs,
ds further incentive for clinicians to get the right answer
ickly and to reduce unnecessary admissions and length of
spital stay. Investigators have tried various diagnostic
ols, such as clinical decision algorithms, cardiac biomark-
s, serial ECGs, echocardiography, myocardial perfusion
aging, and multidetector (e.g., 64-slice) coronary CT an-
ography (CCTA), in an attempt to avoid missing patients
ith MI or UA. The most successful strategies to emerge thus
r are designed to identify MI patients and, when clinically
propriate, screen for UA and underlying CAD. Most
rategies use a combination of cardiac biomarkers, short-
rm observation, diagnostic imaging, and provocative stress
sting. An increasing number of high-quality centers now
e structured protocols, checklists, or critical pathways to
reen patients with suspected MI or UA (87–99). It does not
pear to matter whether the institution designates itself a
est pain center; rather, it is the multifaceted, multidisci-
inary, standardized, and structured approach to the problem
at appears to provide clinical, cost-effective benefit
00,101). One randomized trial has confirmed the safety,
ficacy, and cost-effectiveness of the structured decision-
aking approach compared with standard, unstructured care
02).
Regardless of the approach used, all patients presenting to
e ED with chest discomfort or other symptoms suggestive
MI or UA should be considered high-priority triage cases
d should be evaluated and treated on the basis of a
edetermined, institution-specific chest pain protocol. The
otocol should include several diagnostic possibilities (Fig.
(103). The patient should be placed on a cardiac monitor
mediately, with emergency resuscitation equipment, in-
uding a defibrillator, nearby. An ECG also should be
rformed immediately and evaluated by an experienced
ergency medicine physician, with a goal of within 10 min
ED arrival. If STEMI is present, the decision as to whether
e patient will be treated with fibrinolytic therapy or primary
CI should be made within the next 10 min (1). For cases in
hich the initial diagnosis and treatment plan are unclear to
e emergency medicine physician or are not covered directly
an institutionally agreed-upon protocol, immediate cardi-
ogy consultation is advisable.
Morbidity and mortality from ACS can be reduced signif-
antly if patients and bystanders recognize symptoms early,
tivate the EMS system, and thereby shorten the time to
finitive treatment. Patients with possible symptoms of MI
ould be transported to the hospital by ambulance rather
an by friends or relatives, because there is a significant
sociation between arrival at the ED by ambulance and early
perfusion therapy in STEMI patients (104–107). In addi-
on, emergency medical technicians and paramedics can
ovide life-saving interventions (e.g., early cardiopulmonary
suscitation [CPR] and defibrillation) if the patient develops
rdiac arrest. Approximately 1 in every 300 patients with
est pain transported to the ED by private vehicle goes into
rdiac arrest en route (108).
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline RevisionSeveral studies have confirmed that patients with ACS
equently do not call 9-1-1 and are not transported to the
spital by ambulance. A follow-up survey of chest pain
tients presenting to participating EDs in 20 US communi-
es who were either released or admitted to the hospital with
confirmed coronary event revealed that the average propor-
on of patients who used EMS was 23%, with significant
ographic difference (range 10% to 48%). Most patients
ere driven by someone else (60%) or drove themselves to
e hospital (16%) (109). In the National Registry of Myo-
rdial Infarction 2, just over half (53%) of all patients with
I were transported to the hospital by ambulance (105).
Even in areas of the country that have undertaken substan-
al public education campaigns about the warning signs of
CS and the need to activate the EMS system rapidly, either
ere were no increases in EMS use (58,110–113) or EMS
e increased (as a secondary outcome measure) but was still
boptimal, with a 20% increase from a baseline of 33% in all
communities in the REACT study (63) and an increase
om 27% to 41% in southern Minnesota after a community
mpaign (114). Given the importance of patients using EMS
r possible acute cardiac symptoms, communities, including
edical providers, EMS systems, health care insurers, hos-
tals, and policy makers at the state and local level, need to
ve agreed-upon emergency protocols to ensure patients
gure 3. Patient (Advance) Instructions for NTG Use and EMS Co
patients experience chest discomfort/pain and have been previo
recommended that they be instructed (in advance) to take 1 dos
in is unimproved or worsening 5 min after taking 1 NTG subling
cess EMS. In patients with chronic stable angina, if the symptom
struct the patient or family member/friend/caregiver to repeat NT
ms have not totally resolved. If patients are not previously presc
1-1 if chest discomfort/pain is unimproved or worsening 5 min a
n, patients should notify their physician of the episode. (For thos
ribed NTG, it is appropriate to discourage them from seeking so
ough some trials have used enteric-coated aspirin for initial dosi
rmulations. EMS  emergency medical services; NTG  nitroglyith possible heart attack symptoms will be able to access ho1-1 without barriers, to secure their timely evaluation and
eatment (115).
As part of making a plan with the patient for timely recogni-
n and response to an acute event, providers should review
structions for taking NTG in response to chest discomfort/pain
ig. 3). If a patient has previously been prescribed NTG, it is
commended that the patient be advised to take 1 NTG dose
blingually promptly for chest discomfort/pain. If symptoms
e unimproved or worsening 5 min after 1 NTG dose has been
ken, it also is recommended that the patient be instructed to
ll 9-1-1 immediately to access EMS. Although the traditional
commendation is for patients to take 1 NTG dose sublingually,
min apart, for up to 3 doses before calling for emergency
aluation, this recommendation has been modified by the
A/NSTEMI Writing Committee to encourage earlier contact-
g of EMS by patients with symptoms suggestive of ACS.
hile awaiting ambulance arrival, patients tolerating NTG can
instructed by health care providers or 9-1-1 dispatchers to
ke additional NTG every 5 min up to 3 doses. Self-treatment
ith prescription medication, including nitrates, and with
nprescription medication (e.g., antacids) has been docu-
ented as a frequent cause of delay among patients with
CS, including those with a history of MI or angina (65,116).
oth the rate of use of these medications and the number of
ses taken were positively correlated with delay time to
n the Setting of Non–Trauma-Related Chest Discomfort/Pain.
escribed NTG and have it available (right side of algorithm), it
TG immediately in response to symptoms. If chest discomfort/
is recommended that the patient call 9-1-1 immediately to
significantly improved after taking 1 NTG, it is appropriate to
y 5 minutes for a maximum of 3 doses and call 9-1-1 if symp-
TG (left side of algorithm), it is recommended that they call
tarts. If the symptoms subside within 5 min of when they be-
nts with new-onset chest discomfort who have not been pre-
else’s NTG [e.g., from a neighbor, friend, or relative].) *Al-
re rapid buccal absorption occurs with non–enteric-coatedntact i
usly pr
e of N
ually, it
s are
G ever
ribed N
fter it s
e patie
meone
ng, mospital arrival (65).
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ould be included in these discussions and enlisted as
inforcement for rapid action when the patient experiences
mptoms of a possible ACS (74,117,118) (Fig. 3). For
tients known to their providers to have frequent angina,
ysicians may consider a selected, more tailored message
at takes into account the frequency and character of the
tient’s angina and their typical time course of response to
TG. In many of these patients with chronic stable angina, if
est pain is significantly improved by 1 NTG, it is still
propriate to instruct the patient or family member/friend/
regiver to repeat NTG every 5 min for a maximum of 3
ses and to call 9-1-1 if symptoms have not resolved
mpletely. Avoidance of patient delay associated with self-
edication and prolonged reevaluation of symptoms are
ramount. An additional consideration in high-risk CHD
tients is to train family members in CPR and/or to have
me access to an automatic external defibrillator, now
ailable commercially to the public.
The taking of aspirin by patients in response to acute
mptoms has been reported to be associated with a delay in
lling EMS (109). Patients should focus on calling 9-1-1,
hich activates the EMS system, where they may receive
structions from emergency medical dispatchers to chew
pirin (162 to 325 mg) while emergency personnel are en
ute, or emergency personnel can give an aspirin while
ansporting the patient to the hospital (119). Alternatively,
tients may receive an aspirin as part of their early treatment
ce they arrive at the hospital if it has not been given in the
ehospital setting (117).
Providers should target those patients at increased risk for
CS, focusing on patients with known CHD, peripheral
scular disease, or cerebral vascular disease, those with
abetes, and patients with a 10-year Framingham risk of
HD of more than 20% (120). They should stress that the
est discomfort will usually not be dramatic, such as is
mmonly misrepresented on television or in the movies as a
ollywood heart attack.” Providers also should describe
ginal equivalents and the commonly associated symptoms
ACS (e.g., shortness of breath, a cold sweat, nausea, or
ghtheadedness) in both men and women (56,106), as well as
e increased frequency of atypical symptoms in elderly
tients (72).
.1.1. Emergency Department or
utpatient Facility Presentation
is recommended that patients with a suspected ACS with
est discomfort or other ischemic symptoms at rest for more
an 20 min, hemodynamic instability, or recent syncope or
esyncope to be referred immediately to an ED or a
ecialized chest pain unit. For other patients with a sus-
cted ACS who are experiencing less severe symptoms and
e having none of the above high-risk features, the recom-
endation is to be seen initially in an ED, a chest pain unit,
an appropriate outpatient facility. Outcomes data that
rmly support these recommendations are not available;
wever, these recommendations are of practical importance
cause differing ACS presentations require differing levels
emergent medical interventions, such as fibrinolytics orergency coronary angiography leading to PCI or surgery,
sophisticated diagnostic evaluation such as nuclear stress
sting or CCTA. When symptoms have been unremitting for
ore than 20 min, the possibility of MI must be considered.
iven the strong evidence for a relationship between delay in
eatment and death (121–123), an immediate assessment that
cludes a 12-lead ECG is essential. Patients who present
ith hemodynamic instability require an environment in
hich therapeutic interventions can be provided, and for
ose with presyncope or syncope, the major concern is the
sk of sudden death. Such patients should be encouraged to
ek emergency transportation when it is available. Transport
a passenger in a private vehicle is an acceptable alternative
ly if the wait for an emergency vehicle would impose a
lay of greater than 20 to 30 min.
.1.2. Questions to Be Addressed at the Initial Evaluation
he initial evaluation should be used to provide information
out the diagnosis and prognosis. The attempt should be
ade to simultaneously answer 2 questions:
What is the likelihood that the signs and symptoms
represent ACS secondary to obstructive CAD (Table 6)?
What is the likelihood of an adverse clinical outcome
(Table 7)? Outcomes of concern include death, MI (or
recurrent MI), stroke, HF, recurrent symptomatic isch-
emia, and serious arrhythmia.
For the most part, the answers to these questions form a
quence of contingent probabilities. Thus, the likelihood that
e signs and symptoms represent ACS is contingent on the
kelihood that the patient has underlying CAD. Similarly, the
ognosis is contingent on the likelihood that the symptoms
present acute ischemia. However, in patients with symp-
ms of possible ACS, traditional risk factors for CAD are
ss important than are symptoms, ECG findings, and cardiac
omarkers. Therefore, the presence or absence of these
aditional risk factors ordinarily should not be heavily
eighed in determining whether an individual patient should
admitted or treated for ACS.
.2. Early Risk Stratification
ecommendations for Early Risk Stratification
ASS I
A rapid clinical determination of the likelihood risk of obstruc-
tive CAD (i.e., high, intermediate, or low) should be made in all
patients with chest discomfort or other symptoms suggestive
of an ACS and considered in patient management. (Level of
Evidence: C)
Patients who present with chest discomfort or other ischemic
symptoms should undergo early risk stratification for the risk
of cardiovascular events (e.g., death or [re]MI) that focuses on
history, including anginal symptoms, physical findings, ECG
findings, and biomarkers of cardiac injury, and results should
be considered in patient management. (Level of Evidence: C)
A 12-lead ECG should be performed and shown to an experi-
enced emergency physician as soon as possible after ED
arrival, with a goal of within 10 min of ED arrival for all patients
with chest discomfort (or anginal equivalent) or other symp-
toms suggestive of ACS. (Level of Evidence: B)
4.
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symptomatic and there is high clinical suspicion for ACS, serial
ECGs, initially at 15- to 30-min intervals, should be performed
to detect the potential for development of ST-segment eleva-
tion or depression. (Level of Evidence: B)
Cardiac biomarkers should be measured in all patients who
present with chest discomfort consistent with ACS. (Level of
Evidence: B)
A cardiac-specific troponin is the preferred marker, and if avail-
able, it should be measured in all patients who present with chest
discomfort consistent with ACS. (Level of Evidence: B)
Patients with negative cardiac biomarkers within 6 h of the
onset of symptoms consistent with ACS should have biomark-
ers remeasured in the time frame of 8 to 12 h after symptom
onset. (The exact timing of serum marker measurement should
take into account the uncertainties often present with the
exact timing of onset of pain and the sensitivity, precision, and
institutional norms of the assay being utilized as well as the
release kinetics of the marker being measured.) (Level of
Evidence: B)
The initial evaluation of the patient with suspected with ACS
should include the consideration of noncoronary causes for the
development of unexplained symptoms. (Level of Evidence: C)
ASS IIa
Use of risk-stratification models, such as the Thrombolysis In
Myocardial Infarction (TIMI) or Global Registry of Acute Coro-
nary Events (GRACE) risk score or the Platelet Glycoprotein
IIb/IIIa in Unstable Angina: Receptor Suppression Using Integ-
rilin Therapy (PURSUIT) risk model, can be useful to assist in
decision making with regard to treatment options in patients
with suspected ACS. (Level of Evidence: B)
It is reasonable to remeasure positive biomarkers at 6- to 8-h
intervals 2 to 3 times or until levels have peaked, as an index
of infarct size and dynamics of necrosis. (Level of Evidence: B)
It is reasonable to obtain supplemental ECG leads V7 through
V9 in patients whose initial ECG is nondiagnostic to rule out MI
ble 6. Likelihood That Signs and Symptoms Represent an ACS
Feature
High Likelihood
Any of the following:
Absence
pres
story Chest or left arm pain or discomfort as
chief symptom reproducing prior
documented angina
Known history of CAD, including MI
Chest or
chief
Age grea
Male sex
Diabetes
amination Transient MR murmur, hypotension,
diaphoresis, pulmonary edema, or rales
Extracard
G New, or presumably new, transient ST-
segment deviation (1 mm or greater) or
T-wave inversion in multiple precordial
leads
Fixed Q w
ST depre
invers
rdiac
markers
Elevated cardiac TnI, TnT, or CK-MB Normal
Modified with permission from Braunwald E, Mark DB, Jones RH, et al. Unstab
d Research and the National Heart, Lung, and Blood Institute, U.S. Public Hea
. 94-0602 (124).
ACS acute coronary syndrome; CAD coronary artery disease; CK-MB M
R  mitral regurgitation; TnI  troponin I; TnT  troponin T.due to left circumflex occlusion. (Level of Evidence: B) taContinuous 12-lead ECG monitoring is a reasonable alternative
to serial 12-lead recordings in patients whose initial ECG is
nondiagnostic. (Level of Evidence: B)
ASS IIb
For patients who present within 6 h of the onset of symptoms
consistent with ACS, assessment of an early marker of cardiac
injury (e.g., myoglobin) in conjunction with a late marker (e.g.,
troponin) may be considered. (Level of Evidence: B)
For patients who present within 6 h of symptoms suggestive of
ACS, a 2-h delta CK-MB mass in conjunction with 2-h delta
troponin may be considered. (Level of Evidence: B)
For patients who present within 6 h of symptoms suggestive of
ACS, myoglobin in conjunction with CK-MB mass or troponin
when measured at baseline and 90 min may be considered.
(Level of Evidence: B)
Measurement of B-type natriuretic peptide (BNP) or NT-pro-
BNP may be considered to supplement assessment of global
risk in patients with suspected ACS. (Level of Evidence: B)
ASS III
tal CK (without MB), aspartate aminotransferase (AST, SGOT),
anine transaminase, beta-hydroxybutyric dehydrogenase,
d/or lactate dehydrogenase should not be utilized as primary
sts for the detection of myocardial injury in patients with chest
scomfort suggestive of ACS. (Level of Evidence: C)
.2.1. Estimation of the Level of Risk
he medical history, physical examination, ECG, assessment
renal function, and cardiac biomarker measurements in
tients with symptoms suggestive of ACS at the time of the
itial presentation can be integrated into an estimation of the
sk of death and nonfatal cardiac ischemic events. The latter
clude new or recurrent MI, recurrent UA, disabling angina
at requires hospitalization, and urgent coronary revascular-
ation. Estimation of the level of risk is a multivariable
oblem that cannot be accurately quantified with a simple
dary to CAD
diate Likelihood
-likelihood features and
any of the following:
Low Likelihood
Absence of high- or intermediate-
likelihood features but may have:
pain or discomfort as
70 years
Probable ischemic symptoms in absence
of any of the intermediate likelihood
characteristics
Recent cocaine use
ular disease Chest discomfort reproduced by palpation
5 to 1 mm or T-wave
ter than 1 mm
T-wave flattening or inversion less than 1
mm in leads with dominant R waves
Normal ECG
Normal
a: diagnosis and management. Rockville, MD: Agency for Health Care Policy
ce, U.S. Department of Health and Human Service, 1994. AHCPR publication
on of creatine kinase; ECG electrocardiogram; MI myocardial infarction;Secon
Interme
of high
ence of
left arm
symptom
ter than
mellitus
iac vasc
aves
ssion 0.
ion grea
le angin
lth Servi
B fractible; therefore, Tables 6 and 7 are meant to be illustrative of
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ndings, and the categorization of patients into those at low,
termediate, or high risk of the presence of obstructive CAD
d the short-term risk of cardiovascular events, respectively.
ptimal risk stratification requires accounting for multiple
ognostic factors simultaneously by a multivariable ap-
oach (e.g., the TIMI and GRACE risk score algorithms [see
low]).
.2.2. Rationale for Risk Stratification
ecause patients with ischemic discomfort at rest as a group
e heterogeneous in terms of risk of cardiac death and
nfatal ischemic events, an assessment of the prognosis
ides the initial evaluation and treatment. An estimation of
sk is useful in 1) selection of the site of care (coronary care
it, monitored step-down unit, or outpatient setting) and 2)
lection of therapy, including platelet glycoprotein (GP)
b/IIIa inhibitors (see Section 3.2) and invasive management
rategy (see Section 3.3. For all modes of presentation of an
CS, a strong relationship exists between indicators of the
kelihood of ischemia due to CAD and prognosis (Tables 6
d 7). Patients with a high likelihood of ischemia due to
ble 7. Short-Term Risk of Death or Nonfatal MI in Patients Wi
Feature
High Risk
At least 1 of the following features must
be present:
No hig
story Accelerating tempo of ischemic symptoms
in preceding 48 h
Prior M
dise
aracter of pain Prolonged ongoing (greater than 20 min)
rest pain
Prolon
an
mo
Rest a
rel
Noctur
New-o
III
we
tha
int
CA
inical findings Pulmonary edema, most likely due to
ischemia
New or worsening MR murmur S3 or new/
worsening rales
Hypotension, bradycardia, tachycardia
Age greater than 75 years
Age gr
G Angina at rest with transient ST-segment
changes greater than 0.5 mm
Bundle-branch block, new or presumed
new
Sustained ventricular tachycardia
T-wav
Pathol
de
mu
inf
rdiac markers Elevated cardiac TnT, TnI, or CK-MB (e.g.,
TnT or TnI greater than 0.1 ng per ml)
Slightl
CK-
but
*Estimation of the short-term risks of death and nonfatal cardiac ischemic even
a table such as this; therefore, this table is meant to offer general guidance
idelines No. 10, Unstable Angina: Diagnosis and Management, May 1994 (12
CABG  coronary artery bypass graft surgery; CAD  coronary artery diseas
G  electrocardiogram; MI  myocardial infarction; MR  mitral regurgitatio
gina/non–ST-elevation myocardial infarction.AD are at a greater risk of an untoward cardiac event than the patients with a lower likelihood of CAD. Therefore, an
sessment of the likelihood of CAD is the starting point for
e determination of prognosis in patients who present with
mptoms suggestive of ACS. Other important elements for
ognostic assessment are the tempo of the patient’s clinical
urse, which relates to the short-term risk of future cardiac
ents, principally MI, and the patient’s likelihood of survival
ould an MI occur.
Patients can present with ischemic discomfort but without
T-segment deviation on the 12-lead ECG in a variety of
inical scenarios, including no known prior history of CAD,
prior history of stable CAD, soon after MI, and after
yocardial revascularization with CABG or PCI (12,125,126).
s a clinical syndrome, ischemic discomfort without ST-
gment elevation (UA and NSTEMI) shares ill-defined
rders with severe chronic stable angina, a condition asso-
ated with lower immediate risk, and STEMI, a presentation
ith a higher risk of early death and cardiac ischemic events.
he risk is highest at the time of presentation and subse-
ently declines. Yet, the risk remains high past the acute
ase. By 6 months, UA/NSTEMI mortality rates higher than
NSTEMI*
rmediate Risk
eature, but must have 1
the following:
Low Risk
No high- or intermediate-risk feature but
may have any of the following features:
heral or cerebrovascular
CABG; prior aspirin use
ater than 20 min) rest
w resolved, with
r high likelihood of CAD
reater than 20 min) or
th rest or sublingual NTG
ina
progressive CCS class
gina in the past 2
hout prolonged (greater
in) rest pain but with
te or high likelihood of
Table 6)
Increased angina frequency, severity, or
duration
Angina provoked at a lower threshold
New onset angina with onset 2 weeks to 2
months prior to presentation
an 70 years
es
waves or resting ST-
less than 1 mm in
ad groups (anterior,
teral)
Normal or unchanged ECG
d cardiac TnT, TnI, or
., TnT greater than 0.01
n 0.1 ng per ml)
Normal
(or NSTEMI) is a complex multivariable problem that cannot be fully specified
stration rather than rigid algorithms. Adapted from AHCPR Clinical Practice
Canadian Cardiovascular Society; CK-MB  creatine kinase, MB fraction;
 nitroglycerin; TnI  troponin I; TnT  troponin T; UA/NSTEMI  unstableth UA/
Inte
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisiontes of death, MI, and recurrent instability in contemporary
ndomized controlled trials and registry studies exceed 10%
d are often related to specific risk factors such as age,
abetes mellitus, renal failure, and impairment of left ven-
icular (LV) function. Whereas the early events are related to
e activity of 1 culprit coronary plaque that has ruptured and
the site of thrombus formation, events that occur later are
ore related to the underlying pathophysiological mecha-
sms that trigger plaque activity and that mark active
herosclerosis (128–134).
A few risk scores have been developed that regroup
arkers of the acute thrombotic process and other markers of
gh risk to identify high-risk patients with UA/NSTEMI.
he TIMI, GRACE, and PURSUIT risk scores are discussed
detail in Section 2.2.6.
.2.3. History
atients with suspected UA/NSTEMI may be divided into
ose with and those without a history of documented CAD.
articularly when the patient does not have a known history
CAD, the physician must determine whether the patient’s
esentation, with its constellation of specific symptoms and
gns, is most consistent with chronic ischemia, acute isch-
ia, or an alternative disease process. The 5 most important
ctors derived from the initial history that relate to the
kelihood of ischemia due to CAD, ranked in the order of
portance, are 1) the nature of the anginal symptoms, 2)
ior history of CAD, 3) sex, 4) age, and 5) the number of
aditional risk factors present (135–139). In patients with
spected ACS but without preexisting clinical CHD, older
e appears to be the most important factor. One study found
at for males, age younger than 40 years, 40 to 55 years, and
der than 55 years and for females, age younger than 50
ars, 50 to 65 years, and older than 65 years was correlated
ith low, intermediate, and high risk for CAD, respectively
38). Another study found that the risk of CAD increased in
incremental fashion for each decade above age 40 years,
ith male sex being assigned an additional risk point
39,140). In these studies, being a male older than 55 years
a female older than 65 years outweighed the importance of
l historical factors, including the nature of the chest pain
38,139).
.2.4. Anginal Symptoms and Anginal Equivalents
he characteristics of angina, which are thoroughly described
the ACC/AHA 2002 Guideline Update for the Manage-
ent of Patients With Chronic Stable Angina (4), include
ep, poorly localized chest or arm discomfort that is repro-
cibly associated with physical exertion or emotional stress
d is relieved promptly (i.e., in less than 5 min) with rest
d/or the use of sublingual NTG. Patients with UA/NSTEMI
ay have discomfort that has all of the qualities of typical
gina except that the episodes are more severe and pro-
nged, may occur at rest, or may be precipitated by less
ertion than in the past. Although it is traditional to use the
mple term “chest pain” to refer to the discomfort of ACS,
tients often do not perceive these symptoms to be true pain,
pecially when they are mild or atypical. Terms such as
schemic-type chest discomfort” or “symptoms suggestive
ACS” have been proposed to more precisely capture the acaracter of ischemic symptoms. Although “chest discom-
rt” or “chest press” is frequently used in these guidelines for
iformity and brevity, the following caveats should be kept
early in mind. Some patients may have no chest discomfort
t present solely with jaw, neck, ear, arm, shoulder, back, or
igastric discomfort or with unexplained dyspnea without
scomfort (56,141,142). If these symptoms have a clear
lationship to exertion or stress or are relieved promptly with
TG, they should be considered equivalent to angina. Occa-
onally, such “anginal equivalents” that occur at rest are the
ode of presentation of a patient with UA/NSTEMI, but
ithout the exertional history or known prior history of CAD,
may be difficult to recognize their cardiac origin. Other
fficult presentations of the patient with UA/NSTEMI in-
ude those without any chest (or equivalent) discomfort.
olated unexplained new-onset or worsened exertional dys-
ea is the most common anginal equivalent symptom,
pecially in older patients; less common isolated presenta-
ons, primarily in older adults, include nausea and vomiting,
aphoresis, and unexplained fatigue. Indeed, older adults and
omen with ACS not infrequently present with atypical
gina or nonanginal symptoms. Rarely do patients with ACS
esent with syncope as the primary symptom or with other
nanginal symptoms.
Features that are not characteristic of myocardial ischemia
clude the following:
Pleuritic pain (i.e., sharp or knifelike pain brought on by
respiratory movements or cough)
Primary or sole location of discomfort in the middle or
lower abdominal region
Pain that may be localized at the tip of 1 finger, particularly
over the left ventricular apex or a costochondral junction
Pain reproduced with movement or palpation of the chest
wall or arms
Very brief episodes of pain that last a few seconds or less
Pain that radiates into the lower extremities
Documentation of the evaluation of a patient with sus-
cted UA/NSTEMI should include the physician’s opinion
whether the discomfort is in 1 of 3 categories: high,
termediate, or low likelihood of acute ischemia caused by
AD (Table 6).
Although typical characteristics substantially increase the
obability of CAD, features not characteristic of typical
gina, such as sharp stabbing pain or reproduction of pain on
lpation, do not entirely exclude the possibility of ACS. In
e Multicenter Chest Pain Study, acute ischemia was diag-
sed in 22% of patients who presented to the ED with sharp
stabbing pain and in 13% of patients with pain with
euritic qualities. Furthermore, 7% of patients whose pain
as fully reproduced with palpation were ultimately recog-
zed to have ACS (143). The Acute Cardiac Ischemia
ime-Insensitive Predictive Instrument (ACI-TIPI) project
44,145) found that older age, male sex, the presence of
est or left arm pain, and the identification of chest pain or
essure as the most important presenting symptom all
creased the likelihood that the patient was experiencing
ute ischemia.
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TG in the ED setting is not always predictive of ACS. One
udy reported that sublingual NTG relieved symptoms in
% of patients with active CAD (defined as elevated cardiac
omarkers, coronary vessel with at least 70% stenosis on
ronary angiography, or positive stress test) compared with
% of patients without active CAD (146). Furthermore, the
lief of chest pain by the administration of a “GI cocktail”
.g., a mixture of liquid antacid, viscous lidocaine, and
ticholinergic agent) does not predict the absence of ACS
47).
.2.5. Demographics and History in Diagnosis and
isk Stratification
most studies of ACS, a prior history of MI has been
sociated not only with a high risk of obstructive CAD (148)
t also with an increased risk of multivessel CAD. There are
fferences in the presentations of men and women with ACS
ee Section 6.1). A smaller percentage of women than men
esent with STEMI, and of the patients who present without
T-segment elevation, fewer women than men have MIs
49). Women with suspected ACS are less likely to have
structive CAD than are men with a similar clinical presen-
tion, and when CAD is present in women, it tends to be less
vere. On the other hand, when STEMI is present, the
tcome in women tends to be worse even when adjustment
made for the older age and greater comorbidity of women.
owever, the outcome for women with UA is significantly
tter than the outcome for men, and the outcomes are similar
r men and women with NSTEMI (150,151).
Older adults (see Section 6.4) have increased risks of both
derlying CAD (152,153) and multivessel CAD; furthermore,
ey are at higher risk for an adverse outcome than are younger
tients. The slope of the increased risk is steepest beyond age
years. This increased risk is related in part to the greater
tent and severity of underlying CAD and the more severe LV
sfunction in older patients; however, age itself exerts a strong,
dependent prognostic risk as well, perhaps at least in part
cause of comorbidities. Older adults also are more likely to
ve atypical symptoms on presentation.
In patients with symptoms of possible ACS, some of the
aditional risk factors for CAD (e.g., hypertension, hyper-
olesterolemia, and cigarette smoking) are only weakly
edictive of the likelihood of acute ischemia (145,154) and
e far less important than are symptoms, ECG findings, and
rdiac biomarkers. Therefore, the presence or absence of
ese traditional risk factors ordinarily should not be used to
termine whether an individual patient should be admitted
treated for ACS. However, the presence of these risk
ctors does appear to relate to poor outcomes in patients with
tablished ACS. Although not as well investigated as the
aditional risk factors, a family history of premature CAD
s been demonstrated to be associated with increased coro-
ry artery calcium scores greater than the 75th age percentile
asymptomatic individuals (155) and increased risk of 30-d
rdiac events in patients admitted for UA/NSTEMI (156).
f special interest is that sibling history of premature CAD
s a stronger relationship than parental history (157). How-
er, several of these risk factors have important prognostic md therapeutic implications. Diabetes and the presence of
tracardiac (carotid, aortic, or peripheral) vascular disease
e major risk factors for poor outcome in patients with ACS
ee Section 6.2). For both STEMI (158) and UA/NSTEMI
28), patients with these conditions have a significantly
gher mortality rate and risk of acute HF. For the most part,
is increase in risk is due to a greater extent of underlying
AD and LV dysfunction, but in many studies, diabetes
rries prognostic significance over and above these findings.
imilarly, a history of hypertension is associated with an
creased risk of a poor outcome.
The current or prior use of ASA at the time and presenta-
on of ACS has been associated in 1 database with increased
rdiovascular event risk (159). Although the rationale is not
lly elucidated, it appears those taking prior ASA therapy
ve more multivessel CAD, are more likely to present with
rombus present, may present later in the evolution of ACS,
may be ASA resistant. Surprisingly, current smoking is
sociated with a lower risk of death in the setting of ACS
59–161), primarily because of the younger age of smokers
ith ACS and less severe underlying CAD. This “smokers’
radox” seems to represent a tendency for smokers to
velop thrombi on less severe plaques and at an earlier age
an nonsmokers.
Being overweight and/or obese at the time of ACS presen-
tion is associated with lower short-term risk of death;
wever, this “obesity paradox” is primarily a function of
unger age at time of presentation, referral for angiography
an earlier stage of disease, and more aggressive ACS
anagement (160). Although short-term risk may be lower
r overweight/obese individuals, these patients have a higher
ng-term total mortality risk (161–165). Increased long-term
rdiovascular risk appears to be primarily limited to severe
esity (166).
Cocaine use has been implicated as a cause of ACS,
esumably owing to the ability of this drug to cause coronary
sospasm and thrombosis in addition to its direct effects on
art rate and arterial pressure and its myocardial toxic
operties (see Section 6.6) (167). Recently, the use of
ethamphetamine has grown, and its association with ACS
so should be considered. It is important to inquire about the
e of cocaine and methamphetamine in patients with sus-
cted ACS, especially in younger patients (age less than 40
ars) and others with few risk factors for CAD. Urine
xicology should be considered when substance abuse is
spected as a cause of or contributor to ACS.
.2.6. Estimation of Early Risk at Presentation
number of risk assessment tools have been developed to
sist in assessing risk of death and ischemic events in
tients with UA/NSTEMI, thereby providing a basis for
erapeutic decision making (Table 8; Fig. 4) (158,168,169).
should be recognized that the predictive ability of these
mmonly used risk assessment scores for nonfatal CHD risk
only moderate.
Antman et al. developed the TIMI risk score (159), a
mple tool composed of 7 (1-point) risk indicators rated on
esentation (Table 8). The composite end points (all-cause
ortality, new or recurrent MI, or severe recurrent ischemia
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e TIMI risk score increases. The TIMI risk score has been
lidated internally within the TIMI 11B trial and 2 separate
horts of patients from the Efficacy and Safety of Subcuta-
ous Enoxaparin in Unstable Angina and Non-Q-Wave
yocardial Infarction (ESSENCE) trial (169). The model
mained a significant predictor of events and appeared
latively insensitive to missing information, such as knowl-
ge of previously documented coronary stenosis of 50% or
ore. The model’s predictive ability remained intact with a
toff of 65 years of age. The TIMI risk score was recently
udied in an unselected ED population with chest pain
ndrome; its performance was similar to that in the ACS
pulation in which it was derived and validated (170). The
IMI risk calculator is available at www.timi.org. The TIMI
sk index, a modification of the TIMI risk score that uses the
riables age, systolic blood pressure, and heart rate, has not
ly been shown to predict short-term mortality in STEMI
t has also been useful in the prediction of 30-d and 1-year
ortality across the spectrum of patients with ACS, including
A/NSTEMI (171).
The PURSUIT risk model, developed by Boersma et al.
72), based on patients enrolled in the PURSUIT trial, is
other useful tool to guide the clinical decision-making
ocess when the patient is admitted to the hospital. In the
URSUIT risk model, critical clinical features associated
ith an increased 30-d incidence of death and the composite
death or myocardial (re)infarction were (in order of
rength) age, heart rate, systolic blood pressure, ST-segment
pression, signs of HF, and cardiac biomarkers (172).
The GRACE risk model, which predicts in-hospital mor-
lity (and death or MI), can be useful to clinicians to guide
eatment type and intensity (168,173). The GRACE risk tool
as developed on the basis of 11,389 patients in GRACE,
ble 8. TIMI Risk Score for Unstable Angina/Non–ST-
evation MI
IMI Risk
Score
All-Cause Mortality, New or Recurrent MI, or Severe
Recurrent Ischemia Requiring Urgent Revascularization
Through 14 d After Randomization, %
1 4.7
8.3
13.2
19.9
26.2
7 40.9
The TIMI risk score is determined by the sum of the presence of 7 variables
admission; 1 point is given for each of the following variables: age 65 y or
der; at least 3 risk factors for CAD; prior coronary stenosis of 50% or more;
-segment deviation on ECG presentation; at least 2 anginal events in prior
h; use of aspirin in prior 7 d; elevated serum cardiac biomarkers. Prior
ronary stenosis of 50% or more remained relatively insensitive to missing
formation and remained a significant predictor of events. Reprinted with
rmission from Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score
r unstable angina/non-ST elevation MI: a method for prognostication and
erapeutic decision making. JAMA 2000;284:835–42 (159). Copyright ©
00 American Medical Association.
CAD coronary artery disease; ECG electrocardiogram; MI myocardial
farction; y  year.lidated in subsequent GRACE and GUSTO IIb cohorts, and suedicts in-hospital death in patients with STEMI, NSTEMI,
UA (C statistic  0.83). The 8 variables used in the
RACE risk model are older age (odds ratio [OR] 1.7 per 10
ars), Killip class (OR 2.0 per class), systolic blood pressure
R 1.4 per 20 mm Hg decrease), ST-segment deviation (OR
4), cardiac arrest during presentation (OR 4.3), serum
eatinine level (OR 1.2 per 1-mg per dL increase), positive
itial cardiac biomarkers (OR 1.6), and heart rate (OR 1.3
r 30-beat per min increase). The sum of scores is applied to
reference monogram to determine the corresponding all-
use mortality from hospital discharge to 6 mo. The GRACE
inical application tool can be downloaded to a handheld
DA to be used at the bedside and is available at www.out-
mes-umassmed.org/grace (Fig. 4) (173). An analysis com-
ring the 3 risk scores (TIMI, GRACE, and PURSUIT)
ncluded that all 3 demonstrated good predictive accuracy
r death and MI at 1 year, thus identifying patients who
ight be likely to benefit from aggressive therapy, including
rly myocardial revascularization (174).
The ECG provides unique and important diagnostic and
ognostic information (see also Section 2.2.6.1 below).
ccordingly, ECG changes have been incorporated into
antitative decision aids for the triage of patients presenting
ith chest discomfort (175). Although ST elevation carries
e highest early risk of death, ST depression on the present-
g ECG portends the highest risk of death at 6 months, with
e degree of ST depression showing a strong relationship to
tcome (176).
Dynamic risk modeling is a new frontier in modeling that
counts for the common observation that levels and predic-
rs of risk constantly evolve as patients pass through their
sease process. Excellent models have been developed based
presenting features, but information the next day about
inical (e.g., complications), laboratory (e.g., biomarker
olution), and ECG (e.g., ST resolution for STEMI) changes
ovides additional data relevant to decisions at key
ecision-node” points in care (177). Dynamic modeling
ncepts promise more sophisticated, adaptive, and individ-
lly predictive modeling of risk in the future.
Renal impairment has been recognized as an additional
gh-risk feature in patients with ACS (178). Mild to mod-
ate renal dysfunction is associated with moderately in-
eased short- and long-term risks, and severe renal dysfunc-
on is associated with severely increased short- and long-
rm mortality risks. Patients with renal dysfunction
perience increased bleeding risks, have higher rates of HF
d arrhythmias, have been underrepresented in cardiovascu-
r trials, and may not enjoy the same magnitude of benefit
ith some therapies observed in patients with normal renal
nction (179) (see also Section 6.5).
Among patients with UA/NSTEMI, there is a progres-
vely greater benefit from newer, more aggressive therapies
ch as low-molecular-weight heparin (LMWH) (169,180),
atelet GP IIb/IIIa inhibition (181), and an invasive strategy
82) with increasing risk score.
.2.6.1. ELECTROCARDIOGRAM
he ECG is critical not only to add support to the clinical
spicion of CAD but also to provide prognostic information
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27,175,183,184). A recording made during an episode of
e presenting symptoms is particularly valuable. Impor-
ntly, transient ST-segment changes (greater than or equal to
05 mV [i.e., 0.5 mm]) that develop during a symptomatic
isode at rest and that resolve when the patient becomes
ymptomatic strongly suggest acute ischemia and a very
gh likelihood of underlying severe CAD. Patients whose
gure 4. Risk Calculator for 6-Month Postdischarge Mortality Afte
ecord the points for each variable at the bottom left and sum the
axis of the nomogram plot. The corresponding probability on the
l discharge to 6 months.GRACE Prediction Score Card and Nom
inted with permission from Eagle KA, Lim MJ, Dabbous OH, et a
ome: estimating the risk of 6-month postdischarge death in an in
04 American Medical Association.rrent ECG suggests ischemia can be assessed with greater inagnostic accuracy if a prior ECG is available for compari-
n (Table 6) (185).
Although it is imperfect, the 12-lead ECG lies at the center
the decision pathway for the evaluation and management
patients with acute ischemic discomfort (Fig. 1; Table 6).
he diagnosis of MI is confirmed with serial cardiac biomark-
s in more than 90% of patients who present with ST-
gment elevation of greater than or equal to 1 mm (0.1 mV)
italization for Acute Coronary Syndrome
to calculate the total risk score. Find the total score on the
is the estimated probability of all-cause mortality from hospi-
for All-Cause Mortality From Discharge to 6 Months. Re-
lidated prediction model for all forms of acute coronary syn-
ional registry. JAMA 2004;291:2727–33 (168). Copyright ©r Hosp
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionnsidered candidates for acute reperfusion therapy. Patients
ho present with ST-segment depression are initially consid-
ed to have either UA or NSTEMI; the distinction between
e 2 diagnoses is ultimately based on the detection of
arkers of myocardial necrosis in the blood (11,126,186).
Up to 25% of patients with NSTEMI and elevated CK-MB
on to develop Q-wave MI during their hospital stay,
hereas the remaining 75% have non–Q-wave MI. Acute
brinolytic therapy is contraindicated for ACS patients with-
t ST-segment elevation, except for those with electrocar-
ographic true posterior MI manifested as ST-segment de-
ession in 2 contiguous anterior precordial leads and/or
olated ST-segment elevation in posterior chest leads (187–
9). Inverted T waves may also indicate UA/NSTEMI. In
tients suspected of having ACS on clinical grounds,
arked (greater than or equal to 2 mm [0.2 mV]) symmetrical
ecordial T-wave inversion strongly suggests acute isch-
ia, particularly that due to a critical stenosis of the left
terior descending coronary artery (LAD) (190). Patients
ith this ECG finding often exhibit hypokinesis of the
terior wall and are at high risk if given medical treatment
one (191). Revascularization will often reverse both the
-wave inversion and wall-motion disorder (192). Nonspe-
fic ST-segment and T-wave changes, usually defined as
T-segment deviation of less than 0.5 mm (0.05 mV) or
-wave inversion of less than or equal to 2 mm (0.2 mV), are
ss diagnostically helpful than the foregoing findings. Estab-
shed Q waves greater than or equal to 0.04 s are also less
lpful in the diagnosis of UA, although by suggesting prior
I, they do indicate a high likelihood of significant CAD.
olated Q waves in lead III may be a normal finding,
pecially in the absence of repolarization abnormalities in
y of the inferior leads. A completely normal ECG in a
tient with chest pain does not exclude the possibility of
CS, because 1% to 6% of such patients eventually are
oved to have had an MI (by definition, an NSTEMI), and at
ast 4% will be found to have UA (184,193,194).
The common alternative causes of ST-segment and
-wave changes must be considered. In patients with ST-
gment elevation, the diagnoses of LV aneurysm, pericardi-
s, myocarditis, Prinzmetal’s angina, early repolarization
.g., in young black males), apical LV ballooning syndrome
akotsubo cardiomyopathy; see Section 6.9), and Wolff-
arkinson-White syndrome represent several examples to be
nsidered. Central nervous system events and drug therapy
ith tricyclic antidepressants or phenothiazines can cause
ep T-wave inversion.
Acute MI due to occlusion of the left circumflex coronary
tery can present with a nondiagnostic 12-lead ECG. Ap-
oximately 4% of acute MI patients show the presence ST
evation isolated to the posterior chest leads V7 through V9
d “hidden” from the standard 12 leads (187,195,196). The
esence of posterior ST elevation is diagnostically important
cause it qualifies the patient for acute reperfusion therapy
an acute STEMI (1,197). The presence or absence of
T-segment elevation in the right ventricular (V4R through
6R) or posterior chest leads (V7 through V9) also adds
ognostic information in the presence of inferior ST- Sgment elevation, predicting high and low rates of in-
spital life-threatening complications, respectively (196).
With reference to electrocardiographic true posterior MI,
w terminology recently has been proposed based on the
andard of cardiac magnetic resonance (CMR) imaging
calization. CMR studies indicate that abnormally increased
waves, the Q-wave equivalent in leads V1 and V2, indicate
MI localized to the lateral LV wall and that abnormal Q
aves in I and VL (but not V6) indicate a mid-anterior wall
I. Thus, the electrocardiographic terms “posterior” and
igh lateral MI” refer to anatomic “lateral wall MI” and
id-anterior wall MI” (198). The impact of these findings
d recommendations for standard electrocardiographic ter-
inology are unresolved as of this writing.
Several investigators have shown that a gradient of risk of
ath and cardiac ischemic events can be established based
the nature of the ECG abnormality (183,199,200). Patients
ith ACS and confounding ECG patterns such as bundle-
anch block, paced rhythm, or LV hypertrophy are at the
ghest risk for death, followed by patients with ST-segment
viation (ST-segment elevation or depression); at the lowest
sk are patients with isolated T-wave inversion or normal
CG patterns. Importantly, the prognostic information con-
ined within the ECG pattern remains an independent pre-
ctor of death even after adjustment for clinical findings and
rdiac biomarker measurements (199–202).
In addition to the presence or absence of ST-segment
viation or T-wave inversion patterns as noted earlier, there
evidence that the magnitude of the ECG abnormality
ovides important prognostic information. Thus, Lloyd-
nes et al. (203) reported that the diagnosis of acute
n–Q-wave MI was 3 to 4 times more likely in patients with
chemic discomfort who had at least 3 ECG leads that
owed ST-segment depression and maximal ST depression
greater than or equal to 0.2 mV. Investigators from the
IMI III Registry (199) reported that the 1-year incidence of
ath or new MI in patients with at least 0.5 mm (0.05 mV)
ST-segment deviation was 16.3% compared with 6.8% for
tients with isolated T-wave changes and 8.2% for patients
ith no ECG changes.
Physicians frequently seek out a previous ECG for com-
rison in patients with suspected ACS. Studies have dem-
strated that patients with an unchanged ECG have a
duced risk of MI and a very low risk of in-hospital
fe-threatening complications even in the presence of con-
unding ECG patterns such as LV hypertrophy (204–206).
Because a single 12-lead ECG recording provides only a
apshot view of a dynamic process (207), the usefulness of
taining serial ECG tracings or performing continuous
T-segment monitoring has been studied (175,208). Al-
ough serial ECGs increase the ability to diagnose UA and
I (208–212), the yield is higher with serial cardiac bio-
arker measurements (212–214). However, identification of
w injury on serial 12-lead ECG (and not elevated cardiac
omarkers) is the principal eligibility criterion for emer-
ncy reperfusion therapy, so that monitoring of both is
commended. Continuous 12-lead ECG monitoring to detect
T-segment shifts, both symptomatic and asymptomatic, also
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able devices. An injury current was detected in an addi-
onal 16% of chest pain patients in 1 study (213). The
entification of ischemic ECG changes on serial or contin-
us ECG recordings frequently alters therapy and provides
dependent prognostic information (212,215,216).
.2.6.2. PHYSICAL EXAMINATION
he major objectives of the physical examination are to
entify potential precipitating causes of myocardial isch-
ia, such as uncontrolled hypertension, thyrotoxicosis, or
strointestinal bleeding, and comorbid conditions that could
pact therapeutic risk and decision making, such as pulmo-
ry disease and malignancies, as well as to assess the
modynamic impact of the ischemic event. Every patient
ith suspected ACS should have his or her vital signs
easured (blood pressure in both arms if dissection is
spected, as well as heart rate and temperature) and should
dergo a thorough cardiovascular and chest examination.
atients with evidence of LV dysfunction on examination
ales, S3 gallop) or with acute mitral regurgitation have a
gher likelihood of severe underlying CAD and are at a high
sk of a poor outcome. Just as the history of extracardiac
scular disease is important, the physical examination of the
ripheral vessels can also provide important prognostic
formation. The presence of bruits or pulse deficits that
ggest extracardiac vascular disease identifies patients with
higher likelihood of significant CAD.
Elements of the physical examination can be critical in
aking an important alternative diagnosis in patients with
est pain. In particular, several disorders carry a significant
reat to life and function if not diagnosed acutely. Aortic
ssection is suggested by pain in the back, unequal pulses, or
murmur of aortic regurgitation. Acute pericarditis is sug-
sted by a pericardial friction rub, and cardiac tamponade
n be evidenced by pulsus paradoxus. Pneumothorax is
spected when acute dyspnea, pleuritic chest pain, and
fferential breath sounds are present.
The importance of cardiogenic shock in patients with
STEMI should be emphasized. Although most literature on
rdiogenic shock has focused on STEMI, the SHould we
ergently revascularize Occluded Coronaries for cardio-
nic shocK (SHOCK) study (217) found that approximately
% of all cardiogenic shock complicating MI was associated
ith NSTEMI. The Global Use of Strategies to Open Oc-
uded Coronary Arteries (GUSTO)-II (218) and PURSUIT
28) trials found that cardiogenic shock occurs in up to 5%
patients with NSTEMI and that mortality rates are greater
an 60%. Thus, hypotension and evidence of organ hypo-
rfusion can occur and constitute a medical emergency in
STEMI.
.2.7. Noncardiac Causes of Symptoms and
econdary Causes of Myocardial Ischemia
formation from the initial history, physical examination,
d ECG (Table 6) can enable the physician to classify and
clude from further assessment patients “not having isch-
ic discomfort.” This includes patients with noncardiac pain.g., pulmonary embolism, musculoskeletal pain, or esoph- abeal discomfort) or cardiac pain not caused by myocardial
chemia (e.g., acute pericarditis). The remaining patients
ould undergo a more complete evaluation of the secondary
uses of UA that might alter management. This evaluation
ould include a physical examination for evidence of other
rdiac disease, an ECG to screen for arrhythmias, measure-
ent of body temperature and blood pressure, and determi-
tion of hemoglobin or hematocrit. Cardiac disorders other
an CAD that can cause myocardial ischemia include aortic
enosis and hypertrophic cardiomyopathy. Factors that in-
ease myocardial oxygen demand or decrease oxygen deliv-
y to the heart can provoke or exacerbate ischemia in the
esence of significant underlying CAD or secondary angina;
eviously unrecognized gastrointestinal bleeding that causes
emia is a common secondary cause of worsening angina or
e development of symptoms of ACS. Acute worsening of
ronic obstructive pulmonary disease (with or without su-
rimposed infection) can lower oxygen saturation levels
fficiently to intensify ischemic symptoms in patients with
AD. Evidence of increased cardiac oxygen demand can be
spected in the presence of fever, signs of hyperthyroidism,
stained tachyarrhythmias, or markedly elevated blood pres-
re. Another cause of increased myocardial oxygen demand
arteriovenous fistula in patients receiving dialysis.
The majority of patients seen in the ED with symptoms of
ssible ACS will be judged after their workup not to have a
rdiac problem. One clinical trial of a predictive instrument
aluated 10,689 patients with suspected ACS (75). To
rticipate, patients were required to be greater than 30 years
age with a chief symptom of chest, left arm, jaw, or
igastric pain or discomfort; shortness of breath; dizziness;
lpitations; or other symptoms suggestive of acute ischemia.
fter evaluation, 7,996 patients (75%) were deemed not to
ve acute ischemia.
.2.8. Cardiac Biomarkers of Necrosis and the
edefinition of AMI
ardiac biomarkers have proliferated over recent years to
dress various facets of the complex pathophysiology of
CS. Some, like the cardiac troponins, have become essential
r risk stratification of patients with UA/NSTEMI and for
e diagnosis of MI. Others, such as the inflammatory
arkers, are opening new perspectives on pathophysiology
d risk stratification, and the use in clinical practice of
lected new markers may be recommended for clinical use
the near future. Still other promising markers are being
veloped as part of translational research and await prospec-
ve validation in various populations. New developments are
pected in the fields of proteomic and genomics, cell
arkers and circulating microparticles, and microtechnology
d nanotechnology imaging.
Current markers of necrosis leak from cardiomyocytes
ter the loss of membrane integrity and diffuse into the
rdiac interstitium, then into the lymphatics and cardiac
icrovasculature. Eventually, these macromolecules, collec-
vely referred to as cardiac biomarkers, are detectable in the
ripheral circulation. Features that favor their diagnostic
rformance are high concentrations in the myocardium and
sence in nonmyocardial tissue, release into the blood within
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionconvenient diagnostic time window and in proportion to the
tent of myocardial injury, and quantification with repro-
cible, inexpensive, and rapid and easily applied assays
1). The cardiac troponins possess many of these features
d have gained wide acceptance as the biomarkers of choice
the evaluation of patients with ACS for diagnosis, risk
ratification, and treatment selection.
The traditional definitions of MI were revisited in 2000 in
consensus document of a joint committee of the European
ociety of Cardiology (ESC) and ACC (219) and at the time
publication is being updated by an expanded joint task
rce of the ESC, ACC, AHA, World Heart Federation
HF), and World Health Organization. The new definitions
e inspired by the emergence of new highly sensitive and
ecific diagnostic methods that allow the detection of areas
cell necrosis as small as 1 g. Myocardial necrosis in the
sk force document is defined by an elevation of troponin
ove the 99th percentile of normal. Myocardial infarction,
hich is necrosis related to ischemia, is further defined by the
dition to the troponin elevation of at least 1 of the following
iteria: ischemic ST and T-wave changes, new left bundle-
anch block, new Q waves, PCI-related marker elevation, or
sitive imaging for a new loss of viable myocardium.
yocardial infarction can still be diagnosed in the absence of
easurement of troponin when there is evidence of a new loss
viable myocardium, ST-segment elevation, or new left
ndle-branch block with sudden cardiac death within 1 h of
mptoms, or a postmortem pathological diagnosis. Coronary
tery bypass graft-related MI is diagnosed by an increase of
rdiac biomarkers to more than 5 to 10-fold the 99th
rcentile of normal, new Q waves or new left bundle-branch
ock on the ECG, or a positive imaging test. The task force
rther recommended further defining MI by the circum-
ances that cause it (spontaneous or in the setting of a
agnostic or therapeutic procedure), by the amount of cell
ss (infarct size), and by the timing of MI (evolving, healing,
healed) (219,220). Providing fold-elevations above normal
r diagnostic biomarkers, to allow for meaningful compari-
ns among clinical trials, is also endorsed.
At the present time, the implications of using the new
SC/ACC redefinition of MI have not been fully explored;
uch of the present database for UA/NSTEMI derives from
K/CK-MB–based definitions of MI. Moreover, troponin
says have rapidly evolved through several generations over
e past decade, becoming increasingly more sensitive and
ecific. Thus, it is important to recognize that the recom-
endations in this section are formulated from studies that
equently utilize modified World Health Organization crite-
a or definitions of MI based on earlier-generation troponin
says.
.2.8.1. CREATINE KINASE-MB
reatine kinase-MB, a cytosolic carrier protein for high-
ergy phosphates, has long been the standard marker for the
agnosis of MI. Creatine kinase-MB, however, is less
nsitive and less specific for MI than the cardiac troponins.
ow levels of CK-MB can be found in the blood of healthy
rsons, and elevated levels occur with damage to skeletal
uscle (221). noWhen a cardiac troponin is available, the determination of
K-MB remains useful in a few specific clinical situations.
ne is the diagnosis of early infarct extension (reinfarction),
cause the short half-life of CK-MB compared with troponin
rmits the detection of a diagnostic new increase after initial
ak. Although routine determination of CK-MB has been
ggested for the diagnosis of an eventual infarct extension, a
ngle CK-MB determination obtained when symptoms recur
ay serve as the baseline value for comparison with samples
tained 6 to 12 h later. Another situation is the diagnosis of
periprocedural MI, because the diagnostic and prognostic
lue of CK-MB in these situations has been extensively
lidated. When assessed, CK-MB should be measured by
ass immunoassays and not by other methods previously
ed (222). The use of other, older biochemistry assays of
nspecific markers such as alanine transaminase, aspartate
ansaminase, and lactate dehydrogenase should generally be
oided in contemporary practice.
.2.8.2. CARDIAC TROPONINS
he troponin complex consists of 3 subunits: T (TnT), I
nI), and C (TnC) (223). The latter is expressed by both
rdiac and skeletal muscle, whereas TnT and TnI are derived
om heart-specific genes. Therefore, the term “cardiac tro-
nins” (cTn) in these guidelines refers specifically to either
nT or cTnI. Cardiac troponin as a biomarker provides
bust results that are highly sensitive and specific in detect-
g cell necrosis; an early release is attributable to a cytosolic
ol and a late release to the structural pool (219,224).
Because cTnT and cTnI generally are not detected in the
ood of healthy persons, the cutoff value for elevated cTnT
d cTnI levels may be set to slightly above the upper limit
the performance characteristics of the assay for a normal
althy population. High-quality analytic methods are needed
achieve these high standards (225). One issue with the use
cTnI is the multiplicity of existing assays that have
fferent analytical sensitivities, some being unable to detect
e lower values with a reasonable precision (226). Physi-
ans therefore need to know the sensitivity of the tests used
r TnI in their hospitals at the cutoff concentrations used for
inical decisions. Such heterogeneity does not exist for
nT, which exists as a single test; this test is now a
ird-generation immunoassay that uses recombinant mono-
onal human antibodies (224). Rare patients may have
ocking antibodies to part of the troponin molecule, which
ould result in false-negative results (227).
.2.8.2.1. Clinical Use. Although troponins can be de-
cted in blood as early as 2 to 4 h after the onset of
mptoms, elevation can be delayed for up to 8 to 12 h. This
ming of elevation is similar to that of CK-MB but persists
nger, for up to 5 to 14 d (Fig. 5). An increasing pattern in
rial levels best helps determine whether the event is acute,
stinct from a previous event, subacute, or chronic.
The proportion of patients showing a positive cTn value
pends on the population of patients under evaluation.
pproximately 30% of patients with typical rest chest dis-
mfort without ST-segment elevation who would be diag-
sed as having UA because of a lack of CK-MB elevation
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367tually have NSTEMI when assessed with cardiac-specific
oponin assays. The diagnosis of MI in the community at
rge when cTn is used results in a large increase in the
cidence of MIs, by as much as 41% compared with use of
ly CK-MB alone, and a change in the case mix, with a
rvival rate that is better than that of MI identified by the
evious criteria (228). Troponin elevation conveys prognos-
c information beyond that supplied by the clinical charac-
ristics of the patient, the ECG at presentation, and the
edischarge exercise test (200,201,229–231). Furthermore, a
antitative relationship exists between the amount of eleva-
on of cTn and the risk of death (200,201) (Fig. 6). The
cremental risk of death or MI in troponin-positive versus
oponin-negative patients is summarized in Table 9. It should
cautioned, however, that cTn should not be used as the sole
arker of risk, because patients without troponin elevations
n still have a substantial risk of an adverse outcome.
Although cTn accurately identifies myocardial necrosis, it
es not inform as to the cause or causes of necrosis; these
n be multiple (224) and include noncoronary causes such as
chyarrhythmia, cardiac trauma by interventions, chest
auma from motor vehicle accidents, HF, LV hypertrophy,
gure 5. Timing of Release of Various Biomarkers After Acute
yocardial Infarction. The biomarkers are plotted showing the
ultiples of the cutoff for acute myocardial infarction (AMI) over
e. The dashed horizontal line shows the upper limit of normal
LN; defined as the 99th percentile from a normal reference
pulation without myocardial necrosis; the coefficient of varia-
n of the assay should be 10% or less) The earliest rising bio-
arkers are myoglobin and CK isoforms (leftmost curve). CKMB
ashed curve) rises to a peak of 2 to 5 times the ULN and typi-
lly returns to the normal range within 2 to 3 d after AMI. The
rdiac-specific troponins show small elevations above the ULN
small infarctions (e.g., as is often the case with NSTEMI) but
e to 20 to 50 times the ULN in the setting of large infarctions
.g., as is typically the case in STEMI). The troponin levels may
ay elevated above the ULN for 7 d or more after AMI. Modi-
d from Shapiro BP, Jaffe AS. Cardiac biomarkers. In: Murphy
, Lloyd MA, editors. Mayo Clinic Cardiology: Concise Text-
ok. 3rd ed. Rochester, MN: Mayo Clinic Scientific Press and
ew York: Informa Healthcare USA, 2007: 773–80 (70). Used
ith permission of Mayo Foundation for Medical Education and
esearch. CK  creatine kinase; CKMB  MB fraction of crea-
e kinase; CV  coefficient of variation; MI  myocardial in-
rction; NSTEMI  non–ST-elevation myocardial infarction; UA/
STEMI  unstable angina/non–ST-elevation myocardial
farction.yocarditis, and pericarditis, as well as severe noncardiac Nnditions such as sepsis, burns, respiratory failure, acute
urological diseases, pulmonary embolism, pulmonary hy-
rtension, drug toxicity, cancer chemotherapy, and renal
sufficiency (230). Therefore, in making the diagnosis of
STEMI, cTns should be used in conjunction with other
iteria of MI, including characteristics of the ischemic
mptoms and the ECG.
In all of these situations, equivalent information is gener-
ly obtained with cTnI and cTnT, except in patients with
nal dysfunction, in whom cTnI assessment appears to have
specific role (227). Among patients with end-stage renal
sease and no clinical evidence of acute myocardial necrosis,
% to 53% show increased cTnT, but fewer than 10% have
creased cTnI; dialysis generally increases cTnT but de-
eases cTnI. The exact reasons for the high rates of elevation
the cTn, especially cTnT, in renal failure are not clear; they
n relate to cardiac damage, differential clearance, or to
her biochemical or metabolic abnormalities (227). What-
er the reasons and the sources, an elevation of cTn,
cluding cTnT, in patients with renal insufficiency is asso-
ated with a higher risk of morbidity regardless of the
esence of cardiac symptoms or documented CAD. Among
033 patients enrolled in the GUSTO IV trial with suspected
CS, TnT level was independently predictive of risk across
e entire spectrum of renal function enrolled (233).
Aggressive preventive measures for patients with renal
sufficiency have been suggested, because most deaths in
nal failure are of cardiac origin (227). Unfortunately, some
andard therapies, such as lipid lowering with statins or PCI,
ve been less effective in improving survival in certain
tient populations with advanced renal insufficiency
34,235). Furthermore, patients with suspected UA/
gure 6. Troponin I Levels to Predict the Risk of Mortality in
cute Coronary Syndromes. Mortality rates are at 42 d (without
justment for baseline characteristics) in patients with acute
ronary syndrome. The numbers at the bottom of each bar are
e numbers of patients with cardiac troponin I levels in each
nge, and the numbers above the bars are percentages. p less
an 0.001 for the increase in the mortality rate (and the risk ra-
for mortality) with increasing levels of cardiac troponin I at
rollment. Reprinted with permission from Antman EM, Tanasi-
vic MJ, Thompson B, et al. Cardiac-specific troponin I levels
predict the risk of mortality in patients with acute coronary
ndromes. N Engl J Med 1996;335:1342–9 (201). Copyright ©
96 Massachusetts Medical Society. All rights reserved.STEMI have particularly unfavorable outcomes when in
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crease in creatinine clearance (236–239). A sequential
ange in cTn levels in the first 24 h of observation for a
spected ACS supports new myocardial injury, whereas
changing levels are more consistent with a chronic disease
ate without ACS.
Troponin elevation has important therapeutic implications.
permits the identification of high-risk patients and of
bsets of patients who will benefit from specific therapies.
hus, among patients with UA/NSTEMI, those with elevated
n benefit from treatment with platelet GP IIb/IIIa inhibi-
rs, whereas those without such elevation may not benefit or
ay even experience a deleterious effect. For example, in the
E3 Fab Antiplatelet Therapy in Unstable Refractory An-
na (CAPTURE) trial, the rates of death or nonfatal MI with
nT elevation were 23.9% with placebo versus 9.5% with
ciximab (p  0.002) (240). Similar results have been
ported for cTnI and cTnT with use of tirofiban (241). The
nefit of LMWH was also greater in UA/NSTEMI patients
ith positive cTn. In the Fragmin during Instability in
oronary Artery Disease (FRISC) trial, the rates of death or
nfatal MI through 40 d increased progressively in the
acebo group from 5.7% in the lowest tertile to 12.6% and
.7% in the second and third tertiles, respectively, compared
ith rates of 4.7%, 5.7%, and 8.9%, respectively, in the
lteparin group, which represents risk reductions in events
increasing tertiles of 17.5%, 43%, and 55% (242). Similar
fferential benefits were observed with enoxaparin versus
fractionated heparin (UFH) in the ESSENCE trial (169).
y contrast and of interest, patients with UA/NSTEMI but
ithout elevated cTnT in the Clopidogrel in Unstable angina
prevent Recurrent ischemic Events (CURE) trial benefited
much from clopidogrel, a platelet P2Y12 adenosine
ble 9. Risk of Death Associated With a Positive Troponin Test
Subgroup
Events/Total
Negative Troponin Positive Tr
T
Total death 32/1,187 46/473
Cardiac death 31/1,689 52/744
UA patients* 21/397 26/198
Chest pain patients* 43/2,479 73/1,0
I
Total death 34/1,451 49/815
Cardiac death 3/905 26/384
UA patients* 2/70 2/22
Chest pain patients* 35/2,286 73/1,1
T and TnI combined†
Total death 42/2,088 69/1,0
Cardiac death 28/1,641 55/792
*Outcomes of cardiac death and total death are pooled.
†Some studies provided both troponin T (TnT) and I (TnI) data. For the comb
Reprinted with permission from Heidenreich PA, Go A, Melsop KA, et al. Predict
. 31 (prepared by the UCSF-Stanford Evidence-Based Practice Center under c
althcare Research and Quality, December 2000. Available at: http://www.ncbi.nlm
ACS  acute coronary syndrome; CI  confidence interval; RR  relative rphosphate (ADP) receptor inhibitor, as patients with ele- duted levels (243). The placebo-controlled Intracoronary
tenting and Antithrombotic Regimen–Rapid Early Action
r Coronary Treatment (ISAR-REACT)-2 trial compared
iple-antiplatelet therapy with ASA, clopidogrel, and abcix-
ab to double therapy with ASA and clopidogrel in patients
ith UA/NSTEMI undergoing PCI; 52% of patients were
oponin positive, and 48% were troponin negative. The 30-d
ent rates were similar at 4.6% in patients with normal cTnT
vels but were reduced by close to 30% with the triple
erapy (13.1% vs. 18.3%) in patients with elevated levels
44). The reasons for the differential benefit could pertain to
benefit that does not emerge in the low-risk patient, or that
overshadowed by complications related to treatment.
Such also appears to be the case with the GP IIb/IIIa
tagonists and with an invasive management strategy that
cludes application of interventional procedures. Indeed, in 2
ials that compared an early routine invasive strategy to a
utine noninvasive strategy, the FRISC-II and Treat Angina
ith Aggrastat and determine Cost of Therapy with Invasive
Conservative Strategy (TACTICS) TIMI-18 trials, patients
ho profited from the early invasive treatment strategy were
ose at high risk as determined by cTnT levels and the
mission ECG. In the FRISC study, the invasive strategy
duced the 12-month risk of death or MI by 40% (13.2% vs.
.1%, p  0.001) in the cohort with both ST depression and
cTnT level of 0.03 mcg per liter or greater, but the absolute
in of the invasive strategy was insignificant in the cohorts
ith either ST depression, cTnT level elevation, or neither of
ese findings (245). In the TACTICS TIMI-28 study, sub-
oups of patients with no ECG changes, a low TIMI score,
d no cTn elevation showed no benefit from the invasive
rategy, whereas those with positive cTn, independent of the
esence of elevated CK-MB levels, showed markedly re-
ients With Suspected ACS
Summary RR 95% CI No. of Studies
3.1 2.0 to 4.9 5
3.8 2.4 to 6.0 7
2.5 1.4 to 4.5 5
4.0 2.7 to 5.9 7
3.1 2.0 to 4.9 3
25.0 11 to 55 2
3.2 0.3 to 40 1
5.1 3.4 to 7.6 4
3.3 2.2 to 4.8 7
5.0 3.2 to 7.9 7
alysis, data from 1 marker were chosen randomly.
k for patients with unstable angina. Evidence Report/Technology Assessment
o. 290-97-0013). AHRQ publication no. 01-E001. Rockville, MD: Agency for
/books/bv.fcgi?ridhstat1.chapter.45627. Accessed August 10, 2006 (232).
 unstable angina.in Pat
oponin
19
77
68
ined an
ion of ris
ontract n
.nih.govced odds of adverse clinical events of 0.13 at 30 d (95%
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5% CI  0.16 to 0.52) (246).
.2.8.2.1.1. Clinical Use of Marker Change Scores. A newer
ethod to both identify and exclude MI within 6 h of
mptoms is to rely on changes in serum marker levels
elta values) over an abbreviated time interval (e.g., 2 h)
opposed to the traditional approach of performing serial
easurements over 6 to 8 h (212,214,247–250). Because
says are becoming more sensitive and precise, this
ethod permits the identification of increasing values
hile they are still in the normal or indeterminate range of
e assay. By relying on delta values for the identification
exclusion of MI, higher-risk patients with positive delta
lues can be selected earlier for more aggressive anti-
chemic therapy (e.g., GP IIb/IIIa inhibitors), and lower-
sk patients with negative delta values can be considered
r early stress testing (212,214,249–251). One study of
,042 patients found the addition of a 3-h delta CK-MB
result in a sensitivity of 93% and a specificity of 94% for
I (248). In another study of 2,074 consecutive ED chest
ain patients, a 2-h delta CK-MB in conjunction with a
-h delta troponin I measurement had a sensitivity for
ute MI of 93% and specificity of 94% in patients whose
itial ECG was nondiagnostic for injury. When combined
ith physician judgment and selective nuclear stress testing,
e sensitivity for MI was 100% with specificity of 82%, and
e sensitivity for 30-d ACS was 99.1% with specificity of
% (214). Because there are no manufacturer-recommended
elta cutoff values, the appropriate delta values for identifi-
tion and exclusion of MI should take into account the
nsitivity and precision of the specific assay utilized and
ould be confirmed by in-house studies. It also is important
r delta values to be measured on the same instrument owing
subtle variations in calibration among individual instru-
ents, even of the same model.
Another method to exclude MI within 6 h of symptom
set is the multimarker approach, which utilizes the serial
easurement of myoglobin (i.e., a very early marker) in
mbination with the serial measurements of cTn and/or
K-MB (i.e., a later marker) (252–256). Studies have
ported that multimarker measurements at baseline and
0 min have a sensitivity for MI of approximately 95%
ith a high negative predictive value, thus allowing for the
rly exclusion of MI when combined with clinical judg-
ent (254,255). However, because of the low specificity of
e multimarker strategy (mainly due to the lower speci-
city of myoglobin), a positive multimarker test is inade-
uate to diagnose MI and requires confirmation with a
ter-appearing definitive marker (254,257).
.2.8.2.1.2. Bedside Testing for Cardiac Markers. Cardiac
arkers can be measured in the central chemistry labora-
ry or with point-of-care instruments in the ED with
esktop devices or handheld bedside rapid qualitative
says (229). When a central laboratory is used, results
ould be available as soon as possible, with a goal of
ithin 60 min. Point-of-care systems, if implemented at fie bedside, have the advantage of reducing delays due to
ansportation and processing in a central laboratory and
n eliminate delays due to the lack of availability of
ntral laboratory assays at all hours. Certain portable
evices can simultaneously measure myoglobin, CK-MB,
d troponin I (249). These advantages of point-of-care
stems must be weighed against the need for stringent
uality control and appropriate training of ED personnel
assay performance and the higher costs of point-of-care
sting devices relative to determinations in the central
boratory. In addition, these point-of-care assays at pres-
t are qualitative or, at best, semiquantitative. To date,
edside testing has not succeeded in becoming widely
cepted or applied.
.2.8.3. MYOGLOBIN AND CK-MB SUBFORMS
OMPARED WITH TROPONINS
yoglobin, a low-molecular-weight heme protein found in
th cardiac and skeletal muscle, is not cardiac specific, but
is released more rapidly from infarcted myocardium than
e CK-MB and cTn and can be detected as early as 2 h after
e onset of myocardial necrosis. However, the clinical value
serial determinations of myoglobin for the diagnosis of MI
limited by its brief duration of elevation of less than 24 h.
hus, an isolated early elevation in patients with a nondiag-
stic ECG should not be relied on to make the diagnosis of
I but should be supplemented by a more cardiac-specific
arker (258). Creatine kinase-MB subforms are also efficient
r the early diagnosis of MI and have a similar specificity to
at of CK-MB but require special expertise, with no real
vantage over better standardized and more easily applied
n testing.
.2.8.4. SUMMARY COMPARISON OF BIOMARKERS OF
ECROSIS: SINGLY AND IN COMBINATION
able 10 compares the advantages and disadvantages of cardiac
omarkers of necrosis that are currently used for the evaluation
d management of patients with suspected ACS but without
T-segment elevation on the 12-lead ECG. Given the overlap-
ng time frame of the release pattern of cardiac biomarkers, it is
portant that clinicians incorporate the time from the onset of
e patient’s symptoms into their assessment of the results of
omarker measurements (11,252,259,260) (Fig. 5).
Many patients with suspected ACS have combined assess-
ents of troponin and CK-MB. When baseline troponin and
K-MB were used together for diagnostic and risk assess-
ent across the spectrum of chest pain syndromes in a large
tabase that consisted of several clinical trials, those with
sitive results for both markers were at highest short-term
4 h and 30 d) risk of death or MI (261). However, those
ith baseline troponin elevation without CK-MB elevation
so were at increased 30-d risk, whereas risk with isolated
K-MB elevation was lower and not significantly different
an if both markers were negative (261).
In summary, the cTns are currently the markers of choice
r the diagnosis of MI. They have a sensitivity and speci-city as yet unsurpassed, which allows for the recognition of
ve
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionry small amounts of myocardial necrosis. These small areas
infarction are the consequence of severe ischemia and/or
stal microembolization of debris from an unstable throm-
genic plaque. The unstable plaques are likely responsible
r the high-risk situation. Thus, cTns as biomarkers are not
ly markers of cell necrosis but also of an active thrombo-
nic plaque, and hence, they indicate prognosis and are
eful in guiding therapies. Although not quite as sensitive or
ecific as the cTns, CK-MB by mass assay is a second-
oice marker that remains useful for the diagnosis of MI
tension and of periprocedural MI. Routine use of myoglo-
n and other markers is not generally recommended.
Because many methods exist, many with multiple test
nerations, for cardiac biomarker testing in practice and in
blished reports, physicians should work with their clinical
ble 10. Biochemical Cardiac Markers for the Evaluation and M
gment Elevation on 12-Lead ECG
Marker Advantages Disadvantages
rdiac
troponins
1. Powerful tool for risk
stratification
2. Greater sensitivity and specificity
than CK-MB
3. Detection of recent MI up to 2
weeks after onset
4. Useful for selection of therapy
5. Detection of reperfusion
1. Low sensitivity in
very early phase of
MI (less than 6 h
after symptom onse
and requires repeat
measurement at 8 t
12 h, if negative
2. Limited ability to
detect late minor
reinfarction
-MB 1. Rapid, cost-efficient, accurate
assays
2. Ability to detect early reinfarction
1. Loss of specificity in
setting of skeletal
muscle disease or
injury, including
surgery
2. Low sensitivity durin
very early MI (less
than 6 h after
symptom onset) or
later after symptom
onset (more than
36 h) and for minor
myocardial damage
(detectable with
troponins)
yoglobin 1. High sensitivity
2. Useful in early detection of MI
3. Detection of reperfusion
4. Most useful in ruling out MI
1. Very low specificity
setting of skeletal
muscle injury or
disease
2. Rapid return to
normal range limits
sensitivity for later
presentations
ACS  acute coronary syndrome; CK-MB  MB fraction of creatine kinas
n-ST-elevation MI.boratories to ensure use of and familiarity with contempo- mry test technology, with appropriate, accurate ranges of
rmal and diagnostic cutoffs, specific to the assay used.
.2.9. Other Markers and Multimarker Approaches
esides markers of myocardial necrosis, markers of patho-
ysiological mechanisms implicated in ACS are under
vestigation and could become useful to determine patho-
ysiology, individualize treatment, and evaluate therapeutic
fects. In considering the clinical application of new bio-
arkers, it is important to determine that they provide
cremental value over existing biomarkers. A multimarker
proach to risk stratification of UA/NSTEMI (e.g., simulta-
ous assessment of cTnI, C-reactive protein [CRP], and
NP) has been advocated as a potential advance over single
omarker assessment (262,263). Further evaluation of a
ment of Patients With Suspected ACS But Without ST-
oint-of-Care
Test
Available? Comment
Clinical
Recommendation
Yes Data on diagnostic
performance and potential
therapeutic implications
increasingly available from
clinical trials
Useful as a single test
to efficiently
diagnose NSTEMI
(including minor
myocardial
damage), with
serial
measurements.
Clinicians should
familiarize
themselves with
diagnostic “cutoffs”
used in their local
hospital laboratory
Yes Familiar to majority of
clinicians
Prior standard and
still acceptable
diagnostic test in
most clinical
circumstances
Yes More convenient early marker
than CK-MB isoforms
because of greater
availability of assays for
myoglobin; rapid-release
kinetics make myoglobin
useful for noninvasive
monitoring of reperfusion
in patients with established
MI
 electrocardiogram; h  hours; MI  myocardial infarction; NSTEMI anage
P
t)
o
g
in
e; ECGultimarker approach will be of interest.
2
O
di
st
m
si
C
re
du
cl
is
be
th
bi
pr
(2
2
M
el
m
ha
og
im
by
(2
2
P
vi
a
an
ac
ne
2
S
an
pa
th
pr
w
P
bu
ac
hi
(2
th
al
po
ad
m
(2
zi
ev
pl
pr
to
w
w
va
in
2
O
be
B
up
m
an
ne
ti
fr
va
in
re
m
th
an
N
at
it
w
0.
pr
an
ad
pe
an
2
R
CL
1.
2.
3.
4.
e244 Anderson et al. JACC Vol. 57, No. 19, 2011
ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367.2.9.1. ISCHEMIA
ther new biochemical markers for the detection of myocar-
al necrosis are either less useful or have been less well
udied than those mentioned above. An example is ischemia-
odified albumin found soon after transient coronary occlu-
on and preceding any significant elevations in myoglobin,
K-MB, or cTnI. This modified albumin depends on a
duced capacity of human albumin to bind exogenous cobalt
ring ischemia (264,265). Choline is released upon the
eavage of phospholipids and could also serve as a marker of
chemia. Growth-differentiation factor-15 (GDF-15), a mem-
r of the transforming growth factor- cytokine superfamily
at is induced after ischemia-and-reperfusion injury, is a new
omarker that has been reported to be of incremental
ognostic value for death in patients with UA/NSTEMI
65a).
.2.9.2. COAGULATION
arkers of activity of the coagulation cascade, including
evated plasma levels of fibrinogen, the prothrombin frag-
ents, fibrinopeptide, and D-dimers, are elevated in ACS but
ve little discriminative ability for a specific pathophysiol-
y, diagnosis, or treatment assessments (266,267). In exper-
ental studies, markers of thrombin generation are blocked
anticoagulants but reactivate after their discontinuation
68) and are not affected by clopidogrel (269).
.2.9.3. PLATELETS
latelet activation currently is difficult to assess directly in
vo. New methods, however, are emerging that should allow
better and more efficient appraisal of their state of activation
d of drug effects (270–272). Alternative markers of platelet
tivity are also being studied, including CD40L, platelet-
utrophil coaggregates, P-selectin, and platelet microparticles.
.2.9.4. INFLAMMATION
ystemic markers of inflammation are being widely studied
d show promise for providing additional insights into
thophysiological mechanisms proximal to and triggering
rombosis, as well as suggesting novel therapeutic ap-
oaches. White blood cell counts are elevated in patients
ith MI, and this elevation has prognostic implications.
atients without biochemical evidence of myocardial necrosis
t who have elevated CRP levels on admission or past the
ute-phase reaction after 1 month and who have values in the
ghest quartile are at an increased risk of an adverse outcome
73–275). Elevated levels of interleukin-6, which promotes
e synthesis of CRP, and of other proinflammatory cytokines
so have been studied for their prognostic value (276). Other
tentially useful markers are levels of circulating soluble
hesion molecules, such as intercellular adhesion
olecule-1, vascular cell adhesion molecule-1, and E-selectin
77); the pregnancy–associated plasma protein-A, which is a
nc-binding matrix metalloproteinase released with neor-
ascularization and believed to be a marker of incipient
aque rupture (278); myeloperoxidase, a leukocyte-derived
otein that generates reactive oxidant species that contribute
tissue damage, inflammation, and immune processes
ithin atherosclerotic lesions (279); and others. At thisriting, none of these have been adequately studied or
lidated to be recommended for routine clinical application
UA/NSTEMI.
.2.9.5. B-TYPE NATRIURETIC PEPTIDES
ne newer biomarker of considerable interest that now may
considered in the guidelines recommendations is BNP.
-type natriuretic peptide is a cardiac neurohormone released
on ventricular myocyte stretch as proBNP, which is enzy-
atically cleaved to the N-terminal proBNP (NT-proBNP)
d, subsequently, to BNP. The usefulness of assessing this
urohormone was first shown for the diagnosis and evalua-
on of HF. Since then, numerous prospective studies and data
om large data sets have documented its powerful prognostic
lue independent of conventional risk factors for mortality
patients with stable and unstable CAD (263,280–284). A
view of available studies in ACS showed that when
easured at first patient contact or during the hospital stay,
e natriuretic peptides are strong predictors of both short-
d long-term mortality in patients with STEMI and UA/
STEMI (280). Increasing levels of NT-proBNP are associ-
ed with proportionally higher short- and long-term mortal-
y rates; at 1 year, mortality rates with increasing quartiles
ere 1.8%, 3.9%, 7.7%, and 19.2%, respectively (p less than
001) in the GUSTO-IV trial of 6,809 patients (284). This
ognostic value was independent of a previous history of HF
d of clinical or laboratory signs of LV dysfunction on
mission or during hospital stay (280). B-type natriuretic
ptide and NT-proBNP levels can now be measured easily
d rapidly in most hospital laboratories.
.3. Immediate Management
ecommendations
ASS I
The history, physical examination, 12-lead ECG, and initial
cardiac biomarker tests should be integrated to assign pa-
tients with chest pain into 1 of 4 categories: a noncardiac
diagnosis, chronic stable angina, possible ACS, and definite
ACS. (Level of Evidence: C)
Patients with probable or possible ACS but whose initial
12-lead ECG and cardiac biomarker levels are normal should be
observed in a facility with cardiac monitoring (e.g., chest pain
unit or hospital telemetry ward), and repeat ECG (or continu-
ous 12-lead ECG monitoring) and repeat cardiac biomarker
measurement(s) should be obtained at predetermined, speci-
fied time intervals (see Section 2.2.8). (Level of Evidence: B)
In patients with suspected ACS in whom ischemic heart
disease is present or suspected, if the follow-up 12-lead ECG
and cardiac biomarkers measurements are normal, a stress
test (exercise or pharmacological) to provoke ischemia should
be performed in the ED, in a chest pain unit, or on an outpatient
basis in a timely fashion (within 72 h) as an alternative to
inpatient admission. Low-risk patients with a negative diagnos-
tic test can be managed as outpatients. (Level of Evidence: C)
In low-risk patients who are referred for outpatient stress
testing (see above), precautionary appropriate pharmacother-
apy (e.g., ASA, sublingual NTG, and/or beta blockers) should
be given while awaiting results of the stress test. (Level of
Evidence: C)
5.
6.
7.
8.
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline RevisionPatients with definite ACS and ongoing ischemic symptoms,
positive cardiac biomarkers, new ST-segment deviations, new
deep T-wave inversions, hemodynamic abnormalities, or a
positive stress test should be admitted to the hospital for
further management. Admission to the critical care unit is
recommended for those with active, ongoing ischemia/injury
or hemodynamic or electrical instability. Otherwise, a teleme-
try step-down unit is reasonable. (Level of Evidence: C)
Patients with possible ACS and negative cardiac biomarkers
who are unable to exercise or who have an abnormal resting
ECG should undergo a pharmacological stress test. (Level of
Evidence: B)
Patients with definite ACS and ST-segment elevation in leads
V7 to V9 due to left circumflex occlusion should be evaluated
for immediate reperfusion therapy. (Level of Evidence: A)
Patients discharged from the ED or chest pain unit should be
given specific instructions for activity, medications, additional
testing, and follow-up with a personal physician. (Level of
Evidence: C)
ASS IIa
patients with suspected ACS with a low or intermediate
obability of CAD, in whom the follow-up 12-lead ECG and cardiac
omarkers measurements are normal, performance of a noninva-
ve coronary imaging test (i.e., CCTA) is reasonable as an
ternative to stress testing. (Level of Evidence: B)
By integrating information from the history, physical
amination, 12-lead ECG, and initial cardiac biomarker
sts, clinicians can assign patients to 1 of 4 categories:
ncardiac diagnosis, chronic stable angina, possible ACS,
d definite ACS (Fig. 2).
Patients who arrive at a medical facility in a pain-free state,
ve unchanged or normal ECGs, are hemodynamically
able, and do not have elevated cardiac biomarkers represent
ore of a diagnostic than an urgent therapeutic challenge.
valuation begins in these patients by obtaining information
om the history, physical examination, and ECG (Tables 6
d 7) to be used to confirm or reject the diagnosis of
A/NSTEMI.
Patients with a low likelihood of CAD should be evaluated
r other causes of the noncardiac presentation, including
usculoskeletal pain; gastrointestinal disorders, such as
ophageal spasm, gastritis, peptic ulcer disease, or chole-
stitis; intrathoracic disease, such as musculoskeletal
scomfort, pneumonia, pleurisy, pneumothorax, pulmonary
bolus, dissecting aortic aneurysm, myocarditis, or pericar-
tis; and neuropsychiatric disease, such as hyperventilation
panic disorder (Fig. 2, B1). Patients who are found to have
idence of 1 of these alternative diagnoses should be
cluded from management with these guidelines and re-
rred for appropriate follow-up care (Fig. 2, C1). Reassur-
ce should be balanced with instructions to return for further
aluation if symptoms worsen or if the patient fails to
spond to symptomatic treatment. Chronic stable angina may
so be diagnosed in this setting (Fig. 2, B2), and patients
ith this diagnosis should be managed according to the
CC/AHA 2002 Guideline Update for the Management of
atients With Chronic Stable Angina (4). asPatients with possible ACS (Fig. 2, B3 and D1) are
ndidates for additional observation in a specialized facility
.g., chest pain unit) (Fig. 2, E1). Patients with definite ACS
ig. 2, B4) are triaged on the basis of the pattern of the
-lead ECG. Patients with ST-segment elevation (Fig. 2, C3)
e evaluated for immediate reperfusion therapy (Fig. 2, D3)
d managed according to the ACC/AHA Guidelines for the
anagement of Patients With ST-Elevation Myocardial In-
rction (1), whereas those without ST-segment elevation
ig. 2, C2) are either managed by additional observation
ig. 2, E1) or admitted to the hospital (Fig. 2, H3). Patients
ith low-risk ACS (Table 6) without transient ST-segment
pressions greater than or equal to 0.05 mV (0.5 mm) or
-wave inversions greater than or equal to 0.2 mV (2 mm),
ithout positive cardiac biomarkers, and with a negative
ress test or CCTA (Fig. 2, H1) may be discharged and
eated as outpatients (Fig. 2, I1). Low-risk patients may have
stress test within 3 d of discharge.
.3.1. Chest Pain Units
o facilitate a more definitive evaluation while avoiding the
necessary hospital admission of patients with possible ACS
ig. 2, B3) and low-risk ACS (Fig. 2, F1), as well as the
appropriate discharge of patients with active myocardial
chemia without ST-segment elevation (Fig. 2, C2), special
its have been established that are variously referred to as
hest pain units” and “short-stay ED coronary care units.”
ersonnel in these units use critical pathways or protocols
signed to arrive at a decision about the presence or absence
myocardial ischemia and, if present, to characterize it
rther as UA or NSTEMI and to define the optimal next step
the care of the patient (e.g., admission, acute intervention)
7,214,285,286). The goal is to arrive at such a decision after
finite amount of time, which usually is between 6 and 12 h
t may extend up to 24 h depending on the policies in
dividual hospitals. Typically, the patient undergoes a pre-
termined observation period with serial cardiac biomarkers
d ECGs. At the end of the observation period, the patient is
evaluated and then generally undergoes functional cardiac
sting (e.g., resting nuclear scan or echocardiography) and/or
ress testing (e.g., treadmill, stress echocardiography, or
ress nuclear testing) or noninvasive coronary imaging study
.e., CCTA) (see Section 2.3.2). Those patients who have a
currence of chest pain strongly suggestive of ACS, a
sitive biomarker value, a significant ECG change, or a
sitive functional/stress test or CCTA are generally admitted
r inpatient evaluation and treatment. Although chest pain
its are useful, other appropriate observation areas in which
tients with chest pain can be evaluated may be used as well,
ch as a section of the hospital’s cardiac telemetry ward.
The physical location of the chest pain unit or the site
here patients with chest pain are observed is variable,
nging from a specifically designated area of the ED to a
parate hospital unit with the appropriate equipment to
servational status (24-h admission) on a regular hospital
lemetry ward (287). Similarly, the chest pain unit may be
ministratively a part of the ED and staffed by emergency
ysicians or may be administered and staffed separately or
part of the hospital cardiovascular service. Capability of
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367est pain units generally includes continuous monitoring of
e patient’s ECG, ready availability of cardiac resuscitation
uipment and medications, and appropriate staffing with
rses and physicians. The ACEP has published guidelines
at recommend a program for the continuous monitoring of
tcomes of patients evaluated in such units and the impact
hospital resources (288). A consensus panel statement
om ACEP emphasized that chest pain units should be
nsidered as part of a multifaceted program that includes
forts to minimize patient delays in seeking medical care and
lays in the ED itself (288).
It has been reported, both from studies with historical
ntrols and from randomized trials, that the use of chest pain
its is cost-saving compared with an in-hospital evaluation
“rule out MI” (289,290). The potential cost savings of a
est pain unit varies depending on the practice pattern for the
sposition of chest pain patients at individual hospitals (289).
ospitals with a high admission rate of low-risk patients to
le out MI (70% to 80%) will experience the largest cost
vings by implementing a chest pain unit approach but will
ve the smallest impact on the number of missed MI
tients. In contrast, hospitals with relatively low admission
tes of such patients (30% to 40%) will experience greater
provements in the quality of care because fewer MI
tients will be missed but will experience a smaller impact
costs because of the low baseline admission rate.
Farkouh et al. (102) extended the use of a chest pain unit
a separate portion of the ED to include patients at an
termediate risk of adverse clinical outcome on the basis of
e previously published Agency for Health care Research
d Quality guidelines for the management of UA (124)
able 7). They reported a 46% reduction in the ultimate need
r hospital admission in intermediate-risk patients after a
edian stay of 9.2 h in the chest pain unit. Extension of the
e of chest pain units to intermediate-risk patients in an
fort to reduce inpatient costs is facilitated by making
ailable diagnostic testing modalities such as treadmill
sting and stress imaging (echocardiographic, nuclear, or
agnetic resonance) or CCTA 7 d a week (291).
Patients with chest discomfort for whom a specific diag-
sis cannot be made after a review of the history, physical
amination, initial 12-lead ECG, and cardiac biomarker data
ould undergo a more definitive evaluation. Several catego-
es of patients should be considered according to the algo-
thm shown in Figure 2:
Patients with possible ACS (Fig. 2, B3) are those who had
a recent episode of chest discomfort at rest not entirely
typical of ischemia but who are pain free when initially
evaluated, have a normal or unchanged ECG, and have no
elevations of cardiac biomarkers.
Patients with a recent episode of typical ischemic discom-
fort that either is of new onset or is severe or that exhibits
an accelerating pattern of previous stable angina (espe-
cially if it has occurred at rest or is within 2 weeks of a
previously documented MI) should initially be considered
to have a “definite ACS” (Fig. 2, B4). However, such
patients may be at a low risk if their ECG obtained at
presentation has no diagnostic abnormalities and the initial
serum cardiac biomarkers (especially cardiac-specific tro- teponins) are normal (Fig. 2, C2 and D1). As indicated in the
algorithm, patients with either “possible ACS” (Fig. 2, B3)
or “definite ACS” (Fig. 2, B4) but with nondiagnostic
ECGs and normal initial cardiac markers (Fig. 2, D1) are
candidates for additional observation in the ED or in a
specialized area such as a chest pain unit (Fig. 2, E1). In
contrast, patients who present without ST-segment eleva-
tion but who have features indicative of active ischemia
(ongoing pain, ST-segment and/or T-wave changes, posi-
tive cardiac biomarkers, or hemodynamic instability; Fig. 2,
D2) should be admitted to the hospital (Fig. 2, H3).
.3.2. Discharge From ED or Chest Pain Unit
he initial assessment of whether a patient has UA/NSTEMI
d which triage option is most suitable generally should be
ade immediately on the patient’s arrival at a medical
cility. Rapid assessment of a patient’s candidacy for addi-
onal observation can be accomplished based on the status of
e symptoms, ECG findings, and initial serum cardiac
omarker measurement.
Patients who experience recurrent ischemic discomfort,
olve abnormalities on a follow-up 12-lead ECG or on
rdiac biomarker measurements, or develop hemodynamic
normalities such as new or worsening HF (Fig. 2, D2)
ould be admitted to the hospital (Fig. 2, H3) and managed
described in Section 3.
Patients who are pain free, have either a normal or
ndiagnostic ECG or one that is unchanged from previous
acings, and have a normal set of initial cardiac biomarker
easurements are candidates for further evaluation to screen
r nonischemic discomfort (Fig. 2, B1) versus a low-risk
CS (Fig. 2, D1). If the patient is low risk (Table 7) and does
t experience any further ischemic discomfort and a
llow-up 12-lead ECG and cardiac biomarker measurements
ter 6 to 8 h of observation are normal (Fig. 2, F1), the
tient may be considered for an early stress test to provoke
chemia or CCTA to assess for obstructive CAD (Fig. 2,
1). This test can be performed before the discharge and
ould be supervised by an experienced physician. Alterna-
vely, the patient may be discharged and return for stress
sting as an outpatient within 72 h. The exact nature of the
st may vary depending on the patient’s ability to exercise on
ther a treadmill or bicycle and the local expertise in a given
spital setting (e.g., availability of different testing modali-
es at different times of the day or different days of the week)
92). Patients who are capable of exercise and who are free
confounding features on the baseline ECG, such as
ndle-branch block, LV hypertrophy, or paced rhythms, can
evaluated with routine symptom-limited conventional
ercise stress testing. Patients who are incapable of exercise
who have an uninterpretable baseline ECG should be
nsidered for pharmacological stress testing with either
clear perfusion imaging or 2-dimensional echocardiogra-
y, or magnetic resonance (175,293,294). Alternatively, it is
asonable to perform a non-invasive coronary imaging test
.e., CCTA). An imaging-enhanced test also may be more
edictive in women than conventional ECG exercise stress
sting (see Section 6.1).
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline RevisionTwo imaging modalities, CMR and multidetector com-
ted tomography for coronary calcification and CCTA, are
creasingly becoming clinically validated and applied and
ld promise as alternative or supplementary imaging modal-
ies for assessing patients who present with chest pain
ndromes (25,294,295). Cardiac magnetic resonance has the
pability of assessing cardiac function, perfusion, and via-
lity in the same setting. Its advantages are excellent reso-
tion (approximately 1 mm) of cardiac structures and avoid-
ce of exposure to radiation and iodinated contrast.
isadvantages include long study time, confined space
laustrophobia), and (current) contraindication to the pres-
ce of pacemakers/defibrillators. To evaluate for ischemic
art disease, an adenosine first-pass gadolinium perfusion
udy is combined with assessment of regional and global
nction and viability (gadolinium delayed study). Direct
ronary artery imaging is better assessed by CCTA (see
low). One study indicated a sensitivity of 89% and speci-
city of 87% for combined adenosine stress and gadolinium
layed enhancement (viability) CMR testing for CAD (296).
obutamine CMR stress testing can be used as an alternative
adenosine perfusion CMR (e.g., in asthmatic patients).
Coronary CT angiography with current multidetector tech-
logy (i.e., 64 slices beginning in 2005) has been reported to
ve 90% to 95% or greater sensitivity and specificity for
clusive CAD in early clinical trial experience (297–299).
or evaluation of potential UA/NSTEMI, coronary artery
lcium scoring followed by CCTA is typically done in the
me sitting. The advantages of CCTA are good to excellent
solution (approximately 0.6 mm) of coronary artery anat-
y and short study time (single breath hold). Disadvantages
e radiation dose (8 to 24 mSv), contrast dye exposure, and
cessity to achieve a slow, regular heart rate (beta blockers
e usually required). A lack of large controlled comparative
ials and reimbursement issues are current limitations to
ese technologies. In summary, the high negative predictive
lue of CCTA is its greatest advantage: if no evidence of
ther calcified or noncalcified (soft/fibrous) plaque is found,
en it is highly unlikely that the patient’s symptoms are due
UA/NSTEMI of an atherosclerotic origin. (Note that
imary [micro]vascular dysfunction causes of chest pain are
t excluded.) In contrast, the positive predictive value of
CTA in determining whether a given plaque or stenosis is
using the signs and symptoms of possible UA/NSTEMI is
ss clear because although it gives valuable anatomic infor-
ation, it does not provide functional or physiological
sessment. Coronary CT angiography has been judged to be
eful for evaluation of obstructive CAD in symptomatic
tients (Class IIa, Level of Evidence: B) (25) and appropri-
e for acute chest pain evaluation for those with intermediate
d possibly low pretest probability of CAD when serial ECG
d biomarkers are negative (294). It may be particularly
propriate for those with acute chest pain syndromes with
termediate pretest probability of CAD in the setting of
ndiagnostic ECG and negative cardiac biomarkers (294).
Because LV function is so integrally related to prognosis
d greatly affects therapeutic options, strong consideration
ould be given to the assessment of LV function with
hocardiography or another modality (i.e., CMR, radionu- mide, CCTA, or contrast angiography) in patients with
cumented ischemia. In sites at which stress tests are not
ailable, low-risk patients may be discharged and referred
r outpatient stress testing in a timely fashion. Prescription
precautionary anti-ischemic treatment (e.g., ASA, sublin-
al NTG, and beta blockers) should be considered in these
tients while awaiting results of stress testing. Specific
structions also should be given on whether or not to take
ese medications (e.g., beta blockers) before testing, which
ay vary depending on the test ordered and patient-specific
ctors. These patients also should be given specific instruc-
ons on what to do and how to seek emergency care for
currence or worsening of symptoms while awaiting the
ress test.
Patients who develop recurrent symptoms during observa-
on suggestive of ACS or in whom the follow-up studies
2-lead ECG, cardiac biomarkers) show new abnormalities
ig. 2, F2) should be admitted to the hospital (Fig. 2, H3).
atients in whom ACS has been excluded should be reas-
ssed for need for further evaluation of other potentially
rious medical conditions that may mimic ACS symptom-
ology (e.g., pulmonary embolism and aortic dissection).
Because continuity of care is important in the overall
anagement of patients with a chest pain syndrome, the
tient’s primary physician (if not involved in the care of the
tient during the initial episode) should be notified of the
sults of the evaluation and should receive a copy of the
levant test results. Patients with a noncardiac diagnosis and
ose with low risk or possible ACS with a negative stress test
ould be counseled to make an appointment with their
imary care physician as outpatients for further investigation
to the cause of their symptoms (Fig. 2, I1). They should be
en by a physician as soon after discharge from the ED or
est pain unit as practical and appropriate, that is, usually
ithin 72 h.
Patients with possible ACS (Fig. 5, B3) and those with a
finite ACS but a nondiagnostic ECG and normal cardiac
omarkers when they are initially seen (Fig. 2, D1) at
stitutions without a chest pain unit (or equivalent facility)
ould be admitted to an inpatient unit. The inpatient unit to
hich such patients are to be admitted should have the same
ovisions for continuous ECG monitoring, availability of
suscitation equipment, and staffing arrangements as de-
ribed above for the design of chest pain units.
. Early Hospital Care
atients with UA/NSTEMI, recurrent symptoms suggestive
ACS and/or ECG ST-segment deviations, or positive
rdiac biomarkers who are stable hemodynamically should
admitted to an inpatient unit for bed rest with continuous
ythm monitoring and careful observation for recurrent
chemia (a step-down unit) and managed with either an
vasive or conservative strategy (Table 11). Patients with
ntinuing discomfort and/or hemodynamic instability should
hospitalized for at least 24 h in a coronary care unit
aracterized by a nursing-to-patient ratio sufficient to pro-
de 1) continuous rhythm monitoring, 2) frequent assess-
ent of vital signs and mental status, 3) documented ability to
pe
fi
P
ha
at
ti
ta
ta
to
ul
pe
pa
no
te
U
sh
th
cl
ti
in
ro
ph
ca
ha
ph
co
w
si
te
ou
th
by
re
th
m
do
pa
be
al
pr
pr
ob
ti
di
im
fu
3
R
CL
1.
2.
3.
4.
5.
6.
7.
*R
th
sy
Ta
Ve
P
In
Co
Ac
fra
M
e248 Anderson et al. JACC Vol. 57, No. 19, 2011
ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367rform defibrillation quickly after the onset of ventricular
brillation, and 4) adequate staff to perform these functions.
atients should be maintained at that level of care until they
ve been observed for an adequate period of time, generally
least 24 h, without any of the following major complica-
ons: sustained ventricular tachycardia or fibrillation, sinus
chycardia, high-degree atrioventricular (AV) block, sus-
ined hypotension, recurrent ischemia documented by symp-
ms or ST-segment change, new mechanical defect (ventric-
ar septal defect or mitral regurgitation), or HF. Shorter
riods of monitoring might be appropriate for selected
tients who are successfully reperfused and who have
rmal LV function and minimal or no necrosis.
Once a patient with documented high-risk ACS is admit-
d, standard medical therapy is indicated as discussed later.
nless a contraindication exists, these patients generally
ould be treated with ASA, a beta blocker, anticoagulant
erapy, a GP IIb/IIIa inhibitor, and a thienopyridine (i.e.,
opidogrel; initiation may be deferred until a revasculariza-
on decision is made). Critical decisions are required regard-
g the angiographic (invasive) strategy. One option is a
utine angiographic approach in which coronary angiogra-
y and revascularization are performed unless a contraindi-
tion exists. Within this approach, a common past strategy
s called for a period of medical stabilization. Increasingly,
ysicians are taking a more aggressive approach, with
ronary angiography and revascularization performed
ithin 24 h of admission; the rationale for the more aggres-
ve approach is the protective effect of carefully adminis-
red anticoagulant and antiplatelet therapy on procedural
tcome. The alternative approach, commonly referred to as
e “initial conservative strategy” (see Section 3.3), is guided
ble 11. Selection of Initial Treatment Strategy: Invasive
rsus Conservative Strategy
referred Strategy Patient Characteristics
vasive Recurrent angina or ischemia at rest or with low-level
activities despite intensive medical therapy
Elevated cardiac biomarkers (TnT or TnI)
New or presumably new ST-segment depression
Signs or symptoms of HF or new or worsening mitral
regurgitation
High-risk findings from noninvasive testing
Hemodynamic instability
Sustained ventricular tachycardia
PCI within 6 months
Prior CABG
High risk score (e.g., TIMI, GRACE)
Reduced left ventricular function (LVEF less than
40%)
nservative Low risk score (e.g., TIMI, GRACE)
Patient or physician preference in the absence of
high-risk features
CABG  coronary artery bypass graft surgery; GRACE  Global Registry of
ute Coronary Events; HF  heart failure; LVEF  left ventricular ejection
ction; PCI  percutaneous coronary intervention; TIMI  Thrombolysis In
yocardial Infarction; TnI  troponin I; TnT  troponin T.ischemia, with angiography reserved for patients with hecurrent ischemia or a high-risk stress test despite medical
erapy. Regardless of the angiographic strategy, an assess-
ent of LV function is recommended in patients with
cumented ischemia because of the imperative to treat
tients who have impaired LV function with ACE inhibitors,
ta blockers, and, when HF or diabetes mellitus is present,
dosterone antagonists; when the coronary anatomy is ap-
opriate (e.g., 3-vessel coronary disease), CABG is appro-
iate (see Section 4). When the coronary angiogram is
tained, a left ventriculogram may be obtained at the same
me. When coronary angiography is not scheduled, echocar-
ography, nuclear ventriculography, or magnetic resonance
aging or CT angiography can be used to evaluate LV
nction.
.1. Anti-Ischemic and Analgesic Therapy
ecommendations for Anti-Ischemic Therapy
ASS I
Bed/chair rest with continuous ECG monitoring is recom-
mended for all UA/NSTEMI patients during the early hospital
phase. (Level of Evidence: C)
Supplemental oxygen should be administered to patients with
UA/NSTEMI with an arterial saturation less than 90%, respira-
tory distress, or other high-risk features for hypoxemia. (Pulse
oximetry is useful for continuous measurement of SaO2.) (Level
of Evidence: B)
Patients with UA/NSTEMI with ongoing ischemic discomfort
should receive sublingual NTG (0.4 mg) every 5 min for a total
of 3 doses, after which assessment should be made about the
need for intravenous NTG, if not contraindicated. (Level of
Evidence: C)
Intravenous NTG is indicated in the first 48 h after UA/NSTEMI
for treatment of persistent ischemia, HF, or hypertension. The
decision to administer intravenous NTG and the dose used
should not preclude therapy with other proven mortality-
reducing interventions such as beta blockers or ACE inhibitors.
(Level of Evidence: B)
Oral beta-blocker therapy should be initiated within the first
24 h for patients who do not have 1 or more of the following: 1)
signs of HF, 2) evidence of a low-output state, 3) increased
risk* for cardiogenic shock, or 4) other relative contraindica-
tions to beta blockade (PR interval greater than 0.24 s, second
or third degree heart block, active asthma, or reactive airway
disease). (Level of Evidence: B)
In UA/NSTEMI patients with continuing or frequently recurring
ischemia and in whom beta blockers are contraindicated, a
nondihydropyridine calcium channel blocker (e.g., verapamil or
diltiazem) should be given as initial therapy in the absence of
clinically significant LV dysfunction or other contraindications.
(Level of Evidence: B)
An ACE inhibitor should be administered orally within the first
24 h to UA/NSTEMI patients with pulmonary congestion or LV
ejection fraction (LVEF) less than or equal to 0.40, in the
absence of hypotension (systolic blood pressure less than 100
mm Hg or less than 30 mm Hg below baseline) or known
isk factors for cardiogenic shock (the greater the number of risk factors present,
e higher the risk of developing cardiogenic shock): age greater than 70 years,
stolic blood pressure less than 120 mmHg, sinus tachycardia greater than 110 or
art rate less than 60, increased time since onset of symptoms of UA/NSTEMI.
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisioncontraindications to that class of medications. (Level of Evi-
dence: A)
An angiotensin receptor blocker should be administered to
UA/NSTEMI patients who are intolerant of ACE inhibitors and
have either clinical or radiological signs of HF or LVEF less than
or equal to 0.40. (Level of Evidence: A)
Because of the increased risks of mortality, reinfarction,
hypertension, HF, and myocardial rupture associated with their
use, nonsteroidal anti-inflammatory drugs (NSAIDs), except for
ASA, whether nonselective or cyclooxygenase (COX)-2–selec-
tive agents, should be discontinued at the time a patient
presents with UA/NSTEMI. (Level of Evidence: C)
ASS IIa
It is reasonable to administer supplemental oxygen to all
patients with UA/NSTEMI during the first 6 h after presenta-
tion. (Level of Evidence: C)
In the absence of contradictions to its use, it is reasonable to
administer morphine sulfate intravenously to UA/NSTEMI pa-
tients if there is uncontrolled ischemic chest discomfort de-
spite NTG, provided that additional therapy is used to manage
the underlying ischemia. (Level of Evidence: B)
It is reasonable to administer intravenous (IV) beta blockers at
the time of presentation for hypertension to UA/NSTEMI
patients who do not have 1 or more of the following: 1) signs
of HF, 2) evidence of low-output state, 3) increased risk* for
cardiogenic shock, or 4) other relative contraindications to
beta blockade (PR interval greater than 0.24 s, second or third
degree heart block, active asthma, or reactive ariway disease).
(Level of Evidence: B)
Oral long-acting nondihydropyridine calcium channel blockers
are reasonable for use in UA/NSTEMI patients for recurrent
ischemia in the absence of contraindications after beta block-
ers and nitrates have been fully used. (Level of Evidence: C)
An ACE inhibitor administered orally within the first 24 h of
UA/NSTEMI can be useful in patients without pulmonary
congestion or LVEF less than or equal to 0.40 in the absence
of hypotension (systolic blood pressure less than 100 mm Hg
or less than 30 mm Hg below baseline) or known contraindi-
cations to that class of medications. (Level of Evidence: B)
Intra-aortic balloon pump (IABP) counterpulsation is reason-
able in UA/NSTEMI patients for severe ischemia that is
continuing or recurs frequently despite intensive medical ther-
apy, for hemodynamic instability in patients before or after
coronary angiography, and for mechanical complications of MI.
(Level of Evidence: C)
ASS IIb
The use of extended-release forms of nondihydropyridine cal-
cium channel blockers instead of a beta blocker may be
considered in patients with UA/NSTEMI. (Level of Evidence: B)
Immediate-release dihydropyridine calcium channel blockers in
the presence of adequate beta blockade may be considered in
patients with UA/NSTEMI with ongoing ischemic symptoms or
hypertension. (Level of Evidence: B)
ASS III
Nitrates should not be administered to UA/NSTEMI patients
with systolic blood pressure less than 90 mm Hg or greater
than or equal to 30 mm Hg below baseline, severe bradycardia sh(less than 50 beats per minute), tachycardia (more than 100
beats per minute) in the absence of symptomatic HF, or right
ventricular infarction. (Level of Evidence: C)
Nitroglycerin or other nitrates should not be administered to
patients with UA/NSTEMI who had received a phosphodiester-
ase inhibitor for erectile dysfunction within 24 h of sildenafil or
48 h of tadalafil use. The suitable time for the administration of
nitrates after vardenafil has not been determined. (Level of
Evidence: C)
Immediate-release dihydropyridine calcium channel blockers
should not be administered to patients with UA/NSTEMI in the
absence of a beta blocker. (Level of Evidence: A)
An intravenous ACE inhibitor should not be given to patients
within the first 24 h of UA/NSTEMI because of the increased
risk of hypotension. (A possible exception may be patients
with refractory hypertension.) (Level of Evidence: B)
It may be harmful to administer intravenous beta blockers to
UA/NSTEMI patients who have contraindications to beta
blockade, signs of HF or low-output state, or other risk
factors* for cardiogenic shock. (Level of Evidence: A)
Nonsteroidal anti-inflammatory drugs (except for ASA),
whether nonselective or COX-2–selective agents, should not
be administered during hospitalization for UA/NSTEMI be-
cause of the increased risks of mortality, reinfarction, hyper-
tension, HF, and myocardial rupture associated with their use.
(Level of Evidence: C)
The optimal management of UA/NSTEMI has the twin
als of the immediate relief of ischemia and the prevention
serious adverse outcomes (i.e., death or myocardial [re]in-
rction). This is best accomplished with an approach that
cludes anti-ischemic therapy (Table 12), antithrombotic
erapy (Table 13), ongoing risk stratification, and the use of
vasive procedures. Patients who are at intermediate or high
sk for adverse outcomes, including those with ongoing
chemia refractory to initial medical therapy and those with
idence of hemodynamic instability, should be admitted
henever possible to a critical care environment with ready
cess to invasive cardiovascular diagnosis and therapeutic
ocedures. Ready access is defined as ensured, timely access
a cardiac catheterization laboratory with personnel who
ve appropriate credentials and experience in invasivecoro-
ry procedures, as well as to emergency or urgent cardio-
scular surgery and cardiac anesthesia (2,300).
The approach to the achievement of the twin goals de-
ribed here includes the initiation of pharmacological man-
ement and planning of a definitive treatment strategy for
e underlying disease process. Most patients are stable at
esentation or stabilize after a brief period of intensive
armacological management and, after appropriate counsel-
g, will be able to participate in the choice of an approach for
finitive therapy (see Section 3.3 for a full discussion of
nservative vs. invasive strategy selection). A few patients
ill require prompt triage to emergency or urgent cardiac
theterization and/or the placement of an IABP.
.1.1. General Care
he severity of symptoms dictates some of the general care
at should be given during the initial treatment. Patients
ould be placed on bed rest while ischemia is ongoing but
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mptom free. Subsequent activity should not be inappropri-
ely restrictive; instead, it should be focused on the preven-
on of recurrent symptoms and liberalized as judged appro-
iate when response to treatment occurs. Patients with
anosis, respiratory distress, or other high-risk features
ould receive supplemental oxygen. Adequate arterial oxy-
n saturation should be confirmed with direct measurement
specially with respiratory distress or cyanosis) or pulse
imetry. No evidence is available to support the administra-
on of oxygen to all patients with ACS in the absence of signs
respiratory distress or arterial hypoxemia. Its use based on
e evidence base can be limited to those with questionable
spiratory status and documented hypoxemia. Nevertheless,
is the opinion of the Writing Committee that a short period
initial routine oxygen supplementation is reasonable dur-
g initial stabilization of the patient, given its safety and the
tential for underrecognition of hypoxemia. Inhaled oxygen
ould be administered if the arterial oxygen saturation
aO2) declines to less than 90%. Finger pulse oximetry is
eful for the continuous monitoring of SaO2 but is not
ble 12. Class I Recommendations for Anti-Ischemic
erapy: Continuing Ischemia/Other Clinical High-Risk Features
esent*
ed/chair rest with continuous ECG monitoring
upplemental oxygen with an arterial saturation less than 90%, respiratory
distress, or other high-risk features for hypoxemia. Pulse oximetry can
be useful for continuous measurement of Sa02
TG 0.4 mg sublingually every 5 min for a total of 3 doses; afterward,
assess need for IV NTG
TG IV for first 48 h after UA/NSTEMI for treatment of persistent ischemia,
HF, or hypertension
ecision to administer NTG IV and dose should not preclude therapy with
other mortality-reducing interventions such as beta blockers or ACE
inhibitors
eta blockers (via oral route) within 24 h without a contraindication
(e.g., HF) irrespective of concomitant performance of PCI
hen beta blockers are contraindicated, a nondihydropyridine calcium
channel blocker (e.g., verapamil or diltiazem) should be given as initial
therapy in the absence of severe LV dysfunction or other
contraindications
CE inhibitor (via oral route) within first 24 h with pulmonary congestion, or
LVEF less than or equal to 0.40, in the absence of hypotension (systolic
blood pressure less than 100 mm Hg or less than 30 mm Hg below
baseline) or known contraindications to that class of medications
RB should be administered to UA/NSTEMI patients who are intolerant of
ACE inhibitors and have either clinical or radiological signs of heart
failure or LVEF less than or equal to 0.40.
*Recurrent angina and/or ischemia-related ECG changes (0.05 mV or greater
-segment depression or bundle-branch block) at rest or with low-level
tivity; or ischemia associated with HF symptoms, S3 gallop, or new or
orsening mitral regurgitation; or hemodynamic instability or depressed LV
nction (LVEF less than 0.40 on noninvasive study); or serious ventricular
rhythmia.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor block-
; HF  heart failure; IV  intravenous; LV  left ventricular; LVEF  left
ntricular ejection fraction; NTG  nitroglycerin; MI  myocardial infarction;
I  percutaneous coronary intervention; UA/NSTEMI  unstable angina/
n-ST-elevation myocardial infarction.andatory in patients who do not appear to be at risk of hapoxemia. Patients should undergo continuous ECG moni-
ring during their ED evaluation and early hospital phase,
cause sudden, unexpected ventricular fibrillation is the
ajor preventable cause of death in this early period. Fur-
ermore, monitoring for the recurrence of ST-segment shifts
ovides useful diagnostic and prognostic information, al-
ough the system of monitoring for ST-segment shifts must
clude specific methods intended to provide stable and
curate recordings.
.1.2. Use of Anti-Ischemic Therapies
.1.2.1. NITRATES
itroglycerin reduces myocardial oxygen demand while en-
ncing myocardial oxygen delivery. Nitroglycerin, an
dothelium-independent vasodilator, has both peripheral and
ronary vascular effects. By dilating the capacitance vessels
.e., the venous bed), it increases venous pooling to decrease
yocardial preload, thereby reducing ventricular wall ten-
on, a determinant of myocardial oxygen demand (MVO2).
ore modest effects on the arterial circulation decrease
stolic wall stress (afterload), which contributes to further
ductions in MVO2. This decrease in myocardial oxygen
mand is in part offset by reflex increases in heart rate and
ntractility, which counteract the reductions in MVO2 unless
beta blocker is concurrently administered. Nitroglycerin
lates normal and atherosclerotic epicardial coronary arteries
d smaller arteries that constrict with certain stressors (e.g.,
ld, mental or physical exercise). With severe atheroscle-
tic coronary obstruction and with less severely obstructed
ssels with endothelial dysfunction, physiological responses
changes in myocardial blood flow are often impaired (i.e.,
ss of flow-mediated dilation), so maximal dilation does not
cur unless a direct-acting vasodilator like NTG is admin-
tered. Thus, NTG promotes the dilation of large coronary
teries, as well as collateral flow and redistribution of
ronary blood flow to ischemic regions. Inhibition of platelet
gregation also occurs with NTG (300), but the clinical
gnificance of this action is not well defined.
Intravenous NTG can benefit patients whose symptoms are
t relieved in the hospital with three 0.4-mg sublingual NTG
blets taken 5 min apart (Tables 12 and 14) and with the
itiation of an oral or intravenous beta blocker (when there
e no contraindications), as well as those with HF or
pertension. Note that NTG is contraindicated after the use
sildenafil within the previous 24 h or tadalafil within 48 h
with hypotension (301–303). The suitable delay before
trate administration after the use of vardenafil has not been
termined, although blood pressure had generally returned
baseline by 24 h (304). These drugs inhibit the phospho-
esterase that degrades cyclic guanosine monophosphate,
d cyclic guanosine monophosphate mediates vascular
ooth muscle relaxation by nitric oxide. Thus, NTG-
ediated vasodilatation is markedly exaggerated and pro-
nged in the presence of phosphodiesterase inhibitors. Ni-
ate use within 24 h after sildenafil or the administration of
ldenafil in a patient who has received a nitrate within 24 h
s been associated with profound hypotension, MI, and even
Ta
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Drug* Initial Medical Treatment
During PCI
After PCI At Hospital Discharge
Patient Received Initial
Medical Treatment
Patient Did Not
Receive Initial
Medical Treatment
Oral Antiplatelet Therapy
Aspirin 162 to 325 mg nonenteric
formulation, orally or
chewed
No additional treatment 162 to 325 mg
nonenteric
formulation orally
or chewed
162 to 325 mg daily
should be given† for
at least 1 month after
BMS implantation, 3
months after SES
implantation, and 6
months after PES
implantation, after
which daily chronic
aspirin should be
continued indefinitely
at a dose of 75 to 162
mg
162 to 325 mg daily
should be given for at
least 1 month after
BMS implantation, 3
months after SES
implantation, and 6
months after PES
implantation, after
which daily chronic
aspirin should be
continued indefinitely
at a dose of 75 to 162
mg
Clopidogrel LD of 300 to 600 mg orally
MD of 75 mg orally per day
A second LD of 300 mg
orally may be given to
supplement a prior LD of
300 mg
LD of 300 to 600 mg
orally
For BMS: 75 mg daily for
at least 1 month and
ideally up to 1 year.
For DES, 75 mg daily
for at least 1 year (in
patients who are not
at high risk of
bleeding) (See Fig. 11)
For BMS: 75 mg daily for
at least 1 month and
ideally up to 1 year.
For DES, 75 mg daily
for at least 1 year (in
patients who are not
at high risk of
bleeding) (See Fig. 11)
Ticlopidine LD of 500 mg orally
MD of 250 mg orally twice
daily
No additional treatment LD of 500 mg orally MD of 250 mg orally
twice daily (duration
same as clopidogrel)
MD of 250 mg orally
twice daily (duration
same as clopidogrel)
Anticoagulants
Bivalirudin 0.1 mg per kg bolus, 0.25
mg per kg per h infusion
0.5 mg per kg bolus,
increase infusion to 1.75
mg per kg per h
0.75 mg per kg
bolus, 1.75 mg
per kg per h
infusion
No additional treatment
or continue infusion
for up to 4 h
Dalteparin 120 IU per kg SC every
12 h (maximum 10,000
IU twice daily)‡
IV GP IIb/IIIa planned: target
ACT 200 s using UFH
IV GP IIb/IIIa planned:
60 to 70 U per kg
of UFH
No additional treatment
No IV GP IIb/IIIa planned:
target ACT 250 to 300 s
for HemoTec; 300 to
350 s for Hemochron
using UFH
No IV GP IIb/IIIa
planned: 100 to
140 U per kg of
UFH
Enoxaparin LD of 30 mg IV bolus may
be given
MD  1 mg per kg SC
every 12 h; extend
dosing interval to 1 mg
per kg every 24 h if
estimated creatinine
clearance less than 30
mL per min
Last SC dose less than 8 h:
no additional therapy
Last SC dose greater than
8 h: 0.3 mg per kg IV
bolus
0.5 to 0.75 mg per
kg IV bolus
No additional treatment
ondaparinux 2.5 mg SC once daily.
Avoid for creatinine
clearance less than 30
mL per min
50 to 60 U per kg IV bolus of
UFH is recommended by
the OASIS 5 Investigators¶
50 to 60 U per kg IV
bolus of UFH is
recommended by
the OASIS 5
Investigators¶
No additional treatment
fractionated
heparin
LD of 60 U per kg (max
4,000 U) as IV bolus
MD of IV infusion of 12 U
per kg per h (max 1,000
U per h) to maintain
aPTT at 1.5 to 2.0 times
control (approximately
50 to 70 s)
IV GP IIb/IIIa planned: target
ACT 200 s
No IV GP IIb/IIIa planned:
target ACT 250 to 300 s
for HemoTec; 300 to
350 s for Hemochron
IV GP IIb/IIIa planned:
60 to 70 U per
kg§
No IV GP IIb/IIIa
planned: 100 to
140 U per kg
No additional treatment
(Continued)
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01,304).
Intravenous NTG may be initiated at a rate of 10 mcg per
in through continuous infusion via nonabsorbing tubing and
creased by 10 mcg per min every 3 to 5 min until some
lief of symptoms or blood pressure response is noted. If no
sponse is seen at 20 mcg per min, increments of 10 and,
ter, 20 mcg per min can be used. If symptoms and signs of
ble 13. Continued
Drug* Initial Medical Treatment
During PC
Patient Received Initial
Medical Treatment
Intravenous An
Abciximab Not applicable Not applicable
Eptifibatide LD of IV bolus of 180 mcg
per kg
MD of IV infusion of 2.0
mcg per kg per min;
reduce infusion by
50% in patients with
estimated creatinine
clearance less than 50
mL per min
Continue infusion
Tirofiban LD of IV infusion of 0.4
mcg per kg per min
for 30 min
MD of IV infusion of 0.1
mcg per kg per min;
reduce rate of infusion
by 50% in patients
with estimated
creatinine clearance
less than 30 mL per
min
Continue infusion
Additional considerations include the possibility that a conservatively manage
U per kg of UFH is recommended if fondaparinux was given for initial m
nservatively managed patients in whom enoxaparin was the initial medical t
tion.
*This list is in alphabetical order and is not meant to indicate a particular th
†In patients in whom the physician is concerned about the risk of bleeding, a lo
‡Dalteparin was evaluated for management of patients with UA/NSTEMI in a
d GP IIb/IIIa inhibitors. Its relative efficacy and safety in the contemporary m
§Some operators use less than 60 U per kg of UFH with GP IIb/IIIa blockade
per kg in this setting.
For patients managed by an initial conservative strategy, agents such as e
mpared with an intravenous infusion of UFH. They are also less likely to provok
associated with less bleeding than enoxaparin in conservatively managed pa
¶Personal communication, OASIS 5 Investigators, July 7, 2006, Note that th
ACT  activated clotting time; BMS  bare-metal stent; GP  glycoprotein
aintenance dose; PCI  percutaneous coronary intervention; PES  paclita
/NSTEMI  unstable angina/non–ST-elevation myocardial infarction; UFH chemia are relieved, there is no need to continue to increase pae dose to effect a blood pressure response. If symptoms and
gns of ischemia are not relieved, the dose should be
creased until a blood pressure response is observed. Once a
rtial blood pressure response is observed, the dosage
crease should be reduced and the interval between incre-
ents lengthened. Side effects of NTG include headache and
potension. Systolic blood pressure generally should not be
trated to less than 110 mm Hg in previously normotensive
After PCI At Hospital Discharge
ent Did Not
eive Initial
al Treatment
et Therapy
.25 mg per
IV bolus
0.125 mcg
kg per min
ax 10 mcg
min)
Continue MD infusion for 12
h
V bolus of
0 mcg per kg
owed 10 min
r by second
bolus of 180
g per kg
2.0 mcg per
per min;
uce infusion
50% in
ients with
imated
atinine
arance less
n 50 mL per
Continue MD infusion for 18
to 24 h
V infusion of
mcg per kg
min for 30
IV infusion of
mcg per kg
min; reduce
e of infusion
50% in
ients with
imated
atinine
arance less
n 30 mL per
Continue MD infusion for 18
to 24 h
t may develop a need for PCI, in which case an intravenous bolus of 50 to
eatment; the safety of this drug combination is not well established. For
t, as noted in the table, additional intravenous enoxaparin is an acceptable
reference.
al ASA dose after PCI of 75 to 162 mg/d is reasonable (Class IIa, LOE: C).
fore the widespread use of important therapies such as stents, clopidogrel,
ent era is not well established.
h no clinical trial data exist to demonstrate the efficacy of doses below 60
in and fondaparinux offer the convenience advantage of SC administration
in-induced thrombocytopenia than UFH. Available data suggest fondaparinux
ing the regimens listed.
en has not been rigorously tested in prospective randomized trials.
our; IU  international unit; IV  intravenous; LD  loading dose; MD 
ng stent; SC  subcutaneous; SES  sirolimus-eluting stent; U  units;
onated heparin.I
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in should be avoided in patients with initial systolic blood
essure less than 90 mm Hg or 30 mm Hg or more below
seline or with marked bradycardia or tachycardia. Although
commendations for a maximal dose are not available, a
iling of 200 mcg per min is commonly used. Even pro-
nged (2 to 4 weeks) infusion at 300 to 400 mcg per min
es not increase methemoglobin levels (306).
Topical or oral nitrates are acceptable alternatives for
tients who require antianginal therapy but who do not have
going refractory ischemic symptoms. Tolerance to the
modynamic effects of nitrates is dose and duration depen-
nt and typically becomes important after 24 h of continuous
erapy with any formulation. Patients who require continued
travenous NTG beyond 24 h may require periodic increases
infusion rate to maintain efficacy. An effort must be made
use non–tolerance-producing nitrate regimens (lower doses
d intermittent dosing). When patients have been free of
chemic discomfort and other manifestations of ischemia for
to 24 h, an attempt should be made to reduce the dose of
travenous NTG and to switch to oral or topical nitrates. It is
t appropriate to continue intravenous NTG in patients who
main free of signs and symptoms of ischemia. When
chemia recurs during continuous intravenous NTG therapy,
sponsiveness to nitrates can often be restored by increasing
e dose and, after symptoms have been controlled for several
urs, attempting to add a nitrate-free interval. This strategy
ould be pursued as long as symptoms are not adequately
ntrolled. In stabilized patients, intravenous NTG should
nerally be converted within 24 h to a nonparenteral
ternative (Table 14) administered in a non–tolerance-
oducing regimen to avoid the potential reactivation of
mptoms. A practical method for converting intravenous to
pical NTG has been published (307).
Most studies of nitrate treatment in UA/NSTEMI have
en small and uncontrolled, and there are no randomized,
acebo-controlled trials that address either symptom relief or
duction in cardiac events. One small randomized trial
mpared intravenous NTG with buccal NTG and found no
ble 14. NTG and Nitrates in Angina
Compound Route
G Sublingual tablets 0.3
Spray 0.4
Transdermal 0.2
Intravenous 5 t
sorbide dinitrate Oral 5 t
Oral, slow release 40
sorbide mononitrate Oral 20
Oral, slow release 60
ntaerythritol tetranitrate Sublingual 10
ythritol tetranitrate Sublingual 5 t
Oral 10
Adapted from Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 gui
: http://www.acc.org/qualityandscience (4).
NTG  nitroglycerin.gnificant difference in the control of ischemia (308). An Terview of small studies of NTG in MI from the prefibrino-
tic era suggested a 35% reduction in mortality rates (309);
contrast, both the Fourth International Study of Infarct
urvival (ISIS-4) (310) and Gruppo Italiano per lo Studio
lla Sopravvivenza nell’infarto Miocardico (GISSI-3) (311)
ials formally tested this hypothesis in patients with sus-
cted MI in the reperfusion era and failed to confirm this
agnitude of benefit. However, these large trials are con-
unded by frequent prehospital and hospital use of NTG in
e “control” groups. Nevertheless, a strategy of routine as
posed to selective use of nitrates did not reduce mortality.
he abrupt cessation of intravenous NTG has been associated
ith exacerbation of ischemic changes on the ECG (312), and
graded reduction in the dose of intravenous NTG is
visable. Thus, the rationale for NTG use in UA/NSTEMI is
trapolated from pathophysiological principles and exten-
ve, although uncontrolled, clinical observations (300).
.1.2.2. MORPHINE SULFATE
orphine sulfate (1 to 5 mg IV) is reasonable for patients
hose symptoms are not relieved despite NTG (e.g., after 3
rial sublingual NTG tablets) or whose symptoms recur
spite adequate anti-ischemic therapy. Unless contraindi-
ted by hypotension or intolerance, morphine may be
ministered with intravenous NTG, with careful blood
essure monitoring, and may be repeated every 5 to 30 min
needed to relieve symptoms and maintain patient comfort.
Morphine sulfate has potent analgesic and anxiolytic ef-
cts, as well as hemodynamic effects, that are potentially
neficial in UA/NSTEMI. No randomized trials have de-
ned the unique contribution of morphine to the initial
erapeutic regimen or its optimal administration schedule.
orphine causes venodilation and can produce modest re-
ctions in heart rate (through increased vagal tone) and
stolic blood pressure to further reduce myocardial oxygen
mand. The major adverse reaction to morphine is an
aggeration of its therapeutic effect, causing hypotension,
pecially in the presence of volume depletion and/or vaso-
lator therapy. This reaction usually responds to supine or
ose/Dosage Duration of Effect
mg up to 1.5 mg 1 to 7 min
needed Similar to sublingual tablets
mg per h every 12 h 8 to 12 h during intermittent therapy
cg per min Tolerance in 7 to 8 h
g, 2 or 3 times daily Up to 8 h
r 2 times daily Up to 8 h
ce daily 12 to 24 h
mg once daily
needed Not known
g as needed Not known
g 3 times daily Not known
pdate for the management of patients with chronic stable angina. AvailableD
to 0.6
mg as
to 0.8
o 200 m
o 80 m
mg 1 o
mg twi
to 240
mg as
o 10 m
to 30 m
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367ropine when accompanied by bradycardia; it rarely requires
essors or naloxone to restore blood pressure. Nausea and
miting occur in approximately 20% of patients. Respiratory
pression is the most serious complication of morphine;
vere hypoventilation that requires intubation occurs very
rely in patients with UA/NSTEMI treated with morphine.
aloxone (0.4 to 2.0 mg IV) may be administered for
orphine overdose with respiratory or circulatory depression.
ther narcotics may be considered in patients allergic to
orphine. A cautionary note on morphine use has been raised
data from a large observational registry (n  443 hospi-
ls) that enrolled patients with UA/NSTEMI (n  57,039)
13). Those receiving morphine (30%) had a higher adjusted
kelihood of death (propensity-adjusted OR  1.41, 95% CI
26 to 1.57), which persisted across all subgroups (313).
lthough subject to uncontrolled selection biases, these
sults raise a safety concern and suggest the need for a
ndomized trial. Meanwhile, the Writing Committee has
wngraded the recommendation for morphine use for un-
ntrolled ischemic chest discomfort from a Class I to a Class
a recommendation.
.1.2.3. BETA-ADRENERGIC BLOCKERS
eta blockers competitively block the effects of cat-
holamines on cell membrane beta receptors. Beta-1 adren-
gic receptors are located primarily in the myocardium;
hibition of catecholamine action at these sites reduces
yocardial contractility, sinus node rate, and AV node
nduction velocity. Through these actions, they blunt the
art rate and contractility responses to chest pain, exertion,
d other stimuli. They also decrease systolic blood pressure.
ll of these effects reduce MVO2. Beta-2 adrenergic recep-
rs are located primarily in vascular and bronchial smooth
uscle; the inhibition of catecholamine action at these sites
oduces vasoconstriction and bronchoconstriction (300). In
A/NSTEMI, the primary benefits of beta blockers are due to
hibition of beta-1 adrenergic receptors, which results in a
crease in cardiac work and myocardial oxygen demand.
lowing of the heart rate also has a favorable effect, acting not
ly to reduce MVO2 but also to increase the duration of
astole and diastolic pressure-time, a determinant of forward
ronary flow and collateral flow.
Beta blockers, administered orally, should be started early
the absence of contraindications. Intravenous administra-
on may be warranted in patients with ongoing rest pain,
pecially with tachycardia or hypertension, in the absence of
ntraindications (see below) (Table 12).
The benefits of routine early intravenous use of beta
ockers in the fibrinolytic era have been challenged by 2
ter randomized trials of intravenous beta blockade
14,315) and by a post hoc analysis of the use of atenolol in
e GUSTO-I trial (316). A subsequent systematic review of
rly beta-blocker therapy in STEMI found no significant
duction in mortality (27). Most recently, the utility of early
travenous followed by oral beta blockade (metoprolol) was
sted in 45,852 patients with MI (93% had STEMI, 7% had
STEMI) in the COMMIT study (317). Neither the compos-
e of death, reinfarction, or cardiac arrest nor death alone was
duced for up to 28 d in the hospital. Overall, a modest shduction in reinfarction and ventricular fibrillation (which
as seen after day 1) was counterbalanced by an increase in
rdiogenic shock, which occurred early (first day) and
imarily in those who were hemodynamically compromised
in HF or who were stable but at high risk of development
shock. Thus, early aggressive beta blockade poses a
bstantial net hazard in hemodynamically unstable patients
d should be avoided. Risk factors for shock were older age,
male sex, time delay, higher Killip class, lower blood
essure, higher heart rate, ECG abnormality, and previous
pertension. There was a moderate net benefit for those who
ere relatively stable and at low risk of shock. Whether to
art beta blockade intravenously or orally in these latter
able patients is unclear, and patterns of use vary. In an
tempt to balance the evidence base overall for UA/NSTEMI
tients, beta blockers are recommended in these guidelines
be initiated orally, in the absence of contraindications (e.g.,
F), within the first 24 h. Greater caution is now suggested in
e early use of intravenous beta blockers, which should be
rgeted to specific indications and should be avoided with
F, hypotension, and hemodynamic instability.
The choice of beta blocker for an individual patient is
sed primarily on pharmacokinetic and side effect criteria, as
ell as on physician familiarity (Table 15). There are no
mparative studies between members of this class in the
ute setting. Beta blockers without intrinsic sympathomi-
etic activity are preferred, however. Agents studied in the
ute setting include metoprolol, propranolol, and atenolol.
arvedilol may be added to the list of agents studied for
st-MI use. Comparative studies among different beta block-
s in the chronic setting after UA/NSTEMI also are not
ailable to establish a preference among agents. In patients
ith HF, 1 study suggested greater benefit with carvedilol,
ith mixed beta-blocking and alpha-adrenergic-blocking ef-
cts, than metoprolol, a relatively selective beta-1 blocker
18). In patients with hypertension, the relative cardiovas-
lar benefit of atenolol has been questioned on the basis of
cent clinical trial analyses (319,320).
Patients with marked first-degree AV block (i.e., ECG PR
terval greater than 0.24 s), any form of second- or third-
gree AV block in the absence of a functioning implanted
cemaker, a history of asthma, severe LV dysfunction or HF
.g., rales or S3 gallop) or at high risk for shock (see above)
ould not receive beta blockers on an acute basis (4).
atients with evidence of a low-output state (e.g., oliguria) or
nus tachycardia, which often reflects low stroke volume,
gnificant sinus bradycardia (heart rate less than 50 beats per
inute), or hypotension (systolic blood pressure less than 90
m Hg) should not receive acute beta-blocker therapy until
ese conditions have resolved. Patients at highest risk for
rdiogenic shock due to intravenous beta blockade in the
OMMIT trial were those with tachycardia or in Killip Class
or III (317). However, beta blockers are strongly recom-
ended before discharge in those with compensated HF or
V systolic dysfunction for secondary prevention (321).
atients with significant chronic obstructive pulmonary dis-
se who may have a component of reactive airway disease
ould be given beta blockers very cautiously; initially, low
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionses of a beta-1–selective agent should be used. If there are
ncerns about possible intolerance to beta blockers, initial
lection should favor a short-acting beta-1–specific drug
ch as metoprolol or esmolol. Mild wheezing or a history of
ronic obstructive pulmonary disease mandates a short-
ting cardioselective agent at a reduced dose (e.g., 12.5 mg
metoprolol orally) rather than the complete avoidance of a
ta blocker.
In the absence of these concerns, previously studied
gimens may be used. Intravenous metoprolol may be given
5-mg increments by slow intravenous administration (5 mg
er 1 to 2 min), repeated every 5 min for a total initial dose
15 mg. In patients who tolerate the total 15-mg IV dose,
al therapy can be initiated 15 min after the last intravenous
se at 25 to 50 mg every 6 h for 48 h. Thereafter, patients
ould receive a maintenance dose of up to 100 mg twice
ily. Alternatively, intravenous propranolol may be admin-
tered as an initial dose of 0.5 to 1.0 mg, followed in 1 to 2 h
40 to 80 mg by mouth every 6 to 8 h. Monitoring during
travenous beta-blocker therapy should include frequent
ecks of heart rate and blood pressure and continuous ECG
onitoring, as well as auscultation for rales and bronchos-
sm. Beta blockade also may be started orally, in smaller
itial doses if appropriate, within the first 24 h, in cases in
hich a specific clinical indication for intravenous initiation
absent or the safety of aggressive early beta blockade is a
ncern. Carvedilol, 6.25 mg by mouth twice daily, uptitrated
dividually at 3- to 10-d intervals to a maximum of 25 mg
ice daily, can reduce mortality and reinfarction when given
patients with recent (3 to 21 d) MI and LV dysfunction
21). After the initial intravenous load, if given, patients
ithout limiting side effects may be converted to an oral
gimen. The target resting heart rate is 50 to 60 beats per
inute unless a limiting side effect is reached. Selection of
e oral agent should include the clinician’s familiarity with
e agent. Maintenance doses are given in Table 15.
Initial studies of beta-blocker benefits in ACS were small
d uncontrolled. An overview of double-blind, randomized
ials in patients with threatening or evolving MI suggests an
ble 15. Properties of Beta Blockers in Clinical Use
Drugs Selectivity Partial Agonist Activit
opranolol None No
etoprolol Beta1 No
enolol Beta1 No
dolol None No
molol None No
ebutolol Beta1 Yes
taxolol Beta1 No
soprolol Beta1 No
molol (intravenous) Beta1 No
betalol* None Yes
ndolol None Yes
rvedilol None Yes
*Labetalol and carvedilol are combined alpha and beta blockers. Adapted from
r the management of patients with chronic stable angina. Available at: http://proximately 13% reduction in the risk of progression to MI di22). These trials were conducted prior to the routine use of
SA, heparin, clopidogrel, GP IIb/IIIa inhibitors, and revas-
larization. These trials lack sufficient power to assess the
fects of these drugs on mortality rates for UA. Pooled
sults from the Evaluation of c7E3 for the Prevention of
chemic Complications (EPIC), Evaluation of PTCA and
prove Long-term Outcome by c7E3 GP IIb/IIIa receptor
ockade (EPILOG), Evaluation of Platelet IIb/IIIa Inhibitor
r STENTing (EPISTENT), CAPTURE, and ReoPro in
cute myocardial infarction and Primary PTCA Organization
d Randomization Trial (RAPPORT) studies were used to
aluate the efficacy of beta-blocker therapy in patients with
CS who were undergoing PCI (323). At 30 d, death
curred in 0.6% of patients receiving beta-blocker therapy
rsus 2.0% of patients not receiving such therapy (p less
an 0.001). At 6 months, death occurred in 1.7% of patients
ceiving beta-blocker therapy versus 3.7% not receiving this
erapy (p less than 0.001). Thus, patients receiving beta-
ocker therapy who undergo PCI for UA or MI have a lower
ort-term mortality (323).
Overall, the rationale for beta-blocker use in all forms of
AD, including UA, is generally favorable, with the excep-
on of initial HF. In the absence of contraindications, the new
idence appears sufficient to make beta blockers a routine
rt of care. A related group shown to benefit are high- or
termediate-risk patients who are scheduled to undergo
rdiac or noncardiac surgery (324). A recent exception to
ta-blocker benefit was COMMIT, a large trial of mostly
TEMI patients, which showed no overall mortality effect.
ubgroup analysis suggested this to be due to an increased
sk in those with initial HF or risk factors for cardiogenic
ock (317). In contrast to this adverse experience with early,
gressive beta blockade, carvedilol, begun in low doses 3 to
d after MI in patients with LV dysfunction (ejection
action of 0.40 or less) and gradually uptitrated, decreased
bsequent death or nonfatal recurrent MI when given in
njunction with modern ACS therapies in the most contem-
rary oral beta blocker post-MI trial, CAPRICORN (Carve-
Usual Dose for Angina
20 to 80 mg twice daily
50 to 200 mg twice daily
50 to 200 mg per d
40 to 80 mg per d
10 mg twice daily
200 to 600 mg twice daily
10 to 20 mg per d
10 mg per d
50 to 300 mcg per kg per min
200 to 600 mg twice daily
2.5 to 7.5 mg 3 times daily
6.25 mg twice daily, uptitrated to a maximum of 25 mg twice daily
5, Gibbons PJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update
c.org/qualityandscience (4).y
Table 2lol Post-Infarct Survival Control in LV Dysfunction) (321).
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367In conclusion, evidence for the beneficial effects of the use
beta blockers in patients with UA is based on limited
ndomized trial data along with pathophysiological consid-
ations and extrapolation from experience with CAD pa-
ents who have other types of ischemic syndromes (stable
gina or compensated chronic HF). The duration of benefit
ith long-term oral therapy is uncertain and likely varies with
e extent of revascularization.
.1.2.4. CALCIUM CHANNEL BLOCKERS
alcium channel blockers (CCBs) reduce cell transmembrane
ward calcium flux, which inhibits both myocardial and
scular smooth muscle contraction; some also slow AV
nduction and depress sinus node impulse formation. Agents
this class vary in the degree to which they produce
sodilation, decreased myocardial contractility, AV block,
d sinus node slowing. Nifedipine and amlodipine have the
ost peripheral arterial dilatory effects but few or no AV or
nus node effects, whereas verapamil and diltiazem have
ominent AV and sinus node effects and some peripheral
terial dilatory effects as well. All 4 of these agents, as well
other approved agents, have coronary dilatory properties
at appear to be similar. Although different CCBs are
ructurally and, potentially, therapeutically diverse, superi-
ity of 1 agent over another in UA/NSTEMI has not been
monstrated, except for the increased risks posed by rapid-
lease, short-acting dihydropyridines such as nifedipine
able 16). Beneficial effects in UA/NSTEMI are believed to
due to variable combinations of decreased myocardial
ygen demand (related to decreased afterload, contractility,
d heart rate) and improved myocardial flow (related to
ronary arterial and arteriolar dilation) (300,325). These
ents also have theoretically beneficial effects on LV relax-
ion and arterial compliance. Major side effects include
potension, worsening HF, bradycardia, and AV block.
Calcium channel blockers may be used to control ongoing
ble 16. Properties of Calcium Channel Blockers in Clinical Use
Drug Usual Dose
hydropyridines
Nifedipine* Immediate release: 30 to 90 mg daily orally
Slow release: 30 to 180 mg orally
Amlodipine 5 to 10 mg once daily
Felodipine 5 to 10 mg once daily
Isradipine 2.5 to 10 mg twice daily
Nicardipine 20 to 40 mg 3 times daily
Nisoldipine 20 to 40 mg once daily
Nitrendipine 20 mg once or twice daily
Miscellaneous
ltiazem Immediate release: 30 to 90 mg 4 times daily
Slow release: 120 to 360 mg once daily
rapamil Immediate release: 80 to 160 mg 3 times daily
Slow release: 120 to 480 mg once daily
*Immediate-release nifedipine not recommended for UA/NSTEMI except wit
atterjee K, et al. ACC/AHA 2002 guideline update for the management of patientrecurring ischemia-related symptoms in patients who Cready are receiving adequate doses of nitrates and beta
ockers, in patients who are unable to tolerate adequate
ses of 1 or both of these agents, and in patients with variant
gina (see Section 6.7). In addition, these drugs have been
ed for the management of hypertension in patients with
current UA (325). Rapid-release, short-acting dihydropyri-
nes (e.g., nifedipine) must be avoided in the absence of
ncomitant beta blockade because of increased adverse
tential (326,327,328). Verapamil and diltiazem should be
oided in patients with pulmonary edema or evidence of
vere LV dysfunction (329–331). Amlodipine and felodip-
e are reasonably well tolerated by patients with mild LV
sfunction (329–334), although their use in UA/NSTEMI
s not been studied. The CCB evidence base in UA/
STEMI is greatest for verapamil and diltiazem (328,331).
Several randomized trials during the 1980s tested CCBs in
A/NSTEMI and found that they relieve or prevent signs and
mptoms of ischemia to a degree similar to the beta
ockers. The Danish Study Group on Verapamil in Myocar-
al Infarction (DAVIT) (332,333) studied 3,447 patients
ith suspected UA/NSTEMI. A benefit was not proved, but
ath or nonfatal MI tended to be reduced. The Diltiazem
einfarction Study (DRS) studied 576 patients with UA/
STEMI (329). Diltiazem reduced reinfarction and refractory
gina at 14 d without an increase in mortality rates.
etrospective analysis of the non–Q-wave MI subset of
tients in the Multicenter Diltiazem Postinfarction Trial
DPIT) suggested similar findings (334). The Holland
teruniversity Nifedipine/metoprolol Trial (HINT), tested
fedipine and metoprolol in a 2  2 factorial design in 515
tients (327). The study was stopped early because of
ncern for harm with the use of nifedipine alone. In contrast,
tients already taking a beta blocker appeared to benefit
om the addition of nifedipine (risk ratio [RR] 0.68) (335).
Meta-analyses combining UA/NSTEMI studies of all
n of
on Side Effects
Hypotension, dizziness, flushing, nausea, constipation, edema
Headache, edema
Headache, edema
Headache, fatigue
Headache, dizziness, flushing, edema
Similar to nifedipine
Similar to nifedipine
Hypotension, dizziness, flushing, bradycardia, edema
Hypotension, myocardial depression, heart failure, edema,
bradycardia
mitant beta blockade. Modified from Table 27 in Gibbons RJ, Abrams J,
hronic stable angina. Available at: http://www.acc.org/qualityandscience (4).Duratio
Acti
Short
Long
Long
Medium
Short
Short
Medium
Short
Long
Short
Long
h concoCBs have suggested no overall benefit (322,336), whereas
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ported favorable effects on outcomes (332). Retrospective
alyses of DAVIT and MDPIT suggested that verapamil and
ltiazem can have a detrimental effect on mortality rates in
tients with LV dysfunction (329,330). In contrast, vera-
mil reduced diuretic use in DAVIT-2 (333). Furthermore,
bsequent prospective trials with verapamil administered to
I patients with HF who were receiving an ACE inhibitor
ggested a benefit (330,337). The Diltiazem as Adjunctive
herapy to Activase (DATA) trial also suggested that intra-
nous diltiazem in MI patients can be safe; death, MI, and
current ischemia were decreased at 35 d and 6 months
38).
In summary, definitive evidence for a benefit of CCBs in
A/NSTEMI is predominantly limited to symptom control.
or immediate-release nifedipine, an increase in serious
ents is suggested when administered early without a beta
ocker. The heart rate–slowing CCB drugs (verapamil and
ltiazem) can be administered early to patients with UA/
STEMI without HF without overall harm and with trends
ward a benefit. Therefore, when beta blockers cannot be
ed, and in the absence of clinically significant LV dysfunc-
on, heart rate–slowing CCBs are preferred. Greater caution
indicated when combining a beta blocker and CCB for
fractory ischemic symptoms, because they may act in
nergy to depress LV function and sinus and AV node
nduction. The risks and benefits in UA/NSTEMI of newer
CBs, such as the dihydropyridines amlodipine and felodip-
e, relative to the older agents in this class that have been
viewed here, remain undefined, which suggests a cautious
proach, especially in the absence of beta blockade.
.1.2.5. INHIBITORS OF THE RENIN-ANGIOTENSIN-
LDOSTERONE SYSTEM
ngiotensin-converting enzyme inhibitors have been shown
reduce mortality rates in patients with MI or who recently
d an MI and have LV systolic dysfunction (339–341), in
tients with diabetes mellitus with LV dysfunction (342),
d in a broad spectrum of patients with high-risk chronic
AD, including patients with normal LV function (343).
ollow-up of patients with LV dysfunction after MI in the
RACE (TRAndolapril Cardiac Evaluation) trial showed that
e beneficial effect of trandolapril on mortality and hospital-
ation rate was maintained for at least 10 to 12 years (344).
systematic review assessing potential ASA–ACE inhibitor
teractions showed clinically important benefits with ACE
hibitor therapy, irrespective of whether concomitant ASA
as used, and only weak evidence of a reduction in the
nefit of ACE inhibitor therapy added to ASA (345); these
ta did not solely involve patients with MI. Accordingly,
CE inhibitors should be used in patients receiving ASA and
those with hypertension that is not controlled with beta
ockers. Recent data on ACE inhibitor patients with stable
AD are summarized in the section on long-term medical
erapy (see Section 5.2.3).
In patients with MI complicated by LV systolic dysfunc-
on, HF, or both, the angiotensin receptor blocker valsartan
as as effective as captopril in patients at high risk for
rdiovascular events after MI. The combination of valsartan Td captopril increased adverse events and did not improve
rvival (346). Although not in the acute care setting,
eatment of patients with chronic HF with candesartan (at
ast half of whom had an MI) in the CHARM (Candesartan
Heart failure Assessment in Reduction of Mortality)-
verall program showed a reduction in cardiovascular deaths
d hospital admissions for HF, independent of ejection
action or baseline treatment (347).
The selective aldosterone receptor blocker eplerenone,
ed in patients with MI complicated by LV dysfunction and
ther HF or diabetes mellitus, reduced morbidity and mor-
lity in the Eplerenone Post-acute myocardial infarction
eart failure Efficacy and SUrvival Study (EPHESUS) (348).
his complements data from the earlier Randomized ALda-
one Evaluation Study (RALES), in which aldosterone
ceptor blockade with spironolactone decreased morbidity
d death in patients with severe HF, half of whom had an
chemic origin (349). Indications for long-term use of
dosterone receptor blockers are given in Section 5.2.3.
.1.2.6. OTHER ANTI-ISCHEMIC THERAPIES
ther less extensively studied therapies for the relief of
chemia, such as spinal cord stimulation (350) and prolonged
ternal counterpulsation (351,352), are under evaluation.
ost experience has been gathered with spinal cord stimula-
on in “intractable angina” (353), in which anginal relief has
en described. They have not been applied in the acute
tting for UA/NSTEMI.
The KATP channel openers have hemodynamic and cardio-
otective effects that could be useful in UA/NSTEMI.
icorandil is such an agent that has been approved in a
mber of countries but not in the United States. In a pilot
uble-blind, placebo-controlled study of 245 patients with
A, the addition of this drug to conventional treatment
gnificantly reduced the number of episodes of transient
yocardial ischemia (mostly silent) and of ventricular and
praventricular tachycardia (354). Further evaluation of this
ass of agents is underway.
Ranolazine is a newly approved (January 2006) agent that
erts antianginal effects without reducing heart rate or blood
essure (355). Currently, ranolazine is indicated alone or in
mbination with amlodipine, beta-blockers, or nitrates for
e treatment of chronic angina that has failed to respond to
andard antianginal therapy. The recommended initial dose
500 mg orally twice daily, which can be escalated as
eded to a maximum of 1000 mg twice daily. The mecha-
sm of action of ranolazine has not been fully characterized
t appears to depend on membrane ion-channel effects
imilar to those after chronic amiodarone) (356). It is
ntraindicated in patients with QT-prolonging conditions.
reliminary results of a large (N  6,560) patient trial of
nolazine, begun within 48 h of UA/NSTEMI, suggested
fety and symptom relief (reduction in angina) but did not
hieve the primary efficacy end point of a reduction in the
mposite of cardiovascular death, MI, or recurrent ischemia
azard ratio [HR] 0.92, 95% CI 0.83 to 1.02) (357,357a).
hus, ranolazine may be safely administered for symptom
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ntly improve the underlying disease substrate.
.1.2.7. INTRA-AORTIC BALLOON PUMP COUNTERPULSATION
xperience with IABP for refractory ischemia dates back
ore than 30 years. In a prospective registry of 22,663 IABP
tients, 5,495 of whom had acute MI, placement of an IABP
MI patients primarily was performed for cardiogenic shock,
r hemodynamic support during catheterization and/or angio-
asty, before high-risk surgery, for mechanical complications of
I, or for refractory post-MI UA. Balloon insertions were
ccessful in 97.7% of patients, and major complications oc-
rred in 2.7% of patients during a median use of 3 d (358). The
acement of an IABP could be useful in patients with recurrent
chemia despite maximal medical management and in those
ith hemodynamic instability until coronary angiography and
vascularization can be completed.
.1.2.8. ANALGESIC THERAPY
ecause of the known increased risk of cardiovascular events
ong patients taking COX-2 inhibitors and NSAIDs
59–361), patients who are taking them at the time of
A/NSTEMI should discontinue them immediately (see Sec-
on 5.2.16 for additional discussion). A secondary analysis of
e Enoxaparin and Thrombolysis Reperfusion for Acute
yocardial Infarction Treatment (EXTRACT)-TIMI-25 data
gure 7. Algorithm for Patients With UA/NSTEMI Managed by an
phabetical order and not in order of preference (e.g., Boxes B1 a
ement strategy. ‡Evidence exists that GP IIb/IIIa inhibitors may
0 mg of clopidogrel at least 6 h earlier (Class I, Level of Evidenc
ticoagulant (Class IIa, Level of Evidence B). ASA  aspirin; GP  g
stable angina/non–ST-elevation myocardial infarction; UFH  un62) demonstrated an increased risk of death, reinfarction,F, or shock among patients who were taking NSAIDs within
d of enrollment. Longer term management is considered in
ection 5.2.16.
.2. Recommendations for
ntiplatelet/Anticoagulant Therapy
Patients for Whom Diagnosis of
A/NSTEMI Is Likely or Definite
ecommendations are written as the reader follows the
gorithms for antiplatelet/anticoagulant therapy and triage
r angiography (Figs. 7, 8, and 9). Letters after recommen-
tions refer to the specific box in the algorithm. See Table 13
r dosing recommendations.
.2.1. Antiplatelet Therapy Recommendations
PDATED) For new or updated text, view the 2011
ocused Update. Text supporting unchanged recom-
endations has not been updated.
ASS I
Aspirin should be administered to UA/NSTEMI patients as
soon as possible after hospital presentation and continued
indefinitely in patients not known to be intolerant of that
Invasive Strategy. When multiple drugs are listed, they are in
). *See dosing Table 13. †See Table 11 for selection of man-
necessary if the patient received a preloading dose of at least
r clopidogrel administration) and bivalirudin is selected as the
tein; IV  intravenous; LOE  level of evidence; UA/NSTEMI 
nated heparin.Initial
nd B2
not be
e B fo
lycopromedication. (Level of Evidence: A) (Figs. 7 and 8; Box A)
2.
3.
4.
5.
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dose)* should be administered to UA/NSTEMI patients who
are unable to take ASA because of hypersensitivity or major
gastrointestinal intolerance. (Level of Evidence: A) (Figs. 7
and 8; Box A)
In UA/NSTEMI patients with a history of gastrointestinal
bleeding, when ASA and clopidogrel are administered alone or
in combination, drugs to minimize the risk of recurrent gastro-
ome uncertainty exists about optimum dosing of clopidogrel. Randomized trials
tablishing its efficacy and providing data on bleeding risks used a loading dose of
0 mg orally followed by a daily oral maintenance dose of 75 mg. Higher oral
ading doses such as 600 or 900 mg of clopidogrel more rapidly inhibit platelet
gregation and achieve a higher absolute level of inhibition of platelet aggregation,
t the additive clinical efficacy and the safety of higher oral loading doses have not
gure 8. Algorithm for Patients With UA/NSTEMI Managed by an
alphabetical order and not in order of preference (e.g., Boxes C
anagement strategy. ‡Recurrent symptoms/ischemia, heart failur
ycoprotein; IV  intravenous; LOE  level of evidence; LVEF  l
T-elevation myocardial infarction; UFH  unfractionated heparin.en rigorously established.intestinal bleeding (e.g., proton-pump inhibitors) should be
prescribed concomitantly. (Level of Evidence: B)
For UA/NSTEMI patients in whom an initial invasive strategy is
selected, antiplatelet therapy in addition to aspirin should be
initiated before diagnostic angiography (upstream) with either
clopidogrel (loading dose followed by daily maintenance
dose)* or an intravenous GP IIb/IIIa inhibitor. (Level of Evi-
dence: A) Abciximab as the choice for upstream GP IIb/IIIa
therapy is indicated only if there is no appreciable delay to
angiography and PCI is likely to be performed; otherwise, IV
eptifibatide or tirofiban is the preferred choice of GP IIb/IIIa
inhibitor. (Level of Evidence: B)
For UA/NSTEMI patients in whom an initial conservative (i.e.,
noninvasive) strategy is selected (see Section 3.3), clopi-
Conservative Strategy. When multiple drugs are listed, they are
nd C2). *See dosing Table 13. †See Table 11 for selection of
us arrhythmia. ASA  aspirin; EF  ejection fraction; GP 
tricular ejection fraction; UA/NSTEMI  unstable angina/non–Initial
, C1, a
e, serio
eft vendogrel (loading dose followed by daily maintenance dose)*
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367should be added to ASA and anticoagulant therapy as soon as
possible after admission and administered for at least 1 month
(Level of Evidence: A) and ideally up to 1 year. (Level of
Evidence: B) (Fig. 8; Box C2)
For UA/NSTEMI patients in whom an initial conservative
strategy is selected, if recurrent symptoms/ischemia, HF, or
serious arrhythmias subsequently appear, then diagnostic an-
giography should be performed. (Level of Evidence: A) (Fig. 8;
Box D) Either an intravenous GP IIb/IIIa inhibitor (eptifibatide
or tirofiban; Level of Evidence: A) or clopidogrel (loading dose
followed by daily maintenance dose; Level of Evidence: A)*
should be added to ASA and anticoagulant therapy before
diagnostic angiography (upstream). (Level of Evidence: C)
ASS IIa
For UA/NSTEMI patients in whom an initial conservative
strategy is selected and who have recurrent ischemic discom-
fort with clopidogrel, ASA, and anticoagulant therapy, it is
reasonable to add a GP IIb/IIIa antagonist before diagnostic
angiography. (Level of Evidence: C)
For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to initiate antiplatelet therapy with
both clopidogrel (loading dose followed by daily maintenance
dose)* and an intravenous GP IIb/IIIa inhibitor. (Level of
ome uncertainty exists about optimum dosing. Randomized trials establishing its
cacy and providing data on bleeding risks used a loading dose of 300 mg orally
llowed by a daily oral maintenance dose of 75 mg. Higher oral loading doses such as
0 or 900 mg of clopidogrel may more rapidly inhibit platelet aggregation and achieve
igher absolute level of inhibition of platelet aggregation, but the additive efficacy and
gure 9. Management After Diagnostic Angiography in Patients With
hibitors may not be necessary if the patient received a preloading d
Evidence B for clopidogrel administration) and bivalirudin is selecte
s of UFH is recommended if fondaparinux is selected as the anticoa
ves coronary atherosclerosis is present, albeit without any significan
d other secondary prevention measures should be considered. ASA
tery disease; GP  glycoprotein; IV  intravenous; LD  loading do
ography; UA/NSTEMI  unstable angina/non–ST-elevation myocarde safety of higher oral loading doses have not been rigorously established. diEvidence: B) Abciximab as the choice for upstream GP IIb/IIIa
therapy is indicated only if there is no appreciable delay to
angiography and PCI is likely to be performed; otherwise, IV
eptifibatide or tirofiban is the preferred choice of GP IIb/IIIa
inhibitor.† (Level of Evidence: B)
For UA/NSTEMI patients in whom an initial invasive strategy is
selected, it is reasonable to omit upstream administration of
an intravenous GP IIb/IIIa antagonist before diagnostic angiog-
raphy if bivalirudin is selected as the anticoagulant and at
least 300 mg of clopidogrel was administered at least 6 h
earlier than planned catheterization or PCI. (Level of Evidence: B)
ASS IIb
r UA/NSTEMI patients in whom an initial conservative (i.e.,
ninvasive) strategy is selected, it may be reasonable to add
tifibatide or tirofiban to anticoagulant and oral antiplatelet
erapy. (Level of Evidence: B) (Fig. 8; Box C2)
ASS III
bciximab should not be administered to patients in whom PCI is
t planned. (Level of Evidence: A)
.2.2. Anticoagulant Therapy Recommendations
ASS I
nticoagulant therapy should be added to antiplatelet therapy in
A/NSTEMI patients as soon as possible after presentation.
. For patients in whom an invasive strategy is selected, regi-
mens with established efficacy at a Level of Evidence: A
actors favoring administration of both clopidogrel and GP IIb/IIIa inhibitor
clude: delay to angiography, high-risk features, and early recurrent ischemic
STEMI. *See dosing Table 13. †Evidence exists that GP IIb/IIIa
at least 300 mg of clopidogrel at least 6 h earlier (Class I, Level
e anticoagulant (Class IIa, Level of Evidence B). ‡Additional bo-
(see dosing Table 13). §For patients in whom the clinician be-
-limiting stenoses, long-term treatment with antiplatelet agents
pirin; CABG  coronary artery bypass graft; CAD  coronary
I  percutaneous coronary intervention; pre angio  before an-
rction; UFH  unfractionated heparin.UA/N
ose of
d as th
gulant
t, flow
 as
se; PCscomfort.
bc
CL
Fo
is
an
of
3
A
F
T
u
CL
1
2
3
4
5
‡L
Ta
*L
Ta
tri
do
or
ag
bu
e261JACC Vol. 57, No. 19, 2011 Anderson et al.
May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisioninclude enoxaparin and UFH (Fig. 7; Box B1), and those with
established efficacy at a Level of Evidence: B include bivaliru-
din and fondaparinux (Fig. 7; Box B1).
. For patients in whom a conservative strategy is selected,
regimens using either enoxaparin‡ or UFH (Level of Evidence:
A) or fondaparinux (Level of Evidence: B) have established
efficacy. (Fig. 8; Box C1) ‡See also Class IIa recommendation
below.
. In patients in whom a conservative strategy is selected and
who have an increased risk of bleeding, fondaparinux is pref-
erable. (Level of Evidence: B) (Fig. 8; Box C1)
ASS IIa
r UA/NSTEMI patients in whom an initial conservative strategy
selected, enoxaparin‡ or fondaparinux is preferable to UFH as
ticoagulant therapy, unless CABG is planned within 24 h. (Level
Evidence: B)
.2.3. Additional Management Considerations for
ntiplatelet and Anticoagulant Therapy (UPDATED)
or new or updated text, view the 2011 Focused Update.
ext supporting unchanged recommendations has not been
pdated.
ASS I
. For UA/NSTEMI patients in whom an initial conservative
strategy is selected and no subsequent features appear that
would necessitate diagnostic angiography (recurrent symp-
toms/ischemia, HF, or serious arrhythmias), a stress test
should be performed. (Level of Evidence: B) (Fig. 8; Box O)
a. If, after stress testing, the patient is classified as not at
low risk, diagnostic angiography should be performed.
(Level of Evidence: A) (Fig. 8; Box E1)
b. If, after stress testing, the patient is classified as being at
low risk (Fig. 8; Box E2), the instructions noted below should
be followed in preparation for discharge (Fig. 8; Box K) (Level
of Evidence: A):
1. Continue ASA indefinitely. (Level of Evidence: A)
2. Continue clopidogrel for at least 1 month (Level of
Evidence: A) and ideally up to 1 year. (Level of Evi-
dence: B)
3. Discontinue intravenous GP IIb/IIIa inhibitor if started
previously. (Level of Evidence: A)
4. Continue UFH for 48 h or administer enoxaparin or
fondaparinux for the duration of hospitalization, up to
8 d, and then discontinue anticoagulant therapy. (Level
of Evidence: A)
. For UA/NSTEMI patients in whom CABG is selected as a
postangiography management strategy, the instructions
noted below should be followed (Fig. 9; Box G).
a. Continue ASA. (Level of Evidence: A)
b. Discontinue clopidogrel 5 to 7 d before elective CABG.
(Level of Evidence: B) More urgent surgery, if necessary,
may be performed by experienced surgeons if the incre-
mental bleeding risk is considered acceptable. (Level of
Evidence: C)
c. Discontinue intravenous GP IIb/IIIa inhibitor (eptifibatide
or tirofiban) 4 h before CABG. (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue UFH. (Level of Evidence: B)
imited data are available for the use of other LMWHs (e.g., dalteparin; see
bles 13 and 17) in UA/NSTEMI. be2. Discontinue enoxaparin* 12 to 24 h before CABG and
dose with UFH per institutional practice. (Level of
Evidence: B)
3. Discontinue fondaparinux 24 h before CABG and dose
with UFH per institutional practice. (Level of Evidence: B)
4. Discontinue bivalirudin 3 h before CABG and dose with
UFH per institutional practice. (Level of Evidence: B)
. For UA/NSTEMI patients in whom PCI has been selected as a
postangiography management strategy, the instructions
noted below should be followed (Fig. 9 C; Box H):
a. Continue ASA. (Level of Evidence: A)
b. Administer a loading dose of clopidogrel† if not started
before diagnostic angiography. (Level of Evidence: A)
c. Administer an intravenous GP IIb/IIIa inhibitor (abciximab,
eptifibatide, or tirofiban) if not started before diagnostic
angiography for troponin-positive and other high-risk pa-
tients (Level of Evidence: A). See Class IIa recommenda-
tion below if bivalirudin was selected as the anticoagulant.
d. Discontinue anticoagulant therapy after PCI for uncompli-
cated cases. (Level of Evidence: B)
. For UA/NSTEMI patients in whom medical therapy is selected
as a postangiography management strategy and in whom no
significant obstructive CAD on angiography was found, anti-
platelet and anticoagulant therapy should be administered at
the discretion of the clinician. (Level of Evidence: C) For
patients in whom evidence of coronary atherosclerosis is
present (e.g., luminal irregularities or intravascular ultrasound-
demonstrated lesions), albeit without flow-limiting stenoses,
long-term treatment with ASA and other secondary prevention
measures should be prescribed. (Fig. 9; Box I) (Level of
Evidence: C)
. For UA/NSTEMI patients in whom medical therapy is selected
as a postangiography management strategy and in whom CAD
was found on angiography, the following approach is recom-
mended (Fig. 9; Box J):
a. Continue ASA. (Level of Evidence: A)
b. Administer a loading dose of clopidogrel† if not given
before diagnostic angiography. (Level of Evidence: A)
c. Discontinue intravenous GP IIb/IIIa inhibitor if started
previously. (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue intravenous UFH for at least 48 h or until
discharge if given before diagnostic angiography.
(Level of Evidence: A)
2. Continue enoxaparin for duration of hospitalization, up
to 8 d, if given before diagnostic angiography. (Level of
Evidence: A)
3. Continue fondaparinux for duration of hospitalization,
up to 8 d, if given before diagnostic angiography. (Level
of Evidence: B)
imited data are available for the use of other LMWHs (e.g., dalteparin; see
bles 13 and 17) in UA/NSTEMI.
†Some uncertainty exists about optimum dosing of clopidogrel. Randomized
als establishing its efficacy and providing data on bleeding risks used a loading
se of 300 mg orally followed by a daily oral maintenance dose of 75 mg. Higher
al loading doses such as 600 or 900 mg of clopidogrel more rapidly inhibit platelet
gregation and achieve a higher absolute level of inhibition of platelet aggregation,
t the additive clinical efficacy and the safety of higher oral loading doses have not
en rigorously established.
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–3674. Either discontinue bivalirudin or continue at a dose of
0.25 mg per kg per h for up to 72 h at the physician’s
discretion, if given before diagnostic angiography.
(Level of Evidence: B)
. For UA/NSTEMI patients in whom a conservative strategy is
selected and who do not undergo angiography or stress
testing, the instructions noted below should be followed (Fig. 8;
Box K):
a. Continue ASA indefinitely. (Level of Evidence: A)
b. Continue clopidogrel for at least 1 month (Level of Evi-
dence: A) and ideally up to 1 year. (Level of Evidence: B)
c. Discontinue IV GP IIb/IIIa inhibitor if started previously.
(Level of Evidence: A)
d. Continue UFH for 48 h or administer enoxaparin or fonda-
parinux for the duration of hospitalization, up to 8 d, and
then discontinue anticoagulant therapy. (Level of Evi-
dence: A)
. For UA/NSTEMI patients in whom an initial conservative
strategy is selected and in whom no subsequent features
appear that would necessitate diagnostic angiography (recur-
rent symptoms/ischemia, HF, or serious arrhythmias), LVEF
should be measured. (Level of Evidence: B) (Fig. 8; Box L)
ASS IIa
For UA/NSTEMI patients in whom PCI is selected as a postan-
giography management strategy, it is reasonable to omit
administration of an intravenous GP IIb/IIIa antagonist if
bivalirudin was selected as the anticoagulant and at least 300
mg of clopidogrel was administered at least 6 h earlier. (Level
of Evidence: B) (Fig. 9)
If LVEF is less than or equal to 0.40, it is reasonable to perform
diagnostic angiography. (Level of Evidence: B) (Fig. 8; Box M)
If LVEF is greater than 0.40, it is reasonable to perform a stress
test. (Level of Evidence: B) (Fig. 8; Box N)
ASS IIb
r UA/NSTEMI patients in whom PCI is selected as a postan-
ography management strategy, it may be reasonable to omit an
travenous GP IIb/IIIa inhibitor if not started before diagnostic
giography for troponin-negative patients without other clinical
angiographic high-risk features. (Level of Evidence: C)
ASS III
travenous fibrinolytic therapy is not indicated in patients with-
t acute ST-segment elevation, a true posterior MI, or a pre-
med new left bundle-branch block. (Level of Evidence: A)
ntithrombotic therapy is essential to modify the disease
ocess and its progression to death, MI, or recurrent MI in
e majority of patients who have ACS due to thrombosis on
plaque. A combination of ASA, an anticoagulant, and
ditional antiplatelet therapy represents the most effective
erapy. The intensity of treatment is tailored to individual
sk, and triple-antithrombotic treatment is used in patients
ith continuing ischemia or with other high-risk features and
patients oriented to an early invasive strategy (Table 11;
igs. 7, 8, and 9). Table 13 shows the recommended doses of
e various agents. A problematic group of patients are those
ho present with UA/NSTEMI but who are therapeutically
ticoagulated with warfarin. In such patients, clinical judg-
ent is needed with respect to initiation of the antiplatelet pad anticoagulant therapy recommended in this section. A
neral guide is not to initiate anticoagulant therapy until the
ternational normalized ratio (INR) is less than 2.0. How-
er, antiplatelet therapy should be initiated even in patients
erapeutically anticoagulated with warfarin, especially if an
vasive strategy is planned and implantation of a stent is
ticipated. In situations where the INR is supratherapeutic,
e bleeding risk is unacceptably high, or urgent surgical
eatment is necessary, reversal of the anticoagulant effect of
arfarin may be considered with either vitamin K or fresh-
ozen plasma as deemed clinically appropriate on the basis
physician judgment.
.2.4. Antiplatelet Agents and Trials
spirin, Ticlopidine, Clopidogrel)
.2.4.1. ASPIRIN
ome of the strongest evidence available about the long-term
ognostic effects of therapy in patients with coronary disease
rtains to ASA (363). By irreversibly inhibiting COX-1
ithin platelets, ASA prevents the formation of thromboxane
2, thereby diminishing platelet aggregation promoted by
is pathway but not by others. This platelet inhibition is the
ausible mechanism for the clinical benefit of ASA, both
cause it is fully present with low doses of ASA and because
atelets represent one of the principal participants in throm-
s formation after plaque disruption. Alternative or addi-
onal mechanisms of action for ASA are possible, such as an
ti-inflammatory effect (364), but they are unlikely to be
portant at the low doses of ASA that are effective in
A/NSTEMI. Among all clinical investigations with ASA,
ials in UA/NSTEMI have consistently documented a strik-
g benefit of ASA compared with placebo independent of the
fferences in study design, such as time of entry after the
ute phase, duration of follow-up, and dose used (365–368)
ig. 10).
No trial has directly compared the efficacy of different
ses of ASA in patients who present with UA/NSTEMI;
wever, information can be gleaned from a collaborative
eta-analysis of randomized trials of antiplatelet therapy for
evention of death, MI, and stroke in high-risk patients (i.e.,
ute or previous vascular disease or other predisposing
nditions) (375). This collaborative meta-analysis pooled
ta from 195 trials involving more than 143,000 patients and
monstrated a 22% reduction in the odds of vascular death,
I, or stroke with antiplatelet therapy across a broad spec-
um of clinical presentations that included patients present-
g with UA/NSTEMI. Indirect comparisons of the propor-
onal effects of different doses of ASA ranging from less than
mg to up to 1500 mg daily showed similar reductions in
e odds of vascular events with doses between 75 and 1500
g daily; when less than 75 mg was administered daily, the
oportional benefit of ASA was reduced by at least one half
mpared with the higher doses. An analysis from the CURE
ial suggested that there was no difference in the rate of
rombotic events according to ASA dose, but there was a
se-dependent increase in bleeding in patients receiving
SA (plus placebo): the major bleeding rate was 2.0% in
tients taking less than 100 mg of ASA, 2.3% with 100 to
20
T
pr
m
S
le
in
A
w
tr
sh
ha
bu
ti
of
af
dr
pr
w
ch
su
an
F
co
fo
L
L
A
st
si
bu
(3
du
pr
in
Fi
tr
A
co
va
po
tr
P
Th
an
c7
ar
pl
w
P
P
S
ar
e263JACC Vol. 57, No. 19, 2011 Anderson et al.
May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revision0 mg, and 4.0% with greater than 200 mg per d (243,376).
herefore, maintenance doses of 75 to 162 mg of ASA are
eferred.
The prompt action of ASA and its ability to reduce
ortality rates in patients with suspected MI enrolled in the
econd International Study of Infarct Survival (ISIS-2) trial
d to the recommendation that ASA be initiated immediately
the ED once the diagnosis of ACS is made or suspected.
spirin therapy also can be started in the prehospital setting
hen ACS is suspected. On the basis of prior randomized
ial protocols and clinical experience, the initial dose of ASA
ould be between 162 and 325 mg. Although some trials
ve used enteric-coated ASA for initial dosing, more rapid
ccal absorption occurs with non–enteric-coated formula-
ons (377). After stenting, a higher initial maintenance dose
ASA of 325 mg per d has been recommended for 1 month
ter bare-metal stent implantation and 3 to 6 months after
ug-eluting stent (DES) implantation (2). This was based
gure 10. Older Trials of Antiplatelet and Anticoagulant Therapy i
ials except PRISM compared GP IIb-IIIa with UFH versus UFH. M
SA with placebo, the combination of UFH and ASA with ASA alo
mbination of a platelet GP IIb/IIIa antagonist, UFH, and ASA wit
lue for each trial are shown. The timing of the end point (death o
rted at the 30-d time point. Incremental gain is observed from s
iple antithrombotic therapy with ASA, UFH, and a platelet GP IIb/
CI after 20 to 24 h per study design. Data are taken from PURSU
éroux et al. (367), RISC group (368), ATACS group (369), Gurfink
d PRISM (374). anta.  antagonist; ASA  aspirin; ATACS  An
E3 Fab AntiPlatelet Therapy in Unstable REfractory angina; CI 
tery disease; GP  glycoprotein; hep.  heparin; LMWH  low-
icable; PARAGON  Platelet IIb/IIIa Antagonism for the Reductio
ork; PCI  percutaneous coronary intervention; PRISM  Platele
LUS  Platelet Receptor Inhibition in ischemic Syndrome Manag
URSUIT  Platelet glycoprotein IIb/IIIa in Unstable angina: Recep
tability in Coronary artery disease; UA/NSTEMI  unstable angin
in; VA  Veterans Affairs.imarily on clinical trials that led to approval of these stents, shhich used the higher doses initially. However, a dosage
ange to a range of 162 to 325 mg per d initially has been
bsequently recommended, based on risk of excess bleeding
d an update of current evidence for ASA dosing (Table 13;
ig. 11).
In patients who are already receiving ASA, it should be
ntinued. The protective effect of ASA has been sustained
r at least 1 to 2 years in clinical trials in UA/NSTEMI.
onger term follow-up data in this population are lacking.
ong-term efficacy can be extrapolated from other studies of
SA therapy in CAD. Studies in patients with prior MI,
roke, or transient ischemic attack have shown statistically
gnificant benefit during the first 2 years and some additional
t not statistically significant benefit during the third year
63). In the absence of large comparison trials of different
rations of antiplatelet treatment in patients with CVD or in
imary prevention, it seems prudent to continue ASA indef-
itely unless side effects are present (1,4,365). Thus, patients
STEMI. *Best results group. †GPIIb/IIIa with no heparin. ‡All
alysis of randomized trials in UA/NSTEMI that have compared
combination of an LMWH and ASA with ASA alone, and the
plus ASA. The risk ratio values, 95% CIs, and probability
aried. Results with the platelet GP IIb/IIIa antagonists are re-
erapy with ASA to double therapy with ASA and UFH and to
tagonist. In the CAPTURE trial, nearly all patients underwent
), PRISM-PLUS (130), Lewis et al. (365), Cairns et al. (366),
l. (370), FRISC group (371), CAPTURE (372), PARAGON (373),
botic Therapy in Acute Coronary Syndromes; CAPTURE 
ence interval; FRISC  FRagmin during InStability in Coronary
lar-weight heparin; MI  myocardial infarction; NA  not ap-
cute coronary syndrome events in a Global Organization Net-
ptor Inhibition in ischemic Syndrome Management; PRISM-
in Patients Limited by Unstable Signs and symptoms;
ppression Using Integrilin Therapy; RISC  Research on In-
ST-elevation myocardial infarction; UFH  unfractionated hep-n UA/N
eta-an
ne, the
h UFH
r MI) v
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ntinue the drug indefinitely, unless a contraindication
velops. It is important to emphasize to patients that there is
sound rationale for concomitant use of ASA even if other
tithrombotic drugs, such as clopidogrel or warfarin, are
ministered concurrently (Fig. 11) and that withdrawal or
scontinuation of ASA or clopidogrel has been associated
ith recurrent episodes of ACS, including stent thrombosis
78–380). Finally, because of a drug interaction between
uprofen and ASA, patients should be advised to use an
ternative NSAID or to take their ibuprofen dose at least 30
in after ingestion of immediate-release ASA or at least 8 h
fore ASA ingestion to avoid any potential diminution of the
otective effects of ASA. No recommendations about the
ncomitant use of ibuprofen and enteric-coated low-dose
SA can be made on the basis of available data (381).
Contraindications to ASA include intolerance and allergy
rimarily manifested as asthma with nasal polyps), active
eeding, hemophilia, active retinal bleeding, severe un-
eated hypertension, an active peptic ulcer, or another serious
urce of gastrointestinal or genitourinary bleeding. Gastro-
testinal side effects such as dyspepsia and nausea are
gure 11. Long-Term Antitcoagulant Therapy at Hospital Discharg
grel alone (indefinitely), or try aspirin desensitization. †For clopid
ontinue ASA indefinitely and warfarin longer term as indicated fo
nous, or pulmonary emboli. §When warfarin is added to aspirin p
tional normalized ratio; LOE  Level of Evidence; LV  left vent
farction.frequent with the low doses. Primary prevention trials have Aported a small excess in intracranial bleeding, which is
fset in secondary prevention trials by the prevention of
chemic stroke. It has been proposed that there is a negative
teraction between ACE inhibitors and ASA, with a reduc-
on in the vasodilatory effects of ACE inhibitors, presumably
cause ASA inhibits ACE inhibitor–induced prostaglandin
nthesis. This interaction does not appear to interfere im-
rtantly with the clinical benefits of therapy with either
ent (382). Therefore, unless there are specific contraindi-
tions, ASA should be administered to all patients with
A/NSTEMI.
.2.4.2. ADENOSINE DIPHOSPHATE RECEPTOR
NTAGONISTS AND OTHER ANTIPLATELET AGENTS
wo thienopyridines—ticlopidine and clopidogrel—are ADP
ceptor (P2Y12) antagonists that are approved for antiplate-
t therapy (383). The platelet effects of ticlopidine and
opidogrel are irreversible but take several days to achieve
aximal effect in the absence of a loading dose. The
ministration of a loading dose can shorten the time to
hievement of effective levels of antiplatelet therapy. Be-
use the mechanisms of the antiplatelet effects of ASA and
r UA/NSTEMI. *For aspirin (ASA) allergic patients, use clopi-
llergic patients, use ticlopidine, 250 mg by mouth twice daily.
ific conditions such as atrial fibrillation; LV thrombus; cerebral,
pidogrel, an INR of 2.0 to 2.5 is recommended. INR  inter-
UA/NSTEMI  unstable angina/non–ST-elevated myocardiale Afte
ogrel a
r spec
lus clo
ricular;DP antagonists differ, a potential exists for additive benefit
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionith the combination. In patients with a history of gastroin-
stinal bleeding, when ASA or a thienopyridine is adminis-
red alone or in combination, drugs to minimize the risk of
current gastrointestinal bleeding (e.g., proton-pump inhibi-
rs) should be prescribed concomitantly (384–386).
Ticlopidine has been used successfully for the secondary
evention of stroke and MI and for the prevention of stent
osure and graft occlusion (387). The adverse effects of
clopidine limit its usefulness: gastrointestinal problems
iarrhea, abdominal pain, nausea, and vomiting), neutrope-
a in approximately 2.4% of patients, severe neutropenia in
8% of patients, and, rarely, thrombotic thrombocytopenia
rpura (388). Neutropenia usually resolves within 1 to 3
eeks of discontinuation of therapy but very rarely may be
tal. Thrombotic thrombocytopenia purpura, which is a very
common, life-threatening complication, requires immedi-
e plasma exchange. Monitoring of ticlopidine therapy
quires a complete blood count that includes a differential
unt every 2 weeks for the first 3 months of therapy.
Extensive clinical experience with clopidogrel is derived in
rt from the Clopidogrel versus Aspirin in Patients at Risk of
chaemic Events (CAPRIE) trial (389). A total of 19,185
tients were randomized to receive ASA 325 mg per d or
opidogrel 75 mg per d. Entry criteria consisted of athero-
lerotic vascular disease manifested as recent ischemic
roke, recent MI, or symptomatic peripheral arterial disease.
ollow-up extended for 1 to 3 years. The RR of ischemic
roke, MI, or vascular death was reduced by 8.7% in favor of
opidogrel from 5.8% to 5.3% (p  0.04). The benefit was
eatest for patients with peripheral arterial disease. This
oup had a 24% relative risk reduction (p 0.03). There was
slightly increased, but minimal, incidence of rash and
arrhea with clopidogrel treatment and slightly more bleed-
g with ASA. There was no excess neutropenia with clopi-
grel, which contrasts with ticlopidine. The results provide
idence that clopidogrel is at least as effective as ASA and
pears to be modestly more effective. In 1 report, 11 severe
ses of thrombotic thrombocytopenia purpura were de-
ribed as occurring within 14 d after the initiation of
opidogrel; plasma exchange was required in 10 of the
tients, and 1 patient died (390). These cases occurred
ong more than 3 million patients treated with clopidogrel.
Clopidogrel is reasonable antiplatelet therapy for second-
y prevention, with an efficacy at least similar to that of
SA. Clopidogrel is indicated in patients with UA/NSTEMI
ho are unable to tolerate ASA due to either hypersensitivity
major gastrointestinal contraindications, principally recent
gnificant bleeding from a peptic ulcer or gastritis. In patients
ith a history of gastrointestinal bleeding while taking ASA,
hen a thienopyridine is administered, drugs to minimize the
sk of recurrent gastrointestinal bleeding (e.g., proton-pump
hibitors) should be prescribed concomitantly (384–386).
hen treatment with thienopyridines is considered during the
ute phase, it should be recognized that there is a delay
fore attainment of the full antiplatelet effect. Clopidogrel is
eferred to ticlopidine because it more rapidly inhibits
atelets and appears to have a more favorable safety profile. frAn oral loading dose (300 mg) of clopidogrel is typically
ed to achieve more rapid platelet inhibition. The optimal
ading dose with clopidogrel has not been rigorously estab-
shed. The greatest amount of general clinical experience and
ndomized trial data exist for a clopidogrel loading dose of
0 mg, which is the approved loading dose. Higher loading
ses (600 to 900 mg) have been evaluated (391,392). They
pear to be safe and more rapidly acting; however, it must be
cognized that the database for such higher loading doses is
t sufficiently robust to formulate definitive recommenda-
ons. Most studies to date with higher loading doses of
opidogrel have examined surrogates for clinical outcomes,
ch as measurements of 1 or more markers of platelet
gregation or function. When groups of patients are studied,
general dose response is observed with increasing magni-
de and speed of onset of inhibition of platelet aggregation in
sponse to agonists such as ADP as the loading dose
creases. However, considerable interindividual variation in
tiplatelet effect also is observed with all loading doses of
opidogrel, which makes it difficult to predict the impact of
fferent loading doses of clopidogrel in a specific patient.
mall to moderate-sized trials have reported favorable out-
mes with a 600-mg versus a 300-mg loading dose in
tients undergoing PCI (393); however, large-scale random-
ed trials are still needed to definitively compare the efficacy
d safety of different loading regimens of clopidogrel. This
of particular importance because it is known that patients
dergoing CABG surgery shortly after receiving 300 mg of
opidogrel have an increased risk of bleeding (394); the
lative risk of bleeding associated with higher loading doses
clopidogrel remains to be established. The Writing Com-
ittee endorses the performance of appropriately designed
inical trials to identify the optimal loading dose of clopidogrel.
Two randomized trials compared clopidogrel with ticlopi-
ne. In 1 study, 700 patients who successfully received a
ent were randomized to receive 500 mg of ticlopidine or 75
g of clopidogrel, in addition to 100 mg of ASA, for 4 weeks
95). Cardiac death, urgent target-vessel revascularization,
giographically documented thrombotic stent occlusion, or
nfatal MI within 30 d occurred in 3.1% of patients who
ceived clopidogrel and 1.7% of patients who received
clopidine (p  0.24), and noncardiac death, stroke, severe
ripheral vascular hemorrhagic events, or any adverse event
at resulted in the discontinuation of the study medication
curred in 4.5% and 9.6% of patients, respectively (p 
01). The CLopidogrel ASpirin Stent International Cooper-
ive Study (CLASSICS) (396) was conducted in 1,020
tients. A loading dose of 300 mg of clopidogrel followed
75 mg per d was compared to a daily dose of 75 mg
ithout a loading dose and with a loading dose of 150 mg of
clopidine followed by 150 mg twice per day (patients in
ch of the 3 arms also received ASA). The first dose was
ministered 1 to 6 h after stent implantation; the treatment
ration was 28 d. The trial showed better tolerance to
opidogrel with or without a loading dose than to ticlopidine.
tent thrombosis or major complications occurred at the same
equency in the 3 groups.
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367The CURE trial randomized 12,562 patients with UA and
STEMI presenting within 24 h to placebo or clopidogrel
oading dose of 300 mg followed by 75 mg daily) and
llowed them for 3 to 12 months (243). All patients received
SA. Cardiovascular death, MI, or stroke occurred in 11.5%
patients assigned to placebo and 9.3% assigned to clopi-
grel (RR  0.80, p less than 0.001). In addition, clopi-
grel was associated with significant reductions in the rate
in-hospital severe ischemia and revascularization, as well
the need for fibrinolytic therapy or intravenous GP IIb/IIIa
ceptor antagonists. These results were observed across a
ide variety of subgroups. A reduction in recurrent ischemia
as noted within the first few hours after randomization.
There was an excess of major bleeding (2.7% in the
acebo group vs. 3.7% in the clopidogrel group, p  0.003)
d of minor bleeding but not of life-threatening bleeding.
he risk of bleeding was increased in patients undergoing
ABG surgery within the first 5 d of stopping clopidogrel.
he CURE study was conducted at centers in which there was
routine policy regarding early invasive procedures; revas-
larization was performed during the initial admission in
ly 23% of the patients. Although the addition of a platelet
P IIb/IIIa inhibitor in patients receiving ASA, clopidogrel,
d heparin in CURE was well tolerated, fewer than 10% of
tients received this combination. Therefore, additional
formation on the safety of an anticoagulant and a GP
b/IIIa inhibitor in patients already receiving ASA and
opidogrel should be obtained. Accurate estimates of the
eatment benefit of clopidogrel in patients who received GP
b/IIIa antagonists remain ill-defined.
The CURE trial also provides strong evidence for the
dition of clopidogrel to ASA on admission in the manage-
ent of patients with UA and NSTEMI in whom a noninter-
ntional approach is intended, an especially useful approach
hospitals that do not have a routine policy about early
vasive procedures. The event curves for the 2 groups
parate early. The optimal duration of therapy with clopi-
grel in patients who have been managed exclusively
edically has not been determined, but the favorable results
CURE were observed over a period averaging 9 months
d for up to 1 year.
The PCI-CURE study was an observational substudy of the
tients undergoing PCI within the larger CURE trial (397).
the PCI-CURE study, 2,658 patients had previously been
ndomly assigned to double-blind treatment with clopidogrel
 1,313) as per the CURE protocol or placebo (n 
345). Patients were pretreated with ASA and the study drug
r a median of 10 d. After PCI, most patients received
en-label thienopyridine for approximately 4 weeks, after
hich the blinded study drug was restarted for a mean of 8
onths. Fifty-nine patients (4.5%) in the clopidogrel group
d the primary end point (a composite of cardiovascular
ath, MI, or urgent target-vessel revascularization) within
d of PCI compared with 86 (6.4%) in the placebo group
R  0.70, 95% CI 0.50 to 0.97, p  0.03). Overall,
cluding events before and after PCI, there was a 31%
duction in cardiovascular death or MI (p  0.002). Thus, in
tients with UA and NSTEMI receiving ASA and undergo- rig PCI, a strategy of clopidogrel pretreatment followed by
to 1 year of clopidogrel use (and probably at least 1 year
those with DES; see below) is beneficial in reducing major
rdiovascular events compared with placebo and appears to
cost-effective (the incremental cost-effectiveness ratio for
opidogrel plus ASA compared with ASA alone was
5,400 per quality-adjusted life-year) (398). Therefore,
opidogrel should be used routinely in patients who undergo
CI.
Pathological and clinical evidence particularly highlights
e need for longer-term ADP-receptor blockade in patients
ho receive DES (399). DESs consistently have been shown
reduce stent restenosis. However, this same antiprolifera-
ve action can delay endothelialization, predisposing to stent
rombosis including late (beyond 3–6 months) or very late
fter 1 year) thrombosis after stent placement (399,399a,400).
hese concerns have raised questions about the ideal duration
dual antiplatelet therapy (DAT) and the overall balance of
nefit/risk of DES compared with bare-metal stents (401). A
mber of comparisons of outcomes up to 4 years after DES
d bare-metal stent implantation, including the initial FDA
proval trials, have been published (400,402–404,404a–404f).
hese confirm a marked reduction in restenosis and conse-
ent repeat revascularization procedures with DES (404c).
owever, although results have varied, they also suggest a
all incremental risk (of about 0.5%) of stent thrombosis
04a–404c). Reassuringly, they have not shown an overall
crease in death or MI after DES versus bare-metal stents,
ggesting offsetting advantages of improved revasculariza-
on versus increased stent thrombosis risk. These observa-
ons also emphasize the need for a continued search for more
ocompatible stents that minimize restenosis without in-
easing the risks of thrombosis.
In the ISAR-REACT-2 trial, patients undergoing PCI were
signed to receive either abciximab (bolus of 0.25 mg per kg
body weight, followed by a 0.125-mg per kg per min
aximum, 10 mg per min] infusion for 12 h, plus heparin 70
per kg of body weight) or placebo (placebo bolus and
fusion of 12 h, plus heparin bolus, 140 U per kg) (244). All
tients received 600 mg of clopidogrel at least 2 h before the
ocedure, as well as 500 mg of oral or intravenous ASA. Of
022 patients enrolled, 1,012 were assigned to abciximab
d 1,010 to placebo. The primary end point was reached in
patients (8.9%) assigned to abciximab versus 120 patients
1.9%) assigned to placebo, a 25% reduction in risk with
ciximab (RR 0.75, 95% CI 0.58 to 0.97, p 0.03) (244).
mong patients without an elevated cTn level, there was no
fference in the incidence of primary end-point events
tween the abciximab group (23 [4.6%] of 499 patients) and
e placebo group (22 [4.6%] of 474 patients; RR  0.99,
% CI 0.56 to 1.76, p 0.98), whereas among patients with
elevated cTn level, the incidence of events was signifi-
ntly lower in the abciximab group (67 [13.1%] of 513
tients) than in the placebo group (98 [18.3%] of 536
tients), which corresponds to an RR of 0.71 (95% CI 0.54
0.95, p  0.02; p  0.07 for interaction). There were no
gnificant differences between the 2 groups with regard to the
sk of major or minor bleeding or the need for transfusion.
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionhus, it appears beneficial to add an intravenous GP IIb/IIIa
hibitor to thienopyridine treatment if an invasive strategy is
anned in patients with high-risk features (e.g., elevated cTn
vel; Figs. 7, 8, and 9).
The optimal timing of administration of the loading dose of
opidogrel for those who are managed with an early invasive
rategy cannot be determined with certainty from PCI-CURE
cause there was no comparison of administration of the
ading dose before diagnostic angiography (“upstream treat-
ent”) versus at the time of PCI (“in-lab treatment”). How-
er, based on the early separation of the curves, when there
delay to coronary angiography, patients should receive
opidogrel as initial therapy (Figs. 7, 8, and 9). The Clopi-
grel for the Reduction of Events During Observation
REDO) trial (405), albeit not designed specifically to study
A/NSTEMI patients, provides partially relevant information
the question of timing of the loading dose. Patients with
mptomatic CAD and evidence of ischemia who were
ferred for PCI and those who were thought to be highly
kely to require PCI were randomized to receive clopidogrel
00 mg) or matching placebo 3 to 24 h before PCI. All
bjects received a maintenance dose of clopidogrel (75 mg
ily) for 28 d. Thus, CREDO is really a comparison of the
ministration of a loading dose before PCI versus not
ministering a loading dose at all. There is no explicit
mparison within CREDO of a pre-PCI loading dose versus
loading dose in the catheterization laboratory. In CREDO,
e relative risk for the composite end point of death/MI/
gent target-vessel revascularization was 0.82, in favor of
e group who received a loading dose before PCI compared
ith the opposite arm that did not receive a loading dose, but
is did not reach statistical significance (p 0.23). Subgroup
alyses within CREDO suggest that if the loading dose is
ven at least 6 or preferably 15 h before PCI, fewer events
cur compared with no loading dose being administered
06). One study from the Netherlands that compared pre-
eatment with clopidogrel before PCI versus administration
a loading dose at the time of PCI in patients undergoing
ective PCI showed no difference in biomarker release or
inical end points (407).
Thus, there now appears to be an important role for
opidogrel in patients with UA/NSTEMI, both in those who
e managed conservatively and in those who undergo PCI,
pecially stenting, or who ultimately undergo CABG surgery
08). However, it is not entirely clear how long therapy
ould be maintained (409,410). Whereas increased hazard is
early associated with premature discontinuation of dual
tiplatelet therapy after DES (405,411,412), the benefit of
tended therapy beyond 1 year is uncertain (401,404d,404e).
ence, the minimum requirements for DAT duration should
vigorously applied for each DES type. However, 1 year of
AT may be ideal for all UA/NSTEMI patients who are not
high risk of bleeding given the secondary preventive effects
DAT, perhaps especially after DES. On the other hand, the
mited database at this point in time does not support a
commendation for DAT beyond 1 year for all DES-treated
tients (401,404d,404e). For patients with clinical features
sociated with an increased risk of stent thrombosis, such as 1.abetes or renal insufficiency or procedural characteristics
ch as multiple stents or a treated bifurcation lesion, ex-
nded DAT may be reasonable. Data on the relative merits of
ES versus bare-metal stents in “off-label” patients (such as
ultivessel disease or MI), who are at higher risk and
perience higher event rates, and of the ideal duration of
AT in these patients, are limited and are currently insuffi-
ent to draw separate conclusions (401,404d,404e).
Because of the importance of dual-antiplatelet therapy with
SA and a thienopyridine after implantation of a stent,
pecially if a DES is being considered, clinicians should
certain whether the patient can comply with 1 year of
al-antiplatelet therapy. Patients should also be instructed to
ntact their treating cardiologist before stopping any anti-
atelet therapy, because abrupt discontinuation of antiplate-
t therapy can put the patient at risk of stent thrombosis, an
ent that may result in MI or even death (411). Health care
oviders should postpone elective surgical procedures until
yond 12 months after DES implantation (411). If a surgical
ocedure must be performed sooner than 12 months, an
fort should be made to maintain the patient on ASA and
inimize the period of time of discontinuation of a thien-
yridine (411).
In the CURE study, which predominantly involved medi-
l management of patients with UA/NSTEMI, the relative
sk reduction in events was of a similar magnitude (approx-
ately 20%) during the first 30 d after randomization as
ring the ensuing cumulative 8 months (413). In contrast,
opidogrel was not beneficial in a large trial of high-risk
imary prevention patients (414).
Because clopidogrel, when added to ASA, increases the
sk of bleeding during major surgery, it has been recom-
ended that clopidogrel be withheld for at least 5 d (243) and
to 7 d before surgery in patients who are scheduled for
ective CABG (376,415). In many hospitals in which pa-
ents with UA/NSTEMI undergo rapid diagnostic catheter-
ation within 24 h of admission, clopidogrel is not started
til it is clear that CABG will not be scheduled within the
xt several days. However, unstable patients should receive
opidogrel or be taken for immediate angiography (Figs. 7,
and 9). A loading dose of clopidogrel can be given to a
tient on the catheterization table if a PCI is to be performed
mediately. If PCI is not performed, clopidogrel can be
ven after the catheterization. However, when clopidogrel is
ven before catheterization and urgent surgical intervention
indicated, some experience suggests that “early” bypass
rgery may be undertaken by experienced surgeons at
ceptable incremental bleeding risk. Among 2,858 UA/
STEMI patients in the CRUSADE (Can Rapid Risk Strat-
cation of Unstable Angina Patients Suppress Adverse
utcomes With Early Implementation of the American Col-
ge of Cardiology/American Heart Association Guidelines)
egistry undergoing CABG, 30% received acute clopidogrel
erapy, the majority of these (87%) within 5 d of surgery.
arly” CABG after clopidogrel was associated with a
gnificant increase in any blood transfusion (OR 1.36, 95%
I 1.10 to 1.68) and the need for 4 or more units of blood (OR
70, 95% CI 1.32 to 2.1). In-hospital rates of death were low
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367% to 4%), and no difference was noted in rates of death,
infarction, or stroke with “early” CABG in patients treated
ith versus without acute clopidogrel (394). The Writing
ommittee believes that more data on the overall relative
nefits versus risks of proceeding with early bypass surgery
the presence of clopidogrel therapy are desirable and
cessary in order to formulate better-informed recommen-
tions for the timing of surgery in the UA/NSTEMI patient.
Sulfinpyrazone, dipyridamole, prostacyclin, and prostacy-
in analogs have not been demonstrated to be of benefit in
A or NSTEMI and are not recommended. The thromboxane
nthase blockers and thromboxane A2 receptor antagonists
ve been evaluated in ACS and have not shown any
vantage over ASA. A number of other antiplatelet drugs are
rrently available, and still others are under active investi-
tion. Clopidogrel is currently the preferred thienopyridine
cause of its extensive evidence base, its more rapid onset of
tion, especially after a loading dose (417,418), and its better
fety profile than ticlopidine (396).
Evidence has emerged that there is considerable interpa-
ent variability in the response to clopidogrel, with a wide
nge of inhibition of platelet aggregation after a given dose
19). Patients with diminished responsiveness to clopidogrel
pear to be at increased risk of ischemic events (420,421).
he reasons for the large interpatient variability in respon-
veness to clopidogrel are under investigation, but variation
absorption, generation of the active metabolite, and drug
teractions are leading possibilities. Maneuvers to overcome
or responsiveness to clopidogrel may involve an increase
the dose (422). However, techniques for monitoring for
or response to clopidogrel and the appropriate dosing
rategy when it is uncovered remain to be established.
.2.5. Anticoagulant Agents and Trials
number of drugs are available to clinicians for management
patients with UA/NSTEMI. Although the medical litera-
re sometimes refers to such drugs as “antithrombins,” the
riting Committee has chosen to refer to them as anticoag-
ants because they often inhibit 1 or more proteins in the
agulation cascade before thrombin. Evaluation of antico-
ulant strategies is an active area of investigation. It is
fficult to draw conclusions that 1 anticoagulant strategy is to
preferred over another given the uncertainty of whether
uipotent doses were administered, the different durations of
eatment studied across the trials, and the fact that many
tients were already receiving 1 open-label anticoagulant
fore they were randomized in a trial to another anticoagu-
nt (which makes it uncertain what residual effect the
en-label anticoagulant had in the trial). Other aspects of the
ta set that confound interpretation of the impact of specific
ticoagulant strategies include a range of antiplatelet strat-
ies administered concomitantly with the anticoagulant and
e addition of a second anticoagulant, either because of
inician preference or as part of protocol design (423–425)
patients moved from the medical management phase to the
terventional management phase of treatment for UA/
STEMI.
The Writing Committee also wishes to draw attention toe fact that active-control noninferiority trials are being birformed with increasing frequency as it becomes ethically
creasingly difficult to perform placebo-controlled trials. In
is update, for example, noninferiority (“equivalence”) com-
risons on primary or major secondary end points were
portant in the Acute Catheterization and Urgent Interven-
on Triage strategy (ACUITY) (425), Organization to Assess
trategies for Ischaemic Syndromes (OASIS-5) (424), and
andomized Evaluation of PCI Linking Angiomax to re-
ced Clinical Events (REPLACE-2) (426) studies. Although
actically useful, noninferiority analyses depend on assump-
ons not inherent in classic superiority analytical designs and
us present additional limitations and interpretative chal-
nges (427–429). Noninferiority trials require an a priori
oice of a “noninferiority margin,” typically defined in terms
a fraction of standard treatment effect to be preserved
mpared with a putative placebo (e.g., 0.5) and which rests
clinical judgment and statistical issues (428). Because
ninferiority trials do not have a placebo control, these
sumptions cannot be easily verified. Thus, whether the new
erapy indeed is therapeutically “equivalent” is less certain
an in a superiority trial. Hence, additional caution in
eighing and applying the results of noninferiority trials is
propriate.
The Writing Committee believes that a number of accept-
le anticoagulant strategies can be recommended with a
lass I status but emphasizes the fact that a preference for a
rticular strategy is far from clear (Figs. 7, 8, and 9). It is
ggested that each institution agree on a consistent approach
minimize the chance of medication errors and double
ticoagulation when personal preferences are superimposed
an already-initiated treatment plan. Factors that should be
eighed when one considers an anticoagulant strategy (or set
strategies to cover the range of patient scenarios) include
tablished efficacy, risk of bleeding in a given patient, cost,
cal familiarity with dosing regimens (particularly if PCI is
anned), anticipated need for surgery, and the desire to
omptly reverse the anticoagulant effect if bleeding occurs.
Unfractionated heparin exerts its anticoagulant effect by
celerating the action of circulating antithrombin, a proteo-
tic enzyme that inactivates factor IIa (thrombin), factor IXa,
d factor Xa. It prevents thrombus propagation but does not
se existing thrombi (430). Unfractionated heparin is a
terogeneous mixture of polysaccharide chains of molecular
eights that range from 5,000 to 30,000 Daltons and have
rying effects on anticoagulant activity. Unfractionated hep-
in binds to a number of plasma proteins, blood cells, and
dothelial cells. The LMWHs are obtained through chemical
enzymatic depolymerization of the polysaccharide chains
heparin to provide chains with different molecular
eight distributions. Approximately 25% to 50% of the
ntasaccharide-containing chains of LMWH preparations
ntain more than 18 saccharide units, and these are able to
activate both thrombin and factor Xa. Low-molecular-
eight heparin chains that are fewer than 18 saccharide units
tain their ability to inactivate factor Xa but not thrombin.
herefore, LMWHs are relatively more potent in facilitating
hibition of factor Xa than in the inactivation of thrombin.
istinct advantages of LMWH over UFH include decreased
nding to plasma proteins and endothelial cells and dose-
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisiondependent clearance, with a longer half-life that results in
ore predictable and sustained anticoagulation with once- or
ice-a-day subcutaneous administration. An advantage of
MWHs is that they do not usually require laboratory
onitoring of activity. The pharmacodynamic and pharma-
kinetic profiles of the different commercial preparations of
MWHs vary, with their mean molecular weights ranging
om 4,200 to 6,000 Daltons. Accordingly, their ratios of
ti–factor Xa to anti–factor IIa vary, ranging from 1.9 to 3.8
31). By contrast, the direct thrombin inhibitors specifically
ock thrombin without the need for a cofactor. Hirudin binds
rectly to the anion binding site and the catalytic sites of
rombin to produce potent and predictable anticoagulation
32).
Bivalirudin is a synthetic analog of hirudin that binds
versibly to thrombin and inhibits clot-bound thrombin.
ore upstream in the coagulation cascade are factor Xa
hibitors, such as the synthetic pentasaccharide fondapa-
nux, that act proximally to inhibit the multiplier effects of
e downstream coagulation reactions and thereby reduce the
ount of thrombin that is generated. Advantages of fonda-
rinux compared with UFH include decreased binding to
asma proteins and endothelial cells and dose-independent
earance, with a longer half-life that results in more predict-
le and sustained anticoagulation with fixed-dose, once-a-
y subcutaneous administration. An advantage of these
ents over UFH is that like the LMWHs, fondaparinux does
t require laboratory monitoring of activity. Fondaparinux is
eared renally, as is the anti–Xa activity of enoxaparin. The
ctor Xa inhibitors do not have any action against thrombin
at is already formed or that is generated despite their
ministration, which possibly contributes to the observation
an increased rate of catheter thrombosis when factor Xa
hibitors such as fondaparinux are used alone to support PCI
ocedures. In the case of both the direct thrombin inhibitors
d fondaparinux, it is not possible to reverse the effect with
otamine because they lack a protamine-binding domain;
versal of their action in the event of bleeding requires
scontinuation of their administration and, if needed, trans-
sion of coagulation factors (e.g., fresh-frozen plasma).
In summary, whereas anticoagulant therapy forms a basic
ement of UA/NSTEMI therapy, recommendation of an
ticoagulant regimen has become more complicated by a
mber of new choices suggested by contemporary trials,
me of which do not provide adequate comparative infor-
ation for common practice settings. The Writing Committee
lieves that inadequate unconfounded comparative informa-
on is available to recommend a preferred regimen when an
rly, invasive strategy is used for UA/NSTEMI, and physi-
an and health care system preference, together with indi-
dualized patient application, is advised. Additional experi-
ce may change this viewpoint in the future. On the other
nd, these available trials are less confounded for the large
mber of patients treated with an initial noninvasive or
layed invasive strategy: they suggest an anticoagulant
eference for these patients treated with a noninvasive
rategy in the order of fondaparinux, enoxaparin, and UFH
east preferred), using the specific regimens tested in these
ials. Bivalirudin has not been tested in a noninvasive hrategy and hence cannot be recommended currently. Even
this group, the order of preference often depends on a
ngle, albeit large, trial, so that additional clinical trial
formation will be welcomed.
The optimal duration of anticoagulation therapy remains
defined. Evidence for recurrence of events after cessation
short-duration intravenous UFH and results of studies in
TEMI patients demonstrating superiority of anticoagulant
ents that are administered for the duration of the hospital
ay suggest that anticoagulation duration of more than 2 d for
ose who are managed with a conservative strategy may be
neficial, but this requires further study (433,434).
.2.5.1. UNFRACTIONATED HEPARIN
ix relatively small randomized, placebo-controlled trials
ith UFH have been reported (435–440). The results of
udies that compared the combination of ASA and heparin
ith ASA alone are shown in Figure 10. In the trials that used
FH, the reduction in the rate of death or MI during the first
eek was 54% (p  0.016), and in the trials that used either
FH or LMWH, the reduction was 63%. Two published
eta-analyses have included different studies. In 1 meta-
alysis, which involved 3 randomized trials and an early end
int (less than 5 d) (369), the risk of death or MI with the
mbination of ASA and heparin was reduced by 56% (p 
03). In the second meta-analysis, which involved 6 trials
d end points that ranged from 2 to 12 weeks, the RR was
duced by 33% (p  0.06) (441). Most of the benefits of the
rious anticoagulants are short term, however, and are not
aintained on a long-term basis. Reactivation of the disease
ocess after the discontinuation of anticoagulants may con-
ibute to this loss of early gain among medically treated
tients that has been described with UFH (442), dalteparin
71), and hirudin (443,444). The combination of UFH and
SA appears to mitigate this reactivation in part (442,445),
though there is hematologic evidence of increased thrombin
tivity after the cessation of intravenous UFH (“rebound”)
en in the presence of ASA (446). Uncontrolled observa-
ons suggested a reduction in the “heparin rebound” by
itching from intravenous to subcutaneous UFH for several
ys before the drug is stopped.
Unfractionated heparin has important pharmacokinetic
mitations that are related to its nonspecific binding to
oteins and cells. These pharmacokinetic limitations of UFH
anslate into poor bioavailability, especially at low doses,
d marked variability in anticoagulant response among
tients (447). As a consequence of these pharmacokinetic
mitations, the anticoagulant effect of heparin requires mon-
oring with the activated partial thromboplastin time (aPTT),
test that is sensitive to the inhibitory effects of UFH on
rombin (factor IIa), factor Xa, and factor IXa. Many
inicians have traditionally prescribed a fixed initial dose of
FH (e.g., 5,000 U bolus, 1,000 U per h initial infusion);
inical trials have indicated that a weight-adjusted dosing
gimen can provide more predictable anticoagulation than
e fixed-dose regimen (448–450). The weight-adjusted reg-
en recommended is an initial bolus of 60 U per kg
aximum 4,000 U) and an initial infusion of 12 U per kg per
(maximum 1,000 U per h). The therapeutic range of the
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367rious nomograms differs due to variation in the laboratory
ethods used to determine aPTT. The American College of
hest Physicians consensus conference(451) has therefore
commended dosage adjustments of the nomograms to
rrespond to a therapeutic range equivalent to heparin levels
0.3 to 0.7 U per ml by anti–factor Xa determinations,
hich correlates with aPTT values between 60 and 80 s. In
dition to body weight, other clinical factors that affect the
sponse to UFH include age and sex, which are associated
ith higher aPTT values, and smoking history and diabetes
ellitus, which are associated with lower aPTT values
47,452). At high doses, heparin is cleared renally (451).
Even though weight-based UFH dosing regimens are used,
e aPTT should be monitored for adjustment of UFH dosing.
ecause of variation among hospitals in the control aPTT
lues, nomograms should be established at each institution
at are designed to achieve aPTT values in the target range
.g., for a control aPTT of 30 s, the target range [1.5 to 2.5
mes control] would be 45 to 75 s). Delays in laboratory
rnaround time for aPPT results also can be a source of
riability in care, resulting in over- or under-anticoagulation
r prolonged time periods, and should be avoided. Measure-
ents should be made 6 h after any dosage change and used
adjust UFH infusion until the aPTT exhibits a therapeutic
vel. When 2 consecutive aPTT values are therapeutic, the
easurements may be made every 24 h and, if necessary,
se adjustment performed. In addition, a significant change
the patient’s clinical condition (e.g., recurrent ischemia,
eeding, or hypotension) should prompt an immediate aPTT
termination, followed by dose adjustment, if necessary.
Serial hemoglobin/hematocrit and platelet measurements
e recommended at least daily during UFH therapy. In
dition, any clinically significant bleeding, recurrent symp-
ms, or hemodynamic instability should prompt their imme-
ate determination. Serial platelet counts are necessary to
onitor for heparin-induced thrombocytopenia. Mild throm-
cytopenia may occur in 10% to 20% of patients who are
ceiving heparin, whereas significant thrombocytopenia
latelet count less than 100,000) occurs in 1% to 5% of
tients and typically appears after 4 to 14 d of therapy
53–457). A rare but dangerous complication (less than
2% incidence) is autoimmune UFH-induced thrombocyto-
nia with thrombosis, which can occur both shortly after
itiation of UFH or, rarely, in a delayed (i.e., after 5 to 19 d
more), often unrecognized form (458–460). A high clin-
al suspicion mandates the immediate cessation of all hepa-
n therapy (including that used to flush intravenous lines).
Most of the trials that evaluated the use of UFH in
A/NSTEMI have continued therapy for 2 to 5 d. The
timal duration of therapy remains undefined.
.2.5.2. LOW-MOLECULAR-WEIGHT HEPARIN
a pilot open-label study, 219 patients with UA were
ndomized to receive ASA (200 mg per d), ASA plus UFH,
ASA plus nadroparin (an LMWH) (370). The combination
ASA and LMWH significantly reduced the total ischemic
ent rate, the rate of recurrent angina, and the number of
tients requiring interventional procedures. LThe FRISC study (371) randomized 1,506 patients with
A or non–Q-wave MI to receive subcutaneous administra-
on of the LMWH dalteparin (120 IU per kg twice daily) or
acebo for 6 d and then once a day for the next 35 to 45 d.
alteparin was associated with a 63% risk reduction in death
MI during the first 6 d (4.8% vs. 1.8%, p  0.001), which
atched the favorable experience observed with UFH. Al-
ough an excess of events was observed after the dose
duction to once daily after 6 d, a significant decrease was
served at 40 d with dalteparin in the composite outcome of
ath, MI, or revascularization (23.7% vs. 18.0%, p 0.005),
d a trend was noted toward a reduction in rates of death or
I (10.7% vs. 8.0%, p  0.07).
Because the level of anticoagulant activity cannot be easily
easured in patients receiving LMWH (e.g., aPTT or acti-
ted clotting time [ACT]), interventional cardiologists have
pressed concern about the substitution of LMWH for UFH
patients scheduled for catheterization with possible PCI.
owever, in a study involving 293 patients with UA/
STEMI who received the usual dose of enoxaparin, Collett
al. (461) showed that PCI can be performed safely.
An alternative approach is to use LMWH during the period
initial stabilization. The dose can be withheld on the
orning of the procedure, and if an intervention is required
d more than 8 h has elapsed since the last dose of LMWH,
FH can be used for PCI according to usual practice patterns.
ecause the anticoagulant effect of UFH can be more readily
versed than that of LMWH, UFH is preferred in patients
kely to undergo CABG within 24 h.
.2.5.3. LMWH VERSUS UFH
ine randomized trials have directly compared LMWH with
FH (Table 17). Two trials evaluated dalteparin, another
aluated nadroparin, and 6 evaluated enoxaparin. Heteroge-
ity of trial results has been observed. Trials with dalteparin
d nadroparin reported similar rates of death or nonfatal MI
mpared with UFH, whereas 5 of 6 trials of enoxaparin
und point estimates for death or nonfatal MI that favored
oxaparin over UFH; the pooled OR was 0.91 (95% CI 0.83
0.99). The benefit of enoxaparin appeared to be driven
rgely by a reduction in nonfatal MI, especially in the cohort
patients who had not received any open-label anticoagulant
erapy before randomization.
There are few data to assess whether the heterogeneous
sults are explained by different populations, study designs,
rious heparin dose regimens, properties of the various
MWHs (more specifically, different molecular weights and
ti–factor Xa/anti–factor IIa ratios), concomitant therapies,
other unrecognized influences. Although it is tempting to
mpare the relative treatment effects of the different LMWH
mpounds, the limitations of such indirect comparisons must
recognized. The only reliable method of comparing 2
eatments is through a direct comparison in a well-designed
inical trial or series of trials. The comparison of different
erapies (e.g., different LMWHs) with a common therapy
.g., UFH) in different trials does not allow a conclusion to
made about the relative effectiveness of the different
MWHs because of the variability in both control group and
Ta
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Trial
(Reference) n LMWH/Dose UFH
End Point/Drug
Effect Analysis 95% CI p Major Bleeding (p)
ISC (371) 1,506 (a) 6 d*: dalteparin
120 IU per kg†
SC twice daily
(maximum
10,000 IU)
(b) During first 40 d:
dalteparin 7,500
IU SC once per
day
(a) 6 d: placebo
(b) During first
40 d: placebo
(a) Death or new MI
(6 d): LMWH
1.8%, Placebo
4.8%
(b) Death or new MI
(during first 40
d‡): LMWH 8%,
placebo 10.7%
(a) RR 0.37
ARR 3%
(b) RR 0.75
ARR 2.7%
(a) 0.20 to
0.68
(b) 0.54 to
1.03
(a) 0.001
(b) 0.07
(a) LMWH 0.8%,
placebo 0.5%;
ARR 0.3%
(pNR)
(b) During first 40 d:
LMWH 0.3%,
placebo 0.3%;
ARR 0% (pNR)
SENCE (169) 3,171 Enoxaparin 1 mg per
kg SC twice daily
(minimum. 48 h,
maximum 8 d)
UFH IV bolus
(usually 5,000
units) and
continued IV
infusion
(a) Death, MI, or
recurrent angina
at 14 d: LMWH
16.6%, UFH
19.8%
(b) Death, MI, or
recurrent angina
at 30 d: LMWH
19.8%, UFH
23.3%
(a) OR at 14 d0.80
ARR 3.2%
(b) OR at 30 d0.81
ARR 3.5%
(a) 0.67 to
0.96
(b) 0.68 to
0.96
(a) 0.019
(b) 0.016
At 30 d: LMWH
6.5%, UFH 7%;
ARR 0.5% (p 
0.57)
IC (462) 1,482 (a) Days 1 to 6:
dalteparin 120 IU
per kg SC twice
daily
(b) Days 6 to 45§:
dalteparin 7,500
IU SC once per
day
(a) Days 1 to 6:
UFH 5,000
units IV bolus
and IV infusion
of 1,000 units
per h for 48 h
(b) Days 6 to 45:
placebo SC
once daily
(a) Death, MI, or
recurrence of
angina (Days 1
to 6): LMWH
9.3%, UFH 7.6%
(b) Death, MI, or
recurrence of
angina (Days 6
to 45): 12.3% in
both the LMWH
and UFH groups
(a) Death or MI
(Days 1 to 6):
LMWH 3.9%,
UFH 3.6%
(b) Death or MI
(Days 6 to 45):
LMWH 4.3%,
placebo 4.7%
(a) RR 1.18
ARR 1.7%
(b) RR 1.01
ARR 0%
(a) RR 1.07
ARR 0.3%
(b) RR 0.92
ARR 0.4%
(a) 0.84 to
1.66
(b) 0.74 to
1.38
(a) 0.63 to
1.80
(b) 0.54 to
1.57
(a) 0.33
(b) 0.96
(a) 0.80
(b) 0.76
(a) Days 1 to 6:
LMWH 1.1%,
UFH 1.0%; ARR
0.1% (pNR)
(b) Days 6 to 45:
LMWH 0.5%,
placebo 0.4%;
ARR 0.1%
(p  NR)
AX.I.S. (463) 3,468 (a) Nadroparin 6 d:
nadroparin 86
anti-Xa IU per kg
IV bolus, followed
by nadroparin 86
anti-Xa IU per kg
SC twice daily
for 6 d
(b) Nadroparin 14 d:
nadroparin 86
anti-Xa IU per kg
IV bolus, followed
by nadroparin 86
anti-Xa IU per kg
SC twice daily
for 14 d
(a)  (b) UFH
5,000 units IV
bolus and UFH
infusion at
1,250 units per
h IV for 6 d
(plus or minus
2 d)
Cardiac death, MI,
refractory angina,
recurrence of UA
at Day 14: LMWH
6 d 17.8%,
LMWH 14 d
20.0%, UFH
18.1%
(a) ARR 0.3%
(b) ARR 1.9%
(a) 2.8
to 3.4
(b) 5.1
to 1.3
(a) 0.85
(b) 0.24
At 6 d: UFH 1.6%,
LMWH 1.5%,
ARR 0.1%
At 14 d: UFH 1.6%,
LMWH 3.5%,
ARR 1.9%
(p  0.0035)
I 11B (180) 3,910 (a) Inpatient:
enoxaparin 30
mg IV bolus
immediately
followed by 1 mg
per kg SC every
12 h
(b) Outpatient:
enoxaparin 40
mg SC twice per
day (patients
weighing less
than 65 kg) or
60 mg SC twice
per day (patients
weighing at least
65 kg)
(a) Inpatient: UFH
70 units per
kg bolus and
infusion at 15
units per h
titrated to
aPTT
(treatment
maintained for
a minimum of
3 and
maximum of
8 d at
physician’s
discretion)
(b) Outpatient:
placebo SC
twice per day
Death, MI, urgent
revascularization
(a) At 48 h: LMWH
5.5%, UFH 7.3%
(b) 8 d: LMWH
12.4%, UFH
14.5%
(c) 14 d: LMWH
14.2%, UFH
16.7%
(d) 43 d: LMWH
17.3%, UFH
19.7%
(a) OR 0.75
ARR 1.8%
(b) OR 0.83
ARR 2.1%
(c) OR 0.82
ARR 2.5%
(d) OR 0.85
ARR 2.4%
(a) 0.58 to
0.97
(b) 0.69 to
1.00
(c) 0.69 to
0.98
(d) 0.72 to
1.00
(a) 0.026
(b) 0.048
(c) 0.029
(d) 0.048
At 48 h: LMWH
0.8%, UFH
0.7%; ARR
0.1%
(p0.14)
End of initial
hospitalization:
LMWH 1.5%,
UFH 1%; ARR
0.5%
(p0.143)
Between Day 8 and
Day 43: LMWH
2.9%, placebo
2.9%; ARR 0%
(p0.021)
UTE II (464) 525 Enoxaparin 1 mg per
kg SC every 12 h
UFH 5,000 units
IV bolus and
maintenance
infusion at
1,000 units per
h IV adjusted to
aPTT
(a) Death or
(b) MI at 30 d
(a) LMWH 2.5%,
UFH 1.9%
(b) LMWH 6.7%,
UFH 7.1%
(a) RR 1.3
ARR 0.6%
(b) RR 0.94
ARR 0.4%
(a) 0.06 to
3.93
(b) 0.45 to
2.56
(a) 0.77
(b) 0.86
LMWH 0.3%; UFH
1%; ARR 0.7%
(p0.57)
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fferences in concomitant therapies due to geographic and time
riability, and the play of chance. Similar considerations apply
ble 17. Continued
Trial
(Reference) n LMWH/Dose UFH
End Po
Eff
TERACT¶
(465)
746 Enoxaparin 1 mg per
kg SC every 12 h
UFH 70 units per
kg IV bolus
followed by
continuous
infusion at 15
units per kg
per h
Death or M
LMWH
9.0%
to Z** (466) 3,987 Enoxaparin 1 mg per
kg SC every 12 h
UFH 4,000 units
IV bolus
followed by
900 units per
h IV infusion
for patients
weighing
equal to or
greater than
70 kg
UFH 60 units
per kg
(maximum
4,000 units)
IV bolus
followed by
12 units per
kg per h IV
infusion for
patients
weighing less
than 70 kg
All-cause d
or refra
ischemi
7 d of t
initiation
8.4%, U
NERGY††
(423)
9,978 Enoxaparin 1 mg per
kg SC every 12 h
UFH 60 units per
kg IV bolus
(maximum of
5,000 units)
and followed
by IV infusion
of 12 units
per kg per h
(maximum of
1,000 units
per h initially
Death or n
MI duri
30 d a
random
LMWH 14
14.5%,
For specific interventions and additional medications during the study, see indi
to Z: decrease in hemoglobin of more than 5 mg per dL or intracranial or per
ath, transfusion of at least 2 U of blood, a fall in hemoglobin of 30 g per liter o
eed resulting in death; a bleed in a retroperitoneal, intracranial, or intraocular lo
transfusion of at least 2 U of blood. SYNERGY: TIMI and GUSTO criteria. ACUT
eeding involved a hemoglobin drop greater than 5 g per dL (with or without a
morrhage or cardiac tamponade. INTERACT: Major bleeding included bleedin
companied by a drop in hemoglobin greater than or equal to 3 g per dL. FRIC
at least 20 g per liter, required transfusion, was intracranial, or caused deat
*Primary study end point was first 6 d.
†Initial trial dose of 150 IU per kg SC twice daily decreased to 120 IU per k
eeding episodes and 9 patients or 14% minor episodes among 63 actively tr
‡Follow-up incomplete in 13 patients (8 dalteparin, 5 placebo) at their reque
§Primary study outcome was Days 6 to 45.
All patients in INTERACT received eptifibatide 180 mcg per kg bolus followe
¶All patients in ACUTE II received a tirofiban loading dose of 0.4 mcg per kg p
**All patients enrolled in the A to Z Trial received aspirin and tirofiban.
††Patients also received glycoprotein IIb/IIIa inhibitors, aspirin, clopidogrel
justments made to enoxaparin and UFH during percutaneous coronary interv
A to ZAggrastat to Zocor study; ACUTE IIAntithrombotic Combination
Rabsolute risk reduction; CIconfidence interval; ESSENCEEfficacy and S
farction; FRICFRagmin In unstable Coronary disease; HRhazard ratio; INTER
eatment; IUinternational units; IVintravenous; LDloading dose; MDm
Imyocardial infarction; NRnot reported; RRrelative risk; SCsubcutaneou
ycoprotein IIb/IIIA Inhibitors; TIMI 11BThrombolysis In Myocardial Infarctioncomparisons among platelet GP IIb/IIIa inhibitors. paIn the Enoxaparin Versus Tinzaparin (EVET) trial, 2
MWHs, enoxaparin and tinzaparin, administered for 7 d,
ere compared in 436 patients with UA/NSTEMI. Enoxa-
Analysis 95% CI p Major Bleeding (p)
:
H
RR 0.55
ARR 4%
0.30 to
0.96
0.031 At 96 h: LMWH
1.8%; UFH 4.6%;
ARR 2.8%
(p0.03)
, HR 0.88
ARR 1%
0.71 to
1.08
NR LMWH 0.9%; UFH
0.4%; ARR
0.5% (p0.05)
HR 0.96
ARR 0.5%
0.86 to
1.06
0.40 TIMI minor: LMWH
12.5%, UFH
12.3%; ARR
0.2% (p0.80)
TIMI major: LMWH
9.1%, UFH 7.6%;
ARR 1.5%
(p0.008)
GUSTO severe:
LMWH 2.7%,
UFH 2.2%; ARR
0.5% (p0.08)
tudy references. Major bleeding was classified as follows in the various trials:
bleeding. ESSENCE: Major hemorrhage was defined as bleeding resulting in
or a retroperitoneal, intracranial, or intraocular hemorrhage. TIMI 11B: Overt
a hemoglobin drop of greater than or equal to 3 g per dL; or the requirement
erity was recorded on the basis of the TIMI trial bleeding criteria. TIMI major
ed site, not associated with coronary artery bypass grafting) or intracranial
ting in death, or retroperitoneal hemorrhage, or bleeding at a specific site
ding event was classified as major if it led to a fall in the hemoglobin level
sation of the study treatment.
ice daily due to increased bleeding during first 6 d (4 patients or 6% major
tients).
2.0 mcg per kg per min infusion for 48 h.
over 30 min, followed by a maintenance infusion at 0.1 mcg per kg per min.
ts eligible for enrollment even if LMWH or UFH given before enrollment,
Tirofiban and Enoxaparin; aPTTactivated partial thromboplastin time;
f Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave Myocardial
tegrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome
nce dose; Nnumber of patients; LMWHlow-molecular-weight heparin;
RGYSuperior Yield of the New strategy of Enoxaparin, Revascularization and
unit; UAunstable angina; UFHunfractionated heparin.int/Drug
ect
I at 30 d
5.0%, UF
eath, MI
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leeding rates were similar with the 2 LMWHs.
The advantages of LMWH preparations are the ease of
bcutaneous administration and the absence of a need for
onitoring. Furthermore, the LMWHs stimulate platelets less
an UFH (469) and are less frequently associated with
parin-induced thrombocytopenia (456). In the ESSENCE
ial, minor bleeding occurred in 11.9% of enoxaparin pa-
ents and 7.2% of UFH patients (p less than 0.001), and
ajor bleeding occurred in 6.5% and 7.0%, respectively
69). In TIMI 11B, the rates of minor bleeding in hospital
ere 9.1% and 2.5%, respectively (p less than 0.001), and the
tes of major bleeding were 1.5% and 1.0% (p 0.14) (180).
the FRISC study, major bleeding occurred in 0.8% of
tients given dalteparin and in 0.5% of patients given
acebo, and minor bleeding occurred in 61 (8.2%) of 746
tients and 2 (0.3%) of 760 patients, respectively (371).
The anticoagulant effect of LMWH is less effectively
versed with protamine than that of UFH. In addition,
MWH administered during PCI does not permit monitoring
the ACT to titrate the level of anticoagulation. In the
SSENCE and TIMI 11B trials, special rules were set to
scontinue enoxaparin before PCI and CABG. Because of
mited experience with enoxaparin at the time the ESSENCE
d TIMI 11B trials were conducted, UFH was administered
ring PCI to achieve ACT values of greater than 350 s. In
e Superior Yield of the New Strategy of Enoxaparin,
evascularization and Glycoprotein IIb/IIIa Inhibitors (SYN-
RGY) trial, enoxaparin was compared to UFH during PCI in
tients with high-risk UA/NSTEMI (423) (Fig. 12). More
eeding was observed with enoxaparin, with a statistically
gnificant increase in TIMI-defined major bleeding (9.1% vs.
6%, p  0.008) but a nonsignificant excess in GUSTO-
gure 12. SYNERGY Primary Outcomes at 30 d. CI  confidence
e New strategy of Enoxaparin, Revascularization and Glycoprotefined severe bleeding (2.7% vs. 2.2%, p  0.08) and adansfusions (17.0% vs. 16.0%, p  0.16). A post hoc
alysis from SYNERGY suggested that some of the excess
eeding seen with enoxaparin could be explained by cross-
er to UFH at the time of PCI (470). This remains to be
lidated prospectively, but at the present time, it appears
asonable to minimize the risk of excessive anticoagulation
ring PCI by avoiding crossover of anticoagulants (i.e.,
aintain consistent anticoagulant therapy from the pre-PCI
ase throughout the procedure itself).
An economic analysis of the ESSENCE trial suggested
st savings with enoxaparin (471). For patients who are
ceiving subcutaneous LMWH and in whom CABG is
anned, it is recommended that LMWH be discontinued and
FH be used during the operation. Additional experience
ith regard to the safety and efficacy of the concomitant
ministration of LMWHs with GP IIb/IIIa antagonists and
brinolytic agents is currently being acquired.
.2.5.3.1. Extended Therapy with LMWHs The
RISC, Fragmin in unstable coronary artery disease study
RIC), TIMI 11B, and Fast Revascularization during InSta-
lity in Coronary artery disease-II (FRISC-II) trials evalu-
ed the potential benefit of the prolonged administration of
MWH after hospital discharge (Table 17). In the FRISC
ial, doses of dalteparin were administered between 6 d and
to 45 d; in FRIC, patients were rerandomized after the
itial 6-d treatment period to receive dalteparin for an
ditional 40 d, and the outpatient treatment period lasted 5 to
weeks in TIMI 11B and 1 week in the FRAXiparine in
chaemic Syndromes (FRAXIS) trial. The FRISC-II trial
ed a different study design. Dalteparin was administered to
l patients for a minimum of 5 d (472). Patients were
bsequently randomized to receive placebo or the continued
al; MI  myocardial infarction; SYNERGY  Superior Yield of
Ia Inhibitors (423); UFH  unfractionated heparin.intervministration of dalteparin twice per day for up to 90 d.
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owed a significant reduction with dalteparin in the com-
site end point of death or MI at 30 d (3.1% vs. 5.9%, p 
002) but not at 3 months (6.7% vs. 8.0%, p  0.17). The
mposite of death, MI, or revascularization during the total
eatment period was reduced at 3 months (29.1% vs. 33.4%,
 0.031). The benefits of prolonged dalteparin administra-
on were limited to patients who were managed medically
d to those with elevated TnT levels at baseline. Although
ese results make a case for the prolonged use of an LMWH
selected patients who are managed medically or in whom
giography is delayed, their relevance to contemporary
actice is less clear now that clopidogrel is used more
equently and there is a much greater tendency to proceed to
early invasive strategy.
.2.5.4. DIRECT THROMBIN INHIBITORS
irudin, the prototype of the direct thrombin inhibitors, has
en extensively studied but with mixed results. The
USTO-IIb trial randomly assigned 12,142 patients with
spected MI to 72 h of therapy with either intravenous
rudin or UFH (473). Patients were stratified according to
e presence of ST-segment elevation on the baseline ECG
,131 patients) or its absence (8,011 patients). The primary
d point of death, nonfatal MI, or reinfarction at 30 d
curred in 9.8% of the UFH group versus 8.9% of the
rudin group (OR 0.89, p  0.058). For patients without
T-segment elevation, the rates were 9.1% and 8.3%, respec-
vely (OR 0.90, p  0.22). At 24 h, the risk of death or MI
as significantly lower in the patients who received hirudin
an in those who received UFH (2.1% vs. 1.3%, p  0.001).
owever, the Thrombolysis and Thrombin Inhibition in
yocardial Infarction (TIMI) 9B trial of hirudin as adjunc-
ve therapy to thrombolytic therapy in patients with STEMI
owed no benefit of the drug over UFH either during study
ug infusion or later (474). The GUSTO-IIb and TIMI 9B
ials used hirudin doses of 0.1 mg per kg bolus and 0.1 mg
r kg per h infusion for 3 to 5 d after the documentation of
cess bleeding with higher doses used in the GUSTO-IIA
d TIMI 9A trials (0.6 mg per kg bolus and 0.2 mg per kg
r h infusion) (473,475).
The OASIS program evaluated hirudin in patients with
A/NSTEMI. OASIS 1 (476) was a pilot trial of 909 patients
at compared the low hirudin dose of 0.1 mg per kg per h
fusion and the medium hirudin dose of 0.15 mg per h
fusion with UFH. The latter dose provided the best results,
ith a reduction in the rate of death, MI, or refractory angina
7 d (6.5% with UFH vs. 3.3% with hirudin, p  0.047).
his medium dose was used in the large OASIS 2 (477) trial
at consisted of 10,141 patients with UA/NSTEMI who were
ndomized to receive UFH (5,000 IU bolus plus 15 U per kg
r h) or recombinant hirudin (0.4 mg per kg bolus and 0.15
g per kg per h) infusion for 72 h. The primary end point of
rdiovascular death or new MI at 7 d occurred in 4.2% in the
FH group versus 3.6% patients in the hirudin group (RR
84, p  0.064). A secondary end point of cardiovascular
ath, new MI, or refractory angina at 7 d was significantly
duced with hirudin (6.7% vs. 5.6%, RR 0.83, p  0.011).
here was an excess of major bleeding incidents that required ofansfusion with hirudin (1.2% vs. 0.7% with heparin, p 
014) but no excess in life-threatening bleeding incidents or
rokes. A meta-analysis of the GUSTO-IIB, TIMI 9B,
ASIS 1, and OASIS 2 trials showed a relative risk of death
MI of 0.90 (p  0.015) with hirudin compared with UFH
35 d after randomization; RR values were similar for
tients receiving thrombolytic agents (0.88) and not receiv-
g thrombolytic agents (0.90) (477).
The relative benefits of hirudin versus UFH in ACS
tients undergoing PCI were evaluated in the 1,410-patient
bset in GUSTO-IIb who underwent PCI during the initial
ug infusion. A reduction in nonfatal MI and the composite
death and MI was observed with hirudin that was associ-
ed with a slightly higher bleeding rate (478).
Hirudin (lepirudin) is presently indicated by the US Food
d Drug Administration only for anticoagulation in patients
ith heparin-induced thrombocytopenia (456) and for the
ophylaxis of deep vein thrombosis in patients undergoing
p replacement surgery. It should be administered as a 0.4
g per kg IV bolus over 15 to 20 s followed by a continuous
travenous infusion of 0.15 mg per kg per h, with adjustment
the infusion to a target range of 1.5 to 2.5 times the control
TT values. Argatroban is another direct thrombin inhibitor
at is approved for the management of patients with heparin-
duced thrombocytopenia (479). However, in ACS, the
onovalent direct thrombin inhibitors (including argatroban)
e ineffective antithrombotic agents compared with UFH,
d thus, argatroban should generally not be used in manage-
ent of ACS (480). The recommended initial dose of
gatroban is an intravenous infusion of 2 mcg per kg per
in, with subsequent adjustments to be guided by the aPTT
edical management) or ACT (interventional management).
The REPLACE 2 investigators compared bivalirudin (bo-
s 0.75 mg per kg followed by infusion of 1.75 mg per kg per
with provisional GP IIb/IIIa inhibition) with UFH 65 U per
bolus with planned GP IIb/IIIa inhibition in patients
dergoing urgent or elective PCI (426). Only 14% had been
eated for UA within 48 h before enrollment. Prespecified
finitions of noninferiority were satisfied for bivalirudin,
ith the benefits of a significantly lower bleeding rate (481).
ollow-up through 1 year also suggested similar mortality for
e 2 approaches (482).
Bivalirudin was investigated further in the ACUITY trial
25) (Figs. 13 and 14). The ACUITY trial used a 2  2
ctorial design to compare a heparin (UFH or enoxaparin)
ith or without upstream GP IIb/IIIa inhibition versus bivali-
din with or without upstream GP IIb/IIIa inhibition; a third
m tested bivalirudin alone and provisional GP IIb/IIIa
hibition. The study was randomized but open-label (un-
inded). The main comparisons in the ACUITY trial were of
parin with GP IIb/IIIa inhibition versus bivalirudin with GP
b/IIIa inhibition versus bivalirudin with provisional GP
b/IIIa inhibition. Three primary 30-d end points were
especified: composite ischemia, major bleeding, and net
inical outcomes (composite ischemia or major bleeding).
ivalirudin plus GP IIb/IIIa inhibitors compared with heparin
us GP IIb/IIIa inhibitors resulted in noninferior 30-d ratescomposite ischemia (7.7% vs. 7.3%), major bleeding
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ig. 13). Bivalirudin alone compared with heparin GB plus
b/IIIa inhibitors resulted in noninferior rates of composite
chemia (7.8% vs. 7.3%, p  0.32, RR 1.08, 95% CI 0.93 to
42), significantly reduced major bleeding (3.0% vs. 5.7%, p
ss than 0.001, RR 0.53, 95% CI 0.43 to 0.65), and superior
-d net clinical outcomes (10.1% vs. 11.7% respectively,
 0.015, RR 0.86, 95% CI 0.77 to 0.97). For the subgroup
5,753 patients who did receive a thienopyridine before
giography or PCI, the composite ischemic end point
curred in 7.0% in the bivalirudin-alone group versus 7.3%
the group that received heparin plus GP IIb/IIIa inhibition
gure 13. ACUITY Clinical Outcomes at 30 d. *p for noninferiority
rategY; CI  confidence interval; GP  glycoprotein; UFH  unf
gure 14. ACUITY Composite Ischemia and Bleeding Outcomes.
rategY; CI  confidence interval; GP  glycoprotein; PCI  percutaneoR 0.97, 95% CI 0.80 to 1.17), whereas in the 3,304 patients
ho did not receive a thienopyridine before angiography or
CI, the composite ischemic event rate was 9.1% in the
valirudin-alone group versus 7.1% in the heparin plus GP
b/IIIa inhibition group (RR 1.29, 95% CI 1.03 to 1.63; p for
teraction 0.054) (Fig. 14) (425). The Writing Committee
lieves that this observation introduces a note of caution
out the use of bivalirudin alone, especially when there is a
lay to angiography when high-risk patients who may not be
presented by the ACUITY trial population are being man-
ed, or if early ischemic discomfort occurs after the initial
tithrombotic strategy has been implemented (Figs. 7, 8, and 9).
TY  Acute Catheterization and Urgent Intervention Triage
ated heparin.
Y  Acute Catheterization and Urgent Intervention Triage. ACUIACUIT
us coronary intervention; UFH  unfractionated heparin.
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367he Writing Committee therefore recommends that patients
eeting these criteria be treated with concomitant GP IIb/IIIa
hibitors or a thienopyridine, administered before angiogra-
y to optimize outcomes whether a bivalirudin-based or
parin-based anticoagulant strategy is used. This approach is
so supported by the findings of the ACUITY timing study
at showed a trend toward higher rates of ischemic events,
hich did not meet inferiority criteria, in the deferred GP
b/IIIa inhibitor group compared with the upstream GP
b/IIIa inhibitor. Death/MI/unplanned revascularization for
chemia occurred in 7.1% of routine upstream GP IIb/IIIa
hibitor group versus 7.9% of deferred selective inhibitor
oup; RR 1.12 (95% CI 0.97 to 1.29) (482a,482b). Similarly,
the ACUITY PCI substudy (482c,482d), subjects who did
t receive a thienopyridine pre-PCI had higher rates of the
mposite ischemic end point in the bivalirudin-alone group
mpared with the heparin plus GP IIb/IIIa group. In both the
EPLACE 2 and ACUITY trials, bivalirudin with provisional
P IIb/IIIa blockade was associated with a lower risk of
eeding, whereas this was not the case in ACUITY with the
mbination of bivalirudin and planned GP IIb/IIIa blockade,
ggesting that dosing regimens and concomitant GP IIb/IIIa
ockade plays an important role in bleeding risk (483). The
pact of switching anticoagulants after randomization,
hich has been associated with excess bleeding (423,484), is
clear for bivalirudin. It should be noted that the ACUITY
otocol called for angiography within 24 to 48 h of random-
ation and that the median time to catheterization (from the
me the study drug was started) was approximately 4 h; thus,
e study results of this trial cannot be extrapolated beyond
e group of patients treated in an early invasive fashion.
.2.5.5. FACTOR Xa INHIBITORS
he OASIS 5 investigators evaluated the use of fondaparinux
UA/NSTEMI (424) (Fig. 15). OASIS 5 compared 2
gure 15. OASIS 5 Cumulative Risks of Death, MI, or Refractory
rval; MI  myocardial infarction; OASIS 5  Fifth Organization toticoagulant strategies given for a mean of 6 d; one of which poas amended during the conduct of the trial. In OASIS 5,
tients with UA/NSTEMI were randomized to a control
rategy of enoxaparin 1.0 mg per kg SC twice daily (reduced
1.0 mg per kg once daily for patients with an estimated
eatinine clearance less than 30 ml per min) coupled with
FH when PCI was performed (no additional UFH if the last
se of enoxaparin was less than 6 h before). If the last dose
enoxaparin was given more than 6 h before, the recom-
endation was that an intravenous bolus of UFH 65 U per kg
administered if a GP IIb/IIIa inhibitor was to be used and
0 U per kg if no GP IIb/IIIa inhibitor was to be used. The
posite arm was a strategy of fondaparinux 2.5 mg SC once
ily to be supplemented as follows if PCI was performed:
ithin 6 h of the last subcutaneous dose of fondaparinux, no
ditional study drug was given if a GP IIb/IIIa inhibitor was
ed, and 2.5 mg of fondaparinux was given intravenously if
GP IIb/IIIa inhibitor was used; more than 6 h since the last
se of fondaparinux, an additional intravenous dose of
ndaparinux 2.5 mg was recommended if a GP IIb/IIIa
hibitor was used or 5.0 mg IV if no GP IIb/IIIa inhibitor
as used. As explained by the OASIS 5 investigators, the
tionale for the recommendation to use UFH during PCI in
e enoxaparin arm was based on lack of approval for
oxaparin for PCI in the US by the Food and Drug
dministration, lack of available trial data on the use of
oxaparin during PCI when OASIS 5 was designed, and lack
any recommendations about the use of enoxaparin in the
ailable ACC/AHA or ESC PCI guidelines (personal com-
unication, OASIS 5 Investigators, July 7, 2006). The UFH
sing recommendation in the enoxaparin arm was formu-
ted in consultation with the maker of enoxaparin and was
t altered when the SYNERGY trial did not show superior-
y of enoxaparin over UFH (423). Of note, during the
nduct of the trial, catheter-associated thrombus was re-
ia. *p for noninferiority. †p for superiority. CI  confidence in-
s Strategies for Ischemic Syndromes.Ischemrted 3 times more frequently with the fondaparinux strat-
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,078 patients ultimately enrolled in the trial had been
ndomized, the protocol was amended to remind the inves-
gators to be certain that the intravenous dose of fondapa-
nux was properly flushed in the line and to permit the use of
en-label UFH. As described by the OASIS 5 investigators
ersonal communication, OASIS 5 Investigators, July 7,
06), investigators gave open-label UFH both before and
ring PCI, with the dose being determined at their
scretion.
The number of patients with primary outcome events at 9 d
eath, MI, or refractory ischemia) was similar in the 2 groups
79 with fondaparinux [5.8%] vs. 573 with enoxaparin
.7%]; HR in the fondaparinux group 1.01; 95% CI 0.90 to
13), which satisfied prespecified noninferiority criteria. The
mber of events that met this combined primary efficacy
tcome showed a nonsignificant trend toward a lower value
the fondaparinux group at 30 d (805 vs. 864, p 0.13) and
the end of the study (180 d; 1,222 vs. 1,308, p  0.06;
ig. 12). The rate of major bleeding at 9 d was lower with
ndaparinux than with enoxaparin (217 events [2.2%] vs.
2 events [4.1%]; HR 0.52; p less than 0.001). The com-
site of the primary outcome and major bleeding at 9 d
vored fondaparinux (737 events [7.3%] vs. 905 events
.0%]; HR 0.81; p less than 0.001) (Fig. 15). Fondaparinux
as associated with a significantly reduced number of deaths
30 d (295 vs. 352, p 0.02) and at 180 d (574 vs. 638, p
05). Fondaparinux also was associated with significant
ductions in death, MI, and stroke (p  0.007) at 180 d.
Thus, fondaparinux is another anticoagulant that has been
ven a Class I recommendation in the management of
A/NSTEMI, as noted in Figures 7, 8, and 9. As tested in
ASIS 5, the fondaparinux (plus UFH) strategy was associ-
ed with lower bleeding rates, clearly an attractive feature
ven the relationship between bleeding events and increased
sk of death and ischemic events (486). The excess bleeding
the enoxaparin arm may have been in part a result of the
mbination of enoxaparin and UFH during PCI.
At present, based on experience in both OASIS 5 and
ASIS 6 (433), it appears that patients receiving fondapa-
nux before PCI should receive an additional anticoagu-
nt with anti–IIa activity to support PCI (see Table 13). To
te, the only anticoagulant that has been evaluated with
ndaparinux during PCI is UFH, and based on limited
perience, the OASIS investigators recommend an UFH
se of 50 to 60 U per kg IV when fondaparinux-treated
tients are taken to PCI (personal communication, OASIS
Investigators, July 7, 2006). However, a cautionary note
that this UFH recommendation is not fully evidence-
sed, given its inconsistent and uncontrolled use in
ASIS 5. Hence, additional clinical trial information is
eded to establish more rigorously the safety of intrave-
us UFH at the time of PCI in patients receiving fondapa-
nux as initial medical treatment (Table 13). Because the
ticoagulant effect of UFH can be more readily reversed
an that of fondaparinux, UFH is preferred over fondapa-
nux in patients likely to undergo CABG within 24 h. 0..2.5.6. LONG-TERM ANTICOAGULATION
he long-term administration of warfarin has been evaluated
a few, mostly small studies. Williams et al. (436) random-
ed 102 patients with UA to UFH for 48 h followed by
en-label warfarin for 6 months and reported a 65% risk
duction in the rate of MI or recurrent UA. The Antithrom-
tic Therapy in Acute Coronary Syndromes (ATACS) trial
69) randomized 214 patients with UA/NSTEMI to ASA
one or to the combination of ASA plus UFH followed by
arfarin. At 14 d, there was a reduction in the composite end
int of death, MI, and recurrent ischemia with the combi-
tion therapy (27.0% vs. 10.5%, p  0.004). In a small
ndomized pilot study of 57 patients allocated to warfarin or
acebo in addition to ASA, less evidence was noted of
giographic progression in the culprit lesion after 10 weeks
treatment with warfarin (33% for placebo vs. 4% for
arfarin) and more regression was observed (487). The
ASIS pilot study (488) compared a fixed dosage of warfarin
mg per d or a moderate dose titrated to an INR of 2.0 to 2.5
197 patients and given for 7 months after the acute phase.
ow-intensity warfarin had no benefit, whereas the moderate-
tensity regimen reduced the risk of death, MI, or refractory
gina by 58% and the need for rehospitalization for UA by
%. However, these results were not reproduced in the
rger OASIS 2 trial (477) of 3,712 patients randomized to the
oderate-intensity regimen of warfarin or standard therapy,
ith all patients receiving ASA. The rate of cardiovascular
ath, MI, or stroke after 5 months was 7.7% with the
ticoagulant and 8.4% without (p  0.37) (489). Thus, the
le, if any, of long-term warfarin in patients with UA/
STEMI remains to be defined.
The Coumadin Aspirin Reinfarction Study (CARS) con-
cted in post-MI patients was discontinued prematurely
ing to a lack of evidence of a benefit of reduced-dose ASA
0 mg per d) combined with either 1 or 3 mg of warfarin
ily compared with 160 mg per d of ASA alone (490). The
ombination Hemotherapy And Mortality Prevention study
und no benefit to the use of warfarin (to an INR of 1.5 to
5) plus 81 mg per d of ASA versus 162 mg per d of ASA
one with respect to total mortality (the primary end point),
rdiovascular mortality, stroke, or nonfatal MI (mean
llow-up of 2.7 years) after an index MI (491). Low- or
oderate-intensity anticoagulation with fixed-dose warfarin
us is not recommended for routine use after hospitalization
r UA/NSTEMI. Warfarin should be prescribed, however,
r UA/NSTEMI patients with established indications for
arfarin, such as atrial fibrillation, left ventricular thrombus,
d mechanical prosthetic heart valves.
The Antithrombotics in the Secondary Prevention of
vents in Coronary Thrombosis-2 (ASPECT-2) open-label
ial randomized 999 patients after ACS to low-dose ASA,
gh-intensity oral anticoagulation (INR 3.0 to 4.0), or
mbined low-dose ASA and moderate intensity oral antico-
ulation (INR 2.0 to 2.5) (492). After a median of 12
onths, the primary end point of MI, stroke, or death was
ached in 9% receiving ASA, 5% given anticoagulants (p 
048), and 5% receiving combination therapy (p  0.03).
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367ajor and minor bleeding events occurred in 1% and 5%, 1%
d 8%, and 2% and 15% of patients, respectively.
Similarly, a large (n  3,630) Norwegian open-label study
ARIS-2) compared ASA (160 mg per d), high-intensity
arfarin (INR target 2.8 to 4.2), or ASA (75 mg per d)
mbined with moderate-intensity warfarin (INR 2.0 to 2.5)
er a mean of 4 years after MI (41% with non–Q-wave MI)
93). One third of patients underwent an intervention over
e study period. The primary outcome of death, nonfatal MI,
thromboembolic stroke occurred in 20% of ASA patients,
.7% of warfarin patients, and 15% of combination therapy
tients (p  0.03). The annual major bleeding rate was
62% in both warfarin arms and 0.17% with ASA alone (p
ss than 0.001). Thus, moderate-intensity warfarin with
w-dose ASA appears to be more effective than ASA alone
hen applied to MI patients treated primarily with a nonin-
rventional approach, but it is associated with a higher
eeding risk.
An indication for warfarin (e.g., for atrial fibrillation,
echanical prosthetic valve, or left ventricular thrombus) in
dition to ASA and clopidogrel, which are indicated for
ost high-risk patients, arises occasionally after UA/
STEMI. There are no prospective trials and few observa-
onal data to establish the benefit and risk of such “triple
tithrombotic” therapy (494,495). In the 2004 STEMI
idelines (1), a Class IIb, Level of Evidence: C recommen-
tion was given for the use of warfarin (INR 2.0 to 3.0) in
mbination with ASA (75 to 162 mg) and clopidogrel (75
g per d) for patients with a stent implanted and concomitant
dications for anticoagulation. Similarly, the 2005 PCI
idelines (2) stated that warfarin in combination with
opidogrel and low-dose ASA should be used with great
ution and only when INR is carefully regulated (2.0 to 3.0).
espite a limited amount of subsequent observational data
95), the evidence base remains small, which leaves this
commendation at the Class IIb, Level of Evidence: C.
hen triple-combination therapy is selected for clear indica-
ons and is based on clinical judgment that benefit will
tweigh the incremental risk of bleeding, then therapy
ould be given for the minimum time and at the minimally
fective doses necessary to achieve protection. An expanded
idence base on this issue is strongly needed. Figure 11
ovides recommendations for long-term management of
al- and triple-antithrombotic therapy after UA/NSTEMI.
.2.6. Platelet GP IIb/IIIa Receptor Antagonists
he GP IIb/IIIa receptor is abundant on the platelet surface.
hen platelets are activated, this receptor undergoes a
ange in conformation that increases its affinity for binding
fibrinogen and other ligands. The binding of molecules of
brinogen to receptors on different platelets results in platelet
gregation. This mechanism is independent of the stimulus
r platelet aggregation and represents the final and obliga-
ry pathway for platelet aggregation (496). The platelet GP
b/IIIa receptor antagonists act by occupying the receptors,
eventing fibrinogen from binding, and thereby preventing
atelet aggregation. Experimental and clinical studies have
ggested that occupancy of at least 80% of the receptor
pulation and inhibition of platelet aggregation to ADP (5 to thmicromoles per liter) by at least 80% results in potent
tithrombotic effects (497). The various GP IIb/IIIa antag-
ists, however, possess significantly different pharmacoki-
tic and pharmacodynamic properties (498).
Abciximab is a Fab fragment of a humanized murine
tibody that has a short plasma half-life but strong affinity
r the receptor, which results in some receptor occupancy
at persists in part for weeks. Platelet aggregation gradually
turns to normal 24 to 48 h after discontinuation of the drug.
bciximab also inhibits the vitronectin receptor (alphavbeta3)
endothelial cells and the MAC-1 receptor on leukocytes
99,500). The clinical relevance of occupancy of these
ceptors is unknown.
Eptifibatide is a cyclic heptapeptide that contains the KGD
ys-Gly-Asp) sequence; tirofiban is a nonpeptide mimetic of
e RGD (Arg-Gly-Asp) sequence of fibrinogen (498,501–503).
eceptor occupancy with these 2 synthetic antagonists is, in
neral, in equilibrium with plasma levels. They have half-
ves of 2 to 3 h and are highly specific for the GP IIb/IIIa
ceptor. Platelet aggregation returns to normal in 4 to 8 h
ter discontinuation of these drugs, a finding that is consis-
nt with their relatively short half-lives (504). Glycoprotein
b/IIIa antagonists can bind to different sites on the receptor,
hich results in somewhat different binding properties that
n modify their platelet effects and, potentially and paradox-
ally, activate the receptor (505). Oral antagonists to the
ceptor, previously under investigation, have been aban-
ned because of negative results of 5 large trials of 4 of these
mpounds (506–509).
The efficacy of GP IIb/IIIa antagonists in prevention of the
mplications associated with percutaneous interventions has
en documented in numerous trials, many of them composed
tally or largely of patients with UA (372,510–512) (Table 18).
wo trials with tirofiban and 1 trial with eptifibatide have also
cumented their efficacy in UA/NSTEMI patients, only
me of whom underwent interventions (128,130). Two trials
ere completed with the experimental drug lamifiban
73,513) and 1 with abciximab (514). Few direct compara-
ve data are available for these various antiplatelet agents.
he TARGET study (Do Tirofiban and ReoPro Give Similar
fficacy Trial) assessed differences in safety and efficacy of
rofiban and abciximab in 4,809 patients undergoing PCI
ith intended stenting (515). The composite of death, nonfa-
l MI, or urgent target-vessel revascularization at 30 d
curred more frequently in the tirofiban group (7.6% vs.
0%). The advantage of abciximab was observed exclusively
ong patients presenting with UA/NSTEMI (63% of the
pulation) (515). A possible explanation for the inferior
rformance of in-laboratory initiation of tirofiban for PCI in
e setting of ACS was an insufficient loading dose of
rofiban to achieve optimal early (periprocedural) antiplatelet
fect (516).
Abciximab has been studied primarily in PCI trials, in
hich its administration consistently resulted in reductions in
tes of MI and the need for urgent revascularization (Table
). In subgroups of patients within those trials who had
CS, the risk of ischemic complications within the first 30 d
ter PCI was reduced by 60% to 80% with abciximab
erapy. Two trials with abciximab specifically studied pa-
Table 18. UA/NSTEMI Outcome of Death or Myocardial Infarction in Clinical Trials of GP IIb/IIIa Antagonists Involving More Than 1,000 Patients
Trial (Year) Study Population Drugs
Results
ARR, % RR 95% CI p
Placebo GP IIb/IIIa
n % n %
PCI trials
EPIC (1994) (510) High-risk PTCA Abciximab 72/696 10.3 49/708 6.9* 3.4 0.68 0.47 to 0.95 0.022
EPILOG (1997) (511) All PTCA Abciximab 85/939 9.1 35/935 3.7* 5.4 0.41 0.28 to 0.61 Less than 0.001
CAPTURE (1997) (372) UA Abciximab 57/635 9.0 30/630 4.8 4.2 0.53 0.35 to 0.81 0.003
IMPACT II (1997) (517) All PTCA Eptifibatide 112/1328 8.4 93/1349 6.9* 1.5 0.83 0.63 to 1.06 0.134
RESTORE (1997) (518) UA Tirofiban 69/1070 6.4 54/1071 5.0 1.4 0.78 0.55 to 1.10 0.162
EPISTENT (1998) (512) Elective stenting Abciximab 83/809 10.2 38/794 4.8* 5.4 0.46 0.32 to 0.68 Less than 0.001
ESPRIT (2000) (519) Elective stenting Eptifibatide 104/1024 10.2 66/1040 6.3 3.9 0.62 0.46 to 0.84 0.0016
ISAR-REACT (2004) (520) Elective stenting with
clopidogrel pretreatment
Abciximab 42/1080 3.9 43/1079 4.0 0.1 1.02 0.68 to 1.55 0.91
ACS trials
PRISM-PLUS (1998) (130) UA/NQWMI Tirofiban 95/797 11.9 67/733* 9.1* 2.8 0.70 0.51 to 0.96 0.03
PRISM (1998) (374) UA/NQWMI Tirofiban 115/1616 7.1 94/1616 5.8† 1.3 0.82 0.61 to 1.05 0.11
PURSUIT (1998) (128) UA/NQWMI Eptifibatide 744/4739 15.7 670/4722 14.2* 1.5 0.90 0.82 to 1.00 0.04
PARAGON A (1998) (373) UA/NQWMI Lamifiban 89/758 11.7 80/755 10.6*† 1.1 0.90 0.68 to 1.20 0.48
GUSTO IV ACS (2001) (514) UA/NQWMI Abciximab 209/2598 8.0 450/5202‡ 8.7 0.7 1.08 0.92 to 1.26 0.36
PARAGON B (2002) (521) UA/NQWMI Lamifiban 296/2597 11.4 278/2628 10.6 0.8 0.94 0.77 to 1.09 0.32
ISAR-REACT (2006) (244) UA/NSTEMI§ Abciximab 116/1010 11.5 87/1012 8.6 2.9 0.75 0.57 to 0.97 0.03
All PCI trials 624/7581 8.2 408/7606 5.4 2.8 0.65 0.58 to 0.74 Less than 0.0001
All ACS trials 1664/14 115 11.7 1726/16 668 10.4 1.3 0.86 0.81 to 0.93 Less than 0.0001
All PCI and ACS trials 2288/21 696 10.5 2134/24 274 8.8 1.7 0.83 0.83 to 0.84 Less than 0.0001
*Best treatment group selected for analysis.
†latelet GP IIb/IIIa antagonist without heparin.
‡Pooled results for 24- and 48-h infusion arms.
§Used an invasive (PCI) strategy; all patients received clopidogrel.
ACS  acute coronary syndrome; CAPTURE  c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina; CI  confidence interval; EPIC  Evaluation of c7E3 for the Prevention of Ischemic Complications; EPILOG 
Evaluation of PTCA and Improve Long-term Outcome by c7E3 GP IIb/IIIa receptor blockade; EPISTENT  Evaluation of Platelet IIb/IIIa Inhibitor for STENTing; ESPRIT  Enhanced Suppression of Platelet Receptor GP IIb/IIIa
using Integrilin Therapy; GUSTO IV ACS  Global Use of Strategies to Open Occluded Coronary Arteries IV; IMPACT II  Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II; ISAR-REACT  Intracoronary
Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment; NQWMI  non–Q-wave myocardial infarction; PARAGON  Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events
in a Global Organization Network; PCI  percutaneous coronary intervention; PRISM  Platelet Receptor Inhibition in Ischemic Syndrome Management; PRISM-PLUS  Platelet Receptor Inhibition in Ischemic Syndrome
Management in Patients Limited by Unstable Signs and Symptoms; PTCA percutaneous transluminal coronary angioplasty; PURSUIT Platelet Glycoprotein IIb/IIIa in Unstable 16 Angina: Receptor Suppression Using Integrilin
Therapy; RESTORE  Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis; RR  risk ratio; UA  unstable angina; UA/NSTEMI  unstable angina/non–ST-elevation myocardial infarction.
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rolled patients with refractory UA (372). After angio-
aphic identification of a culprit lesion suitable for angio-
asty, patients were randomized to either abciximab or
acebo administered for 20 to 24 h before angioplasty and
r 1 h thereafter. The rate of death, MI, or urgent revascu-
rization within 30 d (primary outcome) was reduced from
.9% with placebo to 11.3% with abciximab (RR 0.71, p 
012). At 6 months, death or MI had occurred in 10.6% of
e placebo-treated patients versus 9.0% of the abciximab-
eated patients (p  0.19). Abciximab is approved for the
eatment of UA/NSTEMI as an adjunct to PCI or when PCI
planned within 24 h.
The GUSTO IV-ACS trial (514) enrolled 7,800 patients
ith UA/NSTEMI who were admitted to the hospital with
ore than 5 min of chest pain and either ST-segment
pression and/or elevated TnT or TnI concentration. All
ceived ASA and either UFH or LMWH. They were ran-
mized to an abciximab bolus and a 24-h infusion, an
ciximab bolus and a 48-h infusion, or placebo. In contrast
other trials with GP IIb/IIIa antagonists, GUSTO IV-ACS
rolled patients in whom early (less than 48 h) revascular-
ation was not intended. At 30 d, death or MI occurred in
0% of patients taking placebo, 8.2% of patients taking 24-h
ciximab, and 9.1% of patients taking 48-h abciximab,
fferences that were not statistically significant. At 48 h,
ath occurred in 0.3%, 0.7%, and 0.9% of patients in these
oups, respectively (placebo vs. abciximab 48 h, p 0.008).
he lack of benefit of abciximab was observed in most
bgroups, including patients with elevated concentrations of
oponin who were at higher risk. Although the explanation
r these results is not clear, they indicate that abciximab at
e dosing regimen used in GUSTO IV-ACS is not indicated
the management of patients with UA or NSTEMI in whom
early invasive management strategy is not planned.
Tirofiban was studied in the Platelet Receptor Inhibition in
chemic Syndrome Management (PRISM) (374) and Platelet
eceptor Inhibition in Ischemic Syndrome Management in
atients Limited by Unstable Signs and Symptoms (PRISM-
LUS) (130) trials. PRISM directly compared tirofiban with
parin in 3,232 patients with accelerating angina or angina at
st and ST-segment or T-wave changes and with cardiac
arker elevation, a previous MI, or a positive stress test or
giographically documented coronary disease (374). The
imary composite outcome (death, MI, or refractory isch-
ia at the end of a 48-h infusion period) was reduced from
6% with UFH to 3.8% with tirofiban (RR 0.67, p  0.01).
t 30 d, the frequency of the composite outcome was similar
the 2 groups (17.1% for UFH vs. 15.9% for tirofiban, p 
34), but a trend toward reduction in the rate of death or MI
as present with tirofiban (7.1% vs. 5.8%, p  0.11), and a
gnificant reduction in mortality rates was observed (3.6%
. 2.3%, p  0.02). The benefit of tirofiban was mainly
esent in patients with an elevated TnI or TnT concentration
baseline.
The PRISM-PLUS trial enrolled 1,915 patients with clin-
al features of UA/NSTEMI within the previous 12 h and the
esence of ischemic ST-T changes or CK and CK-MB
evation (130). Patients were randomized to tirofiban alone, wFH alone, or the combination for a period varying from 48
108 h. The tirofiban-alone arm was dropped during the trial
cause of an excess mortality rate. The combination of
rofiban and UFH compared with UFH alone reduced the
imary composite end point of death, MI, or refractory
chemia at 7 d from 17.9% to 12.9% (RR 0.68, p  0.004).
his composite outcome also was significantly reduced at
d (22%, p  0.03) and at 6 months (19%, p  0.02). The
d point of death or nonfatal MI was reduced at 7 d (43%,
 0.006), at 30 d (30%, p  0.03), and at 6 months (22%,
 0.06). A high rate of angiography in this trial could have
ntributed to the important reduction in event rates.
omputer-assisted analysis of coronary angiograms obtained
ter 48 h of treatment in PRISM-PLUS also showed a
duction in the thrombus load at the site of the culprit lesion
d improved coronary flow in patients who received the
mbination of tirofiban and UFH (134). Tirofiban, in com-
nation with heparin, has been approved for the treatment of
tients with ACS, including patients who are managed
edically and those undergoing PCI.
Eptifibatide was studied in the PURSUIT trial, which
rolled 10,948 patients who had chest pain at rest within the
evious 24 h and ST-T changes or CK-MB elevation (128).
he study drug was added to standard management until
spital discharge or for 72 h, although patients with normal
ronary arteries or other mitigating circumstances had
orter infusions. The infusion could be continued for an
ditional 24 h if an intervention was performed near the end
the 72-h infusion period. The primary outcome rate of
ath or nonfatal MI at 30 d was reduced from 15.7% to
.2% with eptifibatide (RR 0.91, p 0.042). Within the first
h, a substantial treatment effect was seen (9.1% vs. 7.6%,
 0.01). The benefits were maintained at 6-month follow-
. Eptifibatide has been approved for the treatment of
tients with ACS (UA/NSTEMI) who are treated medically
with PCI. It is usually administered with ASA and heparin.
The cumulative event rates observed during the phase of
edical management and at the time of PCI in the CAP-
URE, PRISM-PLUS, and PURSUIT trials are shown in
igure 16 (523). By protocol design, almost all patients
derwent PCI in CAPTURE. In PRISM-PLUS, angiography
as recommended. A percutaneous revascularization was
rformed in 31% of patients in PRISM-PLUS and in 13% of
tients in PURSUIT. Each trial showed a statistically sig-
ficant reduction in the rate of death or MI during the phase
medical management; the reduction in event rates was
agnified at the time of the intervention.
Although it is tempting to evaluate the drug effect by
mparing patients who had intervention with those who did
t, such an analysis is inappropriate. Patients who do not
dergo intervention include many low-risk patients, patients
ho died before having the opportunity for intervention,
tients with contraindications, and patients with uncompli-
ted courses in countries and practices that use the ischemia-
ided approach; there is no way to adjust for these imbal-
ces. Accordingly, the analysis in Figure 16 includes the
ent rates for all patients during the time when they were
eated medically. It then begins the analysis anew in patients
ho underwent PCI at the time of angiography while taking
dr
no
as
or
st
pa
eq
pa
(O
ob
tr
M
cu
w
ic
an
Fi
pl
Le
m
te
la
of
th
va
th
re
an
Th

ite
ril
e281JACC Vol. 57, No. 19, 2011 Anderson et al.
May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionug or placebo. In the PRISM-PLUS trial, 1,069 patients did
t undergo early PCI. Although tirofiban treatment was
sociated with a lower incidence of death, MI or death, or MI
refractory ischemia at 30 d, these reductions were not
atistically significant (130). In a high-risk subgroup of these
tients not undergoing PCI (TIMI risk score greater than or
ual to 4) (159), tirofiban appeared to be beneficial whether
tients underwent PCI (OR 0.60, 95% CI 0.35 to 1.01) or not
gure 16. Kaplan-Meier Curves Showing Cumulative Incidence of
atelet GP IIb/IIIa receptor antagonist (bold line) or placebo. Data
ft: events during the initial period of medical treatment until the
inistered for 18 to 24 h before the PCI was performed in almost
r the intervention. In PURSUIT, a PCI was performed in 11.2% o
sted 72 h and for 24 h after the intervention. In PRISM-PLUS, an
medical therapy with tirofiban, and the drug infusion was mainta
e time of PCI and the next 48 h, with the event rates reset to 0%
tions exceeding 2 times the upper limit of normal were consider
e upper limit of normal for PCI-related events. Adapted from Boe
ceptor inhibition in non–ST-elevation acute coronary syndromes.
d PRISM-PLUS (134). © Lippincott, Williams & Wilkins. CABG 
erapy in Unstable REfractory angina; GP  glycoprotein; MI  m
percutaneous coronary intervention; PRISM-PLUS  Platelet Re
d by Unstable Signs and symptoms; PURSUIT  Platelet glycop
in Therapy.R 0.69, 95% CI 0.49 to 0.99); however, no benefit was trserved in patients at lower risk (181,525). In the PURSUIT
ial, the impact of eptifibatide on the incidence of death or
I in the subgroup of patients who did not undergo revas-
larization within the first 72 h was modest and consistent
ith the overall trial result, although not individually signif-
ant (15.6% vs. 14.5%, p  0.23) (128).
Boersma et al. performed a meta-analysis of GP IIb/IIIa
tagonists of all 6 large, randomized, placebo-controlled
or MI. Incidence is shown in patients randomly assigned to
rived from the CAPTURE, PURSUIT, and PRISM-PLUS trials.
t of PCI or CABG. In the CAPTURE trial, abciximab was ad-
ents as per study design; abciximab was discontinued 1 h af-
ts during a period of medical therapy with eptifibatide that
ention was performed in 30.2% of patients after a 48-h period
r 12 to 24 h after an intervention. Right: events occurring at
e the intervention. Creatine kinase or creatine kinase-MB ele-
nfarction during medical management and exceeding 3 times
, Akkerhuis KM, Théroux P, et al. Platelet glycoprotein IIb/IIIa
ation 1999;100:2045–8 (523), CAPTURE (240), PURSUIT (172),
ary artery bypass graft; CAPTURE  c7E3 Fab AntiPlatelet
dial infarction; N  number of patients; OR  odds ratio; PCI
Inhibition in ischemic Syndrome Management in Patients Lim-
IIb/IIIa in Unstable angina: Receptor Suppression Using Integ-Death
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ry revascularization (526). In the overall population, the
sk of death or MI by 30 d was modestly reduced in the
tive treatment arms (11.8% vs. 10.8%, OR 0.91, 95% CI
84 to 0.98, p  0.015). Treatment effect appeared to be
eater among higher-risk patients with troponin elevations or
CG ST-segment depressions. Unexpectedly, no benefit was
served in women, but there was no evidence of a sex
fference in treatment effect once patients were stratified by
oponin concentrations (a risk reduction was seen in both
en and women with elevated cTn levels). These and other
ta have elevated troponin level to a major factor in decision
aking for the use of these agents in UA/NSTEMI. Major
eeding complications were increased in the GP IIb/IIIa
tagonist-treated group compared with those who received
acebo (2.4% vs. 1.4%, p less than 0.0001). For special
nsiderations about the use of GP IIb/IIIa antagonists in
omen, see Section 6.1.2.1.
A relationship was observed between revascularization
ocedures and the apparent treatment effect of GP IIb/IIIa
ockade in the meta-analysis by Boersma et al. (526).
evascularization strategies were not specified by trial pro-
cols or randomized, but 5,847 (19%) of the 31,402 patients
derwent PCI or CABG within 5 d, and 11,965 patients
8%) did so within 30 d. Significant reductions in the risk of
ath or MI with GP IIb/IIIa blockade were observed in these
bgroups (OR 0.79, 95% CI 0.68 to 0.91 for patients
vascularized within 5 d; OR  0.89, 95% CI 0.80 to 0.98
r patients revascularized within 30 d), whereas no signifi-
nt treatment effect was present in the other 19,416 patients
ho did not undergo coronary revascularization within 30 d
R for death or MI 0.95, 95% CI 0.86 to 1.05). The authors
ncluded that the benefit of GP IIb/IIIa blockade in patients
ith UA/NSTEMI was “clinically most meaningful in pa-
ents at high risk of thrombotic complications” (526). The
ndings of this meta-analysis in the context of other trials of
P IIb/IIIa blockade during PCI suggest that GP IIb/IIIa
hibitors are of substantial benefit in patients with UA/
STEMI who undergo PCI, are of modest benefit in patients
ho are not routinely scheduled to undergo revascularization
ut who may do so), and are of questionable benefit in
tients who do not undergo revascularization.
Although there is a temptation to use the comparison of
ch of these GP IIb/IIIa inhibitors with placebo to draw
nclusions about relative efficacy, such an exercise could be
isleading. Each trial had different entry criteria, different
proaches to angiographic evaluation, and different criteria
r end-point measurement and took place in different loca-
ons in different time periods. The effects of these differences
nnot be accounted for in an indirect comparison. Head-to-
ad (direct) comparisons are required to draw reliable
nclusions about the relative efficacy of these different
olecules. As noted earlier, 1 trial (TARGET) demonstrated
advantage to in-laboratory initiation of abciximab over
rofiban for UA/NSTEMI patients undergoing PCI with
enting (515). An explanation offered for this difference was
insufficient loading dose of tirofiban to achieve optimal
riprocedural antiplatelet effect (516). adTreatment with a GP IIb/IIIa antagonist increases the risk
bleeding, which is typically mucocutaneous or involves the
cess site of vascular intervention. Unfortunately, each trial
so used a different definition of bleeding and reported
eeding related to CABG differently. In the PRISM trial,
ith no interventions (including CABG) on treatment, major
eeding (excluding CABG) occurred in 0.4% of patients who
ceived tirofiban and 0.4% of patients who received UFH
74). In the PRISM-PLUS trial, major bleeding according to
e TIMI criteria was reported in 1.4% of patients who
ceived tirofiban and 0.8% of patients who received placebo
 0.23), whereas PURSUIT reported major bleeding in
.6% of patients who received eptifibatide and 9.1% of
tients who received placebo (p  0.02) (134,172). In the
URSUIT trial, with the exclusion of patients who underwent
ABG, the rates were 3.0% with eptifibatide and 1.3% with
acebo (p less than 0.001). No trials have shown an excess of
tracranial bleeding with a GP IIb/IIIa inhibitor. As with the
ficacy data, the temptation to make indirect comparisons
ould be tempered by the variability in protocol, circum-
ances, and definitions of the trial.
Aspirin has been used with the intravenous GP IIb/IIIa
ceptor blockers in all trials. A strong case also can be made
r the concomitant use of heparin with GP IIb/IIIa receptor
ockers. The tirofiban arm without UFH in the PRISM-
LUS trial was discontinued early because of an excess of
aths. In addition, the PURSUIT trial reported a higher
ent rate in the 11% of patients who were not treated with
ncomitant heparin (128). In a randomized comparison, a
wer-dose regimen of the GP IIb/IIIa inhibitor lamifiban
ve a more favorable outcome trend when combined with
parin than when administered without heparin (373). Cur-
nt recommendations call for the concomitant use of heparin
ith GP IIb/IIIa inhibitors. Glycoprotein IIb/IIIa inhibitors
n increase the ACT when combined with heparin, which
eans that lower doses of heparin are required to achieve a
rget level of anticoagulation. Moreover, trial data indicate
at lower heparin doses diminish the bleeding risk associated
ith GP IIb/IIIa blockade in the setting of PCI, findings that
kely can be extrapolated to the medical phase of manage-
ent in patients with UA/NSTEMI.
Blood hemoglobin and platelet counts should be monitored
d patient surveillance for bleeding should be performed
ily during the administration of GP IIb/IIIa receptor block-
s. Thrombocytopenia is an unusual complication of this
ass of agents. Severe thrombocytopenia, defined by nadir
atelet counts of less than 50,000 per ml, is observed in 0.5%
patients, and profound thrombocytopenia, defined by nadir
atelet counts of less than 20,000 per ml, is observed in 0.2%
patients. Although reversible, thrombocytopenia is associ-
ed with an increased risk of bleeding (527,528).
Several trials have demonstrated that GP IIb/IIIa inhibitors
n be used with LMWH among patients with unstable
chemic syndromes. In the Antithrombotic Combination
sing Tirofiban and Enoxaparin (ACUTE II) study (529),
FH and enoxaparin were compared in patients with UA/
STEMI receiving tirofiban. The incidence of major and
inor bleeding was similar, and there was a trend to fewer
verse events in patients receiving enoxaparin. More re-
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lative efficacy of enoxaparin versus UFH among patients
ith ACS. One of these, the A to Z Trial (Aggrastat to
ocor), randomized 3,987 patients who were treated with
ncomitant ASA and tirofiban (466). Coronary angiography
as performed in 60% of patients. Nonsignificant trends
ward fewer ischemic end points but more frequent bleeding
ents were observed with enoxaparin than with UFH therapy
66). In the larger SYNERGY trial, 10,027 patients with
gh-risk ACS were randomized to receive either UFH or
oxaparin (423) (Fig. 12). Glycoprotein IIb/IIIa antagonists
ere administered to 57% of patients, and 92% underwent
ronary angiography. No advantage of enoxaparin over
parin was observed for the primary end point of death or
yocardial infarction by 30 d (14.0% vs. 14.5%), but the 2
ndomized therapies offered similar protection against isch-
ic events during PCI. Enoxaparin was associated, how-
er, with an excess risk of TIMI major bleeding (9.1% vs.
6%, p  0.008) (423).
The ACUITY trial investigated the combination of a GP
b/IIIa inhibitor with bivalirudin, a direct thrombin inhibitor
ee Section 3.2.2.4 and Fig. 13) (425). Glycoprotein IIb/IIIa
hibition with bivalirudin resulted in similar (noninferior)
inical outcomes compared with GP IIb/IIIa inhibition with
FH or enoxaparin.
A challenge for the current guidelines is integrating the GP
b/IIIa studies from the 1990s with more recent studies using
eangiography clopidogrel loading, newer anticoagulants,
d varying degrees of patient acuity and risk/benefit. The
rrent evidence base and expert opinion suggest that for
A/NSTEMI patients in whom an initial invasive strategy is
lected, either an intravenous GP IIb/IIIa inhibitor or clopi-
grel should be added to ASA and anticoagulant therapy
fore diagnostic angiography (upstream) for lower-risk,
oponin-negative patients and that both should be given
fore angiography for high-risk, troponin-positive patients
lass I recommendations). For UA/NSTEMI patients in
hom an initial conservative (i.e., noninvasive) strategy is
lected, the evidence for benefit is less; for this strategy, the
dition of eptifibatide or tirofiban to anticoagulant and oral
tiplatelet therapy may be reasonable for high-risk UA/
STEMI patients (Class IIb recommendation).
.2.7. Fibrinolysis
he failure of intravenous fibrinolytic therapy to improve
inical outcomes in the absence of MI with ST-segment
evation or bundle-branch block was clearly demonstrated in
e TIMI 11B, ISIS-2, and GISSI 1 trials (129,530,531). A
eta-analysis of fibrinolytic therapy in UA/NSTEMI patients
owed no benefit of fibrinolysis versus standard therapy
31a). Fibrinolytic agents had no significant beneficial effect
d actually increased the risk of MI (531a). Consequently,
ch therapy is not recommended for the management of
tients with an ACS without ST-segment elevation, a
sterior-wall MI, or a presumably new left bundle-branch
ock (see ACC/AHA Guidelines for the Management of
atients With ST-Elevation Myocardial Infarction (1). (5.3. Initial Conservative Versus Initial
vasive Strategies (UPDATED)
or new or updated text, view the 2011 Focused Update.
ext supporting unchanged recommendations has not been
pdated.
ecommendations
ASS I
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is indicated in UA/NSTEMI
patients who have refractory angina or hemodynamic or elec-
trical instability (without serious comorbidities or contraindi-
cations to such procedures). (Level of Evidence: B)
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is indicated in initially
stabilized UA/NSTEMI patients (without serious comorbidities
or contraindications to such procedures) who have an elevated
risk for clinical events (see Table 11 and Sections 2.2.6 and
3.4.3. (Level of Evidence: A)
ASS IIb
In initially stabilized patients, an initially conservative (i.e., a
selectively invasive) strategy may be considered as a treat-
ment strategy for UA/NSTEMI patients (without serious co-
morbidities or contraindications to such procedures) who have
an elevated risk for clinical events (see Table 11 and Sections
2.2.6 and 3.4.3) including those who are troponin positive.
(Level of Evidence: B) The decision to implement an initial
conservative (vs. initial invasive) strategy in these patients
may consider physician and patient preference. (Level of
Evidence: C)
An invasive strategy may be reasonable in patients with
chronic renal insufficiency. (Level of Evidence: C)
ASS III
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is not recommended in
patients with extensive comorbidities (e.g., liver or pulmonary
failure, cancer), in whom the risks of revascularization and
comorbid conditions are likely to outweigh the benefits of
revascularization. (Level of Evidence: C)
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is not recommended in
patients with acute chest pain and a low likelihood of ACS.
(Level of Evidence: C)
An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) should not be performed in
patients who will not consent to revascularization regardless
of the findings. (Level of Evidence: C)
.3.1. General Principles
addition to aggressive medical therapy, 2 treatment path-
ays have emerged for treating ACS patients. The “initial” or
arly” invasive strategy, now known simply as the “inva-
ve” strategy, triages patients to undergo an invasive diag-
stic evaluation without first getting a noninvasive stress test
without failing medical treatment (i.e., an initial conserva-
ve diagnostic strategy, or sometimes now known as the
elective invasive strategy”; see below and de Winter et al.
32). Patients treated with an invasive strategy generally will
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367dergo coronary angiography within 4 to 24 h of admission;
wever, these patients also are treated with the usual
A/NSTEMI medications, including appropriate anti-
chemic, antiplatelet, and anticoagulant therapy, as outlined
Sections 3.1 and 3.2. These drugs generally are not
ithheld until after angiography. Within the invasive strat-
y, there is a subgroup of patients presenting to the ED who
quire urgent catheterization and revascularization in the
sence of ST deviation because of ongoing ischemic symp-
ms or hemodynamic or rhythm instability. These patients
e often rushed off to the catheterization laboratory within
inutes to a few hours of arrival and are not considered
propriate candidates for a conservative strategy. Even here,
propriate medical therapy is considered; however, with
ese patients, the administration of GP IIb/IIIa inhibitors or
opidogrel may be delayed until the time of angiography, at
physician’s discretion (Figs. 7, 8, and 9). On the other hand,
e longer the interval between presentation and angiography
patients, the greater the incremental benefit of “upstream”
tiplatelet therapy. In summary, the invasive strategy can be
bdivided into: 1) those patients requiring urgent angiog-
phy/revascularization very soon after arrival at the ED,
d 2) those with a UA/NSTEMI presentation who are
signated either by patient/physician discretion or after
sk assessment to benefit from “early” but nonurgent
giography/intervention.
In contrast, the “initial conservative strategy” (also referred
as “selective invasive management”) calls for proceeding
ith an invasive evaluation only for those patients who fail
edical therapy (refractory angina or angina at rest or with
inimal activity despite vigorous medical therapy) or in
hom objective evidence of ischemia (dynamic ECG
anges, high-risk stress test) is identified. Estimating the risk
r an adverse outcome is paramount for determining which
rategy is best applied to an individual ACS patient. Several
sk tools have been validated that are useful in guiding the
pe and intensity of therapy by identifying patients most
kely to benefit from aggressive treatment.
One such valuable tool for risk determination is based on
ta from the TIMI 11B and ESSENCE trials (159) and is
scussed in Section 2.2.6 and Table 8. The TIMI risk
lculator is available at http://www.timi.org/.
Another simple risk-prediction tool has been validated by
ta from GRACE (168) (Fig. 4; Section 2.2.6). The GRACE
lculator can estimate short and intermediate mortality and
useful when making diagnostic and treatment decisions for
CS patients. The GRACE clinical application tool can be
wnloaded to a handheld PDA to be used at the bedside and
available at http://www.outcomes-umassmed.org/grace.
The PURSUIT, TIMI, and GRACE risk scores demon-
rate good predictive accuracy for death and MI. They
ovide valuable information that can be used to identify
tients likely to benefit from early, aggressive therapy,
cluding intravenous GP platelet inhibitors and early coro-
ry revascularization (174).
.3.2. Rationale for the Initial Conservative Strategy
few multicenter trials have shown similar outcomes with
itial conservative and invasive therapeutic strategies pe29,533,534). Some trials (534,535) have emphasized the
rly risk associated with revascularization procedures. The
nservative strategy seeks to avoid the routine early use of
vasive procedures unless patients experience refractory or
current ischemic symptoms or develop hemodynamic insta-
lity. When the conservative strategy is chosen, a plan for
ninvasive evaluation is required to detect severe ischemia
at occurs spontaneously or at a low threshold of stress and
promptly refer these patients for coronary angiography and
vascularization when possible. In addition, as in STEMI
36), an early echocardiogram should be considered to identify
tients with significant LV dysfunction (e.g., LVEF less than
40). Such a finding prompts consideration for angiography to
entify left main or multivessel CAD, because patients with
ultivessel disease and LV dysfunction are at high risk and
uld accrue a survival benefit from CABG (537,538). In
dition, a stress test (e.g., exercise or pharmacological stress)
r the assessment of ischemia is recommended before discharge
shortly thereafter to identify patients who may also benefit
om revascularization. The use of aggressive anticoagulant and
tiplatelet agents has reduced the incidence of adverse out-
mes in patients managed conservatively (see Section 3.3)
28,134,169,180,372,374,523,539). An advantage offered by
e conservative strategy is that many patients stabilize on
edical therapy and will not require coronary angiography.
onsequently, the conservative strategy limits the use of in-
spital cardiac catheterization and may avoid costly and pos-
bly unnecessary invasive procedures.
.3.3. Rationale for the Invasive Strategy
or patients with UA/NSTEMI without recurrent ischemia in
e first 24 h, the use of angiography provides an invasive
proach to risk stratification. It can identify the 10% to 20%
patients with no significant coronary stenoses and the
proximately 20% with 3-vessel disease with LV dysfunc-
on or left main CAD. This latter group can derive a survival
nefit from CABG (see Section 4). In addition, PCI of the
lprit lesion has the potential to reduce the risk for subse-
ent hospitalization and the need for multiple antianginal
ugs compared with the early conservative strategy (TIMI
IB) (129). Just as the use of improved anticoagulant therapy
d/or a platelet GP IIb/IIIa receptor blocker has improved
e outcome in patients managed according to the conserva-
ve strategy, the availability of these agents also makes the
vasive approach more attractive, particularly because the
rly hazard of PCI is lessened. The availability of GP
b/IIIa receptor blockers also has led to 2 alternatives for
e routine invasive approach: immediate angiography or
ferred angiography.
.3.4. Immediate Angiography
xcluding those in need of urgent intervention, 2 alternatives
r the invasive approach have emerged: early (“immediate”)
deferred angiography (i.e., with respect to a 12- to 48-h
indow). Some believe that proceeding immediately to
giography is an efficient approach for the ACS patient.
atients found not to have CAD may be discharged rapidly or
ifted to a different management strategy. Patients with
vious culprit lesions amenable to PCI can have a procedure
rformed immediately, hastening discharge. Patients with
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionft main CAD and those with multivessel disease and LV
sfunction can be sent expeditiously to undergo bypass
rgery, thereby avoiding a risky waiting period. Support for
mediate angiography comes from the Intracoronary Stent-
g with Antithrombotic Regimen Cooling-off Study (ISAR-
OOL) (540). All ACS patients were treated with intensive
edical therapy (including oral and intravenous antiplatelet
erapy). They were randomized to immediate angiography
edian time 2.4 h) or a prolonged “cooling off” period for a
edian of 86 h before undergoing catheterization. Patients
ndomized to immediate angiography had significantly
wer deaths or MIs at 30 d. Importantly, this difference in
tcome was attributed to events that occurred before cathe-
rization in the “cooling off” group, which supports the
tionale for intensive medical therapy and very early angiog-
phy. Data supporting this approach are limited, but addi-
onal clinical trial results are expected in the future.
.3.5. Deferred Angiography
most reports that involve use of the invasive strategy,
giography has been deferred for 12 to 48 h while antithrom-
tic and anti-ischemic therapies are intensified. Several
servational studies, as summarized in Smith et al. (541)
ve found a lower rate of complications in patients under-
ing PCI more than 48 h after admission, during which
parin and ASA were administered, than with early inter-
ntion; however, the value of medical stabilization before
giography has never been assessed formally or proven.
.3.6. Comparison of Early Invasive and
itial Conservative Strategies
rior meta-analyses have concluded that routine invasive
erapy is better than an initial conservative or selectively
vasive approach (542–544). Mehta et al. (543) concluded
at the routine invasive strategy resulted in an 18% relative
duction in death or MI, including a significant reduction in
I alone. The routine invasive arm was associated with
gher in-hospital mortality (1.8% vs. 1.1%), but this disad-
ntage was more than compensated for by a significant
duction in mortality between discharge and the end of
llow-up (3.8% vs. 4.9%). The invasive strategy also was
sociated with less angina and fewer rehospitalizations than
ith the conservative pathway. Patients undergoing routine
vasive treatment also had improved quality of life.
In contrast to these finding, other studies, most recently
TUS (Invasive versus Conservative Treatment in Unstable
ronary Syndromes) (532), have favorably highlighted a
rategy of selective invasive therapy (532). In ICTUS, 1,200
gh-risk ACS patients were randomized to routine invasive
rsus selective invasive management and followed up for 1
ar with respect to the combined incidence of death, MI, and
chemic rehospitalization. All patients were treated with
timal medical therapy that included ASA, clopidogrel,
MWH, and lipid-lowering therapy; abciximab was given to
ose undergoing revascularization. At the end of 1 year,
ere was no significant difference in the composite end point
tween groups. This study suggests that a selective invasive
rategy could be reasonable in ACS patients. A possible
planation for the lack of benefit of the invasive approach in
is trial (and other trials) (545) could be related to the evlatively high rate of revascularization actually performed in
tients treated in the selective invasive arm (47%), thereby
ducing observed differences between treatment strategies
74), and to the lower event rate (lower-risk population) than
other studies. Results were unchanged during longer term
llow-up (545a,545b). Nevertheless, ICTUS required tro-
nin positivity for entry. Thus troponin alone might no
nger be an adequate criterion for strategy selection, espe-
ally with increasingly sensitive troponin assays. The degree
troponin elevation and other high-risk clinical factors taken
gether should be considered in selecting a treatment
rategy.
Other criticisms of ICTUS have included that it was
latively underpowered for hard end points and that it used
controversial definition for post-proceduaral MI (i.e. even
inimal, asymptomatic CK-MB elevation) (532,545a,545b).
Additionally, 1-year follow-up may be inadequate to fully
alize the long-term impact and benefit of the routine
vasive strategy. In the RITA-3 trial (Third Randomized
tervention Treatment of Angina), 5-year but not 1-year
gure 17. Cumulative Risk of Death or Myocardial Infarction or
eath in RITA-3 Cumulative risk of death or myocardial infarc-
n (top) or of death (bottom) in the RITA 3 trial of patients with
n-ST acute coronary syndromes. Reprinted from The Lancet,
6, Fox KAA, Poole-Wilson P, Clayton TC, et al. 5-year out-
me of an interventional strategy in non-ST-elevation acute
ronary syndrome: the British Heart Foundation RITA 3 ran-
mised trial, 914–20. Copyright 2005, with permission from
sevier (546). RITA-3  Third Randomized Intervention Treat-
ent of Angina trial.ent rates favored the early invasive arm (see Fig. 17 and
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ined during a 3-year follow-up (546a).
Thus, these guidelines recommend that in initially stabi-
zed UA/NSTEMI patients, an initial conservative (selective
vasive) strategy may be considered as a treatment option.
he Writing Comittee also believes that additional compara-
ve trials of the selective invasive with the routine initial
vasive strategies are indicated using aggressive contempo-
ry medical therapies in both arms, including routine dual
tiplatelet therapy in medically treated patients (as recom-
ended in Section 5.2.1) as well as aggressive lipid lowering
d other updated secondary prevention measures (as sum-
arized in Section 5.2). Further study could provide a
ronger evidence base for an initial conservative/selective
vasive strategy in initially stabilized patients, as it has for
able angina patients (546a).
Nevertheless, a meta-analysis of contemporary randomized
ials in NSTEMI, including ICTUS, currently supports a
ng-term mortality and morbidity benefit of an early invasive
compared with an initial conservative strategy (547).
onfatal MI at 2 years (7.6% vs. 9.1%, respectively; RR 0.83,
% CI 0.72 to 0.96, p  0.012) and hospitalization (at 13
onths; RR  0.69, 95% CI 0.65 to 0.74, p less than 0.0001)
so were reduced by an early invasive strategy (Fig. 18). A
parate review of contemporary randomized trials in the
ent era using the Cochrane database arrived at similar
nclusions (548). Details of selected contemporary trials of
vasive versus conservative strategies follow.
In the FRISC-II study, 3,048 ACS patients were treated
ith dalteparin for 5 to 7 d (245). Of these patients, 2,457
ho qualified were then randomized (2  2 factorial design)
continue to receive dalteparin or placebo (double blind)
d to receive either a noninvasive or an invasive treatment
rategy, with coronary angiography and revascularization, if
propriate, performed within 7 d of admission. At 6 months,
ere were no differences between continued dalteparin com-
red with placebo. However, death or MI occurred in 9.4%
patients assigned to the invasive strategy versus 12.1% of
ose assigned to the noninvasive strategy (p less than 0.03).
t 1 year, the mortality rate in the invasive strategy group
as 2.2% compared with 3.9% in the noninvasive strategy
oup (p  0.016) (549). It may be concluded from FRISC-II
at patients with UA/NSTEMI who are not at very high risk
r revascularization and who first receive an average of 6 d
treatment with LMWH, ASA, nitrates, and beta blockers
ve a better outcome at 6 months with a (delayed) routine
vasive approach than with a routine conservative approach,
ith very low revascularization rates. Long-term outcomes of
e FRISC-II trial have been published recently (550). At 5
ars, the invasive strategy was favored for the primary end
int of death or nonfatal MI (HR 0.81, p  0.009). Benefit
as confined to men, nonsmokers, and patients with 2 or
ore risk factors.
In the TACTICS-TIMI 18 trial (182), 2,220 patients with
A or NSTEMI were treated with ASA, heparin, and the GP
b/IIIa inhibitor tirofiban. They were randomized to an early
vasive strategy with routine coronary angiography within
h followed by revascularization if the coronary anatomy
as deemed suitable or to a more conservative strategy. In the intter group, catheterization was performed only if the patient
d recurrent ischemia or a positive stress test. Death, MI, or
hospitalization for ACS at 6 months occurred in 15.9% of
tients assigned to the invasive strategy versus 19.4%
signed to the more conservative strategy (p 0.025). Death
MI (182) was also reduced at 6 months (7.3% vs. 9.5%, p
ss than 0.05). The beneficial effects on outcome were
served in medium- and high-risk patients, as defined by an
evation of TnT greater than 0.01 ng per ml, the presence of
T-segment deviation, or a TIMI risk score greater than 3
59). In the absence of these high-risk features, outcomes in
tients assigned to the 2 strategies were similar, which
phasizes the critical importance of appropriate risk strati-
cation. Rates of major bleeding were similar, and lengths of
spital stay were reduced in patients assigned to the invasive
rategy. The benefits of the invasive strategy were achieved
no significant increase in the costs of care over the 6-month
llow-up period.
Thus, both the FRISC-II (245) and TACTICS-TIMI 18
82) trials showed a benefit in patients assigned to the
vasive strategy. In contrast to earlier trials, a large majority
patients undergoing PCI in these 2 trials received coronary
enting as opposed to balloon angioplasty alone. Also, there
as a differential rate of thienopyridine use between the 2
ms; only stented patients were treated. In FRISC-II, the
vasive strategy involved treatment for an average of 6 d in
e hospital with LMWH, ASA, nitrates, and beta blockers
fore coronary angiography, an approach that would be
fficult to adopt in US hospitals. In TACTICS-TIMI 18,
eatment included the GP IIb/IIIa antagonist tirofiban, which
as administered for an average of 22 h before coronary
giography. The routine use of the GP IIb/IIIa inhibitor in
is trial may have eliminated the excess risk of early (within
d) MI in the invasive arm, an excess risk that was observed
FRISC-II and other trials in which there was no routine
pstream” use of a GP IIb/IIIa blocker. Therefore, an
vasive strategy is associated with a better outcome in
A/NSTEMI patients at high risk as defined in Table 11 and
demonstrated in TACTICS-TIMI 18 when a GP IIb/IIIa
hibitor is used (182). Although the benefit of intravenous
P IIb/IIIa inhibitors is established for UA/NSTEMI patients
dergoing PCI, the optimal time to commence these drugs
fore the procedure has not been established. In the PUR-
UIT trial (128), in patients with UA/NSTEMI who were
mitted to community hospitals, the administration of epti-
batide was associated with a reduced need for transfer to
rtiary referral centers and improved outcomes (551).
The RITA-3 trial (546) compared early and conservative
erapy in 1,810 moderate-risk patients with ACS. Patients
ith positive cardiac biomarkers (CK-MB greater than 2
mes the upper limit of normal at randomization) were
cluded from randomization, as were those with new Q
aves, MI within 1 month, PCI within 1 year, and any prior
ABG. The combined end point of death, nonfatal MI, and
fractory angina was reduced from 14.5% to 9.6% by early
vasive treatment. The benefit was driven primarily by a
duction in refractory angina. There was a late divergence of
e curves, with reduced 5-year death and MI in the early
vasive arm (Fig. 17).
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ortality for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. B: Relative risk of recurrent
nfatal myocardial infarction for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. C: Relative
k of recurrent unstable angina resulting in rehospitalization for early invasive therapy compared with conservative therapy at a mean
llow-up of 13 months. Modified from the Journal of the American College of Cardiology, Bavry AA, Kumbhani DJ, Rassi AN, Bhatt
L, Askari AT. Benefit of early invasive therapy in acute coronary syndromes a meta-analysis of contemporary randomized clinical tri-
s, 48:1319–25. Copyright 2006, with permission from Elsevier (547). CI  confidence interval; FRISC-II  FRagmin and fast Revascu-
rization during InStability in Coronary artery disease; ICTUS  Invasive versus Conservative Treatment in Unstable coronary Syn-
omes; ISAR-COOL  Intracoronary Stenting with Antithrombotic Regimen COOLing-off study; RITA-3  Third Randomized
tervention Treatment of Angina trial; RR  relative risk; TIMI-18  Thrombolysis In Myocardial Infarction-18; TRUCS  Treatment of
efractory Unstable angina in geographically isolated areas without Cardiac Surgery; UA/NSTEMI  unstable angina/non–ST-elevation
yocardial infarction; VINO  Value of first day angiography/angioplasty In evolving Non-ST segment elevation myocardial infarction:
pen multicenter randomized trial.
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gioplasty In evolving Non-ST segment elevation myocar-
al infarction: Open multicenter randomized trial) (522), 131
tients with NSTEMI were randomized to cardiac catheter-
ation on the day of admission versus conservative therapy.
espite the fact that 40% of the conservatively treated
tients crossed over to revascularization by the time of the
month follow-up, there was a significant reduction in death
reinfarction for patients assigned to early angiography and
vascularization (6% vs. 22%).
The ISAR-COOL trial (540) randomized 410 intermediate-
high-risk patients to very early angiography and revascu-
rization versus a delayed invasive strategy. All patients
ere treated with intensive medical therapy that included
SA, heparin, clopidogrel (600-mg loading dose), and the
travenous GP IIb/IIIa receptor inhibitor tirofiban. In the
ry early arm, patients underwent cardiac catheterization at
mean time of 2.4 h versus 86 h in the delayed invasive arm.
he very early invasive strategy was associated with signif-
antly better outcome at 30 d, measured by reduction in
ath and large MI (5.9% vs. 11.6%). More importantly, the
nefit seen was attributable to a reduction in events before
rdiac catheterization, which raises the possibility that there
a hazard associated with a “cooling-down” period.
.3.7. Subgroups
ACTICS-TIMI 18 demonstrated a reduction in the 6-month
d point of death or MI in older adult ACS patients. With
spect to gender, controversy exists over revascularization
eatment differences between men and women with ACS.
he FRISC-II trial showed a benefit of early revascularization
men for death or MI that was not observed for women
52). In contrast, death, MI, or rehospitalization rates were
duced for both men and women in TACTICS-TIMI 18
82). Furthermore, an observational study reported that
omen actually did better than men with early interventional
erapy for UA/NSTEMI (553). Finally, RITA-3 (546)
owed that the routine strategy of invasive evaluation
sulted in a beneficial effect in men that was not seen in
omen. Additional research is required to further clarify
ese diverse observations (554).
.3.8. Care Objectives
he objective is to provide a strategy that has the most
tential to yield the best clinical outcome and improve
ng-term prognosis. The purpose of coronary angiography is
provide detailed information about the size and distribution
coronary vessels, the location and extent of atherosclerotic
struction, and the suitability for revascularization. The LV
giogram, which is usually performed along with coronary
giography, provides an assessment of the extent of focal
d global LV dysfunction and of the presence and severity
coexisting disorders (e.g., valvular or congenital lesions).
detailed discussion of revascularization is presented in
ection 4 of these guidelines, as well as in the ACC/AHA
uidelines for Percutaneous Coronary Intervention (2) and
e ACC/AHA Guideline Update for Coronary Artery Bypass
raft Surgery (555). Although general guidelines can be
fered, the selection of appropriate procedures and the
cision to refer patients for revascularization require both stinical judgment and counseling with the patient and the
tient’s family regarding expected risks and benefits.
Although not conducted in patients with UA/NSTEMI, the
llowing studies have addressed the value of stress testing in
iding therapy. The DANish trial in Acute Myocardial
farction (DANAMI) studied 503 patients with inducible
chemia (i.e., a positive exercise stress test) after fibrinolytic
erapy for first MI and compared an ischemia-guided inva-
ve strategy with a conservative strategy (556). The invasive
rategy in the post-MI patients with inducible ischemia
sulted in a reduction in the incidence of reinfarction,
spitalizations for UA, and stable angina. Similarly, in the
symptomatic Cardiac Ischemia Pilot (ACIP) study
57,558), 558 clinically stable patients with ischemia on
ress testing and during daily life (ST-segment depression on
ercise treadmill testing or perfusion abnormality on radio-
clide pharmacological stress test if unable to exercise, in
dition to ST-segment depression on ambulatory ECG
onitoring), most of whom had angina in the previous 6
eeks, were randomized to 1 of 3 initial treatment strategies:
mptom-guided medical care, ischemia-guided medical
re, or revascularization. More than one third of these
tients had “complex” stenoses on angiography. Those
ndomized to early revascularization experienced less am-
latory ischemia at 12 weeks than did those randomized to
itial medical care in whom revascularization was delayed
d symptom driven.
After either STEMI or NSTEMI, the SWISSI II (Swiss
terventional Study of Silent Ischemia Type II) study, which
ndomized 201 patients with silent ischemia, demonstrated
stress imaging, to either revascularization with PCI or
ti-ischemic drug therapy and followed them for an average
10 years. Survival free of cardiac death, nonfatal MI, or
mptom-driven revascularization was significantly reduced
the PCI group. Though relatively small, the study supports
e use of stress testing after UA/NSTEMI for guiding the
lection of invasive evaluation in UA/NSTEMI patients
eated with an initial conservative strategy (558a).
In ACS patients with UA/NSTEMI, the purpose of nonin-
sive testing is both to identify ischemia and to identify
ndidates at high risk for adverse outcomes and to direct
em to coronary angiography and revascularization when
ssible. However, neither randomized trials (129,245,533,534)
r observational data (559) uniformly support an inherent
periority for the routine use of coronary angiography and
vascularization (see Section 4). Accordingly, the decision
garding which strategy to pursue for a given patient should
based on the patient’s estimated outcome risk assisted by
inical and noninvasive test results, available facilities,
evious outcome of revascularization by the team available
the institution in which the patient is hospitalized, and
tient preference.
Coronary angiography can enhance prognostic stratifica-
on. This information can be used to guide medical therapy
d to plan revascularization therapy, but it is important to
phasize that an adverse outcome in ACS is very time
pendent and that after 1 to 2 months, the risk for adverse
tcome is essentially the same as that for low-risk chronicable angina (Fig. 17). Several older studies in patients with
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionable angina, including the Second Randomized Intervention
reatment of Angina (RITA-2) trial (535), have found a
gher early risk of death or MI with an interventional
rategy than with medical management alone. Thus, the
ming of coronary angiography and revascularization is
itically important if patients at high risk are to benefit.
nfortunately, the total number of operative complications is
creased when revascularization procedures are performed
utinely, because some patients who are not in need of
vascularization will be exposed to its hazards. However,
ntemporary use of aggressive medical therapy in UA/
STEMI, including oral and intravenous antiplatelet agents
d anticoagulant agents, has lessened the early hazard and
sk for ischemic complications in patients undergoing early
vasive procedures.
Patients with UA/NSTEMI often can be divided into
fferent risk groups on the basis of their initial clinical
esentation. The TIMI, PURSUIT, and GRACE scores are
eful clinical tools for assigning risk to patients presenting
ith UA/NSTEMI (Table 8; Fig. 4; see Section 2.2.6.).
Risk stratification in turn identifies patients who are most
kely to benefit from subsequent revascularization. For ex-
ple, patients with left main disease or multivessel CAD
ith reduced LV function are at high risk for adverse
tcomes and are likely to benefit from surgical bypass.
linical evaluation and noninvasive testing will aid in the
entification of most patients in the high-risk subset, because
ey often have 1 or more of the following high-risk features:
vanced age (greater than 70 years), prior MI, revascular-
ation, ST-segment deviation, HF or depressed resting LV
nction (i.e., LVEF less than or equal to 0.40) on noninva-
ve study, or noninvasive stress test findings. The presence
any of these risk factors or of diabetes mellitus aids in the
entification of high-risk patients who could benefit from an
vasive strategy.
The majority of patients presenting with UA/NSTEMI,
wever, do not fall into the very high-risk group and do not
ve findings that typically portend a high risk for adverse
tcomes. Accordingly, they are not likely to receive the
me degree of benefit from routine revascularization af-
rded to high-risk patients, and an invasive study is optional
r those at lower risk and can be safely deferred pending
rther clinical developments. Decisions regarding coronary
giography in patients who are not high risk according to
ndings on clinical examination and noninvasive testing can
individualized on the basis of patient preferences and the
gree to which they are affected by clinical symptoms.
The data on which recommendations for invasive or
nservative strategy recommendations are based come from
veral randomized trials. Older trials included TIMI IIIB
29,561), Veterans Affairs Non-Q-Wave Infarction Strate-
es in Hospital (VANQWISH) (534), and Medicine versus
ngiography in Thrombolytic Exclusion (MATE) (533).
ore recent trials, relevant to contemporary practice, include
RISC-II (245), TACTICS-TIMI 18 (182), VINO (522),
ITA-3 (546), ISAR-COOL (540), and ICTUS (532); a large,
ospective, multinational registry, the OASIS registry (559);
d several meta-analyses (542–544). See Section 3.3.1.5 for Sdetailed description of these trials and the more recent
eta-analyses (543,547).
Some selected areas require additional comment. In a
tient with UA, a history of prior PCI within the past 6
onths suggests the presence of restenosis, which often can
treated effectively with repeat PCI. Coronary angiography
ithout preceding functional testing is generally indicated.
atients with prior CABG represent another subgroup for
hom a strategy of early coronary angiography is usually
dicated. The complex interplay between the progression of
tive coronary disease and the development of graft athero-
lerosis with ulceration and embolization is difficult to
tangle noninvasively; these considerations argue for early
ronary angiography. In addition, patients with known or
spected reduced LV systolic function, including patients
ith prior anterior Q-wave MIs, those with known depressed
V function, and those who present with HF, have sufficient
sk that the possibility of benefit from revascularization
ocedures merits early coronary angiography without pre-
ding functional testing.
In patients with UA/NSTEMI, coronary angiography typ-
ally shows the following profile: 1) no severe epicardial
enosis in 10% to 20% with a sex differential, 2) 1-vessel
enosis in 30% to 35%, 3) multivessel stenosis in 40% to
%, and 4) significant (greater than 50%) left main stenosis
4% to 10%. In the early invasive strategy in TIMI IIIB, no
itical obstruction (less than 60% diameter stenosis) was
und in 19% of patients, 1-vessel stenosis in 38%, 2-vessel
enosis in 29%, 3-vessel stenosis in 15%, and left main
enosis (greater than 50%) in 4% (564). Complex plaques are
ually believed to be responsible for the culprit lesions.
hese usually are eccentric and sometimes have irregular
rders and correlate with intracoronary thrombi and an
creased risk of recurrent ischemia at rest, MI, and cardiac
ath (563). Similar findings were noted in more than 80% of
e patients in the VANQWISH trial, and more than 1
mplex lesion was found in most patients (534). Interest-
gly, in TIMI IIIB, many of the patients without severe
enosis had reduced contrast clearance, which suggests
icrovascular dysfunction (564), which can contribute to
paired myocardial perfusion.
Appropriate treatment for women presenting with ACS
ight be different from that in men (see also Section 6.1). In
RISC-II and RITA-3, an improved outcome in the early
vasive arm was seen only in men, whereas the benefit of
rly revascularization was equivalent in men and women in
e TACTICS-TIMI 18 (182) trial provided that the troponin
vel was elevated. In contrast, low-risk women tended to
ve worse outcomes, including a higher risk of major
eeding, with early revascularization therapy, whereas low-
sk men were neither harmed nor benefited by this strategy
65). Most studies showed that women were more likely
an men to have either normal vessels or noncritical steno-
s. High-risk women also were more likely to have elevation
CRP and BNP and less often had elevated troponin
82,565). Women with any positive biomarker benefited
om invasive therapy, whereas those without elevated CRP,
NP, or troponin did better with a conservative approach (see
ection 6.1).
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367Patients with severe 3-vessel stenosis and reduced LV func-
n and those with left main stenosis should be considered for
rly CABG (see Section 4). In low-risk patients, quality of life
d patient preferences should be given considerable weight in
e selection of a treatment strategy. Low-risk patients whose
mptoms do not respond well to maximal medical therapy and
ho experience poor quality of life and functional status and are
epared to accept the risks of revascularization should be
nsidered for revascularization.
The discovery that a patient does not have significant
structive CAD should prompt consideration of whether the
mptoms represent another cause of cardiac ischemia (e.g.,
ndrome X, coronary spasm, coronary embolism, or coro-
ry artery dissection; see Section 6) or pericarditis/
yocarditis or are noncardiac in origin. There is a distinction
tween normal coronaries and vessels with less than 50%
enoses but with atherosclerotic plaque present, which might
demonstrated to be extensive on coronary intravascular
trasound. The latter can include visualization of a culprit
cerated plaque. Noncardiac syndromes should prompt a
arch for the true cause of symptoms. Unfortunately, many
ch patients continue to have recurrent symptoms, are
admitted to the hospital, can become disabled, and continue
consume health care resources even with repeated coronary
giography (566,567).
It is not presently possible to define the extent of comor-
dity that would, in every case, make referral for coronary
giography and revascularization inappropriate. The high-
sk patient with significant comorbidities requires thoughtful
scussion among the physician, patient, and family and/or
tient advocate. A decision for or against revascularization
ust be made on a case-by-case basis.
Examples of extensive comorbidity that usually preclude
vascularization include 1) advanced or metastatic malig-
ncy with a projected life expectancy of 1 year or less, 2)
tracranial pathology that contraindicates the use of systemic
ticoagulation or causes severe cognitive disturbance (e.g.,
lzheimer’s disease) or advanced physical limitations, 3)
d-stage cirrhosis with symptomatic portal hypertension
.g., encephalopathy, visceral bleeding), and 4) CAD that is
own from previous angiography not to be amenable to
vascularization. This list is not meant to be all-inclusive.
ore difficult decisions involve patients with significant
morbidities that are not as serious as those listed here;
amples include patients who have moderate or severe renal
ilure but are stable with dialysis.
Consultation with an interventional cardiologist and a
rdiac surgeon before coronary angiography is advised to
fine technical options and likely risks and benefits. The
erators who perform coronary angiography and revascular-
ation and the facility in which these procedures are per-
rmed are important considerations, because the availability
interventional cardiologists and cardiac surgeons who are
perienced in high-risk and complex patients is essential. As
general principle, the potential benefits of coronary angiog-
phy and revascularization must be carefully weighed
ainst the risks and the conflicting results of the clinical
ials and registries. The Writing Committee endorses further
search into techniques that could reduce bleeding (e.g., redial access and smaller sheath sizes) (568) and the proper
lection and dosing of drugs to minimize bleeding in patients
ith UA/NSTEMI.
.4. Risk Stratification Before Discharge
ecommendations
ASS I
Noninvasive stress testing is recommended in low-risk pa-
tients (Table 7) who have been free of ischemia at rest or with
low-level activity and of HF for a minimum of 12 to 24 h. (Level
of Evidence: C)
Noninvasive stress testing is recommended in patients at
intermediate risk (Table 7) who have been free of ischemia at
rest or with low-level activity and of HF for a minimum of 12 to
24 h. (Level of Evidence: C)
Choice of stress test is based on the resting ECG, ability to
perform exercise, local expertise, and technologies available.
Treadmill exercise is useful in patients able to exercise in
whom the ECG is free of baseline ST-segment abnormalities,
bundle-branch block, LV hypertrophy, intraventricular conduc-
tion defect, paced rhythm, preexcitation, and digoxin effect.
(Level of Evidence: C)
An imaging modality should be added in patients with resting
ST-segment depression (greater than or equal to 0.10 mV), LV
hypertrophy, bundle-branch block, intraventricular conduction
defect, preexcitation, or digoxin who are able to exercise. In
patients undergoing a low-level exercise test, an imaging
modality can add sensitivity. (Level of Evidence: B)
Pharmacological stress testing with imaging is recommended
when physical limitations (e.g., arthritis, amputation, severe
peripheral vascular disease, severe chronic obstructive pulmo-
nary disease, or general debility) preclude adequate exercise
stress. (Level of Evidence: B)
Prompt angiography without noninvasive risk stratification
should be performed for failure of stabilization with intensive
medical treatment. (Level of Evidence: B)
A noninvasive test (echocardiogram or radionuclide angio-
gram) is recommended to evaluate LV function in patients with
definite ACS who are not scheduled for coronary angiography
and left ventriculography. (Level of Evidence: B)
The management of ACS patients requires continuous
sk stratification. Important prognostic information is
rived from careful initial assessment, the patient’s
urse during the first few days of management, and the
tient’s response to anti-ischemic and antithrombotic
erapy. The Braunwald classification (14,260) has been
lidated prospectively and represents an appropriate clin-
al instrument to help predict outcome (569). Angina at
st, within 48 h in the absence of an extracardiac
ndition (primary UA; Braunwald Class III), and UA in
e early postinfarction period (Braunwald class C), along
ith age, male sex, hypertension, and maximal intravenous
tianginal/anti-ischemic therapy, were independent pre-
ctors for death or nonfatal MI. The baseline ECG on
esentation was also found to be extremely useful for risk
ratification in the TIMI III registry (199), as discussed in
ection 2.2.6.2, and in the RISC (Research on InStability
Coronary artery disease) study group (570). In a more
cent database of 12,142 patients presenting within 12 h
of
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionthe onset of ischemic symptoms, the ECG at presenta-
on allowed individualized risk stratification across the
ectrum of ACS (127) (Fig. 19). In many cases, nonin-
sive stress testing provides a very useful supplement to
ch clinically based risk assessment. In addition, as
inted out previously, troponins are very helpful in risk
sessment. Some patients, however, are at such high risk
r an adverse outcome that noninvasive risk stratification
ould not be likely to identify a subgroup with sufficiently
w risk to avoid coronary angiography to determine
hether revascularization is possible. These patients in-
gure 19. Kaplan-Meier Estimates of Probability of Death
ased on Admission Electrocardiogram. Modified with permis-
on from Savonitto S, Ardissino D, Granger CB, et al. Prognos-
value of the admission electrocardiogram in acute coronary
ndromes. JAMA 1999;281:707–13 (127). Copyright © 1999
merican Medical Association.ude those who, despite intensive medical therapy, man- reest recurrent rest angina, hemodynamic compromise, or
vere LV dysfunction. Such patients should be considered
rectly for early coronary angiography without noninva-
ve stress testing; however, referral for coronary angiog-
phy is not reasonable if they are unwilling to consider
vascularization or have severe complicating illnesses
at preclude revascularization. Other patients may have
ch a low likelihood of CAD after initial clinical evalu-
ion that even an abnormal test finding is unlikely to
ompt additional therapy that would further reduce risk
.g., a 35-year-old woman without CAD risk factors).
uch patients would ordinarily not be considered for
ronary angiography and revascularization unless the
agnosis of UA/NSTEMI is unclear. The majority of
tients presenting with UA/NSTEMI do not fall into these
tegories and are accordingly reasonable candidates for
sk stratification with noninvasive testing.
Determination of patient risk on the basis of a validated
oring algorithm (e.g., from the TIMI, GRACE, or PUR-
UIT trial data) can be valuable for identifying high-risk
tients (see Section 2.2.6 and Table 8). They also can assist
selecting those who can benefit most from more aggressive
erapies, such as LMWH or an invasive treatment strategy
ee Section 3.4.1).
.4.1. Care Objectives
he goals of noninvasive testing are to 1) determine the
esence or absence of ischemia in patients with a low or
termediate likelihood of CAD and 2) estimate prognosis.
his information is key for the development of further
agnostic steps and therapeutic measures.
A detailed discussion of noninvasive stress testing in
AD is presented in the ACC/AHA Guidelines for
xercise Testing, ACC/AHA Guidelines for the Clinical
se of Cardiac Radionuclide Imaging, and ACC/AHA
uidelines for the Clinical Application of Echocardiogra-
y (4,571–573) (Tables 19, 20, and 21). Briefly, the
ovocation of ischemia at a low workload (574) or a
gh-risk treadmill score (i.e., greater than or equal to 11)
75) implies severe limitation in the ability to increase
ronary blood flow. This is usually the result of severe
ronary artery obstruction and is associated with a high
sk for an adverse outcome and/or severe angina after
scharge. Unless there are contraindications to revascu-
rization, such patients generally merit referral for early
ronary angiography to direct a revascularization proce-
re, if appropriate. On the other hand, the attainment of a
gher workload (e.g., greater than 6.5 metabolic equiva-
nts [METS]) without evidence of ischemia (low-risk
eadmill score greater than or equal to 5) (575) is associated
ith functionally less severe coronary artery obstruction.
uch patients have a better prognosis and can often be safely
anaged conservatively. Ischemia that develops at greater
an 6.5 METS can be associated with severe coronary artery
struction, but unless other high-risk markers are present
reater than 0.2-mV ST-segment depression or elevation,
ll in blood pressure, ST-segment shifts in multiple leads
flecting multiple coronary regions, or prolonged ST-segment
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367ifts [greater than 6 min] in recovery), these patients also may
safely managed conservatively (Table 20).
Stress radionuclide ventriculography or stress echocardi-
raphy (Table 20) provides an important alternative to
ercise electrocardiography testing. Myocardial perfusion
ble 19. Noninvasive Risk Stratification
igh risk (greater than 3% annual mortality rate)
Severe resting LV dysfunction (LVEF less than 0.35)
High-risk treadmill score (score 11 or less)
Severe exercise LV dysfunction (exercise LVEF less than 0.35)
Stress-induced large perfusion defect (particularly if anterior)
Stress-induced multiple perfusion defects of moderate size
Large, fixed perfusion defect with LV dilation or increased lung uptake
(thallium-201)
Stress-induced moderate perfusion defect with LV dilation or increased
lung uptake (thallium-201)
Echocardiographic wall-motion abnormality (involving more than 2
segments) developing at low dose of dobutamine (10 mcg per kg per
min or less) or at a low heart rate (less than 120 beats per min)
Stress echocardiographic evidence of extensive ischemia
termediate risk (1% to 3% annual mortality rate)
Mild/moderate resting LV dysfunction (LVEF  0.35 to 0.49)
Intermediate-risk treadmill score (11 to 5)
Stress-induced moderate perfusion defect without LV dilation or
increased lung intake (thallium-201)
Limited stress echocardiographic ischemia with a wall-motion
abnormality only at higher doses of dobutamine involving less than or
equal to 2 segments
w risk (less than 1% annual mortality rate)
Low-risk treadmill score (score 5 or greater)
Normal or small myocardial perfusion defect at rest or with stress*
Normal stress echocardiographic wall motion or no change of limited
resting wall-motion abnormalities during stress*
*Although the published data are limited, patients with these findings will
obably not be at low risk in the presence of either a high-risk treadmill score
severe resting LV dysfunction (LVEF less than 0.35). Reproduced from Table
in Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline
date for the management of patients with chronic stable angina: a report of
e American College of Cardiology/American Heart Association Task Force on
actice Guidelines (Committee to Update the 1999 Guidelines for the
anagement of Patients With Chronic Stable Angina). 2002. Available at:
ww.acc.org/qualityandscience/clinical/statements.htm (4).
LV  left ventricular; LVEF  left ventricular ejection fraction.
ble 20. Noninvasive Test Results That Predict High Risk for
dverse Outcome (Left Ventricular Imaging)
Stress Radionuclide
Ventriculography Stress Echocardiography
ercise EF 0.50 or less Rest EF 0.35 or less
st EF 0.35 or less Wall-motion score index greater than 1
ll in EF 0.10 or greater
Adapted from O’Rourke RA, Chatterjee K, Dodge HT, et al. Guidelines for
inical use of cardiac radionuclide imaging, December 1986: a report of the
erican College of Cardiology/American Heart Association Task Force on
sessment of Cardiovascular Procedures (Subcommittee on Nuclear Imaging).
Am Coll Cardiol 1986;8:1471–83 (576); and Cheitlin MD, Alpert JS,
mstrong WF, et al. ACC/AHA guidelines for the clinical application of
hocardiography. Circulation 1997;95:1686–744 (577).SEF  ejection fraction.aging with pharmacological stress (Table 21) is particu-
rly useful in patients who are unable to exercise. The
ognostic value of pharmacological stress testing appears
milar to that of exercise testing with imaging, although there
e few direct comparisons.
As noted earlier (Section 2.3.2.), CMR is a newer imaging
odality that can effectively assess cardiac function, perfu-
on (e.g., with adenosine stress), and viability at the same
udy. The combination of these features has been reported to
eld excellent predictive information in suspected CAD/
CS patients (296).
.4.2. Noninvasive Test Selection
here are no conclusive data that either LV function or
yocardial perfusion at rest and during exercise or pharma-
logical stress is superior in the assessment of prognosis.
oth the extent of CAD and the degree of LV dysfunction are
portant in the selection of the appropriate therapy. Studies
at directly compare prognostic information from multiple
ninvasive tests for ischemia in patients after the stabiliza-
on of UA/NSTEMI are hampered by small sample size.
obutamine stress echocardiography measures both resting
V function and the functional consequences of a coronary
enosis (571). An ischemic response is characterized by
itially improved LV function at low-stress doses, followed
deterioration with increasing dobutamine doses (571).
owever, UA and MI are listed as contraindications for
butamine stress echocardiography (578).
The RISC study evaluated predischarge symptom-limited
cycle exercise testing in 740 men with UA/NSTEMI (579).
ultivariate analysis showed that the extent of ST-segment
pression, expressed as the number of leads with ischemic
anges at a low maximal workload, was negatively corre-
ted independently with infarct-free survival rates at 1 year.
his and other smaller studies permit a comparison of the
fectiveness of exercise ECG with exercise or dipyridamole
allium-201 study for risk stratification. All of these nonin-
sive tests show similar accuracy in dichotomization of the
tal population into low- and high-risk subgroups.
Selection of the noninvasive stress test should be based
imarily on patient characteristics, local availability, and
pertise in interpretation (580). Because of simplicity, lower
st, and widespread familiarity with performance and inter-
etation, the standard low-level exercise ECG stress test
mains the most reasonable test in patients who are able to
ercise and who have a resting ECG that is interpretable for
ble 21. Noninvasive Test Results That Predict High Risk for
dverse Outcome on Stress Radionuclide Myocardial Perfusion
aging
bnormal myocardial tracer distribution in more than 1 coronary artery
region at rest or with stress or a large anterior defect that reperfuses
bnormal myocardial distribution with increased lung uptake
ardiac enlargement
Adapted from O’Rourke RA, Chatterjee K, Dodge HT, et al. Guidelines for
inical use of cardiac radionuclide imaging, December 1986: a report of the
erican College of Cardiology/American Heart Association Task Force on
sessment of Cardiovascular Procedures (Subcommittee on Nuclear Imaging).
Am Coll Cardiol 1986;8:1471–83 (576).T-segment shifts. Patients with an ECG pattern that would
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionterfere with interpretation of the ST segment should have an
ercise test with imaging. Patients who are unable to
ercise should have a pharmacological stress test with
aging. Low- and intermediate-risk patients admitted with
CS may undergo symptom-limited stress testing provided
ey have been asymptomatic and clinically stable for 12 to
h.
The optimal testing strategy in women is less well defined
an in men (see Section 6.1), but there is evidence that
aging studies are superior to exercise ECG evaluation in
omen (580,581). Exercise testing has been reported to be
ss accurate for diagnosis in women. At least a portion of the
wer reported accuracy derives from a lower pretest likeli-
od of CAD in women than in men; the higher prevalence of
chemia secondary to vascular dysfunction (coronary endo-
elial and/or microvascular dysfunction) in the absence of
structive CAD also is a likely contributor to this.
Results of a symptom-limited exercise test performed 3 to
d after UA/NSTEMI were compared with results of a test
nducted 1 month later in 189 patients (534,582). The
agnostic and prognostic values of the tests were similar, but
e earlier test identified patients who developed adverse
ents during the first month, and this represented approxi-
ately one half of all events that occurred during the first
ar. These data illustrate the importance of early noninva-
ve testing for risk stratification.
The VANQWISH trial used symptom-limited thallium
ercise treadmill testing at 3 to 5 d to direct the need for
giography in the 442 non–Q-wave MI patients randomized
an early conservative strategy (534). Among subjects in the
nservative arm meeting VANQWISH stress test criteria to
oss over to coronary angiography, 51% were found to have
rgical CAD and showed favorable outcomes after revascu-
rization (583). These findings support the concept that
ninvasive stress testing can be used successfully to identify
high-risk subset of patients who can be directed to coronary
giography. It is unlikely that any angiographically directed
rly revascularization strategy could alter the very low early
ent rates observed in patients without a high-risk stress test.
Noninvasive tests are most useful for management deci-
ons when risk can be stated in terms of events over time. A
rge population of patients must be studied to derive and test
e equations needed to accurately predict individual patient
sk. No noninvasive study has been reported in a sufficient
mber of patients after the stabilization of UA/NSTEMI to
velop and test the accuracy of a multivariable equation to
port test results in terms of absolute risk. Therefore, data
om studies of stable angina patients must be used for risk,
ported as events over time. Although the pathological
ocess that evokes ischemia may be different in the 2 forms
angina, it is likely that the use of prognostic nomograms
rived from patients with stable angina also are predictive of
sk in patients with recent UA/NSTEMI after stabilization.
ith this untested assumption, the much larger literature
rived from populations that include patients with both
able angina and UA/NSTEMI provides equations for risk
ratification that convert physiological changes observed
ring noninvasive testing into statements of risk expressed
events over time..4.3. Selection for Coronary Angiography
contrast to the noninvasive tests, coronary angiography
ovides detailed structural information to allow an assess-
ent of prognosis and to provide direction for appropriate
anagement. When combined with LV angiography, it also
lows an assessment of global and regional LV function.
dications for coronary angiography are interwoven with
dications for possible therapeutic plans, such as PCI or
ABG.
Coronary angiography is usually indicated in patients with
A/NSTEMI who either have recurrent symptoms or isch-
ia despite adequate medical therapy or are at high risk as
tegorized by clinical findings (HF, serious ventricular
rhythmias) or noninvasive test findings (significant LV
sfunction: ejection fraction less than 0.35, large anterior or
ultiple perfusion defects; Tables 19, 20, and 21.), as
scussed in Section 3.4.2. Patients with UA/NSTEMI who
ve had previous PCI or CABG also should generally be
nsidered for early coronary angiography, unless prior
ronary angiography data indicate that no further revascu-
rization is likely to be possible. The placement of an IABP
ay allow coronary angiography and revascularization in
ose with hemodynamic instability (see Section 3.1.2.7).
atients with suspected Prinzmetal’s variant angina also are
ndidates for coronary angiography (see Section 6.7).
In all cases, the general indications for coronary angiogra-
y and revascularization are tempered by individual patient
aracteristics and preferences. Patient and physician judg-
ents regarding risks and benefits are particularly important
r patients who might not be candidates for coronary
vascularization, such as very frail older adults and those
ith serious comorbid conditions (i.e., severe hepatic, pul-
onary, or renal failure; active or inoperable cancer).
.4.4. Patient Counseling
esults of testing should be discussed with the patient, the
tient’s family, and/or the patient’s advocate in a language
at is understood by them. Test results should be used to help
termine the advisability of coronary angiography, the need
r adjustments in the medical regimen, and the need for
condary prevention measures (see Section 5).
. Coronary Revascularization
.1. Recommendations for Revascularization
ith PCI and CABG in Patients With
A/NSTEMI
ee Fig. 20 for details of the decision tree.)
.1.1. Recommendations for PCI
ASS I
An early invasive PCI strategy is indicated for patients with
UA/NSTEMI who have no serious comorbidity and who have
coronary lesions amenable to PCI and any of the high-risk
features listed in Section 3.3. (See Section 3.3 for specific
recommendations and their Level of Evidence.)
Percutaneous coronary intervention (or CABG) is recom-
mended for UA/NSTEMI patients with 1- or 2-vessel CAD with
3.
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367or without significant proximal left anterior descending CAD
but with a large area of viable myocardium and high-risk
criteria on noninvasive testing. (Level of Evidence: B)
Percutaneous coronary intervention (or CABG) is recom-
mended for UA/NSTEMI patients with multivessel coronary
disease with suitable coronary anatomy, with normal LV func-
tion, and without diabetes mellitus. (Level of Evidence: A)
An intravenous platelet GP IIb/IIIa inhibitor is generally
recommended in UA/NSTEMI patients undergoing PCI.
(Level of Evidence: A) See Section 3.2.3 and Figures 7, 8,
and 9 for details on timing and dosing recommendations
(see Table 13).
ASS IIa
Percutaneous coronary intervention is reasonable for focal
saphenous vein graft (SVG) lesions or multiple stenoses in
UA/NSTEMI patients who are undergoing medical therapy and
who are poor candidates for reoperative surgery. (Level of
Evidence: C)
Percutaneous coronary intervention (or CABG) is reasonable
for UA/NSTEMI patients with 1- or 2-vessel CAD with or
without significant proximal left anterior descending CAD but
with a moderate area of viable myocardium and ischemia on
noninvasive testing. (Level of Evidence: B)
Percutaneous coronary intervention (or CABG) can be benefi-
gure 20. Revascularization Strategy in UA/NSTEMI. *There is co
eferable to PCI. CABG  coronary artery bypass graft; LAD  le
tervention UA/NSTEMI  unstable angina/non–ST-elevation myocial compared with medical therapy for UA/NSTEMI patientswith 1-vessel disease with significant proximal left anterior
descending CAD. (Level of Evidence: B)
Use of PCI is reasonable in patients with UA/NSTEMI
with significant left main CAD (greater than 50% diameter
stenosis) who are candidates for revascularization but are
not eligible for CABG or who require emergent intervention
at angiography for hemodynamic instability. (Level of Evi-
dence: B)
ASS IIb
In the absence of high-risk features associated with UA/
NSTEMI, PCI may be considered in patients with single-vessel
or multivessel CAD who are undergoing medical therapy and
who have 1 or more lesions to be dilated with a reduced
likelihood of success. (Level of Evidence: B)
Percutaneous coronary intervention may be considered for
UA/NSTEMI patients who are undergoing medical therapy who
have 2- or 3-vessel disease, significant proximal left anterior
descending CAD, and treated diabetes or abnormal LV func-
tion, with anatomy suitable for catheter-based therapy. (Level
of Evidence: B)
ASS III
1. Percutaneous coronary intervention (or CABG) is not recom-
mended for patients with 1- or 2-vessel CAD without signifi-
g information about these patients. Most consider CABG to be
rior descending coronary artery; PCI  percutaneous coronary
infarction.nflictin
ft antecant proximal left anterior descending CAD with no current
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myocardial ischemia and who have no ischemia on noninva-
sive testing. (Level of Evidence: C)
2.. In the absence of high-risk features associated with UA/
NSTEMI, PCI is not recommended for patients with UA/
NSTEMI who have single-vessel or multivessel CAD and no
trial of medical therapy, or who have 1 or more of the
following:
a. Only a small area of myocardium at risk. (Level of Evidence: C)
b. All lesions or the culprit lesion to be dilated with morphol-
ogy that conveys a low likelihood of success. (Level of
Evidence: C)
c. A high risk of procedure-related morbidity or mortality.
(Level of Evidence: C)
d. Insignificant disease (less than 50% coronary stenosis).
(Level of Evidence: C)
e. Significant left main CAD and candidacy for CABG. (Level of
Evidence: B)
5. A PCI strategy in stable patients with persistently occluded
infarct-related coronary arteries after NSTEMI is not indi-
cated. (Level of Evidence: B)
.1.2. Recommendations for CABG
ASS I
Coronary artery bypass graft surgery is recommended for
UA/NSTEMI patients with significant left main CAD (greater
than 50% stenosis). (Level of Evidence: A)
Coronary artery bypass graft surgery is recommended for
UA/NSTEMI patients with 3-vessel disease; the survival bene-
fit is greater in patients with abnormal LV function (LVEF less
than 0.50). (Level of Evidence: A)
Coronary artery bypass graft surgery is recommended for
UA/NSTEMI patients with 2-vessel disease with significant
proximal left anterior descending CAD and either abnormal LV
function (LVEF less than 0.50) or ischemia on noninvasive
testing. (Level of Evidence: A)
Coronary artery bypass graft surgery is recommended for
UA/NSTEMI patients in whom percutaneous revascularization
is not optimal or possible and who have ongoing ischemia not
responsive tomaximal nonsurgical therapy. (Level of Evidence: B)
Coronary artery bypass graft surgery (or PCI) is recommended
for UA/NSTEMI patients with 1- or 2-vessel CAD with or
without significant proximal left anterior descending CAD but
with a large area of viable myocardium and high-risk criteria on
noninvasive testing. (Level of Evidence: B)
Coronary artery bypass graft surgery (or PCI) is recommended
for UA/NSTEMI patients with multivessel coronary disease
with suitable coronary anatomy, with normal LV function, and
without diabetes mellitus. (Level of Evidence: A)
ASS IIa
For patients with UA/NSTEMI and multivessel disease, CABG
with use of the internal mammary arteries can be beneficial
over PCI in patients being treated for diabetes. (Level of
Evidence: B)
It is reasonable to perform CABG with the internal mammary
artery for UA/NSTEMI patients with multivessel disease and
treated diabetes mellitus. (Level of Evidence: B) thRepeat CABG is reasonable for UA/NSTEMI patients with
multiple SVG stenoses, especially when there is significant
stenosis of a graft that supplies the LAD. (Level of Evidence: C)
Coronary artery bypass graft surgery (or PCI) is reasonable for
UA/NSTEMI patients with 1- or 2-vessel CAD with or without
significant proximal left anterior descending CAD but with a
moderate area of viable myocardium and ischemia on noninva-
sive testing. (Level of Evidence: B)
Coronary artery bypass graft surgery (or PCI) can be beneficial
compared with medical therapy for UA/NSTEMI patients with
1-vessel disease with significant proximal left anterior de-
scending CAD. (Level of Evidence: B)
Coronary artery bypass graft surgery (or PCI with stenting) is
reasonable for patients with multivessel disease and symptom-
atic myocardial ischemia. (Level of Evidence: B)
ASS IIb
oronary artery bypass graft surgery may be considered in pa-
ents with UA/NSTEMI who have 1- or 2-vessel disease not
volving the proximal LAD with a modest area of ischemic
yocardium when percutaneous revascularization is not optimal
possible. (If there is a large area of viable myocardium and
gh-risk criteria on noninvasive testing, this recommendation
comes a Class I recommendation.) (Level of Evidence: B)
ASS III
oronary artery bypass graft surgery (or PCI) is not recommended
r patients with 1- or 2-vessel CAD without significant proximal
ft anterior descending CAD with no current symptoms or symp-
ms that are unlikely to be due to myocardial ischemia and who
ve no ischemia on noninvasive testing. (Level of Evidence: C)
.2. General Principles
s discussed in Section 3.4.3, coronary angiography is useful
r defining the coronary artery anatomy in patients with
A/NSTEMI and for identifying subsets of high-risk patients
ho can benefit from early revascularization. Coronary re-
scularization (PCI or CABG) is performed to improve
ognosis, relieve symptoms, prevent ischemic complica-
ons, and improve functional capacity. The decision to
oceed from diagnostic angiography to revascularization is
fluenced not only by the coronary anatomy but also by a
mber of additional factors, including anticipated life ex-
ctancy, ventricular function, comorbidity, functional capac-
y, severity of symptoms, and quantity of viable myocardium
risk. These are all important variables that must be
nsidered before revascularization is recommended. For
ample, patients with distal obstructive coronary lesions or
ose who have large quantities of irreversibly damaged
yocardium are unlikely to benefit from revascularization,
rticularly if they can be stabilized with medical therapy.
atients with high-risk coronary anatomy are likely to benefit
om revascularization in terms of both symptom improve-
ent and long-term survival (Fig. 20). The indications for
ronary revascularization in patients with UA/NSTEMI are
milar to those for patients with chronic stable angina and are
esented in greater detail in the ACC/AHA Guidelines for
e Management of Patients With Chronic Stable Angina (4),
e ACC/AHA Guidelines for Coronary Artery Bypass Graft
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pdate for Percutaneous Coronary Intervention (2).
Plaque rupture with subsequent platelet aggregation and
rombus formation is most often the underlying pathophys-
logical cause of UA/NSTEMI (124,126). The management
many patients with UA/NSTEMI often involves revascu-
rization of the underlying CAD with either PCI or CABG.
election of the appropriate revascularization strategy de-
nds on clinical factors, operator experience, and extent of
e underlying CAD. Many patients with UA/NSTEMI have
ronary disease that is amenable to either form of therapy;
wever, some patients have high-risk features, such as
duced LV function, that place them in a group of patients
ho experience improved long-term survival rates with
ABG. In other patients, adequate revascularization with PCI
ight not be optimal or even possible, and CABG would be
e better revascularization choice. In still other patients who
e poor surgical candidates, PCI is preferred.
Findings in large registries of patients with CAD suggest
at the mode of clinical presentation should have little
aring on the subsequent revascularization strategy
,9,13,124,126). In a series of 9,263 patients with CAD, an
mission diagnosis of UA (vs. chronic stable angina) had no
fluence on 5-year survival rates after CABG, percutaneous
ansluminal coronary angioplasty (PTCA), or medical treat-
ent (584). An initial diagnosis of UA also did not influence
rvival 3 years after either CABG or PTCA in 59,576
tients treated in the state of New York (585). Moreover,
ng-term survival rates after CABG are similar for UA
tients who present with rest angina, increasing angina,
w-onset angina, or post-MI angina (586). These observa-
ons suggest that published data that compare definitive
eatments for patients who initially present with multiple
inical manifestations of CAD can be used to guide man-
ement decisions for patients who present with UA/
STEMI. Consequently, the indications for coronary revas-
larization in patients with UA/NSTEMI are, in general,
milar to those for patients with stable angina. The principal
fference is that the impetus for some form of revasculariza-
on is stronger in patients with UA/NSTEMI by the very
ture of the presenting symptoms (586). Moreover, revas-
larization in patients with UA/NSTEMI, particularly those
ith high-risk characteristics, appears to be of most benefit if
rformed early in the hospital course (see Section 3.3).
.3. Percutaneous Coronary Intervention
recent years, technological advances coupled with high
ute success rates and low complication rates have increased
e use of percutaneous catheterization in patients with
A/NSTEMI. Stenting and the use of adjunctive platelet GP
b/IIIa inhibitors have further broadened the use of PCI by
proving both the safety and durability of these procedures.
ercutaneous coronary revascularization (intervention) strat-
ies are referred to in these guidelines as “PCI.” This term
fers to a family of percutaneous techniques, including
andard balloon angioplasty (PTCA), intracoronary stenting,
d atheroablative technologies (e.g., atherectomy, thrombec-
my, or laser angioplasty). “Percutaneous transluminal cor-
ary angioplasty” sometimes is used to refer to studies in 19hich this was the dominant form of PCI, before the
idespread use of stenting. The majority of current PCIs
volve balloon dilation and coronary stenting. Stenting has
ntributed greatly to catheter-based revascularization by
ducing the risks of both acute vessel closure and late
stenosis. Drug-eluting stents have been demonstrated to
arkedly reduce the risk of restenosis compared with bare-
etal stents. Although stenting has become the most widely
ed percutaneous technique, with most laboratories in the
nited States employing stents in 80% to 85% of their PCI
ocedures, other devices continue to be used for specific
sions and patient subsets. Although the technical safety and
ficacy of atheroablative and thrombectomy devices have
en described, few data exist to demonstrate incremental
nefit with regard to clinical outcomes, and even less
formation is available that describes the use of these
rategies specifically in patients with UA/NSTEMI (587).
he need to continue with the development of safer, more
fective PCI techniques is emphasized by recently raised
ncerns about delayed endothelialization over DES and
nsequent increases in late coronary thrombotic events,
tentially leading to death or MI (399,400,402,403,411).
Other techniques and devices, such as the AngioJet throm-
ctomy catheter, have been tested for the treatment of
rombi that are visible within a coronary artery (588).
xperience with these devices has indicated that the angio-
aphic appearance of a coronary stenosis can be improved,
t few comparative data exist to substantiate improvements
clinical outcome.
The reported clinical efficacy of PCI in UA/NSTEMI has
ried. This is likely attributable to differences in study
sign, treatment strategies, patient selection, and operator
perience. Nevertheless, the success rate of PCI in patients
ith UA/NSTEMI overall is quite high. In TIMI IIIB, for
ample, angiographic success was achieved in 96% of
tients with UA/NSTEMI who underwent balloon angio-
asty. With clinical criteria, periprocedural MI occurred in
7% of patients, emergency CABG surgery was required in
4% of patients, and the death rate due to the procedure was
5% (129,589).
The use of balloon angioplasty has been evaluated in
veral other trials of patients with UA versus stable angina
90–595). A large retrospective study compared the results
angioplasty in patients with stable angina to that in patients
ith UA (591). After an effort to manage patients with UA
ith medical therapy, PTCA was performed an average of
d after hospital admission. Compared with patients with
able angina, UA patients showed no significant differences
ith respect to primary clinical success (92% for UA vs. 94%
r stable angina), in-hospital mortality rates (0.3% vs. 0.1%),
the number of adverse events at 6-month follow-up (591).
hese findings suggest that results in immediate and 6-month
tcomes are comparable in patients with stable angina and
A. In addition, in a retrospective analysis, the results in UA
tients were similar regardless of whether the procedure was
rformed early (less than 48 h) or late (greater than 48 h)
ter hospital presentation (590).
Although other earlier studies (predominantly from the
80s) had suggested that patients with UA who undergo
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tients with stable angina (592–596), contemporary catheter
vascularization differs by often involving coronary stenting,
ES, and adjunctive use of platelet GP IIb/IIIa receptor
hibitors, which are likely to affect not only immediate—but
so long-term outcomes (512). Historically, PTCA had been
mited by acute vessel closure, which occurs in approxi-
ately 5% of patients, and by coronary restenosis, which
curred in approximately 35% to 45% of treated lesions
ring a 6-month period. Coronary stenting has offered an
portant alternative to PTCA because of its association with
th a marked reduction in acute closure and lower rates of
stenosis. By preventing acute or threatened closure, stenting
duces the incidence of procedure-related STEMI and need
r emergency CABG surgery and can also prevent other
chemic complications.
In a comparison of the use of the Palmaz-Schatz coronary
ent in patients with stable angina and patients with UA, no
gnificant differences were found with respect to in-hospital
tcome or restenosis rates (597). Another study found
milar rates of initial angiographic success and in-hospital
ajor complications in stented patients with UA compared
ith those with stable angina (598). Major adverse cardiac
ents at 6 months were also similar between the 2 groups,
hereas the need for repeat PCI and target-vessel revascu-
rization was actually less in the UA group. On the other
nd, other data have suggested that UA increases the
cidence of adverse ischemic outcomes in patients undergo-
g coronary stent deployment despite therapy with ticlopi-
ne and ASA, which suggests the need for more potent
tiplatelet therapy in this patient population (599).
Drug-eluting stent use for UA/NSTEMI has increased
amatically in recent years. Kandzari et al. evaluated pat-
rns of DES utilization in 8,852 high-risk UA/NSTEMI
tients who underwent PCI between 2003 and 2004 in 262
spitals in the CRUSADE Quality Improvement Initiative
01). During a 9-month period, DES use increased from
.6% to 78.5% of cases. Differences in selection of DES
mpared with bare bare-metal stents were noted, but ad-
sted rates of death and recurrent infarction were favorable
r DES.
The open artery hypothesis suggested that late patency of
infarct artery is associated with improved LV function,
creased electrical stability, and the provision of collateral
ssels to other coronary beds for protection against future
ents. The Occluded Artery Trial (OAT) (602, 603) tested
e hypothesis that routine PCI for total occlusion 3 to 28 d
ter MI would reduce the composite of death, reinfarction, or
lass IV heart failure. Stable patients (n  2166) with an
cluded infarct artery after MI were randomized to optimal
edical therapy and PCI with stenting or optimal medical
erapy alone. The qualifying period of 3 to 28 d was based
calendar days, thus the minimal time from symptom onset
angiography was just over 24 h. Inclusion criteria included
sence of angina or heart failure at rest and LVEF less than
% or proximal occlusion of a major epicardial artery with
large risk region. Exclusion criteria included NYHA Class
I or IV heart failure, serum creatinine greater than 2.5
g/dL, left main or 3-vessel disease, clinical instability, or acvere inducible ischemia on stress testing if the infarct zone
as not akinetic or dyskinetic.
Percutaneous coronary intervention did not reduce death,
infarction, or HF, and there was a trend toward excess
infarction during 4 years of follow-up. Findings in the
5-patient NSTEMI subgroup were similar to those in the
erall group (n  2,166) and the larger STEMI groups.
hus, a routine PCI strategy in OAT-type patients with
rsistently occluded infarct-related coronary arteries after
STEMI is not indicated.
.3.1. Platelet Inhibitors and
ercutaneous Revascularization
n important advance in the treatment of patients with
A/NSTEMI who are undergoing PCI was the introduction
platelet GP IIb/IIIa receptor inhibitors in the 1990s (see
ection 3.2) (126,128,130,510–512,604–606). This therapy
kes advantage of the fact that platelets play an important
le in the development of ischemic complications that can
cur in patients with UA/NSTEMI or during coronary
vascularization procedures. Currently, 3 platelet GP IIb/IIIa
hibitors are approved by the Food and Drug Administration
the basis of the outcomes of a variety of placebo-
ntrolled clinical trials: abciximab, tirofiban, and eptifi-
tide. The EPIC (510), EPILOG (511), CAPTURE (372),
d EPISTENT (512) trials investigated the use of abcix-
ab; the PRISM (374), PRISM-PLUS (130), and Random-
ed Efficacy Study of Tirofiban for Outcomes and REsteno-
s (RESTORE) (518) trials evaluated tirofiban; and the
tegrilin to Minimize Platelet Aggregation and Coronary
hrombosis (IMPACT) (517), PURSUIT (128), and En-
nced Suppression of Platelet Receptor GP IIb/IIIa using
tegrilin Therapy (ESPRIT) (519) trials studied the use of
tifibatide (Table 18). All 3 of these agents interfere with the
nal common pathway for platelet aggregation. All have
own efficacy in reducing the incidence of ischemic com-
ications in patients with UA/NSTEMI (Fig. 16).
In the only head-to-head comparison of 2 GP IIb/IIIa
hibitors, the TARGET trial randomized 5,308 patients to
rofiban or abciximab before undergoing PCI with the intent
perform stenting (515). The primary end point, a composite
death, nonfatal MI, or urgent target-vessel revasculariza-
on at 30 d, occurred less frequently in those receiving
ciximab than in those given tirofiban (6.0% vs. 7.6%, p 
038). There was a similar direction and magnitude for each
mponent of the end point. Differences in outcome between
e 2 randomized treatment groups were particularly marked
ong patients with UA/NSTEMI (63% of patients), in
hom 30-d composite end point event rates were 9.3% with
rofiban versus 6.3% with abciximab (p  0.002). Although
is finding is subject to the limitations of subgroup analysis,
suggests that any differences in efficacy between GP IIb/IIIa
hibitors might be most apparent among patients undergoing
CI in the setting of UA/NSTEMI. Inferior efficacy observed
ith tirofiban in this trial might have been related to inade-
ate initial (loading) dosing, which was subsequently dem-
strated to result in platelet inhibition that was inadequate
nly 28% to 33% early platelet inhibition) and less than that
hieved with abciximab (65% to 81%) (516). A subsequent
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367udy evaluating a higher bolus dose of tirofiban (25 mcg per
) during PCI was unfortunately discontinued prematurely
cause of funding issues. Eptifibatide has not been compared
rectly to either abciximab or tirofiban.
The question of whether GP IIb/IIIa inhibition is still
eful in UA/NSTEMI patients undergoing PCI who have
ceived a high loading dose (600 mg) of clopidogrel was
ised by a study in CAD patients treated in an elective setting
07). To address this, 2,022 patients with UA/NSTEMI
dergoing PCI were loaded with clopidogrel, 600 mg, at
ast 2 h before the procedure and then randomized to receive
ther abciximab or placebo (ISAR-REACT 2) (244). The
imary end point of death, nonfatal reinfarction, or urgent
rget-vessel revascularization within 30 d was reached in
9% of patients assigned to abciximab versus 11.9% as-
gned to placebo, a 25% difference, and was limited entirely
patients with an elevated troponin level, in whom the
cidence of a primary event was 13.1% in the abciximab
oup compared with 18.3% in the placebo group (p  0.02).
leeding risks were similar in the 2 groups. Thus, GP IIb/IIIa
hibition provides incremental benefit beyond high-oral-
se clopidogrel loading for NSTEMI patients with elevated
rdiac biomarker levels but not for UA patients with normal
vels who are undergoing PCI.
In summary, data from both retrospective observations and
ndomized clinical trials indicate that PCI can lead to
giographic success in most patients with UA/NSTEMI
able 18). The safety of these procedures in these patients is
hanced by the addition of intravenous platelet GP IIb/IIIa
ceptor inhibitors to the standard regimen of ASA, antico-
ulants, clopidogrel, and anti-ischemic medications.
.4. Surgical Revascularization
meta-analysis of 6 trials conducted during the early years of
ABG (between 1972 and 1978) documented a clear survival
vantage for CABG over medical therapy in symptomatic
tients with left main and 3-vessel coronary disease that was
dependent of LV function (322). No survival difference was
cumented between the 2 therapies for patients with 1- or
vessel coronary disease. However, dramatic changes in
th surgical technique (including internal thoracic artery
afting to the LAD) and in medical therapy (e.g., potent
ticoagulant and antiplatelet therapies) have subsequently
curred. Pocock et al. (608) performed a meta-analysis on
e results of 8 randomized trials completed between 1986
d 1993 and compared the outcomes of CABG and PTCA in
371 patients with multivessel CAD before widespread stent
e. Many of these patients presented with UA. At 1-year
llow-up, no difference was documented between the 2
erapies in cardiac death or MI, but a lower incidence of
gina and need for revascularization was associated with
ABG.
The Bypass Angioplasty Revascularization Investigation
ARI) trial, the largest randomized comparison of CABG
d PTCA, was performed in 1,829 patients with 2- or
vessel CAD (609,610). Unstable angina was the admitting
agnosis in 64% of these patients, and 19% had treated
abetes mellitus. A statistically significant advantage in
rvival without MI independent of the severity of presenting Pmptoms was observed for CABG over PCI at 7 years
4.4% vs. 80.9%, p  0.04) (611). Subgroup analysis
monstrated that the survival benefit was confined to pa-
ents with treated diabetes mellitus (76.4% with CABG
mpared with 55.7% for patients treated with PTCA, p 
001). The Coronary Angioplasty versus Bypass Revascu-
rization Investigation (CABRI) trial also showed a survival
nefit for CABG in patients with diabetes mellitus with
ultivessel CAD (612). A confirmatory study from Emory
niversity showed that with correction for baseline differ-
ces, patients requiring insulin with multivessel disease had
proved survival with CABG versus PTCA (613) (see
ection 6.2).
A large patient registry of consecutive CAD compared the
year survival rates for medical treatment, PTCA, and
ABG between 1984 and 1990 (584). Patients with 3- or
vessel disease with a proximal severe (greater than or equal
95%) LAD stenosis treated with CABG had significantly
tter 5-year survival rates than did those who received
edical treatment or PTCA. In patients with less severe
vessel CAD or with 1-vessel CAD, either form of revascu-
rization improved survival relative to medical therapy. The
revascularization treatments were equivalent for patients
ith nonsevere 2-vessel disease. Percutaneous transluminal
ronary angioplasty provided better survival rates than
ABG in patients with 1-vessel disease, except for those with
vere proximal LAD stenosis, for whom the 2 revascular-
ation strategies were equivalent. However, in patients with
ngle-vessel disease, all therapies were associated with high
year survival rates, and the differences among the treatment
oups were very small.
Hannan et al. (585) compared 3-year risk-adjusted survival
tes in 29,646 CABG patients and 29,930 PTCA patients
dergoing revascularization in the state of New York in
93, adjusted for differences in baseline and angiographic
aracteristics. The anatomic extent of disease was the only
riable that interacted with the specific revascularization
erapy that influenced long-term survival. Unstable angina
diabetes mellitus did not result in treatment-related differ-
ces in long-term survival rates. Patients with single-vessel
sease not involving the LAD or with less than 70% LAD
enosis had higher adjusted 3-year survival rates with PTCA
5.3%) than with CABG (92.4%). Patients with proximal
AD stenosis of at least 70% had higher adjusted 3-year
rvival rates with CABG than with PTCA regardless of the
mber of diseased coronary vessels. Patients with 3-vessel
sease had higher adjusted 3-year survival rates with CABG
gardless of proximal LAD disease. Patients with other 1- or
vessel disease had no treatment-related difference in sur-
val rates. The 3-year reintervention rate was significantly
gher in the PCI group than in the CABG group both for
bsequent CABG (10.4% vs. 0.5%) and for subsequent PCI
6.6% vs. 2.8%).
Hannan et al. performed a follow-up study using the
me New York State cardiac registries to compare the
tcomes of 37,212 patients who underwent CABG with
,102 patients who underwent PCI using stents (614). The
aximum follow-up was more than 3 years in each group.
atients were divided into 5 anatomic groups; 2-vessel
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al LAD disease; 2-vessel disease with nonproximal
AD disease; 3-vessel disease with proximal LAD disease;
d 3-vessel disease with nonproximal LAD disease.
atients with single-vessel disease were generally treated
ith PCI. The unanticipated finding was that the risk-
justed long-term mortality of patients in all 5 subsets
as lower in the CABG group. The HR for death after
ABG compared with stent implantation ranged from a
w of 0.64 (95% CI 0.56 to 0.74) for patients with
vessel disease and proximal LAD disease to a high of
76 (95% CI 0.60 to 0.96) for patients with 2-vessel
sease with involvement of the nonproximal LAD. The
sk of long-term mortality also was lower with CABG for
tients with diabetes in each of these anatomic subsets,
ith HRs ranging from 0.59 to 0.69. In all but the subset
patients with 2-vessel disease without LAD disease, the
crease in mortality associated with PCI compared with
ABG was significant for patients with diabetes. The lack
significance in this subset likely reflected smaller
mbers of patients (CABG plus PCI combined). In this
udy (614), as in the earlier study by Hannan et al. (585),
e 3-year reintervention rate was significantly higher in
e PCI group than in the CABG group for both subsequent
ABG (7.8% vs. 0.3%) and subsequent PCI (27.3% vs.
6%). In contrast, the randomized trials of multivessel
sease have shown no differences in patients without
abetes. These disparate results could be due to adverse
lection biases for PCI. On the other hand, the registry is
ry large and included a broad range of angiographic
aracteristics not included in the randomized trials. Con-
stently, however, the location of a coronary stenosis in
e LAD, especially if severe and proximal, is a charac-
ristic associated with higher mortality rates and with a
vorable outcome with CABG.
The BARI and CABRI randomized trials appeared to
entify a subset of diabetic patients who had a better
tcome with CABG than with PTCA, a finding not observed
earlier cohort studies (609,610,612) but confirmed in a
ore recent cohort study that exclusively used stents in the
CI group (614). Analysis of the subgroup with diabetes was
trospective in both the BARI and CABRI trials. Moreover,
e treatment-related effect was not reproduced in the BARI
gistry population (615). A reasonable explanation for these
consistent results is that physicians might be able to
cognize characteristics of CAD in diabetic patients that
rmit patients to more safely undergo one or the other
vascularization therapy. However, when all patients with
abetes are randomly assigned to therapies without the added
sight of clinical judgment, a treatment advantage is appar-
t for CABG. Given the combination of data derived from
ndomized trials and more recent cohort studies comparing
CI using stents with CABG, it is reasonable to consider
ABG as the preferred revascularization strategy for most
tients with 3-vessel disease, especially if it involves the
oximal LAD, and for patients with multivessel disease and
eated diabetes mellitus or LV dysfunction. Alternatively, it
ould be unwise to deny the advantages of PCI to a patient
ith diabetes and less severe coronary disease on the basis of are current information. In addition, the use of GP IIb/IIIa
hibitors together with PCI for UA/NSTEMI in recent years
pears to have resulted in more favorable outcomes
33,616).
An important consideration in a comparison of different
vascularization strategies is that none of the large ran-
mized trials reflect the current practice of interventional
rdiology that includes the routine use of stents, with an
creasing use of DES, and the increasing use of platelet
ceptor inhibitors. Coronary stenting improves procedural
fety, and DES reduce restenosis compared with PTCA or
re-metal stents. The adjuvant use of platelet inhibitors,
rticularly in high-risk patients, is also associated with
proved short- and intermediate-term outcomes. Al-
ough the effects of DES and platelet GP IIb/IIIa inhibi-
rs could have improved the PCI results observed, their
ded benefit relative to CABG cannot be assumed or
sessed on the basis of the previously reported random-
ed trials or large registries. Meanwhile, refinement of
rgical management with right internal mammary artery
afts, radial artery grafts, improved myocardial protection
rategies, and less invasive methodology could have
duced the morbidity and mortality rates for CABG. In
ct, the risk-adjusted mortality for CABG has declined
ogressively during the last decade based on data derived
om the STS National Adult Cardiac Database (617).
The most recent comparisons of PCI and CABG surgery,
levant to current medical practice, can be summarized as
llows: In a randomized study of patients with medically
fractory myocardial ischemia at high risk of adverse out-
mes of CABG surgery (the Angina With Extremely Serious
perative Mortality Evaluation [AWESOME] trial), there
as comparable survival with traditional CABG surgery and
CI, which included stenting or atherectomy (618). A meta-
alysis of CABG versus stenting for the treatment of
ultivessel disease (619) included patients in the randomized
ials Arterial Revascularization Therapy Study (ARTS),
tent or Surgery (SoS), Estudio Randomizado Argentino de
ngioplastia vs. CIrugia-II (ERACI-II), and Multicenter Anti
therosclerotic Study-II (MASS-II) (620–624). ERACI-II
cluded a cohort in which 92% of the patients had UA;
tients in the SoS study did not have apparent recent acute
ents; patients in MASS-II had stable angina and preserved
ntricular function; and those in ARTS (with 5-year
llow-up data) were not specifically described. However,
ese trials, which enrolled patients between 1995 and 2000
d primarily used traditional on-pump CABG surgery and
CI with bare-metal stents, showed no difference in the
imary composite end point of death, MI, and stroke and no
fference in mortality between the CABG and the stent
oups. The ARTS trial, which included but was not limited
patients with UA, randomized patients with multivessel
sease to coronary stenting versus CABG. Three-year sur-
val rates without stroke and MI were identical in both
oups.
Nevertheless, evolutionary changes in revascularization
erapy require randomized trials that incorporate the most
ntemporary therapies. Off-pump CABG and PCI with DES
e 2 examples. Indeed, not all evolutionary changes in
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mized trial data suggest that coronary graft patency rates
e somewhat lower with off-pump CABG (625). The use of
ES has not decreased the occurrence of death or MI
mpared with bare-metal stents, and DES are subject to a
all increase in the rate of late (greater than 6-month,
f-dual-platelet antagonism) stent thrombotic complications and
rombosis-related clinical events (399,400,402,403,411,626).
urther complicating the picture, ASA and clopidogrel and other
edical therapies are increasingly utilized in patients after
ABG (627), which makes comparisons of medical, PCI, and
rgical therapy challenging. The requirement for long-term
llow-up and the need for adequate statistical power add to the
fficulty in defining the unique benefits of each of the available
rms of therapy separately. In summary, it cannot be assumed
at all evolutionary changes in these therapies will have a
neficial impact on long-term outcomes, and clinical judgment
treatment selection for individual patients and a conservative
proach to new therapies are indicated.
.5. Conclusions
general, the indications for PCI and CABG in UA/
STEMI are similar to those for stable angina (628–633).
igh-risk patients with LV systolic dysfunction, patients with
abetes mellitus, and those with 2-vessel disease with severe
oximal LAD involvement or severe 3-vessel or left main
sease should be considered for CABG (Fig. 20). Many
her patients will have less severe CAD that does not put
em at high risk for cardiac death. However, even less severe
sease can have a substantial negative impact on the quality
life. Compared with high-risk patients, low-risk patients
ill have negligibly increased chances of long-term survival
ith CABG (or PCI) and therefore should be managed
edically. However, in low-risk patients, quality of life and
tient preferences may be considered in addition to strict
inical outcomes in the selection of a treatment strategy.
ow-risk patients whose symptoms do not respond well to
aximal medical therapy and who experience a significant
gative impact on their quality of life and functional status
ould be considered for revascularization. Patients in this
oup who are unwilling to accept the increased short-term
ocedural risks to gain long-term benefits or who are
tisfied with their existing capabilities should be managed
edically at first and followed up carefully as outpatients.
ther patients who are willing to accept the risks of revas-
larization and who want to improve their functional status
to decrease symptoms may be considered appropriate
ndidates for early revascularization.
. Late Hospital Care,
ospital Discharge, and
ost-Hospital Discharge Care
he acute phase of UA/NSTEMI is usually over within 2
onths. The risk of progression to MI or the development of
current MI or death is highest during that period. At 1 to 3
onths after the acute phase, most patients resume a clinicalurse similar to that in patients with chronic stable coronary
sease.
The broad goals during the hospital discharge phase are
fold: 1) to prepare the patient for normal activities to the
tent possible and 2) to use the acute event as an opportunity
reevaluate the plan of care, particularly lifestyle and risk
ctor modification. Aggressive risk factor modifications that
n prolong survival should be the main goals of long-term
anagement of stable CAD. Patients who have undergone
ccessful PCI with an uncomplicated course are usually
scharged the next day, and patients who undergo uncom-
icated CABG are generally discharged 4 to 7 d after CABG.
edical management of low-risk patients after noninvasive
ress testing and coronary angiography can typically be
complished rapidly, with discharge soon after testing.
edical management of a high-risk group of patients who are
suitable for or unwilling to undergo revascularization could
quire vigilant inpatient monitoring in order to achieve
equate ischemic symptom control with medical therapy
at will minimize future morbidity and mortality and im-
ove quality of life.
.1. Medical Regimen and
se of Medications
ecommendations
ASS I
Medications required in the hospital to control ischemia should
be continued after hospital discharge in patients with UA/
NSTEMI who do not undergo coronary revascularization, patients
with unsuccessful revascularization, and patients with recurrent
symptoms after revascularization. Upward or downward titration
of the doses may be required. (Level of Evidence: C)
All post-UA/NSTEMI patients should be given sublingual or
spray NTG and instructed in its use. (Level of Evidence: C)
Before hospital discharge, patients with UA/NSTEMI should be
informed about symptoms of worsening myocardial ischemia
and MI and should be instructed in how and when to seek
emergency care and assistance if such symptoms occur.
(Level of Evidence: C)
Before hospital discharge, post-UA/NSTEMI patients and/or
designated responsible caregivers should be provided with
supportable, easily understood, and culturally sensitive in-
structions with respect to medication type, purpose, dose,
frequency, and pertinent side effects. (Level of Evidence: C)
In post-UA/NSTEMI patients, anginal discomfort lasting more
than 2 or 3 min should prompt the patient to discontinue
physical activity or remove himself or herself from any stressful
event. If pain does not subside immediately, the patient should
be instructed to take 1 dose of NTG sublingually. If the chest
discomfort/pain is unimproved or worsening 5 min after 1 NTG
dose has been taken, it is recommended that the patient or a
family member/friend call 9-1-1 immediately to access EMS.
While activating EMS access, additional NTG (at 5-min inter-
vals 2 times) may be taken while lying down or sitting. (Level
of Evidence: C)
If the pattern or severity of anginal symptoms changes, which
suggests worsening myocardial ischemia (e.g., pain is more
frequent or severe or is precipitated by less effort or now
occurs at rest), the patient should contact his or her physician
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testing. (Level of Evidence: C)
In most cases, the inpatient anti-ischemic medical regi-
en used in the nonintensive phase (other than intravenous
TG) should be continued after discharge, and the anti-
atelet/anticoagulant medications should be changed to an
tpatient regimen. The goals for continued medical ther-
y after discharge relate to potential prognostic benefits
rimarily shown for antiplatelet agents, beta blockers,
w-density cholesterol (LDL-C)-lowering agents, and in-
bitors of the renin-angiotensin aldosterone system, espe-
ally for ejection fraction of 0.40 or less), control of
chemic symptoms (nitrates, beta blockers, and CCBs),
d treatment of major risk factors such as hypertension,
oking, dyslipidemia, physical inactivity, and diabetes
ellitus (see Section 5.2). Thus, the selection of a medical
gimen is individualized to the specific needs of each
tient based on the in-hospital findings and events, the
sk factors for CAD, drug tolerability, and recent proce-
ral interventions. The mnemonic ABCDE (Aspirin, an-
anginals, and ACE inhibitors; Beta blockers and blood
essure; Cholesterol and cigarettes; Diet and diabetes;
ducation and exercise) has been found to be useful in
iding treatment (4,634).
An effort by the entire multidisciplinary team with special
ills (physicians, nurses, dietitians, pharmacists, rehabilita-
on specialists, care managers, and physical and occupational
erapists) is often necessary to prepare the patient for
scharge. Both the patient and family should receive instruc-
ons about what to do if ischemic symptoms occur in the
ture (74). Face-to-face patient instruction is important and
ould be reinforced and documented with written instruction
eets. Enrollment in a cardiac rehabilitation program after
scharge can enhance patient education and compliance with
e medical regimen (see Section 5.4).
Telephone follow-up can serve to reinforce in-hospital in-
ruction, provide reassurance, and answer the patient’s ques-
ns (635). If personnel and budget resources are available, the
alth care team should establish a follow-up system in which
rsonnel specially trained to support and assist clinicians in
AD management call patients on the telephone. For example,
lls might occur weekly for the first 4 weeks after discharge.
his structured program can gauge the progress of the patient’s
covery, reinforce the CAD education taught in the hospital,
dress patient questions and concerns, and monitor progress in
eeting risk factor modification goals.
.2. Long-Term Medical Therapy and
econdary Prevention
atients with UA/NSTEMI require secondary prevention for
AD at discharge. The management of the patient with stable
AD is of relevance, as detailed in the ACC/AHA/ACP
uidelines for the Management of Patients With Chronic
table Angina (4), as are the secondary prevention guidelines
) outlined in the more recent ACC/AHA Guidelines for the
anagement of Patients With ST-Elevation MI (1) andecondary Prevention (3,38).A health care team with expertise in aggressively manag-
g CAD risk factors should work with patients and their
milies to educate them in detail regarding specific targets
r LDL-C and high-density lipoprotein cholesterol (HDL-C),
ood pressure, body mass index (BMI), physical activity,
d other appropriate lifestyle modifications (44). These
alth care teams can be hospital-, office-, or community-
sed and may include chronic disease management or
rdiac rehabilitation/secondary prevention programs. The
mily should be instructed on how best to further support the
tient by encouraging reasonable changes in risk behavior
.g., cooking AHA, Mediterranean, or DASH [Dietary Ap-
oach to Stop Hypertension] diet meals for the entire family;
ercising together). This is particularly important when
reening of family members reveals common risk factors,
ch as dyslipidemia, hypertension, secondhand smoke, and
esity. Of recent concern is the national trend to obesity,
hich has increased over the past decade in all 50 states, and
s risk consequences (636). The combination of evidence-
sed therapies provides complementary, added morbidity
d mortality reductions (637,638); prescription of and com-
iance with these combination therapies should be stressed.
.2.1. Convalescent and Long-Term Antiplatelet
herapy (UPDATED)
or new or updated text, view the 2011 Focused Update.
ext supporting unchanged recommendations has not been
pdated.
See Figure 11 for antiplatelet therapy recommendations in
gorithm format.
ASS I
For UA/NSTEMI patients treated medically without stenting,
aspirin* (75 to 162 mg per day) should be prescribed indefi-
nitely (Level of Evidence: A); clopidogrel† (75 mg per day)
should be prescribed for at least 1 month (Level of Evidence: A)
and ideally up to 1 year. (Level of Evidence: B)
For UA/NSTEMI patients treated with bare-metal stents, aspi-
rin* 162 to 325 mg per day should be prescribed for at least 1
month (Level of Evidence: B), then continued indefinitely at a
dose of 75 to 162 mg per day (Level of Evidence: A); clopi-
dogrel should be prescribed at a dose of 75 mg per day for a
minimum of 1 month and ideally for up to 1 year (unless the
patient is at increased risk of bleeding; then it should be given
for a minimum of 2 weeks). (Level of Evidence: B)
For UA/NSTEMI patients treated with DES, aspirin* 162 to
325 mg per day should be prescribed for at least 3 months
after sirolimus-eluting stent implantation and 6 months after
paclitaxel-eluting stent implantation then continued indefi-
nitely at at dose of 75 to 162 mg per day. (Level of Evidence:
B) Clopidogrel 75 mg daily should be given for at least 12
months to all post-PCI patients receiving DES. (Level of
Evidence: B)
Clopidogrel 75 mg daily (preferred) or ticlopidine (in the
absence of contraindications) should be given to patients
recovering from UA/NSTEMI when ASA is contraindicated or
not tolerated because of hypersensitivity or gastrointestinal
or ASA-allergic patients, use clopidogrel alone (indefinitely), or try aspirin
sensitization.
†For clopidogrel-allergic patients, use ticlopidine 250 mg by mouth twice daily.
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pump inhibitors). (Level of Evidence: A)
ASS IIa
r UA/NSTEMI patients in whom the physician is concerned
out the risk of bleeding, a lower initial aspirin dose after PCI of
to 162 mg per day is reasonable. (Level of Evidence: C)
ASS IIb
r UA/NSTEMI patients who have an indication for anticoagula-
on, add warfarin‡ to maintain an international normalization ratio
2.0 to 3.0.§ (Level of Evidence: B)
ASS III
ipyridamole is not recommended as an antiplatelet agent in
st-UA/NSTEMI patients because it has not been shown to be
fective. (Level of Evidence: A)
.2.2. Beta Blockers
ASS I
Beta blockers are indicated for all patients recovering from
UA/NSTEMI unless contraindicated. (For those at low risk, see
Class IIa recommendation below). Treatment should begin
within a few days of the event, if not initiated acutely, and
should be continued indefinitely. (Level of Evidence: B)
Patients recovering from UA/NSTEMI with moderate or severe
LV failure should receive beta-blocker therapy with a gradual
titration scheme. (Level of Evidence: B)
ASS IIa
is reasonable to prescribe beta blockers to low-risk patients
.e., normal LV function, revascularized, no high-risk features)
covering from UA/NSTEMI in the absence of absolute contrain-
cations. (Level of Evidence: B)
.2.3. Inhibition of the Renin-Angiotensin-
ldosterone System
ASS I
Angiotensin-converting enzyme inhibitors should be given and
continued indefinitely for patients recovering from UA/NSTEMI
with HF, LV dysfunction (LVEF less than 0.40), hypertension, or
diabetes mellitus, unless contraindicated. (Level of Evidence: A)
An angiotensin receptor blocker should be prescribed at dis-
charge to those UA/NSTEMI patients who are intolerant of an
ACE inhibitor and who have either clinical or radiological signs
of HF and LVEF less than 0.40. (Level of Evidence: A)
Long-term aldosterone receptor blockade should be prescribed
for UA/NSTEMI patients without significant renal dysfunction
(estimated creatinine clearance should be greater than 30 mL
per min) or hyperkalemia (potassium should be less than or
equal to 5 mEq per liter) who are already receiving therapeutic
doses of an ACE inhibitor, have an LVEF less than or equal to
0.40, and have either symptomatic HF or diabetes mellitus.
(Level of Evidence: A)
ontinue ASA indefinitely and warfarin longer term as indicated for specific
nditions such as atrial fibrillation; LV thrombus; or cerebral, venous, or
lmonary emboli.
§An INR of 2.0 to 2.5 is preferable while given with ASA and clopidogrel,
pecially in older patients and those with other risk factors for bleeding. anASS IIa
Angiotensin-converting enzyme inhibitors are reasonable for
patients recovering from UA/NSTEMI in the absence of LV
dysfunction, hypertension, or diabetes mellitus unless contra-
indicated. (Level of Evidence: A)
Angiotensin-converting enzyme inhibitors are reasonable for
patients with HF and LVEF greater than 0.40. (Level of Evi-
dence: A)
In UA/NSTEMI patients who do not tolerate ACE inhibitors, an
angiotensin receptor blocker can be useful as an alternative to
ACE inhibitors in long-term management provided there are
either clinical or radiological signs of HF and LVEF less than
0.40. (Level of Evidence: B)
ASS IIb
e combination of an ACE inhibitor and an angiotensin receptor
ocker may be considered in the long-term management of
tients recovering from UA/NSTEMI with persistent symptom-
ic HF and LVEF less than 0.40* despite conventional therapy
cluding an ACE inhibitor or an angiotensin receptor blocker
one. (Level of Evidence: B)
Data on the utility of ACE inhibitors in stable CAD in
e presence of HF and LV dysfunction have been com-
lling, whereas data in their absence have been conflict-
g. A reduction in the rates of mortality and vascular
ents was reported in the Heart Outcomes Prevention
valuation (HOPE) Study (343) with the long-term use of
ACE inhibitor (ramipril) in moderate-risk patients with
AD, many of whom had preserved LV function, as well
patients at high risk of developing CAD. Similar but
aller benefits were reported in the EUROPA study
Uropean trial on Reduction Of cardiac events with
erindopril in patients with stable coronary Artery dis-
se), which observed a significant reduction in incidence
cardiovascular death, MI, or cardiac arrest among
oderate-risk patients with known coronary disease with-
t apparent HF randomized to perindopril versus placebo
39). Conflicting results, however, were observed in the
revention of Events with Angiotensin Converting En-
me Inhibition (PEACE) trial, which found no significant
fference in the risk of cardiovascular death, MI, or
ronary revascularization among low-risk patients with
able CAD and preserved LV function when an ACE
hibitor (trandolapril) was added to modern conventional
erapy (640); however, a subsequent meta-analysis of
ese 3 major trials supported benefit across the risk
ectrum studied (641). These and other data may be
rmonized by postulating that ACE inhibitors provide
neral benefit in stable CAD but that the absolute benefit
proportional to disease-related risk, with those at lowest
sk benefiting least (641,642). These and other agents that
ay be used in patients with chronic CAD are listed in
able 22 and are discussed in detail in the ACC/AHA
uidelines for the Management of Patients With Chronic
table Angina (4).
he safety of this combination has not been proven in patients also aldosterone
tagonist and is not recommended.
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ASS I
Nitroglycerin to treat ischemic symptoms is recommended.
(Level of Evidence: C)
.2.5. Calcium Channel Blockers
ASS I
Calcium channel blockers† are recommended for ischemic
symptoms when beta blockers are not successful. (Level of
Evidence: B)
Calcium channel blockers† are recommended for ischemic
symptoms when beta blockers are contraindicated or cause
unacceptable side effects. (Level of Evidence: C)
.2.6. Warfarin Therapy (UPDATED)
or new or updated text, view the 2011 Focused Update.
ext supporting unchanged recommendations has not been
pdated.
ASS I
se of warfarin in conjunction with ASA and/or clopidogrel is
sociated with an increased risk of bleeding and should be
onitored closely. (Level of Evidence: A)
ble 22. Medications Used for Stabilized UA/NSTEMI Patients
ti-Ischemic and Antithrombotic/Antiplatelet
ents Drug
pirin Antiplatelet
opidogrel* or ticlopidine Antiplatelet when aspi
ta blockers Anti-ischemic
EI EF less than 0.40 or H
trates Antianginal
lcium channel blockers (short-acting
dihydropyridine antagonists should be
avoided)
Antianginal
pyridamole Antiplatelet
ents for Secondary Prevention and Other
dications Risk
G-CoA reductase inhibitors LDL cholesterol greate
brates HDL cholesterol less t
acin HDL cholesterol less t
acin or fibrate Triglycerides 200 mg
tidepressant Treatment of depressi
eatment of hypertension Blood pressure greate
greater than 130/80
disease or diabetes
rmone therapy (initiation)† Postmenopausal state
eatment of diabetes HbA1C greater than 7%
rmone therapy (continuation)† Postmenopausal state
X-2 inhibitor or NSAID Chronic pain
tamins C, E, beta-carotene; folic acid, B6, B12 Antioxidant effect; hom
*Preferred to ticlopidine.
†For risk reduction of coronary artery disease.
ACEI  angiotensin-converting enzyme inhibitor; CHF  congestive heart
oprotein; HMG-CoA  hydroxymethyl glutaryl coenzyme A; INR  intern
ti-inflammatory drug; NSTEMI  non–ST-segment elevation myocardial infarhort-acting dihydropyridine calcium channel antagonists should be avoided.ASS IIb
arfarin either without (INR 2.5 to 3.5) or with low-dose ASA (75
81 mg per d; INR 2.0 to 2.5) may be reasonable for patients at
gh CAD risk and low bleeding risk who do not require or are
tolerant of clopidogrel. (Level of Evidence: B)
.2.7. Lipid Management
ASS I
. The following lipid recommendations are beneficial:
a. Lipid management should include assessment of a fasting
lipid profile for all patients, within 24 h of hospitalization.
(Level of Evidence: C)
b. Hydroxymethyl glutaryl-coenzyme A reductase inhibitors
(statins), in the absence of contraindications, regardless
of baseline LDL-C and diet modification, should be given to
post-UA/NSTEMI patients, including postrevascularization
patients. (Level of Evidence: A)
c. For hospitalized patients, lipid-lowering medications
should be initiated before discharge. (Level of Evidence: A)
d. For UA/NSTEMI patients with elevated LDL-C (greater
than or equal to 100 mg per dL), cholesterol-lowering
therapy should be initiated or intensified to achieve an
LDL-C of less than 100 mg per dL. (Level of Evidence: A)
Further titration to less than 70 mg per dL is reasonable.
Class/Level of Evidence
I/A
ntraindicated I/A
I/B
eater than 0.40 I/A IIa/A
I/C for ischemic symptoms
I for ischemic symptoms; when beta blockers are
not successful (B) or contraindicated, or cause
unacceptable side effects (C)
III/A
Class/Level of Evidence
0 mg per dL Ia
mg per dL IIa/B
mg per dL IIa/B
IIa/B
IIb/B
40/90 mm Hg or
if kidney
I/A
III/A
I/B
III/B
IIa/C, IIb/C or III/C
ne lowering III/A
COX-2  cyclooxygenase 2; EF  ejection fraction; HDL  high-density
normalized ratio; LDL  low-density lipoprotein; NSAID  nonsteroidal
 unstable angina.Action
rin is co
F EF gr
Factor
r than 7
han 40
han 40
per dL
on
r than 1
mm Hg
present
ocystei
failure;
ational(Class IIa, Level of Evidence: A)
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mended, including more intense LDL-C–lowering therapy.
(Level of Evidence: B)
f. Dietary therapy for all patients should include reduced
intake of saturated fats (to less than 7% of total calories),
cholesterol (to less than 200 mg per d), and trans fat (to
less than 1% of energy). (Level of Evidence: B)
g. Promoting daily physical activity and weight management
are recommended. (Level of Evidence: B)
. Treatment of triglycerides and non-HDL-C is useful, including
the following:
a. If triglycerides are 200 to 499 mg per dL, non-HDL-C‡
should be less than 130 mg per dL. (Level of Evidence: B)
b. If triglycerides are greater than or equal to 500 mg per dL*,
therapeutic options to prevent pancreatitis are fibrate† or
niacin† before LDL-lowering therapy is recommended. It is
also recommended that LDL-C be treated to goal after
triglyceride-lowering therapy. Achievement of a non-
HDL-C‡ less than 130 mg per dL (i.e., 30 mg per dL greater
than LDL-C target) if possible is recommended. (Level of
Evidence: C)
ASS IIa
. The following lipid management strategies can be beneficial:
a. Further reduction of LDL-C to less than 70 mg per dL is
reasonable. (Level of Evidence: A)
b. If baseline LDL cholesterol is 70 to 100 mg per dL, it is
reasonable to treat LDL-C to less than 70 mg per dL. (Level
of Evidence: B)
c. Further reduction of non-HDL-C‡ to less than 100 mg per dL
is reasonable; if triglycerides are 200 to 499 mg per dL,
non-HDL-C target is less than 130 mg per dL. (Level of
Evidence: B)
d. Therapeutic options to reduce non-HDL-C‡ (after LDL-C
lowering) include niacin† or fibrate* therapy.
e. Nicotinic acid (niacin)† and fibric acid derivatives (fenofi-
brate, gemfibrozil)* can be useful as therapeutic options
(after LDL-C–lowering therapy) for HDL-C less than 40 mg
per dL. (Level of Evidence: B)
f. Nicotinic acid (niacin)† and fibric acid derivatives (fenofi-
brate, gemfibrozil)* can be useful as therapeutic options
(after LDL-C–lowering therapy) for triglycerides greater
than 200 mg per dL. (Level of Evidence: B)
g. The addition of plant stanol/sterols (2 g per d) and viscous
fiber (more than 10 g per d) is reasonable to further lower
LDL-C. (Level of Evidence: A)
ASS IIb
couraging consumption of omega-3 fatty acids in the form of fish§
in capsule form (1 g per d) for risk reduction may be reasonable.
r treatment of elevated triglycerides, higher doses (2 to 4 g per d)
ay be used for risk reduction. (Level of Evidence: B)
on-HDL-C  total cholesterol minus HDL-C.
*Patients with very high triglycerides should not consume alcohol. The use of bile
id sequestrants is relatively contraindicated when triglycerides are greater than 200
g per dL.
†The combination of high-dose statin plus fibrate can increase risk for severe
yopathy. Statin doses should be kept relatively low with this combination. Dietary
pplement niacin must not be used as a substitute for prescription niacin.
‡Non-HDL-C  total cholesterol minus HDL-C.
§Pregnant and lactating women should limit their intake of fish to minimizethposure to methylmercury.There is a wealth of evidence that cholesterol-lowering
erapy for patients with CAD and hypercholesterolemia
43) or with mild cholesterol elevation (mean 209 to 218 mg
r dL) after MI and UA reduces vascular events and death
44,645). Moreover, recent trials have provided mounting
idence that statin therapy is beneficial regardless of
hether the baseline LDL-C level is elevated (646–648).
ore aggressive therapy has resulted in suppression or
versal of coronary atherosclerosis progression and lower
rdiovascular event rates, although the impact on total
ortality remains to be clearly established (649). These data
e discussed more fully elsewhere (3,17,39).
For patients with CHD or CHD equivalents (i.e., athero-
lerosis in other vascular territories, diabetes mellitus, or
-year estimated cardiovascular risk greater than 20%), the
CEP Adult Treatment Panel III recommended a target
DL-C level less than 100 mg per dL (17). Therapeutic
festyle changes are recommended as well. Therapeutic
festyle changes include diet, weight management, and in-
eased physical activity. Specific diet recommendations
clude restriction of calories from saturated fat to less than
of total caloric intake and of cholesterol to less than 200
g per d. Additionally, increased soluble fiber (10 to 25 g per
and plant stanols/sterols (2 g per d) are noted as therapeutic
festyle change dietary options to enhance LDL-C lowering.
eduction in trans fat (to less than 1% of caloric intake)
bsequently has been added to prevention guidelines (3,38).
hese guidelines also recommend consideration of drug
erapy if LDL-C is above goal range, either simultaneously
ith therapeutic lifestyle changes or sequentially, after 3
onths of therapeutic lifestyle changes.
An update to the Adult Treatment Panel III guidelines was
blished in mid 2004 (16). The major change recommended
this update is an LDL-C treatment goal of less than 70 mg
r dL as a reasonable option in very-high-risk patients (such
after UA/NSTEMI). Furthermore, if a high-risk patient has
gh triglycerides (greater than 200 mg per dL) or low
DL-C (less than 40 mg per dL), consideration can be given
combining a fibrate or nicotinic acid with an LDL-lowering
ug. For moderately high-risk patients (2 or more risk factors
d 10-year risk of 10% to 20%), the recommended LDL-C
al is less than 130 mg per dL, but an LDL-C goal of less
an 100 mg per dL is a reasonable option. When drug
erapy is utilized in moderate- to high-risk patients, it is
vised that the intensity of the treatment be sufficient to
hieve a reduction in LDL-C levels of at least 30% to 40%.
herapeutic lifestyle changes to modify existing lifestyle-
sed risk factors are strongly urged regardless of LDL-C
vels.
Two trials further support early intensive lipid lowering
ter ACS. In the PROVE-IT TIMI 22 study (PRavastatin Or
orVastatin Evaluation and Infection Therapy–Thrombolysis
Myocardial Infarction 22), 4,162 patients within 10 d of
CS were randomized to 40 mg of pravastatin or 80 mg of
orvastatin daily (648). The median LDL-C achieved in the
oderately intensive (standard-dose) pravastatin group was
mg per dL compared with a median of 62 mg per dL in the
gressive, high-dose atorvastatin group. A 16% reduction in
e HR for the primary composite end point of all-cause
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erformed at least 30 d after randomization), and stroke was
served in favor of the high-dose regimen. The second trial,
ase Z of the A to Z Trial (647), compared early initiation of
intensive statin regimen (simvastatin 40 mg per d for 1
onth followed by 80 mg per d thereafter) with a delayed
itiation of a less-intensive regimen (placebo for 4 months
llowed by simvastatin 20 mg per d) in patients with ACS.
o difference was observed between the groups during the
rst 4 months of follow-up for the primary end point
omposite of cardiovascular death, nonfatal MI, readmission
r ACS, and stroke). However, from 4 months through the
d of the study, the primary end point was significantly
duced in the aggressive treatment arm, which represented a
vorable trend toward a reduction of major cardiovascular
ents with the early, aggressive statin regimen. The incidence
myopathy (CK greater than 10 times the upper limit of
rmal, with muscle symptoms) occurred more frequently in the
rly/aggressive treatment group, which reinforces the need for
reful monitoring and follow-up with aggressive treatment.
Observational studies have generally supported initiation
lipid-lowering therapy before discharge after ACS both for
fety and for early efficacy (event reduction) (650). In
ntrast, a meta-analysis of randomized trials of early (less
an 14 d) initiation of lipid lowering after ACS, although
pporting its safety, suggests that efficacy is generally
layed beyond 4 months (651).
Short- and long-term compliance is a clear benefit of
-hospital initiation of lipid lowering (652). In a demonstra-
on project, the Cardiovascular Hospitalization Atheroscle-
sis Management Program, the in-hospital initiation of
pid-lowering therapy increased the percentage of patients
eated with statins 1 year later from 10% to 91%, and for
ose with an LDL-C less than 100 mg per dL, the percentage
creased from 6% to 58% (653), which suggests that
edischarge initiation of lipid-lowering therapy enhances
ng-term compliance. Thus, there appear to be no adverse
fects and substantial advantages to the initiation of lipid-
wering therapy before hospital discharge (652,654). Such
rly initiation of therapy also has been recommended in the
date of the third report of the NCEP (16). Adherence to
atin therapy was shown to be associated with improved
rvival in a large, population-based longitudinal observa-
onal study (655).
.2.8. Blood Pressure Control
ASS I
lood pressure control according to JNC 7 guidelines* is recom-
ended (i.e., blood pressure less than 140/90 mm Hg or less than
0/80 mm Hg if the patient has diabetes mellitus or chronic
dney disease). (Level of Evidence: A) Additional measures
commended to treat and control blood pressure include the
llowing:
Patients should initiate and/or maintain lifestyle modifica-
tions, including weight control, increased physical activity,
hobanian AV, Bakris GL, Black HR, et al., for the National High Blood
essure Education Program Coordinating Committee. The seventh report of the
int National Committee on Prevention, Detection, Evaluation, and Treatment oftiigh Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72 (656).alcohol moderation, sodium reduction, and emphasis on in-
creased consumption of fresh fruits, vegetables, and low-fat
dairy products. (Level of Evidence: B)
For patients with blood pressure greater than or equal to
140/90 mm Hg (or greater than or equal to 130/80 mm Hg for
individuals with chronic kidney disease or diabetes mellitus), it
is useful to add blood pressure medication as tolerated, treat-
ing initially with beta blockers and/or ACE inhibitors, with
addition of other drugs such as thiazides as needed to achieve
target blood pressure. (Level of Evidence: A)
All patients with elevated systolic or diastolic blood
essures should be educated and motivated to achieve
rgeted hypertensive control according to JNC 7 guidelines
56) adapted to patients with ischemic heart disease (656a).
ystolic and diastolic blood pressures should be in the normal
nge (i.e., less than 140/90 mm Hg; 130/80 mm Hg if the
tient has diabetes mellitus or chronic kidney disease).
.2.9. Diabetes Mellitus
ASS I
iabetes management should include lifestyle and pharmacother-
y measures to achieve a near-normal HbA1c level of less than
. (Level of Evidence: B) Diabetes management should also
clude the following:
Vigorous modification of other risk factors (e.g., physical
activity, weight management, blood pressure control, and
cholesterol management) as recommended should be initiated
and maintained. (Level of Evidence: B)
It is useful to coordinate the patient’s diabetic care with the
patient’s primary care physician or endocrinologist. (Level of
Evidence: C)
Glycemic control during and after ACS is discussed in
ection 6.2.1.
Overweight patients should be instructed in a weight loss
gimen, with emphasis on the importance of regular exercise
d a lifelong prudent diet to maintain ideal body mass index.
atients should be informed and encouraged that even small
ductions in weight can have positive benefits. This can be
assuring to severely obese patients. In the Diabetes Preven-
on Program study, 3,234 overweight subjects with elevated
sting and postload plasma glucose concentrations were
ndomized to treatment with metformin or a lifestyle mod-
cation program (657). The goals of the lifestyle modifica-
on program were targeted to at least a 7% weight loss and at
ast 150 min of physical activity per week. The incidence of
abetes mellitus was reduced by 58% in the lifestyle modi-
cation group and 31% in the metformin group compared
ith placebo. The study supports the substantial positive
fects of even modest changes in weight and physical
tivity on the development of diabetes, a major risk factor
r cardiovascular events (657–659).
.2.10. Smoking Cessation
ASS I
oking cessation and avoidance of exposure to environmental
bacco smoke at work and home are recommended. Follow-up,
ferral to special programs, or pharmacotherapy (including nico-
ne replacement) is useful, as is adopting a stepwise strategy
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367med at smoking cessation (the 5 As are: Ask, Advise, Assess,
ssist, and Arrange). (Level of Evidence: B)
For patients who smoke, persistent smoking cessation
unseling is often successful and has substantial potential
improve survival. Daly et al. (660) quantified the
ng-term effects of smoking on patients with ACS. Men
ss than 60 years old who continued to smoke had a risk
death due to all causes that was 5.4 times that of men
ho stopped smoking (p less than 0.05). Referral to a
oking cessation program and the use of pharmacological
ents including nicotine patches or gum are recom-
ended (661).
Bupropion, an anxiolytic agent and weak inhibitor of
uronal uptake of neurotransmitters, has been effective when
ded to brief regular counseling sessions in helping patients
quit smoking. The treatment of 615 study subjects for 7
eeks resulted in smoking cessation rates of 28.8% for the
0 mg per d dosage and 44.2% for 300 mg per d compared
ith 19.6% for placebo-assigned patients (p less than 0.001)
61). The abstinence rate at 1 year was 23.0% for those
eated with bupropion 300 mg per d versus 12.4% for those
ceiving placebo (661).
Recently, another nonnicotine replacement therapy, va-
nicline, was approved to assist in smoking cessation.
arenicline is a first-in-class nicotine acetylcholine receptor
rtial agonist, designed to provide some nicotine effects
asing withdrawal symptoms) and to block the effects of
cotine from cigarettes, discouraging smoking. Approval
as based on demonstrated effectiveness in 6 clinical trials
volving a total of 3,659 chronic cigarette smokers (32–34).
2 of the 5 placebo-controlled trials, varenicline also was
mpared to buproprion and found to be more effective.
arenicline is given for an initial 12-week course. Success-
lly treated patients may continue treatment for an additional
weeks to improve the chances of long-term abstinence.
amily members who live in the same household should also
encouraged to quit smoking to help reinforce the patient’s
fort and to decrease the risk of secondhand smoke for
eryone.
.2.11. Weight Management
ASS I
eight management, as measured by body mass index and/or
aist circumference, should be assessed on each visit. A body
ass index of 18.5 to 24.9 kg per m2 and a waist circumference
easured horizontally at the iliac crest) of less than 40 inches for
en and less than 35 inches for women is recommended. (Level of
idence: B) Additional weight management practices recom-
ended include the following:
On each patient visit, it is useful to consistently encourage
weight maintenance/reduction through an appropriate balance
of physical activity, caloric intake, and formal behavioral pro-
grams when indicated to maintain/achieve a body mass index
between 18.5 and 24.9 kg per m2. (Level of Evidence: B)
If waist circumference is 35 inches or more in women or 40
inches or more in men, it is beneficial to initiate lifestyle sychanges and consider treatment strategies for metabolic syn-
drome as indicated. (Level of Evidence: B)
The initial goal of weight loss therapy should be to reduce body
weight by approximately 10% from baseline. With success,
further weight loss can be attempted if indicated through
further assessment. (Level of Evidence: B)
.2.12. Physical Activity
ASS I
The patient’s risk after UA/NSTEMI should be assessed on the
basis of an in-hospital determination of risk. A physical activity
history or an exercise test to guide initial prescription is
beneficial. (Level of Evidence: B)
Guided/modified by an individualized exercise prescription,
patients recovering from UA/NSTEMI generally should be
encouraged to achieve physical activity duration of 30 to 60
min per d, preferably 7 (but at least 5) d per week of moderate
aerobic activity, such as brisk walking, supplemented by an
increase in daily lifestyle activities (e.g., walking breaks at
work, gardening, and household work). (Level of Evidence: B)
Cardiac rehabilitation/secondary prevention programs are rec-
ommended for patients with UA/NSTEMI, particularly those
with multiple modifiable risk factors and/or those moderate- to
high-risk patients in whom supervised exercise training is
particularly warranted. (Level of Evidence: B)
ASS IIb
e expansion of physical activity to include resistance training
2 d per week may be reasonable. (Level of Evidence: C)
Federal and ACC/AHA guidelines recommend that all
mericans strive for at least 30 to 60 min of moderate
ysical activity most days of the week, preferably daily
62). The 30 to 60 min can be spread out over 2 or 3
gments during the day. For post-UA/NSTEMI patients,
ily walking can be encouraged immediately after dis-
arge. Excellent resource publications on exercise pre-
ription in cardiovascular patients are available (45,663).
hysical activity is important in efforts to lose weight
cause it increases energy expenditure and plays an
tegral role in weight maintenance. Regular physical
tivity reduces symptoms in patients with CVD, improves
nctional capacity, and improves other cardiovascular risk
ctors such as insulin resistance and glucose intolerance
5). Beyond the instructions for daily exercise, patients
quire specific instruction on those strenuous activities
.g., heavy lifting, climbing stairs, yard work, and house-
ld activities) that are permissible and those they should
oid. Several activity questionnaires or nomograms, spe-
fic to the cardiac population and general population, have
en developed to help guide the patient’s exercise pre-
ription if an exercise test is not available (664 – 667). As
phasized by the US Public Health Service, comprehen-
ve cardiac rehabilitation services include long-term pro-
ams involving medical evaluation, prescribed exercise,
rdiac risk factor modification, education, and counseling
68). These programs are designed to limit the physio-
gical and psychological effects of cardiac illness, reduce
e risk for sudden death or reinfarction, control cardiac
mptoms, and enhance the psychosocial and vocational
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litation program after discharge can enhance patient
ucation and compliance with the medical regimen and
sist with the implementation of a regular exercise pro-
am (45,47,573,669,670). In addition to aerobic training,
ild- to moderate-resistance training may be considered.
his can be started 2 to 4 weeks after aerobic training has
gun (671). Expanded physical activity is an important
eatment component for the metabolic syndrome, which is
coming increasingly prevalent.
Exercise training can generally begin within 1 to 2
eeks after UA/NSTEMI treated with PCI or CABG to
lieve ischemia (663). Unsupervised exercise may target a
art rate range of 60% to 75% of maximum predicted;
pervised training (see Section 5.4) may target a some-
hat higher heart rate (70% to 85% of maximum pre-
cted) (663). Additional restrictions apply when residual
chemia is present.
.2.13. Patient Education
ASS I
eyond the detailed instructions for daily exercise, patients
ould be given specific instruction on activities (e.g., heavy
ting, climbing stairs, yard work, and household activities) that
e permissible and those that should be avoided. Specific men-
on should be made regarding resumption of driving, return to
ork, and sexual activity. (Level of Evidence: C) Specific recom-
endations for physical activity follow in Section 5.4.
Patients should be educated and motivated to achieve
propriate target LDL-C and HDL-C goals. Patients who
ve undergone PCI or CABG derive benefit from cholesterol
wering (672) and deserve special counseling lest they
istakenly believe that revascularization obviates the need
gure 21. Stepped-Care Approach to Pharmacological Therapy f
isk Factors for Ischemic Heart Disease. *Addition of ASA may no
rmission. American Heart Association Scientific Statement on th
r Clinicians © 2007, American Heart Association, Inc. (673). ASA
flammatory drugs; PPI  proton-pump inhibitor.r significant lifestyle changes. The NHLBI “Your Guide to reetter Health” series provides useful educational tools for
tients (http://hp2010.nhlbihin.net/yourguide/).
.2.14. Influenza
ASS I
n annual influenza vaccination is recommended for patients with
rdiovascular disease. (Level of Evidence: B)
.2.15. Depression
ASS IIa
is reasonable to consider screening UA/NSTEMI patients for
pression and refer/treat when indicated. (Level of Evidence: B)
.2.16. Nonsteroidal Anti-Inflammatory Drugs
ASS I
t the time of preparation for hospital discharge, the patient’s
ed for treatment of chronic musculoskeletal discomfort should
assessed, and a stepped-care approach to treatment should be
ed for selection of treatments (Fig. 21). Pain relief should begin
ith acetaminophen, small doses of narcotics, or nonacetylated
licylates. (Level of Evidence: C)
ASS IIa
is reasonable to use nonselective NSAIDs, such as naproxen, if
itial therapy with acetaminophen, small doses of narcotics, or
nacetylated salicylates is insufficient. (Level of Evidence: C)
ASS IIb
onsteroidal anti-inflammatory drugs with increasing degrees of
lative COX-2 selectivity may be considered for pain relief only for
tuations in which intolerable discomfort persists despite at-
mpts at stepped-care therapy with acetaminophen, small doses
narcotics, nonacetylated salicylates, or nonselective NSAIDs.
all cases, the lowest effective doses should be used for the
ortest possible time. (Level of Evidence: C)
ASS III
onsteroidal anti-inflammatory drugs with increasing degrees of
culoskeletal Symptoms With Known Cardiovascular Disease or
fficient protection against thrombotic events. Reproduced with
of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)-An Update
irin; COX-2  cyclooxygenase-1; NSAIDs  nonsteroidal anti-or Mus
t be su
e Use
 asplative COX-2 selectivity should not be administered to UA/
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367STEMI patients with chronic musculoskeletal discomfort when
erapy with acetaminophen, small doses of narcotics, nonacety-
ted salicylates, or nonselective NSAIDs provides acceptable
vels of pain relief. (Level of Evidence: C)
The selective COX-2 inhibitors and other nonselective
SAIDs have been associated with increased cardiovascular
sk. The risk appears to be amplified in patients with
tablished CVD (1,359–362). In a large Danish observa-
onal study of first-time MI patients (n  58,432), the HRs
d 95% CIs for death were 2.80 (2.41 to 3.25) for rofecoxib,
57 (2.15 to 3.08) for celecoxib, 1.50 (1.36 to 1.67) for
uprofen, 2.40 (2.09 to 2.80) for diclofenac, and 1.29 (1.16
1.43) for other NSAIDS (361). There were dose-related
creases in risk of death and non–dose-dependent trends for
hospitalization for MI for all drugs (360,361). An AHA
ientific statement on the use of NSAIDS concluded that the
sk of cardiovascular events is proportional to COX-2
lectivity and the underlying risk in the patient (673).
onpharmacological approaches were recommended as the
rst line of treatment, followed by the stepped-care approach
pharmacological therapy, as shown in Figure 21.
.2.17. Hormone Therapy
ASS III
Hormone therapy with estrogen plus progestin, or estrogen
alone, should not be given de novo to postmenopausal women
after UA/NSTEMI for secondary prevention of coronary events.
(Level of Evidence: A)
Postmenopausal women who are already taking estrogen plus
progestin, or estrogen alone, at the time of UA/NSTEMI in
general should not continue hormone therapy. However,
women who are more than 1 to 2 years past the initiation of
hormone therapy who wish to continue such therapy for
another compelling indication should weigh the risks and
benefits, recognizing the greater risk of cardiovascular events
and breast cancer (combination therapy) or stroke (estrogen).
Hormone therapy should not be continued while patients are on
bedrest in the hospital. (Level of Evidence: B)
Although prior observational data suggested a protective
fect of hormone therapy for coronary events, a random-
ed trial of hormone therapy for secondary prevention of
ath and MI (Heart and Estrogen/progestin Replacement
tudy [HERS]) failed to demonstrate a beneficial effect
74). Disturbingly, there was an excess risk for death and
I early after hormone therapy initiation. The Women’s
ealth Initiative included randomized primary prevention
ials of estrogen plus progestin and estrogen alone. Both
ials were stopped early owing to an observed increased
sk related to hormone therapy that was believed to
tweigh the potential benefits of further study (675– 677).
is recommended that postmenopausal women receiving
rmone therapy at the time of a cardiovascular event
scontinue its use. Likewise, hormone therapy should not
initiated for secondary prevention of coronary events.
owever, there may be other permissible indications for
rmone therapy in postmenopausal women (e.g., preven-on of perimenopausal symptoms such as flushing, or Gevention of osteoporosis) if the benefits are believed to
tweigh the increased cardiovascular risk).
.2.18. Antioxidant Vitamins and Folic Acid
ASS III
Antioxidant vitamin supplements (e.g., vitamins E, C, or beta
carotene) should not be used for secondary prevention in
UA/NSTEMI patients. (Level of Evidence: A)
Folic acid, with or without B6 and B12, should not be used for
secondary prevention in UA/NSTEMI patients. (Level of Evi-
dence: A)
Although there is an association of elevated homocysteine
ood levels and CAD, a reduction in homocysteine levels
ith routine folate supplementation was not demonstrated to
duce the risk of CAD events in 2 trials (Norwegian Vitamin
rial [NORVIT] and HOPE) that included post-MI or high
sk, stable patients (678–681). Similarly, a large clinical
ials experience with antioxidant vitamins has failed to
monstrate benefit for primary or secondary prevention
8,681a).
.3. Postdischarge Follow-Up
ecommendations
ASS I
Detailed discharge instructions for post-UA/NSTEMI patients
should include education on medications, diet, exercise, and
smoking cessation counseling (if appropriate), referral to a
cardiac rehabilitation/secondary prevention program (when
appropriate), and the scheduling of a timely follow-up appoint-
ment. Low-risk medically treated patients and revascularized
patients should return in 2 to 6 weeks, and higher risk patients
should return within 14 d. (Level of Evidence: C)
Patients with UA/NSTEMI managed initially with a conserva-
tive strategy who experience recurrent signs or symptoms of
UA or severe (Canadian Cardiovascular Society class III)
chronic stable angina despite medical management who are
suitable for revascularization should undergo timely coronary
angiography. (Level of Evidence: B)
Patients with UA/NSTEMI who have tolerable stable angina or
no anginal symptoms at follow-up visits should be managed
with long-term medical therapy for stable CAD. (Level of
Evidence: B)
Care should be taken to establish effective communication
between the post-UA/NSTEMI patient and health care team
members to enhance long-term compliance with prescribed
therapies and recommended lifestyle changes. (Level of Evi-
dence: B)
The risk of death within 1 year can be predicted on the
sis of clinical information and the ECG (see also Section
3). In a study of 515 survivors of hospitalization for
STEMI, risk factors included persistent ST-segment depres-
on, HF, advanced age, and ST-segment elevation at dis-
arge (682). Patients with all high-risk markers present had
14-fold greater mortality rate than did patients with all
arkers absent. Elevated cardiac TnT levels have also been
monstrated to provide independent prognostic information
r cardiac events at 1 to 2 years. For patients with ACS in a
USTO-IIa substudy, age, ST-segment elevation on admis-
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionon, prior CABG, TnT, renal insufficiency, and severe
ronic obstructive pulmonary disease were independently
sociated with risk of death at 1 year (683,684). For
A/NSTEMI patients, prior MI, TnT positivity, accelerated
gina before admission, and recurrent pain or ECG changes
ere independently associated with risk of death at 2 years.
atients managed with an initial conservative strategy (see
ection 3) should be reassessed at the time of return visits for
e need for cardiac catheterization and revascularization.
pecifically, the presence and severity of angina should be
certained. Rates of revascularization during the first year
ve been reported to be high (685). Long-term (7 years)
llow-up of 282 patients with UA demonstrated high event
tes during the first year (MI 11%, death 6%, PTCA 30%,
d CABG 27%); however, after the first year, event rates
ere low (685). Independent risk factors for death/MI were
e greater than 70 years, diabetes, and male sex. A predic-
ve model for the risk of death from discharge to 6 months
ter an ACS has been developed and validated using the
,142-patient GRACE registry database (168). Mortality
eraged 4.8%. Nine predictive variables were identified:
der age, history of MI, history of HF, increased pulse rate at
esentation, lower systolic blood pressure at presentation,
evated initial serum creatinine level, elevated initial serum
rdiac biomarker levels, ST-segment depression on present-
g ECG, and not having a PCI performed in the hospital. The
statistic for the validation cohort was 0.75. The GRACE
ol was suggested to be a simple, robust tool for clinical use.
Certain patients at high risk of ventricular tachyarrhythmia
ter UA/NSTEMI may be candidates for an implantable
rdioverter defibrillator. Indications and timing of an im-
antable cardioverter defibrillator in this setting are pre-
nted in the STEMI guidelines (1) and more recently the
entricular Arrhythmias and Sudden Cardiac Death guide-
nes (686). Indications for testing for atherosclerotic disease
other vascular beds (i.e., carotid, peripheral arterial) are
so covered elsewhere in recent guidelines (687).
Major depression has also been reported to be an indepen-
nt risk factor for cardiac events after MI and occurs in up
25% of such patients (688). Antidepressant therapy (with
rtraline) was safe and effective for relief of depressive
mptoms in a controlled trial in 369 depressed patients with
CS, but it did not conclusively demonstrate a beneficial
fect on cardiovascular end points, perhaps because of
mited sample size (689). Cognitive therapy and, in some
ses, sertraline did not affect late survival after MI in another
ndomized study (Enhancing Recovery in Coronary Heart
isease [ENRICHD]), but those whose depression did not
prove were at higher risk of late mortality (690). The
REATE trial evaluated interpersonal psychotherapy (IPT)
mpared with clinical management and the selective sero-
nin reuptake inhibitor citalopram compared with placebo in
2  2 factorial design among patients with CAD and major
pression (691). The primary end point of Hamilton Depres-
on Rating Scale score was improved in the citalopram group
rsus placebo (mean reduction 14.9 vs. 11.6, p  0.005) but
d not differ for IPT versus clinical management (mean
duction 12.1 vs. 14.4, p  0.06). Likewise, the secondary
d point of reduction in mean Beck Depression Inventory exore was improved in the citalopram group but did not differ
r IPT.
Patients recognized to be at high risk for a cardiac event
ter discharge for any of the above reasons should be seen
r follow-up earlier and more frequently than lower-risk
tients.
The overall long-term risk for death or MI 2 months after
episode of UA/NSTEMI is similar to that of other CAD
tients with similar characteristics. Van Domburg et al.
85) reported a good long-term outcome even after a
mplicated early course. Based on a median follow-up of
most 8 years, mortality in the first year was 6%, then 2% to
annually in the following years (685). When the patient
s returned to the baseline level, typically 6 to 8 weeks after
spitalization, arrangements should be made for long-term
gular follow-up visits, as for stable CAD. Cardiac catheter-
ation with coronary angiography is recommended for any of
e following situations: 1) significant increase in anginal
mptoms, including recurrent UA; 2) high-risk pattern (e.g.,
least 2 mm of ST-segment depression, systolic blood
essure decline of at least 10 mm Hg) on exercise test (see
ection 3.4); 3) HF; 4) angina with mild exertion (inability to
mplete stage 2 of the Bruce protocol for angina); and 5)
rvivors of sudden cardiac death. Revascularization is rec-
mended based on the coronary anatomy and ventricular
nction (see Section 4, ACC/AHA Guidelines for the Man-
ement of Patients With Chronic Stable Angina [4], and
CC/AHA 2004 Guideline Update for Coronary Artery
ypass Graft Surgery [555]).
Minimizing the risk of recurrent cardiovascular events
quires optimizing patients’ compliance with prescribed
erapies and recommended lifestyle modifications. Many
udies exploring predictors of compliance have failed to find
edictive value in simple demographic or socioeconomic
riables. More reliable predictors are the patients’ beliefs
d perceptions about their vulnerability to disease and the
ficacy of the prescribed treatments and, importantly, various
pects of the relationship with their health care provider
92–694). Development of a therapeutic relationship with
e patient and family is likely to enhance compliance. Care
ould be taken to ensure that there is adequate time spent
ith the family focused on explanation of the disease and
oposed treatments, the importance of adhering to the
escribed treatment plan, and exploration of patient-specific
rriers to compliance. Participation in cardiac rehabilitation/
condary prevention programs can help reinforce patient-
ecific secondary prevention issues and can address barriers
compliance. Close communication between the treating
ysician and the cardiac rehabilitation team is important to
aximize effectiveness (3,47,695,696).
.4. Cardiac Rehabilitation
ASS I
ardiac rehabilitation/secondary prevention programs, when
ailable, are recommended for patients with UA/NSTEMI, partic-
arly those with multiple modifiable risk factors and those
oderate- to high-risk patients in whom supervised or monitored
ercise training is warranted. (Level of Evidence: B)
ph
re
ca
pr
of
co
ev
ti
ta
su
m
bi
m
pa
E
ar
tr
m
de
an
m
st
in
M
de
0.
pa
st
re
pa
ch
ex
ca
to
re
de
in
T
ta
th
co
be
m
w
be
au
be
po
ed
im
di
cr
sh
li
sm
ps
to
(7
no
pr
af
N
U
th
ca
th
ab
ho
ho
ca
th
ac
pa
th
m
re
in
re
tw
ca
ti
ca
in
er
ge
as
co
W
re
th
in
pa
gr
fa
to
pr
w
co
po
5
R
63
th
fi
(P
pr
70
di
e310 Anderson et al. JACC Vol. 57, No. 19, 2011
ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367Cardiac rehabilitation programs are designed to limit the
ysiological and psychological effects of cardiac illness,
duce the risk for sudden death or reinfarction, control
rdiac symptoms, stabilize or reverse the atherosclerotic
ocess, and enhance the psychosocial and vocational status
selected patients (668,695,697). Cardiac rehabilitation is a
mprehensive long-term program that involves medical
aluation, prescribed exercise, cardiac risk factor modifica-
on, education, and counseling (668,698). Cardiac rehabili-
tion may occur in a variety of settings, including medically
pervised groups in a hospital, physician’s office, or com-
unity facility (696). Exercise may involve a stationary
cycle, treadmill, calisthenics, walking, or jogging, and
onitoring may include ECG telemetry, depending on a
tient’s risk status and the intensity of exercise training.
ducation and counseling concerning risk factor modification
e individualized, and close communication between the
eating physician and cardiac rehabilitation team may pro-
ote long-term behavioral change (695,696). Alternative
livery approaches, including home exercise, internet-based,
d transtelephonic monitoring/supervision, can be imple-
ented effectively and safely for carefully selected clinically
able patients (668,699).
Witt et al. (700) examined the association of participation
cardiac rehabilitation with survival in Olmstead County,
innesota, and found that participants had a lower risk of
ath and recurrent MI at 3 years (p less than 0.001 and p 
049, respectively). The survival benefit associated with
rticipation was stronger in more recent years (700). In this
udy, half of the eligible patients participated in cardiac
habilitation after MI, although women and older adult
tients were less likely to participate, independent of other
aracteristics.
A pooled-effect estimate for total mortality for the
ercise-only intervention demonstrated a reduction in all-
use mortality (random effects model OR 0.73 [95% CI 0.54
0.98]) compared with usual care. Comprehensive cardiac
habilitation reduced all-cause mortality, although to a lesser
gree (OR 0.87 [95% CI 0.71 to 1.05]). Neither of the
terventions had an effect on the occurrence of nonfatal MI.
he authors concluded that exercise-based cardiac rehabili-
tion appeared to be effective in reducing cardiac deaths but
at it was still unclear whether an exercise-only or a
mprehensive cardiac rehabilitation intervention was more
neficial. The population studied was predominantly male,
iddle-aged, and low risk. The authors suggested that those
ho could have benefited from the intervention might have
en excluded owing to age, gender, or comorbidity. The
thors cautioned that the results were of limited reliability
cause the quality of reporting in the studies was generally
or, and there were high losses to follow-up (698).
Cardiac rehabilitation comprising exercise training and
ucation, counseling, and behavioral interventions yielded
provements in exercise tolerance with no significant car-
ovascular complications, improvements in symptoms (de-
eased anginal pain and improved symptoms of HF such as
ortness of breath and fatigue), and improvements in blood
pid levels; reduced cigarette smoking in conjunction with a
oking cessation program; decreased stress; and improved reychosocial well-being (668). In addition to reductions in
tal cholesterol and LDL-C, increases in HDL-C levels occur
01).
Cardiac rehabilitation has been reported to improve prog-
sis after MI in a cost-effective manner (702,703). In current
actice, referrals for cardiac rehabilitation are more frequent
ter bypass surgery and less frequent after PCI for UA/
STEMI (704). Benefits of rehabilitation after uncomplicated
A/NSTEMI with revascularization and modern medical
erapy are less clear in comparison with STEMI or compli-
ted NSTEMI.
Existing community studies reveal that fewer than one
ird of patients with MI receive information or counseling
out cardiac rehabilitation before being discharged from the
spital (668,705). Only 16% of patients in a study of 5
spitals in 2 Michigan communities were referred to a
rdiac rehabilitation program at discharge, and only 26% of
e patients later interviewed in the community reported
tual participation in such a program; however, 54% of the
tients referred at discharge did participate at the time of
eir follow-up interview (705). Physician referral was the
ost powerful predictor of patient participation in a cardiac
habilitation program. In a longitudinal study of the use of
patient cardiac rehabilitation in 5,204 Worcester, Mass,
sidents hospitalized with MI in seven 1-year periods be-
een 1986 and 1997, patients not referred to inpatient
rdiac rehabilitation were less likely to be prescribed effec-
ve cardiac medications and to undergo risk factor modifi-
tion counseling before discharge (706).
Patient reasons for nonparticipation and noncompliance
clude affordability of service, insurance coverage/noncov-
age, social support from a spouse or other caregiver,
nder-specific attitudes, patient-specific internal factors such
anxiety or poor motivation, and logistical and financial
nstraints, or a combination of these factors (688,705).
omen and the elderly are referred less frequently to cardiac
habilitation programs, even though they derive benefit from
em (38,707–710). Health care systems should consider
stituting processes that encourage referral of appropriate
tients to cardiac rehabilitation/secondary prevention pro-
ams (for example, the use of standardized order sets that
cilitate this, such as the AHA “Get with the Guidelines”
ols). In addition, it is important that referring health care
actitioners and cardiac rehabilitation teams communicate in
ays that promote patient participation. Of note, Medicare
verage for rehabilitation recently was expanded beyond
st-MI, post-CABG, and stable angina to include PCI (711).
.5. Return to Work and Disability
eturn-to-work rates after MI, which currently range from
% (712) to 94% (713), are difficult to influence because
ey are confounded by factors such as job satisfaction,
nancial stability, and company policies (714). In PAMI
rimary Angioplasty in Myocardial Infarction)-II, a study of
imary PTCA in low-risk patients with MI (i.e., age less than
years, ejection fraction greater than 0.45, 1- or 2-vessel
sease, and good PTCA result), patients were encouraged to
turn to work at 2 weeks (715). The actual timing of return
to
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result of this strategy.
Cardiac rehabilitation programs after MI can contribute to
ductions of mortality and improved physical and emotional
ell-being (see Section 5.4). Patients whose expectations for
turn to work were addressed in rehabilitation returned to
ork at a significantly faster rate than the control group in a
ospective study (716).
Lower or absent levels of depressive symptoms before MI
creases the odds of recovery of functional status (717).
atients with high pre-event functional independence mea-
rement have a shorter length of stay and a greater likelihood
discharge to home (718). Pre-event peak aerobic capacity
d depression score are the best independent predictors of
stevent physical function. Women tend to have lower
ysical function scores than men of similar age, depression
ore, and comorbidity. Resting LVEF is not a predictor of
ysical function score.
Patients’ cardiac functional states are not a strong predictor
their probability of returning to work. Diabetes, older age,
-wave MI, and preinfarction angina are associated with
ilure to resume full employment (719). However, psycho-
gical variables such as trust, job security, patient feelings
out disability, expectations of recovery by both physician
d patient, and degree of somatizing are more predictive
20,721). Physical requirements of the job play a role as well
19,721).
To aid occupational physicians in making return-to-work
cisions, Froom et al. (719) studied the incidence of post-MI
ents at 1, 2, 4, 6, 9, and 12 months. Events included cardiac
ath, recurrent infarction, CHF, and UA. They found that the
cidence of events reached a low steady state at 10 weeks.
Return to work can be determined by employer regulations
ther than by the patient’s medical condition. It behooves the
ysician to provide data to prove that the patient’s job does
t impose a prohibitive risk for a cardiac event. An example
the case of Canadian bus drivers reported by Kavanagh et
. (722). These patients were evaluated with a stress test. The
ysician and technologist studied the drivers at work and
owed that the cardiac stress values during driving were
ly half of the average values obtained in the stress
boratory. The calculated risk of sudden cardiovascular
cidents causing injury or death to passengers, other road
ers, and the drivers themselves in the first year after
covery from an MI was 1 in 50,000 driving-years. The bus
ivers were allowed to return to work after they satisfied the
anadian Cardiovascular Society guidelines.
Covinsky et al. (723) performed a mail survey study of
tients with MIs. Three months after discharge, women
ported worse physical and mental health and were more
kely to work less than before the MI. Similarly, women
ere less likely to return to work than men. Contemporary
formation specific to UA/NSTEMI on return to work by
nder is needed.
The current aggressive interventional treatment of ACS
ill have an impact on mortality, morbidity, and hospital
ngth of stay (724). It remains to be determined whether
rlier improvement in cardiac condition after ACS will have
effect on the rate of return to work because of the multiple cancardiac factors that influence disability and return to
ork.
.6. Other Activities
patients who desire to return to physically demanding
tivities early, the safety of the activity can be determined by
mparing performance on a graded exercise test with the
ET level required for the desired activity. Table 23 presents
ergy levels, expressed in METS, required to perform a
riety of common activities (725). This and similar tables
n be helpful in translating a patient’s performance on a
aded exercise test into daily activities that can be under-
ken with reasonable safety.
The health care provider should provide explicit advice
out when to return to previous levels of physical activity,
xual activity, and employment. Daily walking can be
couraged immediately (726). In stable patients without
mplications (Class I), sexual activity with the usual partner
n be resumed within 1 week to 10 d. Driving can begin 1
eek after discharge if the patient is judged to be in
mpliance with individual state laws. Each state’s Depart-
ent of Motor Vehicles or its equivalent has mandated
rtain criteria, which vary from state to state and must be
et before operation of a motor vehicle after serious illness
27). These include such caveats as the need to be accom-
nied and to avoid stressful circumstances such as rush hour,
clement weather, night driving, heavy traffic, and high
eeds. For patients who have experienced a complicated MI
ne that required CPR or was accompanied by hypotension,
rious arrhythmias, high-degree block, or CHF), driving
ould be delayed 2 to 3 weeks after symptoms have
solved.
Most commercial aircraft are pressurized to 7,500 to 8,000
et and therefore could cause hypoxia due to the reduced
veolar oxygen tension. The maximum level of pressuriza-
on is limited to 8,000 feet (2440 m) by Federal Aviation
dministration regulation (728). Therefore, air travel within
e first 2 weeks of MI should be undertaken only if there is
angina, dyspnea, or hypoxemia at rest or fear of flying.
he individual must have a companion, must carry NTG, and
ust request airport transportation to avoid rushing and
creased cardiac demands. Availability of an emergency
edical kit and automated external defibrillator has been
andated as of April 12, 2004 (729), in all aircraft that carry
least approximately 30 passengers and have at least 1 flight
tendant.
Patients with UA (i.e., without infarction) who are revas-
larized and otherwise stable may accelerate return to work,
iving, flying, and other normal activities (often, within a
w days).
.7. Patient Records and
ther Information Systems
ffective medical record systems that document the course
d plan of care should be established or enhanced. Both
per-based and electronic systems that incorporate
idence-based guidelines of care, tools for developing cus-
mized patient care plans and educational materials, and
pture of data for appropriate standardized quality measure-
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such tools are the ACC’s “Guidelines Applied in Practice”
d the AHA’s “Get With the Guidelines.” All computerized
ovider order entry (CPOE) systems should incorporate
ese attributes as well. In some settings, the regular and
nsistent use of such systems and tools has been shown to
gnificantly improve quality of care and patient safety. The
tient’s medical record from the time of hospital discharge
ould indicate the discharge medical regimen, the major
structions about postdischarge activities and rehabilitation,
d the patient’s understanding and plan for adherence to the
commendations. After resolution of the acute phase of
A/NSTEMI, the medical record should summarize cardiac
ents, current symptoms, and medication changes since
spital discharge or the last outpatient visit and should
cument the plan for future care. Processes for effective and
mely transfer of relevant prehospital and postdischarge
tient information between all participating caregivers
ould be continuously enhanced in accordance with existing
gulatory standards. This should include providing all pa-
ents with the tools to facilitate access to and understanding
ble 23. Energy Levels Required to Perform Some Common Act
ss Than 3 METS 3–5 METS 5–7
Se
ashing
aving
essing
sk work
ashing dishes
iving auto
ght housekeeping
Cleaning windows
Raking
Power lawn mowing
Bed making/stripping
Carrying objects (15 to 30 lb)
Easy digging in
Level hand law
Climbing stairs
Carrying object
Occu
tting (clerical/
assembly)
ping
sk work
anding (store
clerk)
Stocking shelves (light
objects)
Auto repair
Light welding/carpentr
Carpentry (exte
Shoveling dirt
Sawing wood
Operating pneu
Recr
lf (cart)
itting
nd sewing
Dancing (social)
Golf (walking)
Sailing
Tennis (doubles)
Volleyball (6 persons)
Table tennis
Marital sex
Badminton (com
Tennis (singles
Snow skiing (d
Light backpack
Basketball
Football
Stream Fishing
Physical
alking (2 mph)
ationary bike
ry light
calisthenics
Level walking (3–4 mph)
Level biking (6–8 mph)
Light calisthenics
Level walking
Bicycling (9–1
Swimming, bre
Adapted with permission from Haskell WL. Design and implementation of ca
e Coronary Patient. New York, NY: Churchill Livingstone, 1978 (725).
METS  metabolic equivalents; mph  miles per hour.the nature and importance of their most current plan ofre. With the increasing numbers of patients who have
gular access to the Internet, awareness of online informa-
on reflecting current evidence-based and professionally
veloped standards of care should be encouraged and
omoted. Several sites with reliable health care information
levant to UA/NSTEMI are available to patients (http://
ww.heartauthority.com/; http://www.nhlbi.nih.gov/health/
i/index.html; http://www.nlm.nih.gov/medlineplus/tutorial.
ml; http://www.fda.gov/hearthealth/index.html).
. Special Groups
.1. Women
ecommendations
ASS I
Women with UA/NSTEMI should be managed with the same
pharmacological therapy as men both in the hospital and for
secondary prevention, with attention to antiplatelet and anti-
7–9 METS More Than 9 METS
ng
)
60 lb)
Sawing wood
Heavy shoveling
Climbing stairs (moderate
speed)
Carrying objects (60 to 90 lb)
Digging vigorously
Carrying loads upstairs
(objects more than
90 lb)
Climbing stairs
(quickly)
Shoveling heavy snow
l
ols
Digging ditches (pick and
shovel)
Forestry
Farming
Lumber jack
Heavy laborer
Shoveling (heavy)
) Canoeing
Mountain climbing
Paddle ball
Walking (5 mph)
Running (12 min. mile)
Mountain or rock climbing
Soccer
Handball
Football (competitive)
Squash
Ski touring
Vigorous basketball
(game)
ning
mph)
ke
Level jogging (5 mph)
Swimming (crawl stroke)
Rowing machine
Heavy calisthenics
Bicycling (12 mph)
Running (more than 6
mph)
Bicycling (more than
13 mph)
Rope jumping
Walking uphill (5 mph)
nditioning program. In: Wenger NL, Hellerstein HK, editors. Rehabilitation ofivities
METS
lf-Care
garden
n mowi
(slowly
s (30 to
pationa
rior)
matic to
eational
petitive
)
ownhill)
ing
Conditio
(4.5–5.0
0 mph)
ast stro
rdiac cocoagulant doses based on weight and renal function; doses of
2.
3.
4.
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionrenally cleared medications should be based on estimated
creatinine clearance. (Level of Evidence: B)
Recommended indications for noninvasive testing in women
with UA/NSTEMI are similar to those for men. (Level of
Evidence: B)
For women with high-risk features, recommendations for inva-
sive strategy are similar to those of men. See Section 3.3.
(Level of Evidence: B)
In women with low-risk features, a conservative strategy is
recommended. (Level of Evidence: B)
Although at any age, women have a lower incidence of
AD than men, they account for a considerable proportion of
A/NSTEMI patients, and UA/NSTEMI is a serious and
mmon condition among women. It is important to over-
me long-held notions that severe coronary manifestations
e uncommon in this population; however, women can
anifest CAD somewhat differently than men (679). Women
ho present with chest discomfort are more likely than men
have noncardiac causes and cardiac causes other than fixed
structive coronary artery stenosis. Other cardiac causes
clude coronary vasospasm, abnormal vasodilator reserve,
d other mechanisms (679,731–733). Women with CAD
e, on average, older than men and are more likely to have
morbidities such as hypertension, diabetes mellitus, and HF
ith preserved systolic function; to manifest angina rather
an MI; and, among angina and MI patients, to have atypical
mptoms (150,734–736).
.1.1. Profile of UA/NSTEMI in Women
onsiderable clinical information about UA/NSTEMI in
omen has emerged from many randomized trials and
gistries (150,552,554,734,737). As in other forms of CAD,
omen are older and have more comorbidities (diabetes
ellitus and hypertension) and stronger family histories than
en (150,734–736). Women are less likely to have had a
evious MI or cardiac procedures (734), more likely to have
history of HF, but less likely to have LV systolic dysfunc-
on. Women present with symptoms of similar frequency,
ration, and pattern, but more often than men, they have
ginal-equivalent symptoms such as dyspnea or atypical
mptoms (72,141,738). The frequency of ST-segment
anges is similar to that for men, but women more often
ve T-wave inversion. There are notable differences in the
ofiles of cardiac biomarkers for women and men, with a
nsistent finding in trials and registries that women less
ten have elevated levels of troponin (552,554,565,737). In
analysis of TACTICS-TIMI 18, women also less often had
evation of CK-MB; however, women more often had
creased levels of high-sensitivity CRP or BNP than men.
portantly, the prognostic value of elevated biomarkers is
milar in men and women (739). Coronary angiograms in
th trials and registries revealed less extensive CAD in
omen, as well as a higher proportion with nonobstructive
AD. The rate of nonobstructive CAD can be as high as 37%
spite selection of women according to strict inclusion
iteria in clinical trials (150,554).
A differing symptom pattern in women than men, the lower
equency of positive cardiac biomarkers despite high rates of
T-T abnormalities on the ECG, and the higher frequency of einobstructive CAD in women make it challenging to con-
rm the diagnosis of UA/NSTEMI. This is a likely cause of
derutilization of several therapies in women compared with
en (737). There are important mechanisms of ischemic
est pain other than platelet/thrombus aggregates on plaque
osion or ulceration in women (see Section 6.8). Although
me studies report that female sex is a risk factor for poor
tcome in UA/NSTEMI on the basis of unadjusted event
tes (72,737), multivariate models have not found female sex
be an independent risk factor for death, reinfarction, or
current ischemia. This is in contrast to an apparent inde-
ndent risk of death for women compared with men with
TEMI, particularly for younger women.
.1.2. Management
.1.2.1. PHARMACOLOGICAL THERAPY
studies that span the spectrum of CAD, women tend to
ceive less intensive pharmacological treatment than men
34,737,740), perhaps in part because of a general percep-
on of lower frequency and severity of CAD in women.
lthough the specifics vary regarding beta blockers and other
ugs (150,734,741), a consistent (and disturbing) pattern is
at women are prescribed ASA and other antithrombotic
ents less frequently than men (150,737,740). Women
rive the same treatment benefit as men from ASA, clopi-
grel (54), anticoagulants, beta blockers, ACE inhibitors,
d statins (54,742). A meta-analysis of GP IIb/IIIa antago-
sts in ACS demonstrated an interaction between sex and
eatment effect, with an apparent lack of efficacy in women
26); however, women with elevated troponin levels re-
ived the same beneficial effect as men treated with GP
b/IIIa antagonists. The findings of a beneficial effect of a
rect invasive strategy in women treated with a GP IIb/IIIa
tagonist in TACTICS-TIMI 18 (see Section 6.1.2.3) further
pports the similar efficacy of these agents in this cohort of
omen and men.
Despite the clear benefit of antiplatelet and anticoagulant
erapy for women with ACS, women are at increased risk of
eeding. A low maintenance dose of ASA (75 to 162 mg)
ould be used to reduce the excess bleeding risk, especially
combination with clopidogrel (54). Estimated creatinine
earance instead of serum creatinine levels should guide
cisions about dosing and the use of agents that are renally
eared, e.g., LMWHs and the small-molecule GP IIb/IIIa
tagonists. In a large community-based registry study, 42%
patients with UA/NSTEMI received excessive initial
sing of at least 1 antiplatelet or anticoagulant agent (UFH,
MWH, or GP IIb/IIIa inhibitor) (743). Female sex, older
e, renal insufficiency, low body weight, and diabetes were
edictors of excessive dosing. Dosing errors predicted an
creased risk of major bleeding (743). The formula used to
timate creatinine clearance for dose adjustment in clinical
udies and labeling that defines adjustments for several
edications have been based on the Cockroft-Gault formula
r estimating creatinine clearance, which is not identical to
e Modification of Diet and Renal Disease (MDRD) formula
cently recommended for screening for renal disease (744),
ther in units or cutpoints for adjustment. Weight-based
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refully where recommended.
The use of hormone therapy in postmenopausal women is
scussed in Section 5.2.17.
.1.2.2. CORONARY ARTERY REVASCULARIZATION
ontemporary studies have cast doubt on the widely held
lief that women fare worse with PCI and CABG than do
en because of technical factors (e.g., smaller artery size,
eater age, and more comorbidities) (150,735,742,745–749).
the case of PCI, it has been suggested that angiographic
ccess and late outcomes are similar in women and men,
though in some series, early complications occurred more
equently in women (745,746,750–753). However, the out-
ok for women undergoing PCI appears to have improved, as
idenced by the NHLBI PTCA registry (754). Earlier studies
women undergoing CABG showed that women were less
kely to receive internal mammary arteries or complete
vascularization and had a higher mortality rate (RR 1.4 to
4) than men (748,749,755). However, more recent studies
CABG in patients with ACS show a more favorable
tlook for women than previously thought (see Section 6.3)
56,757,757a).
A Mayo Clinic review of 3,014 patients (941 women) with
A who underwent PCI reported that women had similar
rly and late results as men (735). The BARI trial of 1,829
tients compared PTCA and CABG, primarily in patients
ith UA, and showed that the results of revascularization
ere, if anything, better in women than men when corrected
r other factors. At an average 5.4-year follow-up, mortality
tes for men and women were 12% and 13%, respectively,
t when adjusted for baseline differences (e.g., age, diabetes,
d other comorbidities), there was a lower risk of death (RR
60, 95% CI 0.43 to 0.84, p  0.003) but a similar risk of
ath or MI (RR 0.84, 95% CI 0.66 to 1.07, p  0.16) in
omen compared with men (755). The NHLBI Dynamic
egistry has reported improved outcomes for women who
derwent PCI in 1997 to 1998 compared with 1985 to 1986.
ompared with men, women had similar procedural success,
-hospital death, MI, and CABG (754). Although the 1-year
ent rate was higher for women, female sex was not
dependently associated with death or MI because women
nded to be older and had more comorbidities. A prospective
udy of 1,450 patients with UA/NSTEMI who underwent an
direct or direct invasive strategy with coronary stenting
ported that female sex was independently associated with a
wer rate of death and MI (HR 0.51, 95% CI 0.28 to 0.95)
53).
.1.2.3. INITIAL INVASIVE VERSUS
ITIAL CONSERVATIVE STRATEGY
the modern era, clinical trials assessing a direct invasive
rategy compared with an initial conservative strategy for the
anagement of UA/NSTEMI have consistently demonstrated
benefit for men (552,554,565). Approximately one third of
e cohorts in these trials were women (n  2,179), and the
sults on the efficacy and safety of a direct invasive strategy
women have been conflicting. Each trial was underpow-ed to evaluate the subgroup of women, and there were inbstantial differences among the trials (Table 24). A meta-
alysis of trials in the era of stents and GP IIb/IIIa antago-
sts has failed to show a survival benefit of a direct invasive
rategy in women at 6 to 12 months (OR for women 1.07,
% CI 0.82 to 1.41; OR for men 0.68, 95% CI 0.57 to 0.81)
42).
In TACTICS-TIMI 18, there was a significant reduction in
e primary end point of death, nonfatal MI, or rehospitaliza-
on for an ACS with a direct invasive strategy (OR 0.45, 95%
I 0.24 to 0.88, p  0.02) (182). All subjects in this trial (n
754) were treated with an early GP IIb/IIIa antagonist
irofiban). A similar overall reduction in the primary com-
site end point of death, MI, or rehospitalization for ACS at
months was observed for women and men (adjusted OR
72, 95% CI 0.47 to 1.11 and adjusted OR 0.64, 95% CI 0.47
0.88, respectively). Women were older, more frequently
d hypertension, and less frequently had previous MI,
ABG, and elevated cardiac biomarkers (p less than 0.001
r all), but there was no significant difference in TIMI risk
ore distribution by sex (p  0.76) (565). A similar
duction in composite risk was observed in women with
termediate (3 to 4) or high (5 to 7) TIMI risk scores as in
en. However, in contrast to men with a low TIMI risk score
ho had similar outcomes with an invasive and conservative
rategy, low-risk women had an OR for events of 1.59 (95%
I 0.69 to 3.67) for the invasive compared with the conser-
tive strategy (565). However, the number of events was
all (n 26 events), and the p value for interaction between
rategy, TIMI risk score, and sex on outcome did not achieve
gnificance (p  0.09). An elevated biomarker, including
NP, CRP, CK-MB, and troponin, also identified women
nd men) who benefited differentially from a direct invasive
rategy. The reduction in risk was enhanced in women with
evated TnT levels (adjusted OR 0.47, 95% CI 0.26 to 0.83),
ith a similar reduction in the primary end point noted for
omen and men with elevated troponin. However, in contrast
the similar outcome for the invasive versus conservative
rategy in men with a negative TnT marker (OR 1.02, 95%
I 0.64 to 1.62, p  0.04), the primary end point of death,
I, and rehospitalization occurred significantly more fre-
ently in women with negative troponin randomized to an
vasive strategy (OR 1.46, 95% CI 0.78 to 2.72) (565).
The RITA-3 trial enrolled 682 women (38% of 1,810
tients) (758). There was a significant interaction between
x and treatment strategy (invasive versus conservative) on
tcome in RITA-3 (p  0.042). In contrast to a reduction in
ath or MI for men assigned to an invasive strategy, the HR
r women was 1.09. Women assigned to an initial conser-
tive strategy had a lower rate of death and MI (5.1%) at 1
ar than the women enrolled in TACTICS-TIMI 18 (9.7% at
months). Consistent with this difference, 37% of women in
ITA-3 had no significant obstructive CAD, compared with
% of women in TACTICS-TIMI 18 (759). Other notable
fferences between RITA-3 and TACTICS-TIMI 18 include
utine use of GP IIb/IIIa antagonist in TACTICS-TIMI 18
d different criteria for the MI end point in both the
nservative and the invasive treatment groups. The RITA-3
vestigators have reported that the rates of death and MI for
Table 24. Invasive Versus Conservative Strategy Results for UA/NSTEMI by Gender
Study (Reference) Timing End Point Overall Result Results in Men Results in Women Comment
TACTICS-TIMI 18 (182,565) 2002
n  2220
34% female
Angiography 4 to
48 h
Death, MI 30 d
Inv: 4.7%
Cons: 7.0%, p  0.02
ARR2.3%
6 months
Inv: 7.3%
Cons: 9.5%
OR  0.74 (95% CI 0.54 to 1.00)
ARR2.2%
6 months
Inv: 7.6%
Cons: 9.4%
OR  0.68 (95% CI 0.43 to 1.05)
ARR  1.8%
6 months
Inv: 6.6%
Cons: 9.7%
OR  0.45 (95% CI 0.24 to 0.88)
ARR  3.1%
Benefit greater in women with
high cTnT; OR  0.47
(95% CI 0.26 to 0.83) for
death, MI, and
rehospitalization
RITA-3 (758) 2002
n  1810
38% female
Angiography
within 48 h
Death, MI,
refractory
angina
Death, MI
4 months
Inv: 9.6%
Cons: 14.5%, p  0.001
RR  0.66 (95% CI 0.51 to 0.85)
ARR  4.9%
1 year
Inv: 7.0%
Cons: 8.3%, p  0.58
RR  0.91 (95% CI 0.67 to 1.25)
ARR  0.7%
4 months
Inv: 8.8%
Cons: 17.3%
ARR  8.5%
1 year
Inv: 7.0%
Cons: 10.1%
Arr  3.1%
4 months
Inv: 10.9%
Cons: 9.6%, p  NS
ARR  1.3%
1 year
Inv: 8.6%
Cons: 5.1%
ARR  3.5%
Angina reduced with invasive
strategy
FRISC II (245,549,552) 1999
n  2457
30% female
Revascularization
within 7 d
Death, MI 6 months
Inv: 9.4%
Cons: 12.1%, p  0.3
ARR  2.7%
1 year
Inv: 10.4%
Cons: 14.1%, p  0.005
ARR  3.7%
1 year
Inv: 9.6%
Cons: 15.8% p less than 0.001
ARR  6.2%
6 months
Inv: 10.5%
Cons: 8.3%, RR  1.26 (95% CI
0.80 to 1.97)
ARR  1.9%
1 year
Inv: 12.4%
Cons: 10.5%, p  NS
ARR  1.9%
Mortality benefit at 1 year
(2.2% vs. 3.9%)
ARR  1.7% p  0.02, not
seen in women (4% vs.
3.3%)
ARR  0.7%
TIMI-IIIB (150) 1997
n  1423
34% female
Angiography 1 to
48 h
Death, MI 1 year
Inv: 10.8%
Cons: 12.2%, p  0.42
ARR  1.4%
Death at 6 weeks
Inv: 2.6%
Cons: 1.4%
ARR  1.2%
MI at 6 weeks
Inv: 5.5%
Cons: 6.0%
ARR  0.5%
Death at 6 weeks
Inv: 2%
Cons: 4.4%
ARR  2.4%
MI at 6 weeks
Inv: 4.4%
Cons: 5.2%
ARR  0.8%
Invasively treated patients had
less angina and fewer
rehospitalizations for
ischemia
Reproduced with permission from Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare professionals from the American Heart Association © 2005, American Heart
Association, Inc (742).
ACS  acute coronary syndrome; ARR  absolute risk reduction; CI  confidence interval; Cons  conservative; cTnT  cardiac troponin T; FRISC II  Fast Revascularization during InStability in Coronary artery disease-II;
Inv  invasive; MI  myocardial infarction; n  number of patients; NS  nonsignificant; NSTEMI  non–ST-segment elevation MI; OR  odds ratio; PTCA  percutaneous transluminal coronary angioplasty; RITA-3  Third
Randomized Intervention Treatment of Angina; RR  risk ratio; TACTICS-TIMI 18  Treat Angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy–Thrombolysis In Myocardial Infarction 18;
TIMI IIIB  Thrombolysis In Myocardial Infarction III; UA  unstable angina. e315
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vasive strategy, respectively, that is, not significantly dif-
rent, when there was a lower threshold for cardiac marker
agnosis of MI among the conservatively treated group
54).
In the only trial that showed an overall survival benefit for
invasive strategy, FRISC-II, there was a significant inter-
tion in outcome between treatment strategy, which included
systematic but delayed interventional approach within 7 d
symptom onset, and sex (549,552). Thirty percent of the
457 enrolled patients were women, and the death and MI
te at 1 year was nonsignificantly higher for invasively
eated versus conservatively treated women, in contrast to a
rge reduction in death and MI for men. Female sex was
dependently associated with events in the invasively as-
gned patients. However, the poor outcome of women was
rgely driven by a 9.9% death rate at 1 year in women who
derwent CABG. In contrast, the death rate for women who
derwent PCI in the invasive strategy group was similar to
at of men (1.5% vs. 1.0%; RR 1.50, 95% CI 0.27 to 8.28;
 nonsignificant [NS]).
In summary, women with UA/NSTEMI and high-risk
atures, including elevated cardiac biomarkers, appear to
nefit from an invasive strategy with early intervention and
junctive GP IIb/IIIa antagonist use. There is no benefit of a
rect invasive strategy for low-risk women, and the weight
evidence from the recent randomized clinical trials sug-
sts that there may be excess risk associated with a direct
vasive strategy in this group. The challenges in the diagno-
s of UA/NSTEMI and the varied pathophysiology of isch-
ic pain in women who present with rest discomfort suggest
at perhaps the excess risk of a direct invasive strategy
served in low-risk women could be due to intervention on
stable incidental coronary lesion in a woman with another
echanism for rest pain.
.1.3. Stress Testing
general, ECG exercise testing is less predictive in women
an in men, primarily because of the lower pretest probabil-
y of CAD (581,760–762). Perfusion studies using sestamibi
ve good sensitivity and specificity in women (763). Breast
tenuation is less of a problem than previously with thallium-
1 stress testing with new tissue software. Stress echocar-
ography (dobutamine or exercise) is therefore an accurate
d cost-effective technique for CAD detection in women
81). Newer perfusion methods such as adenosine-stress
MR also appear to be promising in women. Cardiac mag-
tic resonance imaging (for function, perfusion, and viabil-
y) and multislice CCTA are 2 new diagnostic modalities that
uld prove particularly useful in women because of their
omise of both greater sensitivity and specificity (improved
agnostic accuracy). Evidence of ischemia by objective
easures without obstructive CAD carries an adverse prog-
sis(4,764) and is suggestive of vascular dysfunction (cor-
ary endothelial or microvascular dysfunction) as an etio-
gical mechanism.
Recommendations for noninvasive testing in women are
e same as in men (see Section 3.4) (733,764). A report of
6 women who underwent treadmill exercise suggests thate Duke Treadmill Score provides accurate diagnostic and
ognostic estimates in both women and men (765). The
uke Treadmill Score actually performed better for women
an for men in the exclusion of CAD. There were fewer
w-risk women than men with any significant CAD (at least
vessel with greater than 75% stenosis; 20% in women vs.
% in men, p less than 0.001).
Regarding dobutamine stress echocardiography, pilot
ase data from the Women’s Ischemia Syndrome Evaluation
ISE) indicated that in women, the test reliably detects
ultivessel disease (sensitivity 81.8%, similar to that in men)
t not 1-vessel disease (766). Several studies have indicated
at women with positive stress tests tend not to be evaluated
aggressively as men (741), which is inappropriate given
e adverse prognosis of ischemia as demonstrated in WISE
d other studies (733,767–774).
In the TIMI IIIB registry, women underwent exercise
sting in a similar proportion as men (150,734). The frequen-
es of stress test positivity were also similar, although
omen were less likely to have a high-risk stress test result.
oreover, women were less likely to undergo angiography
R 0.71, p less than 0.001), perhaps because of the lower
rcentage with high-risk test results on noninvasive testing.
.1.4. Conclusions
omen with UA/NSTEMI are older and more frequently
ve comorbidities compared with men but have more
ypical presentations and appear to have less severe and less
tensive obstructive CAD. Women receive ASA less fre-
ently than do men, but patients with UA/NSTEMI of either
x benefit from and should receive this agent, as well as
her Class I recommended agents. Doses should be adjusted
the basis of weight and estimated creatinine clearance for
nally cleared drugs for all recommended agents when
propriate. Image-enhanced stress testing has similar prog-
stic value in women as in men.
.2. Diabetes Mellitus (UPDATED)
or new or updated text, view the 2011 Focused Update.
ext supporting unchanged recommendations has not been
pdated.
ecommendations
ASS I
Medical treatment in the acute phase of UA/NSTEMI and
decisions on whether to perform stress testing, angiography,
and revascularization should be similar in patients with and
without diabetes mellitus. (Level of Evidence: A)
In all patients with diabetes mellitus and UA/NSTEMI, atten-
tion should be directed toward aggressive glycemic manage-
ment in accordance with current standards of diabetes care
endorsed by the American Diabetes Association and the Amer-
ican College of Endocrinology. Goals of therapy should include
a preprandial glucose target of less than 110 mg per dL and a
maximum daily target of less than 180 mg per dL. The
postdischarge goal of therapy should be HbA1C less than 7%,
which should be addressed by primary care and cardiac care-
givers at every visit. (Level of Evidence: B)
An intravenous platelet GP IIb/IIIa inhibitor should be admin-
istered for patients with diabetes mellitus as recommended for
CL
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2.
3.
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The benefit may be enhanced in patients with diabetes melli-
tus. (Level of Evidence: B)
ASS IIa
For patients with UA/NSTEMI and multivessel disease, CABG
with use of the internal mammary arteries can be beneficial
over PCI in patients being treated for diabetes mellitus. (Level
of Evidence: B)
Percutaneous coronary intervention is reasonable for UA/
NSTEMI patients with diabetes mellitus with single-vessel
disease and inducible ischemia. (Level of Evidence: B)
In patients with UA/NSTEMI and diabetes mellitus, it is
reasonable to administer aggressive insulin therapy to achieve
a glucose less than 150 mg per dL during the first 3 hospital
(intensive care unit) days and between 80 and 110 mg per dL
thereafter whenever possible. (Level of Evidence: B)
Please see Section 4 for further explanation of revascular-
ation strategies.
.2.1. Profile and Initial Management of Diabetic and
yperglycemic Patients With UA/NSTEMI
oronary artery disease accounts for 75% of all deaths in
tients with diabetes mellitus (50,51), and approximately
% to 25% of all patients with UA/NSTEMI have diabetes
10,734,775–778). Patients with UA/NSTEMI and diabetes
ve more severe CAD (776,779,780), and diabetes is an
portant independent predictor for adverse outcomes (death,
I, or readmission with UA at 1 year; RR 4.9) (781–784). In
dition, many patients with diabetes who present with
A/NSTEMI have already undergone CABG (785).
Patients with diabetes tend to have more extensive non-
ronary vascular comorbidities, hypertension, LV hypertro-
y, cardiomyopathy, and HF. In addition, autonomic dys-
nction, which occurs in approximately one third of patients
ith diabetes, influences heart rate and blood pressure, raises
e threshold for the perception of angina, and may be
companied by LV dysfunction (786–788). On coronary
giography, patients with diabetes and UA have a greater
oportion of ulcerated plaques (94% vs. 60%, p  0.01) and
tracoronary thrombi (94% vs. 55%, p  0.004) than
tients without diabetes (789). These findings suggest a
gher risk of plaque instability.
According to American Diabetes Association standards of
re (790), the relationship of controlled blood glucose levels
d reduced mortality in the setting of MI has been demon-
rated. The American College of Endocrinology has also
phasized the importance of careful control of blood glu-
se targets in the range of 110 mg per dL preprandially to a
aximum of 180 mg per dL. In 1 study (791), admission
ood glucose values were analyzed in consecutive patients
ith MI. Analysis revealed an independent association of
mission blood glucose and mortality. The 1-year mortality
te was significantly lower in subjects with admission
asma glucose less than 101 mg per dL (5.6 mmol per liter)
an in those with plasma glucose 200 mg per dL (11 mmol
r liter). In the first Diabetes and Insulin-Glucose Infusion in
cute Myocardial Infarction (DIGAMI) study (792,793)
sulin-glucose infusion followed by subcutaneous insulin aneatment in diabetic patients with MI was examined. Mean
ood glucose in the intensive insulin intervention arm was
2.8 mg per dL (9.5 mmol per liter) compared with 211 mg
r dL (11.6 mmol per liter) in the “conventional” group.
verall, the intensive approach reduced long-term relative
ortality (at 3.4 years of follow-up) by 25% in the insulin-
eated group. The broad range of blood glucose levels within
ch arm limits the ability to define specific blood glucose
rget thresholds.
In the second DIGAMI study (794), 3 treatment strategies
ere compared in a randomized trial among 1,253 patients
ith type 2 diabetes mellitus and suspected MI: acute
sulin-glucose infusion followed by insulin-based long-term
ucose control, insulin-glucose infusion followed by stan-
rd glucose control, and routine metabolic management
cording to local practice. Blood glucose was reduced more
24 h in those receiving insulin-glucose infusions, but
ng-term glucose control, assessed by HbA1C, did not differ
tween the groups, and the fasting glucose in group 1 (8.0
mol per liter) did not reach target (5 to 7 mmol per liter).
he primary end point of all-cause mortality between groups
and 2 did not differ significantly (23.4% vs. 22.6%) at a
edian of 2.1 years of follow-up. Morbidity also did not
ffer among the 3 groups. Although the DIGAMI-2 regimen
acutely introduced, long-term insulin treatment in the
tting of suspected acute MI was not demonstrated to
crementally reduce morbidity and mortality, epidemiologi-
l analyses still support a strong, independent relationship
tween glucose levels and long-term mortality in patients
ith ischemic heart disease (794).
Attainment of targeted glucose control in the setting of
rdiac surgery is associated with reduced mortality and risk
deep sternal wound infections in cardiac surgery patients
ith diabetes (795,796). This supports the concept that
rioperative hyperglycemia is an independent predictor of
fection in patients with diabetes mellitus, with the lowest
ortality in patients with blood glucose less than or equal to
0 mg per dL (8.3 mmol per liter) (797).
A mixed group of patients with and without diabetes
mitted to a surgical intensive care unit (ICU) were random-
ed to receive intensive insulin therapy (target blood glucose
to 110 mg per dL [4.4 to 6.1 mmol per liter]). Achieve-
ent of a mean blood glucose of 103 mg per dL (5.7 mmol
r liter) reduced mortality during the ICU stay and decreased
erall in-hospital mortality (798). Subsequent analysis dem-
strated that for each 20-mg per dL (1.1-mmol per liter)
ucose elevation above 100 mg per dL (5.5 mmol per liter),
e risk of death during the ICU stay increased. Hospital and
U survival were linearly associated with ICU glucose
vels, with the highest survival rates occurring in patients
hieving an average blood glucose less than or equal to 110
g per dL (6.1 mmol per liter).
Although beta blockers can mask the symptoms of hypo-
ycemia or lead to it by blunting the hyperglycemic re-
onse, they nevertheless should be used with appropriate
ution in patients with diabetes mellitus and UA/NSTEMI.
iuretics that cause hypokalemia can inhibit insulin release
d thereby worsen glucose intolerance.
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367Elevated blood glucose among critically ill patients even in
e absence of clinical diabetes mellitus has received recent
tention as an important risk factor for mortality (799). A
ndomized trial in the surgical ICU setting (800) found that
rict glycemic control with insulin reduced both morbidity
d in-hospital mortality (800). More recently, the role of
tensive insulin therapy in the medical ICU setting has been
udied (801) in 1,200 medical ICU patients (some with
VD) randomized to conventional therapy (insulin adminis-
red when glucose exceeded 215 mg per dL, tapering
fusion when glucose fell below 180 mg per dl) or to
tensive insulin therapy (targeting a glucose of 80 to 110 mg
r dl). Overall, intensive insulin did not significantly reduce
-hospital mortality, the primary end point (37.3% in the
tensive therapy arm, 40% in the conventional arm, p 
33), but secondary outcomes of acquired kidney injury,
me to ventilator weaning, and ICU and hospital discharge
ays were reduced. Hypoglycemia was more common but
ten consisted of a single, asymptomatic episode. However,
hen analysis was restricted to the intended population of
7 patients whose ICU stay was at least 3 d, in-hospital
ath was reduced from 52.5% to 43% (p  0.009) and ICU
ath from 38.1% to 31.3% (p  0.005). In addition,
condary outcomes of time to ventilator weaning, days to
U discharge and to hospital discharge, acquired kidney
jury, hyperbilirubinemia, and CRP levels were reduced.
ending results of additional randomized clinical trials (802),
reasonable approach is to apply a less aggressive glucose
ntrol strategy during the first 3 ICU days (e.g., goal of less
an 150 mg per dL) in very ill patients (e.g., with ventilators
on parenteral feeding) (803). Thereafter, and in less ill
tients, a more intensive insulin regimen could be instituted,
ith a goal of normoglycemia (80 to 110 mg per dL).
.2.2. Coronary Revascularization
pproximately 20% of all patients who undergo CABG (804)
d PCI (746,747,750,751,779,780) have diabetes mellitus.
ata regarding outcomes are complex. In the Coronary
rtery Surgery Study (CASS) of CABG, patients with
abetes had a 57% higher mortality rate than patients without
abetes. A striking advantage for CABG over PCI was found
treated patients with diabetes in the BARI trial (776), a
ndomized trial of PCI versus CABG in 1,829 stable patients
ith multivessel disease, of whom 19% were patients with
abetes (see Section 4). As in other studies, patients with
abetes mellitus had increased comorbidity rates. Five years
ter randomization, patients who required treatment for
abetes had a lower survival rate than patients without
abetes (73.1% vs. 91.3%, p less than 0.0001), whereas
rvival rates in patients without and with diabetes who did
t require hypoglycemic treatment were similar (93.3% vs.
.1%, p NS). Outcomes for CABG in treated patients with
abetes were far better than those for PCI (80.6% vs. 65.5%
rvival, p  0.0003). An interesting finding was that the
ortality rate during the 5.4 years of the study in patients
ith diabetes who received SVGs (18.2%) was similar to that
patients who underwent PCI (20.6%); whereas the mortal-
y rate in patients who received internal mammary arteries
as much lower (2.9%). Results of the Emory Angioplasty Ersus Surgery Trial (EAST) at 8 years showed a similar
end but were less conclusive (805). The increased mortality
te noted in randomized trials in patients with diabetes
eated with PTCA has been confirmed in a registry study
om Emory University (613). Uncorrected, there was little
fference in long-term mortality rates. The CABG patients
d more severe disease, and with correction for baseline
fferences, there was an improved survival rate in insulin-
quiring patients with multivessel disease who were revas-
larized with CABG rather than with PCI. That the more
verely diseased patients, in a nonrandomized registry, were
lectively sent more often for CABG than for PCI probably
presents good clinical decision making.
A 9-year follow-up of the NHLBI registry showed a
milar disturbing pattern for patients with diabetes undergo-
g PCI (779). Immediate angiographic success and com-
eteness of revascularization were similar, but compared
ith patients without diabetes, patients with diabetes (who,
ain, had more severe CAD and comorbidities) had in-
eased rates of hospital mortality (3.2% vs. 0.5%), nonfatal
I (7.0% vs. 4.1%), death and MI (10.0% vs. 4.5%), and the
mbined end point of death, MI, and CABG (11% vs. 6.7%;
less than 0.01 for all). At 9 years, rates of mortality (35.9%
. 17.9%), MI (29% vs. 18.5%), repeat PCI (43.0% vs.
.5%), and CABG (37.6% vs. 27.4%) were all higher in
tients with diabetes than in those without (779).
However, as discussed in Section 4, other data point to a
sser differential effect of PCI in patients with diabetes. For
ample, data from the BARI registry varied from those of
e BARI trial. In the registry, there was no significant
fference in cardiac survival for patients with diabetes
dergoing PCI (92.5%) and CABG (94%; p  NS)
15,806). In the Duke University registry, patients with
abetes and PCI or CABG were matched with the BARI
pulation (807). The outcome in patients with diabetes was
orse than that without diabetes with either CABG or PCI,
t there was no differential effect by therapy. The 5-year
rvival rate for PCI and CABG adjusted for baseline
aracteristics was 86% and 89% in patients with diabetes
d 92% and 93% without diabetes, respectively (807).
Stents could improve the outcome of patients with diabetes
ho undergo PCI. In a study with historical controls, the
tcome after coronary stenting was superior to that after
TCA in patients with diabetes, and the restenosis rate after
enting was reduced (63% vs. 36%, diabetes vs. no diabetes
ith balloon PTCA at 6 months, p  0.0002, compared with
% and 27% with stents, p  NS) (805). On the other hand,
tients with diabetes who underwent atherectomy had a
bstantial restenosis rate (60% over 6 months) (808). Using
ta derived from the Northern New England registries, a
ntemporary BARI-like comparison of long-term survival
ter PCI (64% with at least 1 stent) versus CABG found
gnificantly better risk-adjusted long-term survival in CABG
tients with 3-vessel disease (HR  0.60, p less than 0.01)
09). Similar benefits of CABG over PCI were demonstrated
r patients with diabetes.
Three trials have shown that abciximab considerably im-
oved the outcome of PCI in patients with diabetes. In the
PILOG trial, abciximab resulted in a greater decline in
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R 0.36, 95% CI 0.21 to 0.61) than in those without diabetes
R 0.60, 95% CI 0.44 to 0.83) (810). Similar results have
en reported for tirofiban in the PRISM-PLUS trial
33,811). EPISTENT was a randomized trial that compared
ent plus placebo with stent plus abciximab and balloon plus
ciximab in 2,399 patients, of whom 20.5% had diabetes and
.3% had UA (512). The 30-d event rate (death, MI, and
gent revascularization) in patients with diabetes declined
om 12.1% (stent plus placebo) to 5.6% (stent plus abcix-
ab; p  0.040). At 6 months, the drug reduced revascular-
ation of target arteries in patients with diabetes (16.6% vs.
1%, p 0.02). Death or MI was reduced to a similar degree
patients with diabetes as that in patients without diabetes
12). These benefits were maintained at 1 year (813). Thus,
the 6-month data, initial GP IIb/IIIa therapy, as well as
enting, considerably improved the safety of PCI in patients
ith diabetes. In a comparative trial of abciximab and
rofiban (TARGET), both agents were associated with com-
rable event rates, including similar rates of 6-month target-
ssel revascularization and 1-year mortality (814).
.2.3. Conclusions
iabetes occurs in approximately one fifth of patients with
A/NSTEMI and is an independent predictor of adverse
tcomes. It is associated with more extensive CAD, unstable
sions, frequent comorbidities, and less favorable long-term
tcomes with coronary revascularization, especially with
TCA. It is unclear whether these differences are due to more
equent restenosis and/or severe progression of the underly-
g disease (779). The use of stents, particularly with abcix-
ab, appears to provide more favorable results in patients
ith diabetes, although more data are needed, including with
ES. Coronary artery bypass grafting, especially with 1 or
th internal mammary arteries, leads to more complete
vascularization and a decreased need for reintervention than
CI, even when bare-metal stents are used in diabetic patients
ith multivessel disease. Given the diffuse nature of diabetic
ronary disease, the relative benefits of CABG over PCI
ay well persist for diabetic patients, even in the era of DES.
.3. Post-CABG Patients
ecommendations
ASS I
Medical treatment for UA/NSTEMI patients after CABG should
follow the same guidelines as for non–post-CABG patients with
UA/NSTEMI. (Level of Evidence: C)
Because of the many anatomic possibilities that might be
responsible for recurrent ischemia, there should be a low
threshold for angiography in post-CABG patients with UA/
NSTEMI. (Level of Evidence: C)
ASS IIa
Repeat CABG is reasonable for UA/NSTEMI patients with
multiple SVG stenoses, especially when there is significant
stenosis of a graft that supplies the LAD. Percutaneous
coronary intervention is reasonable for focal saphenous vein
stenosis. (Level of Evidence: C) (Note that an intervention on ma native vessel is generally preferable to that on a vein graft
that supplies the same territory, if possible.)
Stress testing with imaging in UA/NSTEMI post-CABG pa-
tients is reasonable. (Level of Evidence: C)
Overall, up to 20% of patients presenting with UA/
STEMI have previously undergone CABG (785). Con-
rsely, approximately 20% of post-CABG patients develop
A/NSTEMI during an interval of 7.5 years (815), with a
ghly variable postoperative time of occurrence (816). Post-
ABG patients who present with UA/NSTEMI are at higher
sk, with more extensive CAD and LV dysfunction than
ose patients who have not previously undergone surgery.
.3.1. Pathological Findings
athologically, intimal hyperplasia or atherosclerosis may
velop in SVGs, and there is a particular tendency for
rombotic lesions to develop in these vessels (in 72% of
afts resected in 1 study) (817–820). In addition, post-
ABG patients may develop atherosclerosis in their native
ssels, and this can lead to UA/NSTEMI (820,821). How-
er, obstructive lesions are more likely to occur in SVGs
3% within 5 years, 76% at 5 to 10 years, and 92% at greater
an 10 years) (822), and there is a high rate of early graft
ilure in current practice (occlusion in up to one third at 1
ar). Spasm in grafts or native vessels (823,824) and
chnical complications may also play a role in the develop-
ent of UA/NSTEMI during the early postoperative period
15,825). Both angioscopic and angiographic findings indi-
te that SVG disease is a serious and unstable process.
ngioscopically, friable plaques occur uniquely in SVGs
4% vs. 0% in native coronary arteries), whereas rough and
hite plaques occur in both SVGs and native coronary
teries (826). Angiographically, the SVGs more frequently
ve complex lesions (i.e., overhanging edges, irregular
rders, ulcerations, or thrombosis), thrombi (37% vs. 12%,
 0.04), and total occlusions (49% vs. 24%, p  0.02)
22).
.3.2. Clinical Findings and Approach
ompared with UA/NSTEMI patients without prior CABG,
st-CABG patients are more often male (presumably be-
use more men than women have undergone CABG), older,
d more likely to have diabetes. They have more extensive
tive-vessel CAD and more previous MIs and LV dysfunc-
on. Symptomatically, these patients have more prolonged
est pain than ACS patients without prior CABG. More than
% of post-CABG patients have resting ECG abnormalities,
d ECG stress tests are therefore less conclusive (827);
wever, a test that becomes positive after having been
gative is helpful in the diagnosis of ischemia. Myocardial
ress perfusion imaging and dobutamine echocardiography
e often helpful diagnostically (828). Furthermore, a positive
aging test can help to define the area of ischemia in
st-CABG patients with complex disease.
The outcomes of UA/NSTEMI in post-CABG patients are
ss favorable than those in patients who have not undergone
ABG. There is a high rate of embolization of atherosclerotic
aterial from friable grafts at the time of intervention, which
akes these procedures more difficult and which is associated
wca
po
ev
w
w
co
un
al
pa
po
th
w
ve
in
N
st
ca
pe
A
gr
cu
6
P
hi
di
in
gr
w
te
iz
C
6
R
CL
1.
2.
3.
4.
5.
ri
bu
co
th
no
ha
ol
pa
w
ag
w
pe
w
ra
yo
C
st
up
li
as
sy
tr
th
yo
Ta
Le
45
55
65
75
85
de
of ronary E
e320 Anderson et al. JACC Vol. 57, No. 19, 2011
ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367ith higher rates of complications (829). In one matched
se-control study of UA, the initial course was similar, but
st-CABG patients had twice the incidence of adverse
ents (death, MI, or recurrent UA) during the first year. This
as attributed to a lower rate of complete revascularization,
hich was possible in only 9 of 42 post-CABG patients
mpared with 39 of 52 patients who had not previously
dergone CABG (p  0.001) (815). Results were direction-
ly similar in the TIMI III registry of ACS, in which 16% of
tients were post-CABG. Here again, early outcomes in
st-CABG patients and others were equivalent, but at 1 year,
e rate of adverse events (death, MI, or recurrent ischemia)
as 39.3% for those who had previously undergone CABG
rsus 30.2% for those who had not (p  0.002) (830).
Revascularization with either PCI or reoperation often is
dicated and is possible in post-CABG patients with UA/
STEMI. In a randomized controlled trial that compared
ents with PTCA of obstructed SVGs, there was no statisti-
lly significant difference in restenosis during a 6-month
riod, although a trend favored stents (34% vs. 46%) (831).
lthough hemorrhagic complications were higher in the stent
oup, clinical outcomes (freedom from MI or repeat revas-
larization) were better (73% vs. 58%, p  0.03) (831).
.3.3. Conclusions
ost-CABG patients, especially those with only SVGs, are at
gh risk of UA/NSTEMI. There is a higher likelihood of
sease in SVGs than in native arteries, and this difference
creases with postoperative time. Pathologically and angio-
aphically, disease in SVGs has characteristics associated
ith instability. There also are difficulties with treadmill ECG
sting and less favorable outcomes with repeat revascular-
ation than in patients who have not undergone previous
ABG.
.4. Older Adults
ecommendations
ASS I
Older patients with UA/NSTEMI should be evaluated for appro-
priate acute and long-term therapeutic interventions in a
similar manner as younger patients with UA/NSTEMI. (Level of
Evidence: A)
Decisions on management of older patients with UA/NSTEMI
should not be based solely on chronologic age but should be
ble 25. Impact of Age on Outcomes of Acute Coronary Syndro
Age Group
No. of Deaths
(Hospital Mortality Rate)*
ss than 45 y 20 (1.3)
to 54 y 79 (2.0)
to 64 y 171 (3.1)
to 74 y 373 (5.5)
to 84 y 439 (9.3)
y or more 260 (18.4)
*All p less than 0.0001. The GRACE risk model includes systolic blood pressur
viation, and cardiac arrest at hospital arrival. Modified with permission from A
acute coronary syndrome: observations from the Global Registry of Acute Copatient-centered, with consideration given to general health, anfunctional and cognitive status, comorbidities, life expectancy,
and patient preferences and goals. (Level of Evidence: B)
Attention should be given to appropriate dosing (i.e., adjusted
by weight and estimated creatinine clearance) of pharmaco-
logical agents in older patients with UA/NSTEMI, because
they often have altered pharmacokinetics (due to reduced
muscle mass, renal and/or hepatic dysfunction, and reduced
volume of distribution) and pharmacodynamics (increased
risks of hypotension and bleeding). (Level of Evidence: B)
Older UA/NSTEMI patients face increased early procedural
risks with revascularization relative to younger patients, yet
the overall benefits from invasive strategies are equal to or
perhaps greater in older adults and are recommended. (Level of
Evidence: B)
Consideration should be given to patient and family prefer-
ences, quality-of-life issues, end-of-life preferences, and socio-
cultural differences in older patients with UA/NSTEMI. (Level
of Evidence: C)
Older adults represent a group of patients in whom baseline
sk is higher (Table 25) and who have more comorbidities
t who derive equivalent or greater benefit (e.g., invasive vs.
nservative strategy) compared to younger patients. Al-
ough a precise definition of “older patients” or “elderly” has
t been established in the medical literature, many studies
ve used this term to refer to those who are 75 years and
der. On the basis of a large national ACS registry, older
tients make up a substantial portion of those presenting
ith UA/NSTEMI, with 35% older than 75 years and 11%
ed more than 85 years (832). Older persons also present
ith a number of special and complex challenges. First, older
rsons who develop UA/NSTEMI are more likely to present
ith atypical symptoms, including dyspnea and confusion,
ther than with the chest pain typically experienced by
unger patients with acute myocardial ischemia (833).
onversely, noncardiac comorbidities such as chronic ob-
ructive lung disease, gastroesophageal reflux disease,
per-body musculoskeletal symptoms, pulmonary embo-
sm, and pneumonia also are more frequent and may be
sociated with chest pain at rest that can mimic classic
mptoms of UA/NSTEMI. Hence, successful recognition of
ue myocardial ischemia in the elderly is often more difficult
an in younger patients. Second, they are more likely than
unger patients to have altered or abnormal cardiovascular
ACE Risk Model
Crude OR (95% CI) Adjusted OR (95% CI)
Reference Reference
1.47 (0.90 to 2.41) 1.95 (1.06 to 3.61)
2.35 (1.47 to 3.74) 2.77 (1.53 to 4.99)
4.34 (2.76 to 6.83) 4.95 (2.78 to 8.79)
7.54 (4.80 to 11.8) 8.04 (4.53 to 14.3)
16.7 (10.5 to 26.4) 15.7 (8.77 to 28.3)
serum creatinine, heart rate, initial cardiac enzyme, Killip class, ST-segment
, Makdisse M, Spencer F, et al. Impact of age on management and outcome
vents (GRACE). Am Heart J 2005;149:67–73 (835).me: GR
e, initial
vezum Aatomy and physiology, including a diminished beta-
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creased arterial compliance and arterial hypertension, or-
ostatic hypotension, cardiac hypertrophy, and ventricular
sfunction, especially diastolic dysfunction (834). Third,
der patients typically have developed significant cardiac
morbidities and risk factors, such as hypertension, prior
I, HF, cardiac conduction abnormalities, prior CABG,
ripheral and cerebrovascular disease, diabetes mellitus,
nal insufficiency, and stroke. Fourth, because of this larger
rden of comorbid disease, older patients tend to be treated
ith a greater number of medications and are at higher risk
r drug interactions and polypharmacy. Hence, among an
ready high-risk population, older age is associated with
gher disease severity and higher disease and treatment risk
presentation (832).
.4.1. Pharmacological Management
verall, although the elderly have been generally underrep-
sented in randomized controlled trials, when examined,
der subgroups appear to have relatively similar relative risk
ductions and similar or greater absolute risk reductions in
any end points as younger patients for commonly used
eatments in the management of UA/NSTEMI. In spite of an
creasing number of possible relative contraindications as-
ciated with older age, the rates of serious adverse events for
ost older patients generally remain low when evidence-
sed treatment for UA/NSTEMI is provided. Despite gen-
ally similar benefits, recent studies such as CRUSADE
32), TACTICS-TIMI 18 (182), and GRACE (835) have
cumented significantly lower use of evidence-based thera-
es in the elderly, including less use of an aggressive, early
vasive strategy and of key pharmacotherapies, including
ticoagulants, beta blockers, clopidogrel, and GP IIb/IIIa
hibitors.
With this said, precautions need to be taken to personalize
ese therapies (i.e., beginning with lower doses than in
unger patients, whenever appropriate, and providing care-
l observation for toxicity). Older persons are particularly
lnerable to adverse events from cardiovascular drugs due to
tered drug metabolism and distribution, as well as to
aggerated drug effects. Reductions in cardiac output and in
nal and hepatic perfusion and function decrease the rate of
imination of drugs in the elderly. Additionally, older pa-
ents typically have lower drug distribution volumes (due to
lower body mass). As a result, drugs need to be carefully
lected and individually adjusted. Current evidence demon-
rates that older adults are frequently excessively dosed. In a
mmunity-based registry, among treated patients aged 75
ars or older, 38% received an excessive dose of UFH, 17%
ceived excessive LMWH, and 65% received an excessive
se of a GP IIb/IIIa antagonist (832). A subsequent study
om the same registry found that 15% of major bleeding in
A/NSTEMI patients could be attributed to excessive dosing
43). Mortality and length of stay also were higher in
tients receiving excessive dosing.
In the elderly, drugs such as beta blockers that undergo
rst-pass hepatic metabolism exhibit increased bioavailability
36). Exaggerated pharmacodynamic responses to drugs
ten resulted from lower cardiac output, plasma volume, and risomotor tone, as well as blunted baroreceptor and beta-
renergic responses.
.4.2. Functional Studies
lder persons can have difficulty performing standardized
ercise tolerance tests because of age-related medical prob-
ms, such as general deconditioning, decreased lung capac-
y, chronic pain, sensory neuropathy, osteoarthritis, and
uscle weakness. Furthermore, the higher prevalence of
eexisting resting ECG abnormalities (782), arrhythmias
40,837), and cardiac hypertrophy often make the interpre-
tion of a standard stress ECG inconclusive or impossible. In
ch patients, alternative methods for evoking evidence of
ute myocardial ischemia, such as pharmacological stress
sting with dynamic cardiac imaging, may be substituted
ee also Section 3.4).
.4.3. Percutaneous Coronary Intervention in
lder Patients
ecent evidence from several major interventional trials has
monstrated a clear benefit for older patients. A collabora-
ve meta-analysis of several more recently published PCI
ials (FRISC-II, TACTICS, RITA-3, VINO, and MATE)
ve suggested that the majority of the benefit from an
vasive strategy in the elderly has accrued from contempo-
ry strategies used in trials published after 1999 and in
tients with positive troponins or their cardiac biomarkers
43). These trials indicated that compared with younger
tients, the elderly gain important absolute benefits from an
rly invasive strategy but at a cost of increased bleeding.
pecifically, a significant benefit was seen in reduction of the
mbined end point of death and recurrent MI, but only a
end to reduction in death was noted. A recent observational
alysis in a community population failed to show an early
nefit on in-hospital survival with an invasive strategy in the
der subgroup (75 years or older), which highlights the need
r continued caution in applying trial results uniformly in
der patients (837a). Thus, selection of older patients for an
rly invasive strategy is complex, including risk from
sease and risk from intervention, but given the absolute
nefits observed in these trials, age should not preclude
nsideration.
Despite these potential benefits, older patients are also far
ss likely to undergo angiography (RR 0.65, p less than
001 at 6 weeks) and coronary revascularization (RR 0.79,
 0.002 at 6 weeks) after a UA/NSTEMI episode than
unger patients. This apparent underuse of potentially ben-
cial interventions might be due in part to practitioner
ncerns about the increased risk of complications. Finding
e appropriate balance between benefit and risk of aggres-
ve therapies to maximize net clinical outcome remains a
allenge in the elderly.
.4.4. Contemporary Revascularization Strategies in
lder Patients
everal studies of PCI in patients aged 65 to 75 years have
own that success rates with experienced medical profes-
onals are similar to those in younger patients, but with even
der patients, success rates decline and complication rates
se. On the other hand, a Mayo Clinic review of PCI in
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vealed an overall success rate of 93.5%, an immediate
-hospital mortality rate of 1.4%, and a need for emergency
ABG rate of only 0.7% (838). Angiographic outcome
anged little between the 65-to-69-year-old group and the
eater than 75-year-old group, and the 1-year event rate
eath, MI, CABG, repeat PCI, or severe angina) was 45.1%
all patients greater than 65 years old (838). Predictors of
tcomes (i.e., extent and severity of CAD and comorbidi-
es) after PCI in older patients were the same as those in
unger patients (839). Similarly, a review of coronary
enting in the elderly reported that procedural success rates
ere high (95% to 98%) and periprocedural complication
tes were low (MI 1.2% to 2.8%, urgent CABG 0.9% to
8%, repeat PCI 0% to 0.6%) in the elderly, with little
fference between those greater than 75 years old and those
ss than 65 years old (840). Subgroup analyses in both TIMI
IB (129) and FRISC-II (245) showed a greater advantage of
e invasive strategy in patients older than 65 years of age.
ore contemporary studies have confirmed this advantage,
cluding TACTICS-TIMI 18 (841). Among patients older
an 75 years of age, the early invasive strategy conferred an
solute reduction of 10.8 percentage points (to 10.8% from
.6%; p  0.016) and a relative reduction of 56% in death
MI at 6 months; however, benefits came with an increased
sk of major bleeding events (16.6% vs. 6.5%; p  0.009).
A review of 15,679 CABG procedures performed in
tients greater than 70 years old from the Toronto Hospital
42) reported encouraging results. Operative mortality rates
clined from 7.2% in 1982 to 1986, to 4.4% in 1987 to 1991
nd from 17.2% to 9.1% for high-risk patients) but showed
ttle further change in the period of 1992 to 1996. Predictors
operative death (LV dysfunction, previous CABG, periph-
al vascular disease, and diabetes) were similar to those in
unger patients.
Operative morbidity and mortality rates increase for
ABG with advanced age, but outcomes have been favorable
mpared with medical therapy, and quality of life improves
43–847). A recent retrospective review of 662,033 patients
ho underwent cardiac surgical procedures performed using
e STS National Cardiac Database (848) found a CABG
erative mortality of 2.8% for patients 50 to 79 years of age,
1% for patients 80 to 89 years of age, and 11.8% for
tients aged 90 years or more. This study included more than
000 patients over 90 years of age and 5 centenarians and
cumented that the 57% of nonagenarians without certain
sk factors (renal failure, IABP, emergency surgery, or
ripheral or cerebrovascular disease) constituted a relatively
w-risk group with an operative mortality of only 7.2%,
milar to the overall risk in octogenarians. Thus, with
propriate selection, CABG surgery can be an appropriate
vascularization strategy in even the oldest patient sub-
oups.
.4.5. Conclusions
lder patients with UA/NSTEMI tend to have atypical
esentations of disease, substantial comorbidity, ECG stress
sts that are more difficult to interpret, and different physio-
gical responses to pharmacological agents compared with beunger patients. Although they are at highest risk, guideline-
commended therapies are used less frequently. Even though
eir outcomes with interventions and surgery are not as
vorable as those of younger patients, coronary revascular-
ation should be recommended when the same group of
ognostic risk factors that play a role in the younger age
oup are taken into account. The approach to these patients
so must consider general medical and cognitive status,
eeding risk and other risk of interventions, anticipated life
pectancy, and patient or family preferences.
.5. Chronic Kidney Disease (UPDATED)
or new or updated text, view the 2011 Focused Update.
ext supporting unchanged recommendations has not been
pdated.
ecommendations
ASS I
Creatinine clearance should be estimated in UA/NSTEMI pa-
tients, and the doses of renally cleared drugs should be
adjusted appropriately. (Level of Evidence: B)
In chronic kidney disease patients undergoing angiography,
isosmolar contrast agents are indicated and are preferred.
(Level of Evidence: A)
Chronic kidney disease (CKD) is not only a coronary risk
uivalent for ascertainment of coronary risk but also a risk
ctor for the development and progression of CVD (744).
hronic kidney disease constitutes a risk factor for adverse
tcomes after MI (849), including NSTEMI and other
ronary patient subsets. In the highly validated GRACE risk
ore, serum creatinine is 1 of the 8 independent predictors of
ath (168,835). In recent study, even early CKD constituted
significant risk factor for cardiovascular events and death
49,850). Chronic kidney disease also predicts an increase in
current cardiovascular events (851). Cardiovascular death is
to 30 times higher in dialysis patients than in the general
pulation. The underrepresentation of patients with renal
sease in randomized controlled trials of CVD is of concern
79). Most of the limited evidence available and current
inion suggest that when appropriately monitored, cardio-
scular medications and interventional strategies can be
plied safely in those with renal impairment and provide
erapeutic benefit (849). However, not all recent evidence is
nsistent with this premise: atorvastatin did not significantly
duce the primary end point of cardiovascular death, nonfa-
l MI, or stroke in a prospective randomized trial of patients
ith diabetes and end-stage CKD who were undergoing
modialysis (234). The preference for primary PCI has also
en questioned (235).
Particularly in the setting of ACS, bleeding complications
e higher in this patient subgroup because of platelet
sfunction and dosing errors; benefits of fibrinolytic therapy,
tiplatelet agents, and anticoagulants can be negated or
tweighed by bleeding complications; and renin-
giotensin-aldosterone inhibitors can impose a greater risk
cause of the complications of hyperkalemia and worsening
nal function in the CKD patient. Angiography carries an
creased risk of contrast-induced nephropathy; the usual
nefits of percutaneous interventions can be lessened or
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline Revisionolished; and PCI in patients with CKD is associated with a
gher rate of early and late complications of bleeding,
stenosis, and death (179). Thus, the identification of CKD is
portant in that it represents an ACS subgroup with a far
ore adverse prognosis but for whom interventions have less
rtain benefit.
Coronary arteriography is a frequent component of the care
ACS patients. As such, contrast-induced nephropathy can
nstitute a serious complication of diagnostic and interven-
onal procedures. In patients with CKD or CKD and diabe-
s, isosmolar contrast material lessens the rise in creatinine
d is associated with lower rates of contrast-induced ne-
ropathy than low-osmolar contrast media. This has been
cumented in a randomized clinical trial (RECOVER [Renal
oxicity Evaluation and Comparison Between Visipaque
odixanol) and Hexabrix (Ioxaglate) in Patients With Renal
sufficiency Undergoing Coronary Angiography]) compar-
g iodixanol with ioxaglate (852) and in a meta-analysis of
727 patients from 16 randomized clinical trials (853).
entification of CKD patients as recommended in the AHA
ience advisory on detection of chronic kidney disease in
tients with or at increased risk of cardiovascular disease
ould guide the use of isosmolar contrast agents (744).
To increase awareness of CKD, an AHA science advisory
r the detection of CKD in patients with or at increased risk
r CVD recently was developed in collaboration with the
ational Kidney Foundation (744).The advisory recommen-
tions are that all patients with CVD be screened for
idence of kidney disease by estimating glomerular filtration
te, testing for microalbuminuria, and measuring the
bumin-to-creatinine ratio (Class IIa, Level of Evidence: C).
glomerular filtration rate less than 60 ml per min per 1.73
uare meters of body surface should be regarded as abnor-
al (Class I, Level of Evidence: B). Furthermore, the
bumin-to-creatinine ratio should be used to screen for the
esence of kidney damage in adult patients with CVD, with
lues greater than 30 mg of albumin per 1 g of creatinine
garded as abnormal (Class IIa, Level of Evidence: B).
A diagnosis of renal dysfunction is critical to proper
edical therapy of UA/NSTEMI. Many cardiovascular drugs
ed in UA/NSTEMI patients are renally cleared; their doses
ould be adjusted for estimated creatinine clearance (see
so Section 3). In a large community-based registry study,
% of patients with UA/NSTEMI received excessive initial
sing of at least 1 antiplatelet or antithrombin agent (UFH,
MWH, or GP IIb/IIIa inhibitor) (743). Renal insufficiency
as an independent predictor of excessive dosing. Dosing
rors predicted an increased risk of major bleeding. Clinical
udies and labeling that defines adjustments for several of
ese drugs have been based on the Cockroft-Gault formula
r estimating creatinine clearance, which is not identical to
e MDRD formula. Use of the Cockroft-Gault formula to
nerate dose adjustments is recommended. The impact of
nal dysfunction on biomarkers of necrosis (i.e., troponin) is
scussed in Section 2.2.8.2.1.
To increase the meager evidence base and to optimize care
r this growing high-risk population, the recognition of CKD
tients with or at risk of CVD and the inclusion and blporting of renal disease in large CVD trials must be
creased in the future.
.6. Cocaine and Methamphetamine Users
ecommendations
ASS I
Administration of sublingual or intravenous NTG and intrave-
nous or oral calcium channel blockers is recommended for
patients with ST-segment elevation or depression that accom-
panies ischemic chest discomfort after cocaine use. (Level of
Evidence: C)
Immediate coronary angiography, if possible, should be per-
formed in patients with ischemic chest discomfort after co-
caine use whose ST segments remain elevated after NTG and
calcium channel blockers; PCI is recommended if occlusive
thrombus is detected. (Level of Evidence: C)
Fibrinolytic therapy is useful in patients with ischemic chest
discomfort after cocaine use if ST segments remain elevated
despite NTG and calcium channel blockers, if there are no
contraindications, and if coronary angiography is not possible.
(Level of Evidence: C)
ASS IIa
Administration of NTG or oral calcium channel blockers can be
beneficial for patients with normal ECGs or minimal ST-
segment deviation suggestive of ischemia after cocaine use.
(Level of Evidence: C)
Coronary angiography, if available, is probably recommended
for patients with ischemic chest discomfort after cocaine use
with ST-segment depression or isolated T-wave changes not
known to be previously present and who are unresponsive to
NTG and calcium channel blockers. (Level of Evidence: C)
Management of UA/NSTEMI patients with methamphetamine
use similar to that of patients with cocaine use is reasonable.
(Level of Evidence: C)
ASS IIb
dministration of combined alpha- and beta-blocking agents (e.g.,
betalol) may be reasonable for patients after cocaine use with
pertension (systolic blood pressure greater than 150 mm Hg) or
ose with sinus tachycardia (pulse greater than 100 beats per
in) provided that the patient has received a vasodilator, such as
TG or a calcium channel blocker, within close temporal proximity
.e., within the previous hour). (Level of Evidence: C)
ASS III
oronary angiography is not recommended in patients with chest
in after cocaine use without ST-segment or T-wave changes and
ith a negative stress test and cardiac biomarkers. (Level of
idence: C)
The use of cocaine can produce myocardial ischemia,
ereby leading to UA/NSTEMI (854–857). The widespread
e of cocaine makes it mandatory to consider this cause,
cause its recognition mandates special management. Spe-
fically, initial management recommendations for cocaine-
duced ACS include NTG and calcium channel antagonists.
ssessment for resolution of chest discomfort and ECG
anges is then undertaken before fibrinolytic therapy is
itiated or angiography is considered. The use of beta
ockers in close proximity (i.e., within 4 to 6 h) of cocaine
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ACCF/AHA UA/NSTEMI Guideline Revision May 10, 2011:e215–367posure is controversial, with some evidence for harm; thus,
hen used, the guidelines recommend combination alpha and
ta blockade in addition to a vasodilator. There are no data
guide recommendations for beta blockade later after
posure, after cocaine elimination.
The action of cocaine is to block presynaptic reuptake of
urotransmitters such as norepinephrine and dopamine,
hich produces excess concentrations at the postsynaptic
ceptors that lead to sympathetic activation and the stimu-
tion of dopaminergic neurons (858). There may also be a
rect contractile effect on vascular smooth muscle (855).
etoxification is accomplished with plasma and liver cholin-
terases, which form metabolic products that are excreted in
e urine. Infants, elderly patients, and patients with hepatic
sfunction lack sufficient plasma cholinesterase to metabo-
ze the drug (859) and therefore are at high risk of adverse
fects with cocaine use.
.6.1. Coronary Artery Spasm With Cocaine Use
he basis for coronary spasm has been demonstrated in both
vitro (859) and in vivo (855,860–864) experiments in
imals and humans. Reversible vasoconstriction of rabbit
rtic rings has been demonstrated with cocaine in concen-
ations of 103 to 108 mol per liter. Pretreatment with
lcium channel blockers markedly inhibits cocaine-induced
soconstriction. Coronary injection of cocaine produces
soconstriction in miniswine with experimentally induced
nocclusive atherosclerotic lesions (865).
Nademanee et al. (866) performed 24-h ECG monitoring in
male cocaine users after admission to a substance abuse
eatment center and found that 8 had frequent episodes of
T-segment elevation, most during the first 2 weeks of
ithdrawal. In cocaine users with prolonged myocardial
chemia, coronary arteriography can reveal coronary artery
asm with otherwise normal-appearing coronary arteries or
ith underlying minimally obstructive coronary atheroscle-
sis (855,857,860). The cocaine-induced increase in coro-
ry vascular resistance is reversed with calcium channel
ockers (861,867). Cocaine increases the response of plate-
ts to arachidonic acid, thus increasing thromboxane A2
oduction and platelet aggregation (868). In addition, revers-
le combined reduction in protein C and antithrombin III has
en observed in patients with cocaine-related arterial throm-
sis (869). All of these effects favor coronary thrombosis
55,862,870). Coronary thrombosis can also develop as a
nsequence of coronary spasm.
Cocaine users can develop ischemic chest discomfort that
indistinguishable from the UA/NSTEMI secondary to
ronary atherosclerosis. The patient who presents with
olonged myocardial ischemia should be questioned about
e use of cocaine. In a study by Hollander et al. (871), the
esence or absence of cocaine use was assessed in only 13%
patients who presented to the ED with chest pain. Table 26
sts the clinical characteristics of a typical patient with
caine-related chest pain or MI (857).
Most patients who present to the ED with cocaine-
sociated chest pain do not develop MI (872). MI develop-
ent has been reported to occur only in 6% of such patients
57). chAccelerated coronary atherosclerosis has been reported in
ronic users of cocaine (873,874); coronary artery spasm is
ore readily precipitated at sites of atherosclerotic plaques
60). Cocaine causes sinus tachycardia, as well as an
crease in blood pressure and myocardial contractility,
ereby increasing myocardial oxygen demand (861). These
creases can precipitate myocardial ischemia and UA/
STEMI in both the presence and absence of obstructive
ronary atherosclerosis and coronary spasm.
Aortic dissection (875) and coronary artery dissection
55,875) have been reported as consequences of cocaine use.
ther reported cardiac complications are myocarditis(874)
d cardiomyopathy (876,877).
.6.2. Treatment
hen a patient with or suspected of cocaine use is seen in the
D with chest pain compatible with myocardial ischemia and
T-segment elevation, sublingual NTG or a calcium channel
ockers (e.g., diltiazem 20 mg IV) should be administered
55,864). If there is no response, immediate coronary
giography should be performed, if possible. Fibrinolytic
erapy has been successfully employed in patients with MI
ter cocaine use, although these patients frequently have
ntraindications to fibrinolysis, including hypertension, sei-
res, or aortic dissection. Thus, PCI may be a preferred
ethod of revascularization in this setting. However, even
is therapeutic strategy is problematic in subjects with
caine-related MI; those in whom stents are deployed are at
bstantial risk of subsequent in-stent thrombosis unless
uble-antiplatelet therapy (ASA and clopidogrel) is ingested
gularly and predictably for several months afterward, and
ose who partake in substance abuse often are unreliable in
hering to such a regimen. Thus, bare-metal stents, which
quire a shorter duration of dual-antiplatelet therapy, gener-
ly are preferred to DES in cocaine abusers. If thrombus is
esent and PCI is unavailable or ineffective, fibrinolytic
ents may be administered if there are no contraindications
78,879). If catheterization is not available, intravenous
brinolytic therapy may be considered in patients with
T-segment elevation and clinical symptoms consistent with
I.
If the ECG is normal or shows only minimal T-wave
ble 26. Clinical Characteristics in the Typical Patient With
caine-Related Chest Pain, Unstable Angina, or Myocardial
farction
ung age, usually less than 40 years
ale gender
igarette smoker, but no other risk factors for atherosclerosis
hronic or first-time cocaine user
ymptom onset minutes or even several hours after cocaine use
ssociated with all routes of administration
ay occur with small or large doses
ften associated with concomitant use of cigarettes and/or alcohol
Reprinted from Progressive Cardiovascular Disease, Pitts WF, Lange RA,
garroa JE, Hillis LD. Cocaine-induced myocardial ischemia and infarction:
thophysiology, recognition, and management, 40:65–76. Copyright 1997,
ith permission from Elsevier (857).anges and there is a history of chest pain compatible with
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al NTG or an oral calcium channel blocker and be
served. After cocaine use, increased motor activity, skeletal
uscle injury, and rhabdomyolysis can occur, causing CK
d even CK-MB elevation in the absence of MI (880).
roponin I and TnT are more specific for myocardial injury
d therefore are preferred. Blood should be drawn twice for
rum markers of myocardial necrosis at 6-h intervals. If the
CG shows ST-segment changes and the cardiac biochemical
arkers are normal, the patient should be observed in the
spital in a monitored bed for 24 h; most complications will
cur within 24 h (881). If the patient’s clinical condition is
changed and the ECG remains unchanged after 24 h, the
tient can be discharged (879). A shorter observation period
9 to 12 h, with measurement of troponin levels at 3, 6, and
h after presentation, also has been validated (882).
Many observers believe that beta blockers are contraindi-
ted in cocaine-induced coronary spasm because there is
idence from a single double-blind, randomized, placebo-
ntrolled trial that beta-adrenergic blockade augments
caine-induced coronary artery vasoconstriction (883). Oth-
s believe that if the patient has a high sympathetic state with
nus tachycardia and hypertension, beta blockers should be
ed (855). Labetalol, an alpha and beta blocker, has been
vocated, because it has been shown not to induce coronary
tery vasoconstriction (884) even though its beta-
renergic–blocking action predominates over its alpha-
renergic–blocking activity in the doses that are commonly
ed (884). Therefore, in cocaine-induced myocardial isch-
ia and vasoconstriction, NTG and calcium channel block-
s are the preferred drugs. Both NTG and verapamil have
en shown to reverse cocaine-induced hypertension, coro-
ry arterial vasoconstriction (864,883), and tachycardia
erapamil).
.6.3. Methamphetamine Use and UA/NSTEMI
iven the rapid increase in methamphetamine abuse, recognition
its cardiovascular risk is of mounting importance. Currently,
e evidence base for UA/NSTEMI after methamphetamine and
treatment is limited to a few publications of case reports and
all series (885–888). These suggest that ACS is increasingly
mmon in patients evaluated in the ED for chest discomfort
ter methamphetamine use and that the frequency of other
tentially life-threatening arrhythmias is not negligible (886).
linical presentation resembles that of cocaine-associated ACS.
n the basis of the similarities in pathophysiology and these few
inical observations, therapy similar to that of cocaine-induced
A/NSTEMI is recommended pending information more spe-
fic to methamphetamine.
.7. Variant (Prinzmetal’s) Angina
ecommendations
ASS I
Diagnostic investigation is indicated in patients with a clinical
picture suggestive of coronary spasm, with investigation for
the presence of transient myocardial ischemia and ST-segment
elevation during chest pain. (Level of Evidence: A) wCoronary angiography is recommended in patients with epi-
sodic chest pain accompanied by transient ST-segment eleva-
tion. (Level of Evidence: B)
Treatment with nitrates and calcium channel blockers is
recommended in patients with variant angina whose coronary
angiogram shows no or nonobstructive coronary artery lesions.
Risk factor modification is recommended, with patients with
atherosclerotic lesions considered to be at higher risk. (Level
of Evidence: B)
ASS IIb
Percutaneous coronary intervention may be considered in
patients with chest pain and transient ST-segment elevation and
a significant coronary artery stenosis. (Level of Evidence: B)
Provocative testing may be considered in patients with no
significant angiographic CAD and no documentation of tran-
sient ST-segment elevation when clinically relevant symptoms
possibly explained by coronary artery spasm are present.
(Level of Evidence: C)
ASS III
ovocative testing is not recommended in patients with variant
gina and high-grade obstructive stenosis on coronary angiogra-
y. (Level of Evidence: B)
Variant angina (Prinzmetal’s angina, periodic angina) is a
rm of UA that usually occurs spontaneously and is charac-
rized by transient ST-segment elevation that spontaneously
solves or resolves with NTG use without progression to MI
89). The earliest stages of MI can also be associated with
clic ST-segment elevations, but MI does not possess the
ture of periodic angina. The spasm is most commonly focal
d can occur simultaneously at more than 1 site (890). Even
ronary segments that are apparently normal on coronary
giography often have evidence of mural atherosclerosis on
travascular ultrasound (891). This can result in localized
dothelial dysfunction and coronary spasm.
Patients with Prinzmetal’s angina frequently have coronary
tery plaques that can be either nonobstructive or obstructive
92). Walling et al. (893) reported that coronary arteriogra-
y showed 1-vessel disease in 81 (39%) of 217 patients and
ultivessel disease in 40 (19%). Rovai et al. (894) found a
milar high prevalence of obstructive disease in 162 patients
ith variant angina.
.7.1. Clinical Picture
lthough chest discomfort in the patient with variant angina
n be precipitated by exercise, it usually occurs without any
eceding increase in myocardial oxygen demand; the major-
y of patients have normal exercise tolerance, and stress
sting may be negative. Because the anginal discomfort
ually occurs at rest without a precipitating cause, it may
mulate UA/NSTEMI secondary to coronary atherosclerosis.
pisodes of Prinzmetal’s angina often occur in clusters, with
olonged asymptomatic periods of weeks to months. Attacks
n be precipitated by an emotional stress, hyperventilation
95), exercise (896), or exposure to cold (897). A circadian
riation in the episodes of angina is most often present, with
ost attacks occurring in the early morning (898). Compared
ith patients with chronic stable angina, patients with variant
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ronary risk factors (899,900). Some studies have shown an
sociation of variant angina with other vasospastic disorders,
ch as migraine headache and Raynaud’s phenomenon
01). The presence of syncope during an episode of chest
in suggests severe ischemia related to an acute occlusion,
ten due to focal spasm.
Most often, the attacks of angina resolve spontaneously
ithout evidence of MI. However, a prolonged vasospasm
ay result in complications such as MI, a high degree of AV
ock, life-threatening ventricular tachycardia, or sudden
ath (902,903).
.7.2. Pathogenesis
he pathogenesis of focal coronary spasm in this condition is
t well understood. The probable underlying defect is the
esence of dysfunctional endothelium that exposes the me-
al smooth muscle to vasoconstrictors such as cat-
holamines, thromboxane A2, serotonin, histamine, and
dothelin (904). Endothelial dysfunction also can impair
ronary flow-dependent vasodilatation owing to the de-
eased production and release of nitric oxide (905) and
hanced phosphorylation of myosin light chains, an impor-
nt step in smooth muscle contraction (906). There can be an
balance between endothelium-produced vasodilator factors
.e., prostacyclin, nitric oxide) and vasoconstrictor factors
.e., endothelin, angiotensin II) that favors the latter (907).
here also is evidence of involvement of the autonomic
rvous system, with reduced parasympathetic tone and
hanced reactivity of the alpha-adrenergic vascular recep-
rs (905,908,909). Regardless of the mechanism, the risk for
cal spasm is transient but recurrent.
.7.3. Diagnosis
he key to the diagnosis of variant angina is the documen-
tion of ST-segment elevation in a patient during transient
est discomfort (which usually occurs at rest, typically in the
rly morning hours, and nonreproducibly during exercise)
d that resolves when the chest discomfort abates. Typically,
TG is exquisitely effective in relieving the spasm. ST-
gment elevation implies transmural focal ischemia associ-
ed with complete or near-complete coronary occlusion of an
icardial coronary artery in the absence of collateral circu-
tion. In variant angina, the dynamic obstruction can be
perimposed on severe or nonsevere coronary stenosis or
pervene in an angiographically normal coronary artery
gment. Hence, coronary angiography is usually part of the
orkup of these patients and can help orient treatment.
It is noteworthy that spasm often develops spontaneously
ring angiography, which aids the diagnosis in patients with
previously documented ST-segment elevation; catheter-
duced spasm is not, however, an indicator of vasospastic
sease. Diagnostic tests for Prinzmetal’s angina are based on
e recording of transient ST-segment elevation during an
isode of chest pain. Continuous 12-lead ECG monitoring
n be performed for this purpose in-hospital or as an
tpatient; recording during numerous episodes of pain im-
oves diagnostic sensitivity. A treadmill exercise test is also
eful; one third of patients will show ST-segment elevation,
other third ST-segment depression, and one third no veT-segment change. Interestingly, the results may not be
producible within the same patients and are more often
sitive when the test is performed in the early morning
urs. A 2-dimensional echocardiogram or the injection of a
clear marker at the time of chest pain may help document
e presence of transmural ischemia. A number of other
ovocative tests can be used to precipitate coronary artery
asm when the diagnosis is suspected but not objectively
cumented. Nitrates and calcium channel blockers should be
ithdrawn well before provocative testing. These tests are
ore often used during coronary angiography; the spasm can
en be visualized before the appearance of chest pain and
omptly relieved by the intracoronary injection of NTG. The
st can also be performed in a coronary care unit setting
hile the patient is monitored for ST-segment elevation, but
is is recommended only if the coronary anatomy is known.
uch nonpharmacological tests include the cold pressor test
d hyperventilation performed for 6 min in the morning,
one or after exercise (910). Pharmacological tests in general
ovide a better diagnostic yield. Ergonovine, methylergon-
ine, and ergometrin have been most widely studied and
ed in the past, but methylergonovine and ergometrin are no
nger generally available, and the use of ergonovine is
mited. Acetylcholine and methacholine are now predomi-
ntly used for this diagnostic purpose. Although the spasm is
ually promptly relieved with NTG administered intracoro-
rily or intravenously, it may at times be refractory to
erapy with NTG and other vasodilators and may be recur-
nt in the same segment or in other coronary artery seg-
ents, resulting in prolonged ischemia, MI, or occasionally,
ath (911). For these reasons, provocative tests are now
rely used and are limited to a few indications, such as
tients with suggestive symptoms that could be helped by an
propriate diagnosis not otherwise reached, patients in
hom treatment with nitrates and calcium channel blockers
s failed, and patients with a life-threatening disease in
hom the physician wants to verify the efficacy of the
eatment. Thus, patients with a positive hyperventilation test
e more likely to have a higher frequency of attacks,
ultivessel spasm, or high degree of AV block or ventricular
chycardia than are patients with a negative hyperventilation
st (910), and high-risk patients whose tests become negative
ith treatment are more likely to have a favorable long-term
urse. The investigation of coronary spasm in patients with
ronary artery lesions of borderline significance can be com-
emented by other diagnostic procedures such as intravascular
trasound, functional flow reverse, and other functional testing
assess more accurately the significance of the obstruction.
.7.4. Treatment
oronary spasm is usually very responsive to NTG, long-
ting nitrates, and calcium channel blockers (912–914),
hich are considered first-line therapies. (Beta-blockers have
eoretical adverse potential, and their clinical effect is
ntroversial.) Smoking should be discontinued. Usually, a
lcium channel blocker in a moderate to high dose (e.g.,
rapamil 240 to 480 mg per d, diltiazem 180 to 360 mg per
or nifedipine 60 to 120 mg per d) is started; patients with
ry active disease can require a combination of nitrates and
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hydropyridine with verapamil or diltiazem). Alpha-receptor
ockers have been reported to be of benefit, especially in
tients who are not responding completely to calcium
annel blockers and nitrates (906). In patients who develop
ronary spasm (with or without provocation) during coro-
ry angiography, 0.3 mg of NTG should be infused directly
to the coronary artery that is involved.
.7.5. Prognosis
he prognosis of variant angina is usually excellent in
tients with variant angina who receive medical therapy,
pecially in patients with normal or near-normal coronary
teries. Yasue et al. (915) reported an 89% to 97% overall
year survival rate. In a 7-year follow-up in approximately
0 patients, the incidence of sudden death was 3.6% and the
cidence of MI was 6.5% (915). Patients with coronary
tery vasospasm superimposed on a fixed obstructive CAD
ve a worse prognosis. In a study of 162 patients with
riant angina by Rovai et al. (894), patients with normal
ronary arteries and single-vessel disease had a 5-year
rvival rate of 95% compared with a rate of 80% for those
ith multivessel disease. Almost identical survival rates were
ported in an earlier study by Walling et al. (893). Occa-
onal patients may require instrumentation with a pacemaker
prevent transient AV block associated with ischemia or
ith a defibrillator to prevent sudden death associated with
chemia-induced ventricular fibrillation. Treatment can at
mes be very frustrating in the occasional patient refractory
standard medication. Cardiac denervation has been used in
ese patients with marginal benefit.
.8. Cardiovascular “Syndrome X”
ecommendations
ASS I
Medical therapy with nitrates, beta blockers, and calcium
channel blockers, alone or in combination, is recommended in
patients with cardiovascular syndrome X. (Level of Evidence: B)
Risk factor reduction is recommended in patients with cardio-
vascular syndrome X. (Level of Evidence: B)
ASS IIb
Intracoronary ultrasound to assess the extent of atherosclero-
sis and rule out missed obstructive lesions may be considered
in patients with syndrome X. (Level of Evidence: B)
If no ECGs during chest pain are available and coronary spasm
cannot be ruled out, coronary angiography and provocative
testing with acetylcholine, adenosine, or methacholine and
24-h ambulatory ECG may be considered. (Level of Evidence: C)
If coronary angiography is performed and does not reveal a
cause of chest discomfort, and if syndrome X is suspected,
invasive physiological assessment (i.e., coronary flow reserve
measurement) may be considered. (Level of Evidence: C)
Imipramine or aminophylline may be considered in patients
with syndrome X for continued pain despite implementation of
Class I measures. (Level of Evidence: C)
Transcutaneous electrical nerve stimulation and spinal cord
stimulation for continued pain despite the implementation of drClass I measures may be considered for patients with syn-
drome X. (Level of Evidence: B)
ASS III
edical therapy with nitrates, beta blockers, and calcium channel
ockers for patients with noncardiac chest pain is not recom-
ended. (Level of Evidence: C)
.8.1. Definition and Clinical Picture
ardiovascular “syndrome X” refers to patients with angina
angina-like discomfort with exercise, ST-segment depres-
on on exercise testing, and normal or nonobstructed coro-
ry arteries on arteriography (916). This entity should be
fferentiated from the metabolic syndrome X (metabolic
ndrome), which describes patients with insulin resistance,
perinsulinemia, dyslipidemia, hypertension, and abdominal
esity. It also should be differentiated from noncardiac chest
in. Syndrome X is more common in women than in men
79,916–918). Chest pain can vary from that of typical
gina pectoris to chest pain with atypical features to chest
in that simulates UA secondary to CAD (917). Other
ypical features can be prolonged chest pain at rest and chest
in that is unresponsive to NTG (919). Most often, the chest
in occurs with activity and simulates angina pectoris due to
able CAD. However, because chest pain can accelerate in
equency or intensity or may occur at rest, the patient can
esent with the clinical picture of UA. Therefore, this
ndrome is discussed in this guideline.
The cause of the discomfort and ST-segment depression in
tients with syndrome X is not well understood. The most
equently proposed causes are impaired endothelium-
pendent arterial vasodilatation with decreased nitric oxide
roduction, impaired microvascular dilation (non–
dothelium-dependent), increased sensitivity to sympathetic
imulation, or coronary vasoconstriction in response to
ercise (731,920,921). Increased levels of plasma endothelin
rrelate with impaired coronary microvascular dilation
22). There is increasing evidence that these patients fre-
ently also have an increased responsiveness to pain and an
normality in pain perception.
The diagnosis of syndrome X is suggested by the triad of
ginal-type chest discomfort, objective evidence of isch-
ia, and absence of obstructive CAD. The diagnosis can be
nfirmed by provocative coronary angiographic testing with
etylcholine for coronary endothelium-dependent function
d adenosine for non–endothelium-dependent microvascu-
r function. Other causes of angina-like chest discomfort not
sociated with cardiac disease, such as esophageal dysmo-
lity, fibromyalgia, and costochondritis, must also be elimi-
ted. In addition, in patients with a clinical presentation
nsistent with variant angina, coronary spasm must be ruled
t by the absence of ST-segment elevation with the anginal
scomfort or by provocative testing. Myocardial perfusion
anning may be abnormal owing to a patchy abnormal
sponse to exercise of the microvasculature that can lead to
duced coronary flow to different regions of the myocardium
31). Magnetic resonance imaging studies also may suggest
yocardial ischemia (923,924).
The intermediate-term prognosis of patients with syn-
ome X has been reported to be excellent in older studies
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rvival rate in patients with anginal-type chest pain, normal
ronary arteriograms, and an LVEF greater than 0.50 (926).
owever, testing for ischemia was not performed in CASS.
ore recent data from WISE indicate that the prognosis in
ndrome X, validated by ischemia testing, is not entirely
nign with respect to risk of cardiac death and nonfatal MI
18,919). The WISE data demonstrate that the prognosis is
lated to the extent of angiographic disease across the range
20% stenosis to obstructive lesions (918). Long-term
llow-up shows that ventricular function usually remains
rmal (919), although there have been reports of progressive
V dysfunction, and many patients continue to have chest
in that requires medication (927).
Additional data from WISE (733,767–774) suggest ad-
rse outcomes in some women with myocardial ischemia on
ninvasive testing and nonobstructive CAD. A number of
riables may be contributory. Intramural lesions, evidence
an atherosclerotic burden, are evident on intravascular
trasound. A decrease in coronary flow reserve appears to
dependently predict major coronary events. In addition,
ere is important coronary endothelial dysfunction that may
related to hormonal influences, inflammatory markers, or
idative stress and possibly to a clustering of risk factors as
seen in the metabolic syndrome. Other microvascular
sfunction may be present. Although half of the WISE
omen with myocardial ischemia documented on noninva-
ve testing had no flow-limiting coronary obstructive disease
angiography, not only were there persisting symptoms, but
ere was a subsequent significant occurrence of coronary
ents. Evaluation of the 4-year risk-adjusted freedom from
ath or MI showed that women with no or minimal obstruc-
ve disease had a total rate of occurrence of these end points
9.4% by 4 years. Pending additional data, aggressive
ronary risk factor reduction appears to be appropriate.
.8.2. Treatment
ersistence of symptoms is common, and many patients do
t return to work (919). The demonstration of normal
ronary arteries on angiography can be reassuring. In 1
udy, after a normal coronary arteriogram, there was a
duced need for hospitalization and a reduction in the
mber of hospital days for cardiac reasons (566). However,
en minimal atherosclerotic disease on angiography war-
nts risk factor modification.
Both beta blockers and calcium channel blockers have
en found to be effective in reducing the number of episodes
chest discomfort (928,929). Beneficial effects with nitrates
e seen in approximately one half of patients (930). The use
alpha-adrenergic blockers would appear to be a rational
erapy, but the results of small trials are inconsistent (931).
ipramine 50 mg daily has been successful in some chronic
in syndromes, including syndrome X, reducing the fre-
ency of chest pain by 50% (932). Transcutaneous electrical
rve stimulation and spinal cord stimulation can offer good
in control (933,934). Estrogen in postmenopausal women
ith angina and normal coronary arteriograms has been
own to reverse the acetylcholine-induced coronary arterial
soconstriction, presumably by improving endothelium- Upendent coronary vasomotion (935), and to reduce the
equency of chest pain episodes by 50% (936). However,
cause of increased cardiovascular and other risks docu-
ented in randomized controlled trials of primary and sec-
dary coronary prevention, hormone therapy is not recom-
ended for chronic conditions (29). Statin therapy and
ercise training have improved exercise capacity, endothe-
al function, and symptoms (937,938).
It is recommended that patients be reassured of the
cellent intermediate-term prognosis and treated with long-
ting nitrates. If the patient continues to have episodes of
est pain, a calcium channel blocker or beta blocker can be
arted (929). Finally, 50 mg of imipramine daily has been
ccessful in reducing the frequency of chest pain episodes
32). Cognitive behavioral therapy can be beneficial (939).
symptoms persist, other causes of chest pain, especially
ophageal dysmotility, should be ruled out.
.9. Takotsubo Cardiomyopathy
disorder, or group of disorders, with several names (stress-
duced cardiomyopathy, transient LV apical ballooning,
akotsubo cardiomyopathy, and broken heart syndrome) is an
common but increasingly reported cause of ACS. Takot-
bo cardiomyopathy is noteworthy for the absence of ob-
ructive coronary artery disease, typical precipitation by
tense psychological or emotional stress, and predominant
currence in postmenopausal women. The characteristic
nding of apical LV ballooning is seen on left ventriculog-
phy or echocardiography, with transient ST elevation or
ep T-wave inversions on the surface ECG. Despite the
esence of positive cardiac biomarkers and frequent hemo-
namic compromise or even cardiogenic shock, almost all
tients recover completely, typically with normal wall mo-
on within 1 to 4 weeks (730,940,941).
. Conclusions and Future Directions
he last quarter century has witnessed enormous strides in the
derstanding of ACS pathophysiology and its management.
hese have included the critical role of coronary thrombosis
42), the novel concept and suggestion of a therapeutic
nefit of reperfusion therapy (943–946), and finally, the
monstration of mortality reductions with fibrinolysis in
rge, multicenter trials (531a). However, these trials also
covered the paradox that fibrinolysis did not benefit or even
rmed NSTEMI patients (531a). This central management
chotomy, together with other differences between STEMI
d UA/NSTEMI (13), has been reflected since 2000 in
parate practice guidelines. Despite these differences, more
mains in common than distinct, including the discovery that
herothrombosis is an active, inflammatory process
47,948). Further inquiry has led to the concept of the
lnerable plaque and the vulnerable patient (949,950).
Whereas the incidence and risk of STEMI have decreased
er the past 25 years, the relative frequency of UA/NSTEMI
s increased, and its risk has remained relatively high (now
mparable to that of STEMI) (951). Hence, improving
A/NSTEMI outcomes remains a challenge for the future.
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May 10, 2011:e215–367 ACCF/AHA UA/NSTEMI Guideline RevisionA contemporary multinational observational study has
phasized the benefits of applying evidence-based guide-
nes in clinical practice (951a). Between 1999 and 2006,
,558 patients with UA/NSTEMI in 14 countries were
rolled and followed for 6 months after discharge. Increases
er the 7 years of enrollment were observed in the use of
terventional therapy and of major pharmacological thera-
es, including beta blockers, statins, ACE inhibitors (or
RBs), low molecular weight heparin, GP IIb/IIa inhibitors,
d thienopyridines. These changes were accompanied by
arked declines (by one half) in in-hospital rates of heart
ilure or cardiogenic shock and recurrent MI and in 6-month
tes of death (from 4.9% to 3.3%) and stroke (1.4% to 0.7%).
proved outcomes occurred despite an increase in patient
sk profile. The future should emphasize further improve-
ents in evidence-based guideline applications.
Improving prehospital and ED assessment should aim at
ore efficient entry into the health care system (e.g., limiting
lays for NTG-refractory angina before calling 9-1-1),
agnosis and risk stratification (e.g., using marker changes
hile they are still in the normal range; in the future, with the
d of nontraditional biomarkers), and initiation of therapy.
he future will see the increasing use of new imaging tests to
sess the chest pain patient. By simultaneously assessing
rdiac function, perfusion, and viability, CMR can yield a
gh sensitivity and specificity for diagnosis of CAD/ACS
96). Multislice cardiac computed tomography, which com-
nes coronary calcium scoring with noninvasive coronary
giography (current resolution 0.5mm), has undergone fa-
rable initial evaluation for assessment of the low- to
termediate-risk chest pain patient (297). The current status
d appropriate application of CMR and cardiac CT are
dressed in recent ACC/AHA documents (25,294).
The concept of a network of “heart attack centers” has been
oposed as a way to improve MI care in the future (952–
4). These heart attack centers would be organized and
rtified to provide the highest levels of care and would be
ographically readily accessible to virtually all patients.
For high-risk patients, the concept of establishing and
aintaining normal levels of myocardial perfusion mechan-
ally continues to gain support, with evidence favoring
tervention at even shorter (e.g., less than 6 to 24 h) rather
an longer (i.e., greater than 48 to 96 h) intervals (540). The
ture should bring additional important information on this
sue.
In contrast, for low-risk patients, evidence is growing that
initially noninvasive approach may be preferred (e.g., PCI
ows benefit in high-risk women, as in men, but carries
verse risk potential in low-risk women) (532,565). This
pendence of therapeutic benefit on disease risk has also
en shown for antiplatelet and anticoagulant therapies.
ence, there is an increasing need to optimally stratify risk;
me progress has been made (e.g., with the use of biomark-
s integrated into an overall clinical risk score; see Section
2), but further development of risk assessment algorithms
ill be welcome in the future.
Platelets play a critical role UA/NSTEMI, and antiplatelet
erapy continues to undergo testing. Higher (e.g., 600 mg or
ore of clopidogrel) and earlier loading doses of oral Lienopyridine have been tested since the previous guidelines
ere published (see Section 3.2), with evidence of earlier
tiplatelet activity. However, an incremental benefit of
iple-antiplatelet therapy (ASA, GP IIb/IIIa inhibitor, and
opidogrel) over double therapy with clopidogrel plus ASA
ithout GP IIb/IIIa inhibition) was recently shown for PCI
the setting of UA/NSTEMI (244).
Late thrombosis of DES (400,402,403,955), associated
ith delayed endothelialization (399,399a), recently has
erged as a therapeutic issue (401). Thus, longer periods
dual-antiplatelet therapy (i.e., at least 1 year) increas-
gly are advocated (see Section 3.2). Missing is an
dividualized approach to antiplatelet management: the
ture should bring efficient, validated platelet function
sting to allow titration of the type, intensity, and duration
antiplatelet therapy. More choices in antiplatelet therapy
n be expected, including intravenously administered and
pidly acting ADP receptor antagonists and more potent
d/or more readily reversible oral agents. Biocompatible
ents can also be expected looking forward, including
odegradable stents.
Triple-anticoagulant therapy (e.g., ASA, a thienopyridine,
d warfarin) increasingly has a potential indication (e.g.,
CI plus atrial fibrillation, cardiac or vascular thrombosis, or
echanical heart valve). Its current Class IIb recommenda-
on (to be used “with caution” (1,2); Fig. 11) is in need of a
rmer evidence base (1,2).
Anticoagulant choices have proliferated since the last
idelines were published. Although LMWH (e.g., enoxa-
rin) gained recognition as an alternative or preferred
ticoagulant in the previous guidelines, subsequent study
the setting of an early PCI strategy has suggested that
ther UFH or LWMH is acceptable (423). Meanwhile,
ents from 2 new classes have been tested favorably (see
ection 3.2) (424,425). Fondaparinux, a synthetic factor
a inhibitor, was noninferior to enoxaparin at 9 d, with a
wer bleeding risk. However, catheter-related thrombosis
ith fondaparinux raises concerns about its use with PCI,
concern amplified by its failure with PCI in STEMI
33). In contrast, fondaparinux is an appealing choice
ith a noninvasive approach to UA/NSTEMI, especially in
ose at higher risk of bleeding.
The ACUITY study, which tested bivalirudin for UA/
STEMI, has led to a guidelines change to allow bivalirudin
an anticoagulant option (425). Bivalirudin was found to be
ninferior to UFH/LMWH when given with a GP IIb/IIIa
hibitor. When given without a GP inhibitor, bleeding rates
ere lower but ischemic risk was higher unless clopidogrel
erapy had been given before the procedure. Bivalirudin use
as not tested with a conservative strategy. These guidelines
esent several options for anticoagulant/antiplatelet regi-
ens, but whether there are clear preferences must await
ditional analysis and an enriched evidence base and could
ry depending on the health care setting, the preferred
eatment strategy (e.g., invasive vs. conservative), and indi-
dual patient factors.
This guideline revision recognizes ongoing develop-
ents in prevention (see Section 5.1.1). More aggressive
DL-C lowering (i.e., to the optimal LDL-C goal of less
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though an incremental mortality benefit remains to be
own (956). An additional tool for smoking cessation has
peared (varenicline), and others are in testing (see
ection 5.2). High compliance with recommended second-
y prevention measures has been shown to improve
tcomes, but optimal compliance is still lacking, includ-
g at hospitals peer-rated as top tier (957). The evidence
se for therapeutic lifestyle change continues to grow; the
allenge for the future is more successful implementation
ee Section 5.2).
Primary prevention remains a major challenge. Risk is
rrently assessed by traditional factors (e.g., Framingham
sk score) and the intensity of treatment by risk score-
termined goals. The majority of coronary events occur in a
rge segment of the population whose risk is intermediate
either very low nor very high). Routine individual screen-
g for asymptomatic disease is widely accepted for common
ncers (e.g., colon and breast cancer) but not for atheroscle-
sis. Application of an “atherosclerosis test” (e.g., coronary
tery calcium scoring or carotid intima-media thickness
sessment) to middle-aged adults at intermediate risk has
en proposed (25,294,949,950). The future will determine
w broadly extended primary screening will be accepted to
entify the “ACS-vulnerable” patient.
Progress in UA/NSTEMI remains uneven, with rapid
olution in some areas but slow progress in others. Our hope
that guidelines increasingly become based on levels of
idence A (or B). Writing these guidelines has highlighted
e many holes in the fabric of the current evidence base.
cademia, regulatory agencies, practicing physicians, profes-
onal organizations, and patient advocacy groups, as well as
dustry, must cooperate to achieve the universal goal of a
lly evidence-based management strategy for UA/NSTEMI
the future. Strategies must include not only innovations inagnosis and treatment but also fresh approaches to motivat-
g lifestyle changes, leading to improved diet, weight con-
ol, physical activity, and tobacco avoidance, as well as to
tter compliance with evidence-based medical therapies
80).
.1. Recommendations for Quality of Care
nd Outcomes for Acute Coronary Syndromes
EW SECTION)
or new or updated text, view the 2011 Focused Update.
ext supporting unchanged recommendations has not been
pdated.
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FP American Academy of Family Physicians
C American College of Cardiology
CF American College of Cardiology Foundation
E angiotensin converting enzyme
EP American College of Emergency Physicians
P American College of Physicians
S acute coronary syndrome
T activated clotting time
UITY Acute Catheterization and Urgent Intervention Triage strategy
A American Heart Association
I acute myocardial infarction
TT activated partial thromboplastin time
TS Arterial Revascularization Therapy Study
A aspirin
T, SGOT aspartate aminotransferase
atrioventricular
RI Bypass Angioplasty Revascularization Investigation
P B-type natriuretic peptide
BG coronary artery bypass graft
BRI Coronary Angioplasty versus Bypass Revascularization Investigation
D coronary artery disease
PTURE c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina trial
SS Coronary Artery Surgery Study
B calcium channel blocker
TA coronary computed tomographic angiogram
D coronary heart disease
confidence interval
D chronic kidney disease
-MB creatine kinase-myocardial band
R cardiac magnetic resonance
MMIT CIOpidogrel and Metoprolol in Myocardial Infarction Trial
X cyclooxygenase
R cardiopulmonary resuscitation
EDO Clopidogrel for the Reduction of Events During Observation trial
P C-reactive protein
computed tomography
n cardiac troponin
RE Clopidogrel in Unstable Angina to Prevent Recurrent Events trial
D cardiovascular disease
day
VIT Danish Study Group on Verapamil in Myocardial Infarction
S drug-eluting stent
GAMI Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction
G electrocardiogram
emergency department
S emergency medical services
IC Evaluation of c7E3 for the Prevention of Ischemic Complications
ILOG Evaluation of PTCA and Improve Long-term Outcome by c7E3 GP IIb/IIIa receptor blockade
ISTENT Evaluation of Platelet IIb/IIIa Inhibitor for STENTing
ACI-II Estudio Randomizado Argentino de Angioplastia vs. Clrugia-II
C European Society of Cardiology
SENCE Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q Wave Myocaridal Infarction trial
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IC FRagmin In ustable Coronary artery disease
ISC Fast Revascularization During Instability in Coronary Artery Disease
ISC-II Fast Revascularization During Instability in Coronary Artery Disease-II
SSI Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto-1 1 trial
SSI-3 Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico
glycoprotein
ACE Global Registry of Acute Coronary Events
STO Global Utilization of Streptokinase and t-PA for Occluded Arteries
STO-II Global Use of Strategies to Open Occluded Coronary Arteries II
hour
hemoglobin
L-C high-density lipoprotein cholesterol
heart failure
PE Heart Outcomes Prevention Evaluation Study
hazard ratio
BP intra-aortic balloon pump
TUS Invasive versus Conservative Treatment in Unstable coronary Syndromes
U intensive care unit
T interpersonal psychotherapy
R international normalized ratio
AR-REACT Intracoronary stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment
IS-2 Second International Study of Infarct Survival
IS-4 Fourth International Study of Infarct Survival
international unit
intravenous
C 7 Seventh Joint National Committee on High Blood Pressure
kilogram
D left anterior descending coronary artery
L-C low-density lipoprotein choloesterol
WH low-molecular-weight heparin
left ventricular
EF left ventricular ejection fraction
ASS II Multicenter Anti Atherosclerotic Study II
ATE Medicine versus Angiography in Thrombolytic Exclusion
DPIT Multicenter Diltiazem Postinfarction Trial
DRD Modification of Diet and Renal Disease
ETS metabolic equivalents
I myocardial infarction
VO2 myocardial oxygen demand
EP National Cholesterol Education Program
LBI National Heart, Lung, and Blood Institute
nonsignificant
TEMI non-ST-segment elevation myocardial infarction
G nitroglycerin
-proBNP N-terminal B-type natriuretic peptide
SIS Organization to Assess Strategies for Ischemic Syndromes
odds ratio
I percutaneous coronary intervention
A personal digital assistant
ISM Platelet Receptor Inhibition in Ischemic Syndrome Management
ISM-PLUS Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms
CA percutaneous transluminal coronary angioplasty
RSUIT Platelet Glycoprotein IIb/IIIa in Unstable 16 Angina: Receptor Suppression Using Integrilin Therapy
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ACT Rapid Early Action for Coronary Treatment
PLACE-2 Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events
TA Research Group in Instability in Coronary Artery Disease trial
risk ratio
O2 arterial oxygen saturation
subcutaneous
AI Society for Cardiovascular Angiography and Interventions
OCK SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK study
S Stent or Surgery
EMI ST-elevation myocardial infarction
S Society of Thoracic Surgeons
G saphenous vein graft
NERGY Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors trial
CTICS-TIMI 18 Treat Angina with Aggrastat and determine Cost of therapy with Invasive or Conservative Strategy (TACTICS) TIMI-18 trial
RGET Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial
MI Thrombolysis In Myocardial Infarction
I troponin I
T troponin T
units
unstable angina
/NSTEMI unstable angina/non-ST-elevatioin myocardial infarction
H unfractionated heparin
NQWISH Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital
NO Value of first day angiography/angioplasty In evolving Non-ST-Segment elevation myocardial infarction: Open randomized trial
ISE Women’s Ischemia Syndrome Evaluation
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